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Abstract  
This thesis describes the progress made towards the synthesis of the natural product 
phacelocarpus-2-pyrone A and the development of novel synthetic methodology for the 
synthesis of functionalised 2-pyrones.  Initial studies focused on the synthesis of the 
natural product and the applications of Pd-catalysed cross-coupling reactions using the 
interesting palladium catalyst, CatCat. 
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Key findings in the studies towards the natural product include: i) the synthesis of 
two 6-alkyl-4-hydroxy-2-pyrone intermediates suitable for providing a synthetic platform 
for future work; ii) the first synthesis of a 2-pyrone bound vinyl ether; iii) the synthesis of a 
19 membered macrocycle containing 2-pyrone and 1,4-en-yne functionality. 
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In addition, the first Pd-catalysed intramolecular C-H arylation of a 2-pyrone has 
been developed and applied to a number of substrates. 
O
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PPh3 (4 mol%), Cs2CO3 (3 eq.), 
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Chapter 1: Introduction 
 
1.1 Introduction to natural products 
 
Natural products have formed the basis of medicine for many hundreds of years.  It 
is well documented in historical literature with examples dating back to the ancient 
Egyptians, who used tea brewed from willow bark to treat conditions such as fever.1  The 
analgesic effect of this treatment is now known to have originated from the medicinal 
properties of salicylic acid (1), a natural product found within willow bark.  Subsequently a 
more potent form of 1 was developed, namely acetylsalicylic acid (more commonly known 
as Aspirin) one of the biggest selling pharmaceutical products in today’s market.1  Other 
molecules can be found throughout nature which posess medicinal properties, such as 
quinine (2) (a treatment for malaria).1  
Natural products are usually in very limited supply, and in some cases as little as a 
few milligrams of the desired product can be isolated from a kilogram of biological 
material.  As a result, the harvesting of natural products from nature rarely represents a 
feasible supply of such compounds, however the overexpression of the relevant gene in 
bacteria, such as E. coli, and subsequent fermentation can provide large scale quantities.2  
Unfortunately, the fermentation approach is not feasible for the screening of large numbers 
of natural products and has consequently resulted in the development of natural product 
synthesis as one of the key areas of research in organic synthesis. This has far ranging 
effects on organic chemistry, as many of these compounds require the development of new 
synthetic methodology. 
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Figure 1.1: Common natural products. 
 
The total synthesis of natural products originates from Wöhler’s serendipitous 
synthesis of urea (3), whilst attempting to prepare ammonium cyanate (Scheme 1.1).3 
 2 
NH4.CNO
O
NH2H2N
Pb(CNO)2  + 2NH3 +  2H2O
Pb(OH)2
2 2.
 
Scheme 1.1: Wöhler’s synthesis of urea 
 
 Wöhler’s discovery is largely considered the foundation of modern organic 
chemistry through disproving vitalism,4 which previously stated that organic matter could 
not be created from inorganic matter.  Since this discovery, the field of natural products 
has attracted much interest.  Notably, this area has seen the award of various Nobel prizes.  
Arguably one of the most important prizes was awarded to E. J. Corey in 1990 for his work 
on natural product synthesis through the introduction of retrosynthetic analysis (RSA).4  
The use of RSA has proven to be an extremely efficient way to approach the synthesis of 
natural products and is now widely applied by organic chemists in the modern era. 
 As the demand for new therapeutically viable compounds increases, through the 
resistance of certain diseases to their current treatments or for conditions which have no 
effective treatments, scientists have continued to turn to nature as a source of inspiration.  
New natural products are constantly being screened for biological activity, providing 
starting points for the synthesis of promising biologically active targets.5  
One of the most important attributes for these compounds is to show target 
selectivity.  Often the most biologically active compounds also pose interesting synthetic 
problems, such as those possessing stereochemistry, regiochemistry and other interesting 
structural features (e.g. large ring and polycyclic ring systems).  To date, there have been 
hundreds of succesfully synthesised natural products, many of which prove to either lack 
the desired level of biological activity or prove too costly to synthesise on a large scale.  
Fortunately, some prove to be very effective, such as cortisone (4) (a potent anti-
inflammatory)6 and discodermolide (5) (an anti-tumour agent) which has attracted alot of 
attention, with various analogues undergoing preclinical trials.7 
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Figure 1.2: Medicinally important natural products. 
 
One natural product class described as being therapeutically viable are the 
epothilones.8  These compounds show an interesting array of structural complexity with 
alkene, carbonyl and thiazole functionalities being present, as well as complex 
stereochemistry throughout the molecule. Significant interest was shown in this class of 
compounds by the group of Danishefsky et al.9 who reported the first total synthesis of 6 in 
1996.  Due to the high level of bioactivity shown against certain cancer cell lines these 
compounds have continued to be studied with many hundreds of analogues having now 
been synthesised and biological evaluated; some derivatives are currently undergoing 
clinical trials.8 
 
1.2 Introduction to pyrones and natural products containing the pyrone motif  
There are many types of natural products which exhibit similar structural features 
such as polyketide chains, macrocyclic rings, saccharides and heterocycles.10 The pyranone 
(or pyrone) substructure is commonly found in bacteria, plants, animals and insects. The 
pyrone motif often shows biological activity in the form of defence against foreign bodies. 
It is also found in biosynthetic precursors/intermediates and can be easily metabolised.11  
This particular facet of the pyrone ring system makes them very interesting to study as 
potential pharmaceutical agents.12 
Pyrones can exist in one of two major isomeric forms, 2-pyrone and 4-pyrone (also 
known as α and γ pyrones, respectively) which are assigned on the position of the carbonyl 
 4 
relative to the oxygen atom within the ring system (Fig. 1.3).  The parent compounds for 
both types of pyrone ring system are susceptible to ring-opening by nucleophilic reagents, 
particularly hydroxide ions, which will predominantly attack the carbonyl position on the 
2-pyrone, or in a Michael fashion in 4-pyrone.13  
2 O 1
O
4
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1
O
Pyran-2-one
(2-Pyrone)
Pyran-4-one
(4-Pyrone)
7 8
 
Figure 1.3: The two variations of the pyrone motif. 
 
Due to this reactivity, 2- and 4-pyrones in nature are often found to be substituted 
on the ring, particularly at the positions most susceptible to nucleophilic attack. 2-Pyrones 
are often found to contain substituents at the C-4 and C-6 positions, the positions which 
can stabilise the intermediate species through resonance. 
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Scheme 1.2: Nucleophilic attack on 2-pyrone. 
 
Two such examples are 4-hydroxy-6-methyl-2-pyrone (triacetic acid lactone 9) and 
3-acetyl-4-hydroxy-6-methyl-2-pyrone (tetraacetic acid lactone 10). 4-Hydroxy-6-methyl-
2-pyrone 9 is an interesting compound due to its ability to tautomerise to 4-pyrone and 
promote electrophilic substitution at both C-3 and C-7 positions. 14   Both of these 
compounds are biologically synthesised from acetic acid and are metabolised back to 
acetic acid in vivo.15  A vital aspect in drug discovery and design is the metabolism of the 
test compound, but crucially one needs to know whetherby-products affect the host.  The 
formation of this non-toxic chemical, combined with the reactivity at the C-3, -OH and C-7 
positions, make these compounds an excellent starting point for the synthesis of complex 
natural product targets.16,17 
 5 
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Figure 1.4: Simple 2-pyrones found in nature. 
  
The 2-pyrone motif is found in many types of natural products such as 
bufadienolides (11), peripyrones (12), gibepyrones (13), fusapyrones (14) and coumarins 
(15) (Fig. 1.5).10  Such examples show the extensive diversity in the size and complexity of 
natural products containing the 2-pyrone motif.  
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Figure 1.5: Complex 2-pyrone containing natural products. 
 
The structural diversity shown by 2-pyrone-containing natural products is mirrored 
through their biological effects, e.g. as anti-bacterials, anti-fungals, agents acting against 
Alzheimer’s disease, HIV, cholesterol-lowering and cancer treatments.  The biological 
activity in all of these examples is thought to be as a result of enzyme inhibition. 18,19, 20, 21, 
22
 
 6 
Due to the biological effects of 2-pyrone-containing natural products, it is 
understandable that they have been the source of study for many years, and subsequently a 
number of synthetic routes have been developed in order to access the 2-pyrone motif.  
4-Hydroxy-6-alkyl-2-pyrones are commonly obtained via a biomimetic synthesis 
using a polyketide chain (Scheme 1.3).  Treatment of the appropriately substituted 3,5-
diketo ester with a suitable base generates the  desired 2-pyrone.  
O
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RHO
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O R
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O O
R O
H O
O R
OO
H
Base
 
Scheme 1.3: Biomimetic route to 4-hydroxy-6-alkyl-2-pyrones. 
 
Many other synthetic routes to 2-pyrones have utilised novel methodology 
involving both organic and organometallic pathways.  Transition metals have been shown 
to be highly useful for the formation of 2-pyrones, with palladium proving particularly 
popular.  In 2001, Bellina et al. showed that 5,6-difunctionalised 2-pyrones were easily 
accessible through the reaction of ene-ynoic acids with iodine, followed by either Stille or 
Negishi cross-coupling (Scheme 1.4-A).23,24  Parrain et al. improved upon the use of Stille 
reactions in 2-pyrone formation, where 2-pyrones could be formed in a one step reaction of 
an acyl chloride with a distannane (Scheme 1.4-B).25  Another interesting stille based 
approach was that of Liebeskind and Wang who demonstrated Pd-catalysed carbonylative 
cross-couplings of chlorinated cyclobutenones with various stannanes, which then 
underwent rearrangement to form the 2-pyrone motif (Scheme 1.4-C).26  Other innovative 
approaches have focused on more traditional organic methods to generate the 2-pyrone 
moiety, such as that of Dieter and Fishpaugh who in 1987 utilised vinyl thiol ethers to 
create 2-pyrones showing excellent functional group diversity (Scheme 1.4-D).27  
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Scheme 1.4: Examples of organometallic and organic syntheses of 2-pyrones 
 
Palladium-catalysed reactions utilising 2-pyrones has been widely studied.  In 
addition to the examples shown in Scheme 1.4, work by Fairlamb and co-workers has 
shown that halides or pseudo-halides derived from 9 are able to undergo a number of Pd-
catalysed reactions including Suzuki, Sonogashira and Negishi cross-couplings (Scheme 
1.5-A).28  In addition, the C-3 and C-5 positions are easily halogenated and the subsequent 
C-X bond can participate in a multitude of Pd-catalysed reactions (Scheme 1.5-B/C).29, 30  
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Scheme 1.5: Cross-coupling reactions of halogenated 2-pyrones. 
 8 
The examples given in Scheme 1.5 rely on the 2-pyrone providing the organohalide 
derivative for Pd-catalysed cross-couplings, however it is also possible for the 2-pyrone to 
provide the organometallic derivative. One of the first organometallic 2-pyrone derivatives 
synthesised was the cuprio-pyrone devised by Posner and co-workers as an effective 
nucleophile. 31  More recent work has shown the 2-pyrone can support stannane and 
boronate functionality for Pd-catalysed cross-couplings, as shown by Liu and Meinwald 
and also Gravett et al. in their respective approaches to the bufadienolides (Scheme 1.6).32, 
33
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Scheme 1.6: A) Posner’s cuprio-pyrone; B) Cross-coupling approaches to bufadienolides 
 
1.3 Introduction to skipped dienes and natural products containing the skipped diene 
motif 
 
A diene is a structural motif that contains two alkenes, which can be separated by 
any number of other atoms.  The most common is a 1,3-diene, whereby two alkenes are 
positioned such that only a single bond separates them.  In this instance the two π-systems 
are able to overlap to form an extended conjugated system through the delocalisation of 
electrons through the extended π-system.  The delocalisation results in the formation of a 
degree of double bond character in the single bond, thus making it a stronger bond and 
more stable to a variety of conditions. Another common form is the 1,4- or ‘skipped’ diene, 
where two single bonds separate the alkenes and prevent conjugation.34 
1,3-diene 1,4-diene
4
3
2
1
R
R
3
4
5
2
1
RR
 
Figure 1.6: Two common diene motifs. 
 9 
 Though relatively stable to most conditions, skipped dienes are particularly 
vulnerable to oxidation.  For example, radical formation can occur at the central carbon 
allowing a facile rearrangement of the skipped diene to form the more stable 1,3-
conjugated form.  Upon termination of the radical the more stable 1,3-diene will always be 
preferred (Scheme 1.7).35  
RR RR
RRRR
A
AH
A
AH
 
Scheme 1.7: Radical rearrangement of a skipped diene 
 
The skipped 1,4-diene motif is regularly observed in natural products despite this 
instability with the most prevalent occurence being within the long hydrocarbon chains of 
fatty acids.  One example is the essential fatty acid, linoleic acid (17) which is 
biosynthesised via a polyketide extension reduction pathway,36 to give octadecanoic acid 
(16), which then undergoes successive desaturation by ∆9 and ∆12 desaturases to give 16 
(Scheme 1.8). 37,38  
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Scheme 1.8: Biosynthesis of Linoleic Acid (17) 
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Linoleic acid is a vital precursor to many bioactive natural products including 
arachidonic acid (18),39 epilachnadiene (19)40 and isoprostanes (20)41 which all maintain 
the enzymatically acquired skipped 1,4-diene (Fig. 1.7).  
OH
O
Arachidonic Acid
18
O
O
NH
Epilachnadiene
19
HO
HO
OH
OOH
iPF3α −VI
20
*
*Stereochemistry not defined
 
Figure 1.7: Skipped 1,4-diene containing natural products. 
 
Skipped 1,4-diene containing natural products are known to be involved in many 
important biological functions such as cell signalling, control of inflammation, anti-
asthmatic,42 anti-predatorial,43 and anti-diabetic.25  The laboratory synthesis of this motif 
has therefore been subject to synthetic studies for over four decades.  Due to the long-term 
instability of these compounds, the skipped 1,4-diene motif is often generated towards the 
end of the synthesis, with a simple motif used instead, which is stable to various conditions 
and leads to facile access of the alkenes required.  
Alkynes are stable to a number of chemical environments and can easily be 
protected by a dicobalt(0) hexacarbonyl motif.44 The selective hydrogenation of alkynes to 
cis-alkenes by Lindlar catalyst45 provides a straightforward method for introduction of  the 
alkene functionality.  The use of the alkynyl strategy was exemplified by Osbond et al. in 
1959 during the total synthesis of arachidonic acid (18) (Scheme 1.9).46  The iterative use 
of propargylic units to generate the 1,4-alkyne motif was complemented by a final step 
hydrogenation of four alkynes to generate 18. 
COOH
HOOC
H2 - Pd/Lindlar
18
21
 
Scheme 1.9: Osbond’s approach to 18 
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The use of other transition metals in the selective hydrogenation of alkynes are also 
known using copper,47 nickel48 and titanium.49  Other approaches have utilised methods 
which give access to the skipped diene directly, employing the repetitive use of the Wittig 
reaction, as usedby Santelli et al.50 (Scheme 1.10-A), or the Stille cross-coupling of vinyl 
stannanes with allylic halides as utilised by Badone et al. (Scheme 1.10-B).51  
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Scheme 1.10: Various syntheses of the skipped diene motif. 
 
1.4 Introduction to palladium catalysis in natural product synthesis 
 
The use of transition metals, particularly palladium,52  has become increasingly 
popular in the synthesis of natural products, with recent examples such as Takahashi’s 
synthesis of dysiherbaine (22),53 and Jacobsen’s synthesis of the γ-pyrone aureothin (23) 
(Fig. 1.8).54 
O O
O
OMeO2NO
NHMe
OHO
HOOC
NH2
HOOC
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Suzuki
Dysiherbaine
Negishi
Allylic substitution
22 23
 
Figure 1.8: Use of Pd catalysed cross-coupling reactions in natural product synthesis. 
 
Palladium’s ability to catalytically mediate various transformations, increasingly 
centred around C-C bond formation, making it an essential tool for the modern day organic 
chemist.  The conditions required for catalysis can vary extensively, depending on both the 
reaction and the palladium complex (including surrounding ligands) being employed.  One 
 12 
of the most commonly employed palladium catalysts is [Pd(PPh3)4], although in recent 
times the importance of the mono-ligated species “Pd(PPh3)n” (n = 1) has become more 
understood and led to the development of many palladium complexes in a search to 
identify more catalytically active species for any given reaction.55 
O
N
X
O
Bu3Sn OEt
N
O
O
OEt
X = OH
X = Br
25
26
24
Pd(PPh3)4
 
Scheme 1.11: Stille reaction used in a study of the inthomycins. 
 
During a synthetic study towards the inthomycins by the groups of Fairlamb and 
Taylor, it was observed that a Stille cross-coupling reaction would only proceed when the 
preceeding bromination of 24 was performed using NBS and PPh3 in CH2Cl2. 56  If the 
bromination was performed using CBr4 as an alternative source of bromine then the 
consequent Stille coupling failed unless trace of amounts of NBS were added to the crude 
bromide (24) material (Scheme 1.11).  This was attributed to the oxidative addition of 
NBS to palladium(0) and led to the discovery of a novel catalyst species for certain 
coupling reactions.  The cis-succinimido palladium(II) complex (cis-27) was later shown to 
be highly efficient for the Stille cross-coupling of both benzylic and allylic bromides under 
relatively mild conditions and therefore could be a suitable catalyst for  use in the synthesis 
of molecules containing sensitive functionality.57  The cis-complex can be isomerised to 
the trans-complex (known colloquially as “CatCat”) by simple heating in toluene.  
 
N
O
O
Pd
Br PPh3
Ph3P N
O
O
Pd
PPh3
Br
Ph3P
Bromobis(triphenylphosphine)(N-succinimide)palladium(II)
trans-27 cis-27(CatCat)
 
Figure 1.9: A novel palladium (II) precatalyst. 
 
To date, relatively little work has been carried out in order to ascertain the 
efficiency of the precatalyst in other Pd-catalysed coupling processes, such as Negishi, 
Suzuki and Buchwald-Hartwig cross-couplings.  This project was set up to consider the use 
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of various palladium catalysts towards the synthesis of a phacelocarpus 2-pyrone, 
including simple precatalysts such as 27, but also more complex catalyst systems 
possessing ligands such as those reported by Buchwald58  (28) Hartwig59  (29) and the 
phosphine free N-heterocyclic carbene (30)60, which will be used in combination with 
other palladium precursor sources, e.g. Pd2(MeO-dba)3 or Pd(OAc)2 (Fig. 1.10).61 
N N
28 29
..
(Q-Phos)
30
Fe
P
Ph
Ph
Ph
PhPhP
 
Figure 1.10: Alternative ligands for palladium catalysts. 
 
1.5 Introduction to the Phacelocarpus pyrones 
 
Considering approximately two thirds of the earth is covered by water it comes as 
no surprise that many natural products are found from the abundance of life in the world’s 
oceans, seas and lakes, with over 17,000 different marine natural products reported since 
1965.62  The area of marine natural products is split into several categories based on the 
microorganism from which the natural products were isolated, which include algae (red, 
green and brown), sponges and molluscs to name just a few.  As of 2002, red algae 
accounted for approximately 6% of the natural products isolated from marine organisms, 
many of which have been found to contain brominated polyphenols and terpenes.16,63  The 
presence of multiple alkenes is also notable in many of the structures including the 
oxylipins (31) and eicosanoids (32), where the alkenes are found to occur in both isomeric 
forms (E/Z), and also in conjugated (1,3) and non-conjugated (1,4) systems. 
OH
COOH
O
O
H
H
H
O OH
Oxylipin
31 Agardilactone(Eicosanoid)
32
 
Figure 1.11: Alkene-rich marine natural products isolated from red algae. 
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The skipped 1,4-diene motif was also discovered in a unique type of natural 
product isolated from the Australian marine red alga Phacelocarpus Labillardieri by 
Kazlauskas et al.64  Further studies of the alga by Shin et al.65 and Murray et al.66 has 
resulted in the discovery of nine unique 2- and 4-pyrone macrocycles (e.g. 33-38)  each 
containing the 1,4-skipped alkene motif.  These structures also contain an important motif 
whereby the macrocycle is completed through a vinyl ether found in both E and Z isomers.  
Although the vinyl ether motif is well known in natural products,67 pyronyl vinyl ethers are 
a novel substructure seen only in the phacelocarpus pyrones.  
O
O
O
E/Z
O
O
O
O
O
O
O
O
O
Br
Br
O
O
O
Br
Br
O
O
O
Br
Br
2-Pyrone A
2-Pyrone B
(E/Z) 4-Pyrone A
4-Pyrone B
4-Pyrone C
4-Pyrone D
34
38
3533
36 37
 
Figure 1.12: Macrocyclic 2- and 4-pyrones isolated from Phacelocarpus 
Labillardieri.64,65,66 
 
Crude extracts of the alga have proven to exhibit neuromuscular inhibition, exciting 
interest amongst chemists due to the unique structure of these compounds. Seven out of the 
nine isolated pyrone macrocycles contain the 4-pyrone motif, with the remaining two being 
2-pyrone analogues.  Due to the presence of both 2- and 4-pyrones, the likely biological 
pathway originates from the cyclisation of a 3,5-diketo acid, followed by an enzymatic 
reaction with an alcohol to yield one of the two regioisomers, depending on which position 
the alcohol attacks (Scheme 1.12).  Should the alcohol in question be tethered to the other 
 15 
side of the ketolactone intermediate, then the formation of the 2-pyrone and the 
macrocyclisation can potentially occur in a single step. 
O
OHO
R
O
O
O
OR
HO
R'
O
O
OR
R'
O
O
OR
R'
+
-H2O -H2O
 
Scheme 1.12: Proposed biosynthesis of 2- and 4-pyrones. 
 
Previous work within the group has focused on the synthesis of various 2-pyrones 
using Pd-mediated cross-coupling reactions and the determination of their biological 
activity.18, 68 , 69  The phacelocarpus-2-pyrones offer a chance to further develop cross-
coupling methodologies and apply them in the synthesis of intricate and challenging 
molecules.  
To date the only studies towards 33 have been performed by Fürstner and co-
workers, where they utilised alkyne metathesis in order to generate the desired macrocycle 
(Scheme 1.13).70 Although the macrocyclisation proceeds well, the approach utilised by 
Fürstner was solely for the generation of the macrocycle, and does not address the 
additional alkenes present in the desired product, which are likely to complicate the 
macrocyclisation, possibly through additional ene-yne side reactions occurring.71 
O
O
O
O
O
O
(tBuO)3W
39 40
(16 mol%)
Toluene (0.001M), 80 °C
50 mins
(84%)
 
Scheme 1.13: Fürstner’s approach to macrocycle formation. 
 
1.6 Retrosynthetic analysis of phacelocarpus-2-pyrone A 
 
The proposed RSA of 33 (Scheme 1.14) is centred on breaking down the 
compound into smaller fragments at points of functionality in order to piece the molecule 
together in a convergent manner.  The RSA of 33 consists of four main disconnections to 
give four unique fragments.  Fragment A (9) is a commercially available material, making 
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this the ideal point from which to start a forward synthesis. Fragments B and C are known 
in the literature, whereas fragment D is unknown and will require a novel synthesis.  
It is envisaged that Pd-catalysed reactions such as the Sonogashira cross-coupling 
and Hartwig etherification will be incorporated into the synthetic route, however the 
development of current methodologies may be required for their efficient application. 
O
O
O
O
O
O
XO
O
HO
O
O
HO
X
O
O
HO
X
Metathesis
Hartwig 
etherification
+
+
Sonogashira
coupling
+
Lithiation
/Alkylation
Fragment A Fragment B
Fragment C
Fragment D
33
9
AB Fragment
ABC Fragment
DABC FragmentI
II
III
IV
 
Scheme 1.14: RSA of 2-pyrone 33.  
(Note: Fragment nomenclature throughout defined by clockwise combination of individual 
fragments) 
  
 
1.7 Proposed forward synthesis of phacelocarpus-2-pyrone A 
 
The initial coupling of fragments A and B utilizes synthetic methodology 
developed by Zhang et al.10 whereby the 2-pyrone 9 is lithiated at the C-7 position 
followed by alkylation using an alkyl electrophile.  In order for fragment B to react by the 
correct path, in the presence of n-butyllithium, the terminal alkyne needs to protected as a 
silane (Scheme 1.15). 
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Si
HO
Si
HO
O
HO
O
Si
O
HO
O
O
HO
O
FGI
i-Pr3
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41 42 43
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45
i-Pr3
n-BuLi
TBAF
i-Pr3SiCl
n-BuLi
i-Pr3
 
Scheme 1.15: Proposed synthetic route to 45. 
 
The synthesis of fragment C (50) can be envisaged from the known reaction of the 
highly active allyl bromide (46) with propargyl alcohol (47) via the formation of an 
organocuprate derived from the terminal alkyne.72  Selective alkyne hydrogenation of the 
enyne 48 in the presence of a surface catalyst, such as Lindlar catalyst, would ensure the 
cis-stereochemistry of the central alkene resulting in 1,4-diene 49.  Conversion of 49 to a 
halide (or pseudo-halide) would produce the desired fragment for Sonogashira cross-
coupling to 45 in as few as three steps (Scheme 1.16). 
X
OH
Br OH
OH
O
HO
O
+
CuI, NaI, Base Pd Hydrogenation
FGI
51
46 47 48
49
50
O
HO
O
cat. Pd
45
 
Scheme 1.16: Proposed synthesis of 51. 
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The formation of the vinyl ether poses one of the greatest challenges in the 
proposed synthetic route due to the potential difficulty associated with the preparation of 
the fragment D.  In order for a Pd-catalysed cross-coupling to be carried out, a vinyl halide 
precursor would need to be formed.  It is likely that this compound would be highly 
unstable, although recent work by Yu and Jin has found a route to the synthesis of α-halo 
vinyl ethers.73  The use of a pseudohalide such as a tosyl group could allow the formation 
of the desired fragment 55 through the increased stability that this group may provide.  The 
final step of the proposed synthesis would be a macrocyclisation using an metathesis 
catalyst such as Grubbs’ 1st or 2nd generation catalysts.74  The important factor to consider 
in this step would be the selective generation of the cis-alkene to form the natural product 
33 (Scheme 1.17). 
Br
I
O
O
O
O
O
O
+
55
Grubbs catalyst
33
Schwarz 
reagentCuI, NaI, Base
46 52 53 54
O
HO
O
cat. Pd
51
(Target)
 
Scheme 1.17: Proposed synthesis of 55 and 33. 
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1.8 Aims and objectives 
 
The overall aim of the work detailed in this thesis is the development of the first 
synthetic route towards the macrocyclic 2-pyrone 33. Incorporated into this aim is the 
desire to develop novel methodology for the synthesis of highly functionalised 2-pyrone 
derivatives and exploit any interesting observations (e.g. C-H activation). 
 
In Chapter 2 we will investigate a methodology towards the total synthesis of 33. 
As a part of this work a number of objectives will be followed, namely;  
• Extend the use of CatCat in Suzuki cross-coupling processes, particularly towards 
more difficult benzylic and allylic substrates. 
• Explore cross-coupling strategies in the synthesis of 33. 
• Extend the lithiation chemistry of 6-alkyl-2-pyrones. 
• Develop a vinyl ether synthesis involving the 2-pyrone motif possesing a suitable 
handle for further manipulations. 
• Evaluate alkene metathesis as a macrocyclisation strategy for 2-pyrones. 
• Formally identify all novel and known compounds (Chapter 4). 
 
In Chapter 3 we will investigate a novel intramolecular Pd catalysed C-H 
functionalisation, observed during the course of work towards 33. As a part of this work a 
number of objectives will be followed, namely; 
• Develop the use of palladium to perform an intramolecular cyclisation  
• Extend optimised synthetic methodology to a range of substrates.  
• Assess the limitations of the reaction. 
• Investigate potential reaction intermediates involved in the catalytic cycle. 
• Formally identify all novel and known compounds (Chapter 5). 
 
 
 
 
 
 
 
 
 20 
Chapter 2: Synthetic studies towards phacelocarpus-2-
pyrone A 
 
2.1 Suzuki-Miyaura cross-couplings 
 One of the key aims towards the synthesis of 33 is the formation of a 1,4-skipped 
diene, which can be envisaged through a Suzuki cross-coupling reaction of allylic and 
vinylic substrates. Whilst this type of cross-coupling has been previously reported, there 
are limited reports of simple efficient catalytic systems which can perform this type of 
transformation.75  
 
2.1.1 Suzuki-Miyaura cross-couplings of benzyl bromides with aryl boronic acids 
 Preliminary studies focused on the Suzuki-Miyaura cross-coupling reactions of 
various arylboronic acids with benzyl bromides using CatCat, namely [trans-Pd(Br)N-
Succ(PPh3)2] (27), as the precatalyst.  The primary aim of this section of work was to 
investigate the use of heteroaromatic components, and evaluate the efficacy of CatCat. 
Stille couplings of organostannanes are reported to be mediated well by CatCat, 
particularly for benzylic and allylic bromides,76 whereas Suzuki-Miyaura cross-coupling 
reactions remain unreported. The results from these experiments are shown in Table 2.1.  
The results of this study demonstrate that CatCat is a useful catalyst for the Suzuki-
Miyaura coupling of several thiophene boronic acid substrates with benzyl bromides.  The 
fluorinated boronic acids 67 and 69 proved to be difficult substrates for the reaction, with 
the poor reactivity attributed to the steric influence of the ortho-substitution.   
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Table 2.1: Yields for Suzuki-Miyaura cross-couplings using CatCat. 
Br B(OH)2
R R
+
CatCat (1.0 mol%)
2M Na2CO3(aq), THF
60 oC56
 
Entry Aryl boronic acids Products Time (h) Av. Yield (%)* 
 
1 
B(OH)2
 
57 
 
58 
2 88 
 
2 
S B(OH)2H3COC
 
59 
SH3COC
 
60 
4 78 
 
3 
S B(OH)2Cl
 
61 
SCl
 
62 
4 78 
 
4 
S
B(OH)2
 
63 
S
 
64 
4 93 
 
5 
S B(OH)2
O
 
65 
S
O
 
66 
4 60 
6† B(OH)2
FF
F
F F
 
67 
F
F
F
FF
 
68 
5 5 
7 B(OH)2
F
F
F
 
69 
F
FF
 
70 
5 0 
8 B(OH)2
F
F
 
71 
F
F
 
72 
5 69 
 
9 
S B(OH)2
 
73 
S
 
74 
4 91 
 
10‡ 
O B(OH)2
 
75 
O
 
76 
5 0 
11‡ 
O B(OH)2
O
 
77 
O
O
 
78 
5 0 
* Yields based on an average of two runs. 
† The reaction was carried out at 80 ºC. 
‡ These reactions have since been successful using a different batch of 75 and 77 
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Throughout the course of these reactions one of the common problems encountered 
was the hydrodeborylation of the organoboronic acid (Scheme 2.1).  This was particularly 
noticeable with the furan derivatives although further studies within the group showed that 
coupling occurs when using a different batch of 2-furanboronic acid.  This indicates that 
hydrodeborylation may be occurring as a result of moisture in the air prior to the reaction, 
as opposed to during the reaction.77  
O B
OH
OH
OH
O OB
OH
OH
OH H2O
-B(OH)3
-NaOH
NaOH
Na
 
Scheme 2.1: Hydrodeborylation of 2-furanboronic acid. 
 
2.1.2 Suzuki-Miyaura cross-couplings of prenyl and terpenyl substrates 
 
The coupling of the prenyl (79) and geranyl (80/81) halides (Scheme 2.2) were 
attempted to test a system more similar to the natural product, allowing an assessment to be 
made as to the feasibility of using this type of coupling process in the synthesis of the 
natural product.  Unfortunately, preliminary results indicated that the allylic bromides are a 
poor substrate for the Suzuki-Miyaura cross-couplings, which stands in contrast to the high 
reactivity observed with the same substrates in the Stille reaction (reaction with 
organostannanes). 76  
The high reactivity of allylic and benzylic bromides in the Stille coupling, 
compared to high reactivity towards benzylic substrates and low reactivity of allylic 
substrates in the Suzuki-Miyaura coupling could indicate the possibility of a different 
mechanism for CatCat in these apparently similar reactions.  Alternatively, the rate of 
transmetallation could be slowed in the presence of the allylic substrate. Finally, the 
presence of aqueous base may be hydrolysing the allylic bromides into the allylic alcohols 
under the reaction conditions. 
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B(OH)2
Br
+
THF, 60 oC, 16 h
2M Na2CO3 (aq)
1 mol% CatCat
57 79
Recovery of S.M
B(OH)2
Br
+
80 oC
57 80
Recovery of S.M
B(OH)2
Cl
+
80 oC
57 81
Recovery of S.M
As above
As above
 
Scheme 2.2: Couplings of terpenyl substrates. 
 
2.2 Studies towards the total synthesis of phacelocarpus-2-pyrone A65,78 
 
2.2.1 Alkylation/ lithiation strategy to AB fragment 
 
The originally proposed route to the AB fragment (45) was via the synthesis of a 
brominated 2-pyrone for use in a Negishi type reaction with fragment B (43).  The results 
shown below correlate to the most selective route to the brominated 2-pyrone (83) 
(Scheme 2.3), with the major problem being the formation of the unwanted dibrominated 
product (84).  
O
O
HO
O
O
O
O O
O
O
O O
O
O
O
Br Br
Br+
(19%)
83 84829
AcCl, 
Pyridine, 0 oC
NBS, AIBN
60 oC
(64%)
 
Scheme 2.3: Synthetic route to 6-(bromomethyl)-2-pyrone 83. 
 
Suzuki et al.79  reported an alternative method (Scheme 2.4) which avoids this 
problem by employing a SeO2 oxidation to form a primary alcohol on the C-6-methyl 
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group (85), with subsequent conversion of this newly formed primary allylic alcohol to an 
allylic bromide. The results reported show a slightly improved yield, however an 
alternative strategy has recently been developed which may offer a synthetic advantage.   
83859
O
O
HO
O
O
HO
Br
NBS, AIBN
60 oCO
O
HO
OH
SeO2, t-BuOOH
 
Scheme 2.4: Suzuki’s approach to 83. 
 
Recent work by Swidorski et al. has shown that the direct addition of organohalides 
to unprotected 4-hydroxy-6-methyl-2-pyrone can be selective for the methyl group. 80,81  
The implications of this novel methodology for the natural product synthesis are important, 
as no alterations to the commercially available 2-pyrone 9 would be required, thereby 
circumventing the formation of the problematic bromide.  In the reports by Swidorski et al. 
two synthetic routes were examined (Scheme 2.5). 
O
O
HO
O
O
HO
R
O
O
HO
O
O
HO
R
1. HMDS, 90 °C, 1 h
2. n-BuLi (1.3 eq.), THF,
   RX, -78 to 22 °C, 16 h
n-BuLi (2.5 eq.), 
THF/HMPA(6:1),
RX, -78 to 22 °C, 16 h
Route A
Route B
 
Scheme 2.5: Routes to direct alkylation of 4-hydroxy-6-methyl-2-pyrone 
 
Route A relies on an assumed complete TMS protection of the C-4-hydroxy group, 
followed by selective monolithiation at the methyl position, electrophilic organohalide 
attack and removal of the TMS group upon work-up.  Route B uses the introduction of 
HMPA to stabilise a dilithiated intermediate, and was found to be a more effective 
procedure. 
O
O
HO
O
O
HO
X+
43 449
TIPS
TIPS
 
Scheme 2.6: Proposed route to AB fragment. 
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Studies focused on the possibility of using this chemistry for the initial coupling 
step in the natural product synthesis (Scheme 2.6).  Preliminary results came from the 
coupling of various allylic and alkyl halides to 4-hydroxy-6-methyl-2-pyrone, however 
poor yields of the desired products were obtained with a major problem being double 
addition onto both the hydroxyl and methyl positions (Scheme 2.7).  
O
O
HO
O
O
O
(2%)
(26%)
86
87
O
O
HO
n-BuLi (2.2 eq.), THF
-78 °C, 1 h
Br
88
-78 to 22 °C, 16 h
 
Scheme 2.7: Initial results from alkylation/ lithiation studies. 
 
The extent of this problem, though not discussed in the literature,17 led to attempts 
to reproduce the literature results (Table 2.2). 
 
Table 2.2: Repetition of literature procedure for lithiation/ alkylation of 9. 
n-BuLi, THF
-78 to 22 °C, 16 h
O
O
HO
ClPh
Ph
O
O
HO
+
909 89
(see table for 
further details)
 
HMDS eq. of n-BuLi Additive Yield (%) Lit. Yield (%)17 
10 eq. 1.0 None 13 - 
None 2.2 None 7 - 
None 2.2 HMPA 15 80 
 
The literature result for the direct addition of benzyl chloride was 80%, almost six 
times higher than the yields achieved here.  The formation of the double addition product 
was still visible in these cases, and for this reason the addition to the 4-methoxy-6-methyl-
2-pyrone 91 was attempted, to remove the interference of the hydroxyl group.  
Unfortunately, no product was isolated in this case.  
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In order to better understand these reactions, research was directed into finding 
where the majority of lithiation was occurring under the conditions used, through 
deuteration studies on both the hydroxyl and methoxyl systems (Scheme 2.8).  Preliminary 
results showed that the C-5 position of the 2-pyrone underwent no lithiation, allowing 
levels of deuteration to be calculated by proton integrations correlated to this position on 
the 2-pyrone ring (by 1H NMR spectroscopy). 
3
5
O
O
7HO
O
O
HO
D
3
5
O
O
7HO
O
O
HO
D
3
5
O
O
7HO
O
O
HO
D
D
3
5
O
O
7O
O
O
O
D
D
1. n-BuLi (2.2 eq.), 
THF, -78 °C, 1 h
2. n-BuLi (2.2 eq.), THF
-78 oC, 1 h
1. HMDS, 80 °C, 1 h
1. n-BuLi (2.2 eq.), HMPA 
THF, -78 °C, 1 h
1. n-BuLi (1.3 eq.), THF
-78 °C, 1 h
9
9
9
91
0.39
0.93
0.04
0.69
0.80
0.84
2. D2O
3. D2O
2. D2O
2. D2O
A
B
C
D
 
Scheme 2.8: Deuteration study of 9 and 91  
(yields not recorded; generally high recovery of material). 
 
The initial study was towards the dilithiation without any additives, resulting in 
limited evidence of C-7 functionalisation, with only 39% deuterium incorporation 
(Scheme 2.8-A). The use of an in situ silylation using HMDS followed by monolithiation 
resulted in excellent deuterium incorporation (Scheme 2.8-B). The use of Swidorski’s 
optimised conditions, with HMPA additive to stabilise the dilithiated intermediate, resulted 
in reasonable deuterium incorporation at C-7, but also some incorporation at the undesired 
C-3 position (Scheme 2.8-C). A methyl derivative 91 was also subjected to mono-
lithiation conditions, however, increased lithiation is apparent at the C-3 position (Scheme 
2.8-D). 
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These findings show that although lithiation does occur at the C-7 position, further 
lithiation is apparent.  In further studies, an isopropyl derivative (92) was tested to prevent 
lithiation occurring at the C-3 position through increased steric bulk.  This approach 
showed that lithiation still occurred at the C-3 position (Scheme 2.9). 
2. D2O
O
O
O
O
O
HO
O
O
O
D
929
0.76
1. n-BuLi (1.3 eq.), THF
-78 °C, 1 h
IPA, PPh3, DIAD
THF, 22 °C, 16 h
(70%)
 
Scheme 2.9: Deuteration study of a hindered 2-pyrone. 
 
The deuteration study indicated that the electronics of the 2-pyrone ring are 
sufficiently changed by the introduction of an alkoxy group, resulting in a reduction in the 
lithiation selectivity towards C-7.  In the original direct alkylations (Scheme 2.4), it was 
suggested that the HMDS in route A was acting as a silylating agent prior to lithiation.  
Although there is no mechanism suggested for this transformation, it is possible that the 
relatively high acidity of the 2-pyrone hydroxyl group leads to the formation of an 
ammonium salt when combined with the lone pair of the nitrogen in HMDS.  The 
ammonium salt can then act as the protecting group itself, or form the silyloxy species due 
to the high temperatures employed, with loss of the more volatile TMS amine. 
O
O
O
80 oC
NH
TMS H
O
O
O
N
H2
SiTMS
O
O
TMSO
- TMS NH2
TMS 9 93
 
Scheme 2.10: Silyl protection of 9 using HMDS. 
 
The HMDS procedure does not appear to affect the selectivity for the alkoxy 
derivatives, but increases the level of lithiation occurring at the C-7 position (Scheme 2.8).  
This led to attempts to isolate a silylated 2-pyrone.  Despite various bases and water free 
work-up procedures being employed, no successful silylations were achieved (starting 
material recovered in all cases- See Appendix 1.1).  It is suspected that any silylations that 
may be occurring are rapidly hydrolysed upon isolation, through trace amounts of water 
found in the atmosphere. 
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Scheme 2.11: Silylation of 4-hydroxy-6-methyl-2-pyrone (9). 
 
Following these results, work returned to the use of HMDS for which the best 
deuteration results were observed.  As these results showed, the problem was not with the 
extent of lithiation, but with the resulting alkylation.  It was found that an increase in the 
amount of organohalide gives more efficient alkylation, without an increase in the 
generation of the unwanted dialkylated product, though still not to the level described 
within the literature.  
 The lithiation/ alkylation procedure was tested against a range of different 
electrophiles, with respectable yields observed throughout (Table 2.3). In particular, the 
synthesis of 95 is important due to the pentyne motif observed, which is also present in the 
natural product. Whilst the yield of 95 is relatively low, these results still represent an 
acceptable level to apply to the natural product system. 
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Table 2.3: Results of lithiation/ alkylations of various organohalides. 
O
HO
O
O
HO
O
R
1. HMDS, 80 oC, 1 h
2. n-BuLi (1.3 eq.), RX
THF, -78 oC,16 h
 
Organohalide (RX) eq. of 
RX 
Product 
Yield 
(%) 
Br
 
56 
2.3 
O
HO
O
 
90 
40 
Br
 
86 
2.3 
O
O
HO
 
87 
49 
I
 
94 
1.4* 
O
O
HO
 
95 
32 
Br
 
45 
2.3 
O
O
HO
 
96 
53 
Cl
 
81 
2.3 
O
O
HO  
97 
36 
Br
 
98 
1.0* 
O
O
HO
 
99 
17 
*
 Equivalents of RX limited due to availability. 
 
 30 
2.2.2 Synthesis of fragment B 
 
The synthesis of fragment B for coupling to the 2-pyrone has also been studied. 
Starting from the commercially available 1-hydroxy-pent-4-yne (41), TIPS protection, 
followed by halogenation of the alkyl alcohol, should lead to the desired product in two or 
three steps.  
The TIPS protection of the alkyne 41 is known in literature through one of two 
routes,82,83 both of which require initial protection of the alcohol (Scheme 2.12).  The 
original route is through initial TMS protection of the alcohol, followed by TIPS protection 
of the terminal alkyne.  Alternatively, the higher yielding route involves the reaction of two 
equivalents of a Grignard reagent, followed by addition of TIPSCl, which gives 42 in 
excellent yield.  
HO
SiHO
H
HO
H
HO
Si
1. EtMgBr (2.1 eq.), THF, 80 °C, 16 h
2. TIPS-Cl (1 eq.), 80 °C, 6 h
(90%)
1. n-BuLi (0.1 eq.),  THF, 0 °C, 0.5 h
2. TMS-Cl (1 eq.), 0 - 20 °C, 1 h
3. n-BuLi (2 eq.), 0 °C, 0.5 h
4. TIPS-Cl (1 eq.), 0 - 20 °C, 4 h
(40%)
42
42
41
41
 
Scheme 2.12: TIPS protection of 1-hydroxy-pent-4-yne. 
 
The halogenation of 42 proved more problematic – three different synthetic routes 
were attempted.  Mesylation (42→43a), followed by reaction with NaI, proved successful. 
However, 1-(triisopropyl)silyl-5-iodo-1-pentyne 43b has proven to be sensitive to light and 
silica-gel, causing problems with purification.  Further studies have focused on the 
formation of the 1-(triisopropyl)silyl-5-bromo-1-pentyne 43c.  Two classical brominating 
reagents have been employed: PBr3 and PPh3/NBS.  Unfortunately due to the acidic nature 
of PBr3 generating trace quantities of H3PO4, silyl deprotection of 42 occurred, whereas the 
use of PPh3/NBS led to only 50% conversion.  The use of the bromide for the alkylation 
step was therefore deemed as unacceptable due to the inefficiency of the bromination step.  
Therefore the tosylated pentyne (43d) was also synthesised to provide an additional option, 
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whereby the use of either the mesylate or tosylate can be used as a pseudo-halide leaving 
group for the lithiation/alkylation step. 
HO
Si Si
OMs
Si
I
MsCl (2 eq.), TEA
DCM, -10 °C, 2 h
(96%)
NaI (2 eq.), Acetone
16 h, 22 °C,
2 h, 45 °C
(78%)
43a 43b42
HO Br
DCM, 22 °C, 18 h
(50% conversion)
43c42
SiSi PPh3, NBS
 
43c42
HO Br
THF, 0 °C, 2 h
(10%)
SiSi PBr3
 
HO OTs
TsCl (2 eq.), TEA
DCM, -10 °C, 2 h
(44%)
43d42
SiSi
 
Scheme 2.13: Halogenation of TIPS protected fragment B. 
 
2.2.3 Synthesis of AB fragment 
 
In order to synthesise the AB fragment via the lithiation/alkylation route discussed 
above, the terminal alkyne was protected to prevent deprotonation of the alkyne in the 
presence of n-butyl lithium.  Should this occur then it would severely hamper the desired 
reaction. However, should deprotonation of the alkyne not occur under the reaction 
conditions, the use of the TIPS protection can be avoided.  To test whether the 
lithiation/alkylation of 9 would occur in the presence of an unprotected alkyne, model 
substrate 100 was prepared. 
 Due to the low molecular weight of the unprotected pentyne 41, it was decided that 
the use of tosylate would aid the isolation and handling of this compound.  Tosylation of 
41 proceeded under standard conditions to give 100 in 90% yield. As expected the use of 
100 in the lithiation/alkylation reaction with 9 proved unsuccessful.  
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DCM, -10 °C, 2 h
O
O
HOO
O
HO
9
HO OTs
TsCl (2 eq.), TEA
(90%)
10041
2. n-BuLi (2.2 eq.), 100 (2.3 eq.)
 THF, -78 oC, 16 h
1. HMDS, 80 oC, 1 h
45
X
 
Scheme 2.14: Synthesis and use of tosylate 100. 
 
Although the tosylate was used in this case instead of a halide, it is suggested that 
the cause of the failure was due to the free alkyne as opposed to an issue with the tosyl 
group.  Due to the poor bromination of the TIPS protected alkyne 41 and the instability of 
the iodo compound 43b, the lithiation/alkylation of 9 was attempted using both the 
mesylate 43a and tosylate 43d (as pseudo-halides).  Unfortunately, in both cases this 
reaction proved unsuccessful, indicating that the leaving group is important for the 
reaction.  Consequently, the iodo compound 43b, generated via a Finkelstein reaction from 
the mesylate 43a, was used immediately after its formation without any purification.  The 
reaction proceeded in good yield despite fewer equivalents of organohalide being 
employed, affording the desired TIPS protected AB fragment 44 (Table 2.4).  
 
Table 2.4: Synthesis of TIPS protected AB fragment 44. 
O
O
HO
Si
X
Si
O
O
HO
1. HMDS, 80 oC, 1 h
2. n-BuLi, THF, -78 oC, 16 h
9 44
 
X Eq. of organohalide Yield (%) 
OMs 2.3 0 
OTs 2.3 0 
I 1.7* 70 
*
 Equivalents of organohalide limited due to availability. 
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Figure 2.1: 1H NMR spectrum of AB fragment 45 (400 MHz, CDCl3). 
O
O
HO
45
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The synthesis of the desired AB fragment was achieved by desilylation of 44 using 
TBAF in THF at 22 ºC to afford 45. Initial attempts using one equivalent of TBAF led to 
no desilylation occurring, but increasing the amount to three equivalents led to 
deprotection in 95% yield, affording fragment AB (45) in approximately 60% overall yield 
from five linear steps.  
O
O
HO
45
O
O
HO
44
TBAF, THF, 22 oC, 16 h
(95%)
TIPS
 
Scheme 2.15: Deprotection of 44 to afford 45. 
 
 The 1H NMR spectrum of 45 is shown in Figure 2.1.  This confirms the structure 
of the desired product, despite the presence of trace impurities.  The chemical shifts of the 
2-pyrone proton signals at δ 5.98 and 5.57 remain largely unchanged in comparison to the 
signals observed in the starting material.  However, the singlet methyl group has 
disappeared and replaced by a triplet signal (δ 2.51), confirming that alkylation has 
occurred at the C-7 position.  The sharp triplet signal with a small J coupling (~2 Hz) at δ 
1.95 also confirms the presence of a terminal alkyne proton. 
 
 2.2.4 Synthesis of fragment C (49) 
 
One of the most important aspects in the synthesis of fragment C is the introduction 
of the 1,4-skipped alkene motif and the cis-geometry of the internal double bond.  One 
method of introducing a cis-alkene would be via a selective hydrogenation of an internal 
alkyne using a heterogeneous catalyst such as Lindlar catalyst or a zinc-copper couple.84  
The precursor for the hydrogenation was synthesised via the reaction of allyl bromide 46 
and propargyl alcohol 47, incorporating the in situ formation of a organocuprate and allylic 
iodide.  The reaction proceeded in excellent yield to afford the desired product 48 for the 
next hydrogenation step (Scheme 2.16). 
OHOHBr +
CuI (1 eq.), NaI (2 eq.)
K2CO3 (2 eq.), Acetone,
22 oC, 5 h
(90%) 48
4746
 
Scheme 2.16: Synthesis of fragment C precursor. 
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The hydrogenation of 48 to form the cis-alkene was attempted under a variety of 
conditions, without further hydrogenation of either of the alkene motifs.  The use of 
Lindlar catalyst for selective alkyne hydrogenation is well documented and studies were 
focused on the use of this as the catalyst (Table 2.5).85 
 
Table 2.5: Hydrogenation studies of hex-5-ene-2-yn-1-ol 48. 
OH
OH
Pd, Poison, H2, 22 °C
48 49
(see table for other conditions)
 
Entry Solvent 
Time 
(h) 
Catalyst 
Cat. 
mol% 
Poison 
Poison. 
mol% 
Hydrogenation 
of alkyne (%) 
1 MeOH 3  Lindlar 1 Quinoline 10 0  
2 MeOH 5  Lindlar 1 Quinoline 2 8  
3 Hexane 5  Lindlar 1 Quinoline 1 6  
4 MeOH 5  Lindlar 1 Quinoline 1 30 
5 MeOH 16 Lindlar 1 Quinoline 1 25  
6 MeOH 16  Pd/C 1 Quinoline 1 >99 * 
7 MeOH 16  Lindlar 1 - - 0  
8 MeOH 5  Lindlar 1 Pyridine 1 25  
9 MeOH 3  Lindlar 4 Quinoline 4 50  
10 MeOH 16 Lindlar 5 Quinoline 5 >99  
* Complete hydrogenation of both alkenes and alkynes was observed. 
 
The hydrogenation studies of 48 first examined the use of low mol% catalyst 
utilising quinoline as a catalyst poison, however despite varying the quantities of poison 
and solvent (Entries 1-4) limited hydrogenation had occurred.  Moving to a more active 
Pd/C as a more active surface catalyst led to complete hydrogenation of all unsaturated 
bonds (Entry 6).  After extensive studies, the use of 5 mol% Lindlar Catalyst with an equal 
amount of Quinoline over 16 hours proved to be the most effective (Entry 10).  The 
completion of fragment C was achieved by an Appel reaction86 of 49 to give bromide 50 in 
modest yield (Scheme 2.17).  
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BrHO
PPh3, CBr4,
DCM, 22 oC, 3 h
5049 (50%)
 
Scheme 2.17: Appel bromination of 49. 
 
Though successful, this reaction would be expected to proceed in much higher 
yield.87  One possible problem associated with this system is the possible formation of both 
a primary and secondary bromide, dependant upon the point of attack of the incoming 
bromide anion. 
 
2.2.5 Buchwald-Hartwig etherifications 
 
The preliminary focus on the left hand side of the macrocycle was the introduction 
of the novel vinyl ether motif seen in this class of natural product.  The initial RSA 
suggested the use of Buchwald-Hartwig etherification chemistry, however in order to 
generate the desired vinyl ether, a new synthetic methodology was required.  
Buchwald-Hartwig etherifications have been the focus of extensive study, although 
limited to those of mono and biaryl systems.88, 89  The nature of the reaction dictates the 
use of extremely active and often sterically bulky phosphines is required in order to 
promote the reductive elimination.  Initial studies focused on trying to generate an aryl-
pyronyl ether in order to generate methodology which could then be transferred to the 
natural product system (Table 2.6).  
The results of these reactions indicated that the 4-hydroxy-6-methyl-2-pyrone 9 is 
not sufficiently nucleophilic for these reactions to occur.  In a Pd-catalysed cross-coupling, 
the reactive intermediate formed after oxidative addition can react in one of two ways.  
Primarily (and desired) is transmetallation which occurs via the exchange of a nucleophile 
with the halide.  However, if the rate of exchange is too slow, the Pd intermediate can 
undergo halide-aryl exchange/scrambling.90  The resulting “LPd(Ar)2” complex can then 
reductively eliminate to yield homocoupled product (Scheme 2.18).  The “PdX2” 
intermediate will be reduced under the reaction conditions to also give Pd(0) by a path 
which has not been defined. 
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Table 2.6: Buchwald-Hartwig etherification results 
Br
R
O
R
O
O
HO
+ O
O
Pd(OAc)2, Phosphine, K3PO4
Toluene, 100 oC, 16 h
 
Entry Phosphine Organohalide Product 
Yield 
(%) 
1 
Br
CF3 
101 
CF3F3C
 
102 
70 
2 
Br
O
 
103 
OO
 
104 
85 
3 
P
 
28 IO
O  
105 
No Product. - 
4 Fe
P
Ph
Ph
Ph
PhPh
 
29 (Q-Phos) 
Br
CF3 
101 
CF3F3C
 
102 
82 
5 
P
 
106 
Br
CF3 
101 
No Product - 
 
Pd
X
Ar
Ln
Pd
X
Ar
Ln
O R
X
Pd
O
Ar
Ln
R
Ar
O
R
Pd
Ar
Ar
LnPd
X
X
Ln +
R.E.
R.E.
Ar Ar
 
Scheme 2.18: Homocoupling in palladium cross-coupling 
 
The product of oxidative addition is usually short-lived, with transmetalation 
occurring rapidly in the presence of a suitable nucleophile; homocoupling can be 
minimised by the use of low palladium concentrations (halide-aryl exchange/scrambling 
could also occur via dimer complexes). 91 If a poor nucleophile is used, the Pd(II) oxidative 
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addition intermediate experiences a longer lifetime and consequently the reaction with 
another Pd(II) intermediate becomes possible.  The results detailed in Table 2.6 indicate 
that the coupling partners in this case are incompatible.  Although these reactions do not 
work with the 2-pyrone possessing a 4-hydroxy group, it is possible to convert 4-hydroxy-
6-methyl-2-pyrone 9 into 4-bromo-6-methyl-2-pyrone 106 and then use various phenols as 
the coupling partners.  Unfortunately, despite the successful use of 4-bromo-6-methyl-2-
pyrone 106 in various cross-couplings by Fairlamb et al.,Error! Bookmark not defined. this 
methodology is not feasible for the synthesis of the natural product due to the required 
coupling partner. So, in the synthesis of phacelocarpus 2-pyrones, the coupling partner 
required would be an enol which would be found predominately as a ketone, the more 
stable tautomer. 
 
2.2.6 Synthesis of functionalised vinyl ethers 
 
The failure of Hartwig etherification reactions with regards to the synthesis of 
pyronyl ethers rendered the originally planned RSA obsolete.  In order for a new RSA to 
be prepared, it is logical to first identify a suitable method for the introduction of the vinyl 
ether.  
An alternative route is via the introduction of a suitable moiety which could then be 
functionalised further.  One suitable motif is a terminal vinyl ether which could be used to 
undergo cross metathesis or an intermolecular Heck reaction.  Two vinyl ethers were 
synthesised to develop methodology for these reactions; a natural product analogue (110) 
and also a simple vinyl ether with no substituents (113).  Compound 109 was synthesised 
through the selective tosylation of butane-1,2-diol (107), followed by a Mitsunobu reaction 
with 4-hydroxy-6-methyl-2-pyrone (9) (Scheme 2.19).  
OH
OH
OTs
OH
TsCl, TEA, DCM
20 °C, 16 h
(80%) DIAD, PPh3, DCM
20 °C, 16 h
(95%)
O
O
O
OTs107 108 109
O
O
HO
9
 
Scheme 2.19: Synthesis of 109. 
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The resultant product was subjected to various elimination conditions, utilising 
organic bases such as MTBD and DBU to avoid hydroxide-mediated decomposition of the 
2-pyrone, to generate the desired product 110 (Table 2.7).  Initial studies using MTBD as 
the organic base showed no elimination (entry 1), however, with the addition of NaI the 
reaction gave a reasonable yield (entries 2 and 3).  Changing the base to DBU resulted in 
an excellent yield (entry 4).  Further variations in time and temperature failed to give rise 
to any improvement in yield. (entries 5-9). 
 
Table 2.7:  Tosylate elimination reaction optimisation. 
109
OTs
O
O
O
O
O
O
Base
110
(See table for conditions)
 
Entry Solvent Base eq. NaI Temp (°C) Time (h) Yield (%) 
1 Toluene MTBD - 85 16 0 
2 Toluene MTBD 3 85 16 52 
3 DME MTBD 3 85 16 40 
4 DME DBU 3 85 16 89 
5 Acetone DBU 3 50 16 49 
6 DME DBU 3 85 3 30 
7 DME DBU 3 8 48 0 
8 DME DBU 3 85 4 50 
9 Acetone DBU 3 8 48 0 
 
The vinyl analogue (113), which does not contain the ethyl side chain featured in 
the natural product, was subsequently obtained via the same route except commercially 
available 2-bromoethanol was utilised.  In the final elimination reaction, the conditions 
utilised yielded a much lower quantity of product (Scheme 2.20).  This has since been 
attributed to the formation of the vinyl ether in good yield, followed by the degradation of 
the product under the conditions employed.  
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9
DIAD, PPh3, THF
20 °C, 16 h
(82%)
O
O
HO O
O
O
O
O
O
Br
DBU, NaI, DME
85 °C, 16 h
(47%)OH
Br
111
112 113
 
Scheme 2.20: Synthesis of 111 
 
Compounds 110 and 113 were then screened unsuccessfully against a range of 
cross-metathesis conditions utilising various catalysts, temperatures and solvents (Scheme 
2.21). 
O
O
O
R
Br
Br
O
O
O
R
+
Ru Catalyst
R = Et (110)
R = H (113)
X
86 R = Et (114)R = H (115)
(see Appendix 1.2 
for full details)
 
Scheme 2.21: Cross metathesis reactions of 110 and 113.  
 
The electron deficient nature of the vinyl ether, combined with the 1,1-disubstituted 
motif of 110, results in poor viability towards cross-coupling despite the use of high 
temperatures and the most active catalysts.92  
Due to the poor reactivity of the substrates in the alkene metathesis reaction, 
compound 110 was subsequently tested towards an intermolecular Heck reaction with 
iodobenzene (Scheme 2.22).  Previous work by Nilsson et al. showed that vinyl ethers are 
susceptible to Heck reactions, particularly at the electron rich position adjacent to the 
oxygen atom although secondary reactions also occurred at the terminal positions once the 
α-position was blocked.93  Similar conditions were adopted for the synthesis 108, utilising 
various sources of catalytic Pd at high temperatures. However, no reaction at the vinyl 
ether was observed and most of the starting material was found to have decomposed. 
O
O
O
PhI, cat Pd, PPh3, 
DMF, 100 °C, 16 h
(Degradation of S.M.
only)X
O
O
O
Ph
110 116
 
Scheme 2.22: Heck reactions of 110. 
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Although this reaction cannot be applied to the total synthesis, the degradation of 
the vinyl ether motif above 100 °C gives an insight into the stability of the natural product, 
and allows any routes demanding high temperatures to be ruled out of any future synthesis. 
During the synthesis of alkene 110, an alternative route was studied via a two step 
process.  Initially, the 4-hydroxy-6-methyl-2-pyrone 9 was reacted with propionyl chloride 
117 to generate 118, which could subsequently undergo a Tebbe reaction to give 110 
(Scheme 2.23). 
O
O
O
O
O
OO
O
O
HO
O
Cl (89%)
Tebbe reagent
pyridine, THF
-40 to 20  °C, 4 h
X+
TEA, DCM, 
25 °C, 2 h
117 1101189
 
Scheme 2.23: Tebbe route to 110. 
 
Although Tebbe conditions proved unsuccessful, work by Takai et al. showed that 
1,1-dibromo alkanes were able to undergo a modified Tebbe reaction to generate 
functionalised  vinyl ethers, with good selectivity towards esters.94  This reaction was 
attempted to discover if the reaction presented a feasible route to functionalised vinyl 
ethers.  Unfortunately no selectivity towards the external ester was observed, and 
degradation of the starting material proved to be prolific (Scheme 2.24). 
O
O
OO
119
X
Br
Br
O
O
O
TiCl4, Zn, TMEDA
118
 
Scheme 2.24: Modified Tebbe reaction. 
 
The poor reactivity of the terminal alkenes suggested the need to develop a vinyl 
ether which would provide a better handle for further reactions.  Work by Zhou et al. 
reported that under basic conditions, relatively acidic alcohols such as phenols can act as 
nucleophiles towards terminal alkynes to generate vinyl ethers.95  The use of this type of 
chemistry can be envisaged in the synthesis of the natural product.  Preliminary 
investigations focused on screening phenyl acetylene 120 against various bases to develop 
conditions which would be compatible with 4-hydroxy-6-alkyl-2-pyrones (Scheme 2.25).  
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XO
O
HO
Ph
O
O
O
Ph
+
Base
9 120 121
(see Appendix 1.3 
for full details)
 
Scheme 2.25: Nucleophilic addition of 9 into 120. 
  
The reaction of 9 with 120 proved to be unsuccessful despite the use of a range of 
organic and inorganic bases, high temperatures and extended reaction times.  The most 
likely reason for poor reactivity is due to the nature of the intermediate when using phenyl 
acetylene (120).  The deprotonated alcohol attacks the alkyne, which subsequently 
abstracts the proton back from the conjugate base to generate the alkene. However the 
choice of EWG is important due to the reversible nature of the initial attack (Scheme 
2.26).  If the carbanion intermediate is not stabilised then the equilibrium of the first step 
will lie far to the left and very little reaction will occur.  
O
O
O
EWG
O
O
O
EWG
Base-H
Base-H
O
O
O
EWG
 
Scheme 2.26: Mechanism for the addition of 9 to a terminal alkyne. 
 
Although an aromatic ring is able to stabilise the carbanion to an extent, it appears 
the intermediate requires a much greater degree of stabilisation.  In order to greatly 
stabilise a carbanion, a mesomeric form must be available whereby the charge is 
transferred to a more electrophilic atom.  The choice of substrate for this reaction was an 
alkynoate.  The reaction could then be expected to proceed in a Michael type reaction to 
form an allenolate intermediate which places the charge on the oxygen and greatly 
improves the chance of reaction.  This reaction quickly proved to be successful under both 
thermal and microwave conditions, with an optimum yield obtained after 16 hours at reflux 
(Table 2.8). 
 
Table 2.8: Optimisation of the synthesis of 121. 
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O
O
HO
O
O
O
O
MeO
O
MeO
TEA, DCM
+
122 9 123
(see table for details)
 
Entry Temperature (°C) Time  (h) Yield (%) 
1 20 2 48 
2 20 16 63 
3 45 16 82 
4 80 (mw) 0.5 67 
 
The ester group present in 123 also presents a useful handle for further steps. 
Hydride reduction of the ester would present allylic alcohol 124 (Scheme 2.28).  
O
O
O
O
MeO
O
O
OHO
Hydride
123 124
 
Scheme 2.27: Possible transformation of 121 to allylic alcohol 122. 
 
The generation of an allylic alcohol (124) would then be suitable to be used directly 
in a Suzuki cross-coupling with a vinyl boronic acid, as reported by Tsukamoto et al. or 
alternatively can be converted into an allylic halide for use in further Pd-catalysed cross-
couplings. 96  The incorporation of this sub-unit can now provide a platform to re-evaluate 
the original RSA. 
 
2.3 Revised RSA and synthesis 
 
2.3.1 Revised RSA 
 
The revised RSA utilises most of the same disconnections as were suggested 
originally, and also involves the same AB fragment (45) previously synthesised.  The key 
difference is the incorporation of the allylic/vinylic coupling generated by disconnection II 
(Scheme 2.28) and the resulting fragment E formed as a result of the Michael addition 
previously shown to provide a means of forming the vinyl ether.  The appropriate coupling 
partner to perform both a Sonogashira reaction and a vinylic/allylic coupling can now be 
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envisaged as the novel fragment F, which would contain all of the cis-alkenes required in 
the natural product. 
O
O
O
O
O
O
+
33
O
O
O
Br
O
O
O
X
B
OH
O
O
Sonogashira
Suzuki-Miyaura
Reduction
Fragment E
125
O
O
HO
O
O
+
Fragment F
AB Fragment
45
III
I II
EtO
O
EAB Fragment
 
Scheme 2.28: Revised RSA of 33. 
 
A proposed forward synthesis will now utilise the previously synthesised AB 
fragment (45) in a Michael addition onto the commercially available alkynoate 127, 
followed by hydride reduction to the allylic alcohol 127, generating the advanced EAB 
fragment.  The original example of a Michael addition of a 4-hydroxy-6-methyl-2-pyrone 
(9) to an alkynoate was performed on a terminal alkyne, however the natural product 
requires the inclusion of an ethyl side chain.  In order to include this side chain, it is 
necessary for the Michael addition to be performed on alkynoate 125 which already 
contains the desired ethyl unit (Scheme 2.29).  The addition of this ethyl side chain will 
sterically restrict the access of the nucleophilic 2-pyrone to the alkyne in order for the 
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reaction to occur, and as a result will require development of the original methodology to 
account for the increased complexity. 
O
O
O
O
O
HO
TEA
DIBAL
44 126 127
EtO
O
125
OH
EAB Fragment
O
O
OEtO
O
 
Scheme 2.29: Proposed synthesis of the advanced EAB fragment (127). 
 
The next step would require the cross-coupling of 127 with the novel fragment F.  
The synthesis of fragment F can be envisaged via a five step procedure to form the desired 
vinyl boronic acid pinacol ester 133 (Scheme 2.30).  
cat. Pd
HO OH HO OTBDMS TfO OTBDMS
OTBDMSOTBDMSPinB
OTBDMS
BPin
Li
TBDMS-Cl
LDA
PinB O
Lindlar / H2
O
O
O
O
O
O
OTBDMS
128 129 130
131132
133
134
127
Fragment F
Tf2O
OH
 
Scheme 2.30: Proposed forward synthesis and use of fragment F. 
 
The Pd-catalysed reaction with the allylic alcohol dictates that the additional allylic 
group on fragment F cannot be either a halide or acetate due to their receptivity towards 
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Pd(0).  The choice of a silyl protected alcohol allows a simple deprotection followed by 
conversion to triflate or halide for the macrocyclisation. 
 
2.3.2 Synthesis of EA and EAB fragments 
 
The steric influence of the 6-alkyl chain required for the natural product, increases 
the complexity of the Michael addition.  It is therefore important to optimise the conditions 
with simple analogues such as 9 as opposed to wasting valuable intermediates.  An 
important factor in the choice of analogue is that the chemical environment of the reacting 
group mimics that of the parent compound as closely as possible.  In this case, the most 
important factor is the pKa of the alcohol, although steric influence may also play a part. 
 The mechanism of this reaction requires deprotonation of the alcohol, so it is 
important that the pKa of the two alcohols are similar.  Using pKa prediction software it is 
possible to compare the two 2-pyrones to assess the suitability of the chosen mimic. 
Although the prediction software cannot be assumed to be entirely accurate, it is possible 
to compare known values to judge the error.  The prediction shows that the extended 
aliphatic chain has little influence on the acidity of the alcohol, which combined with the 
large difference between the pKa of protonated bases such as HN+Et3 indicates that 9 is a 
suitable analogue on this occasion.  
O
O
HO
O
O
HO
pKa (calc.)= 5.03
Actual (H2O) = 4.94 pKa (calc.)= 5.12
9 45
 
Figure 2.2: pKa predictions of alcohol in compounds 9 and 45.97 
 
The effect of C-6 functionalisation on the pKa of 4-hydroxy-2-pyrones appears to 
be minimal when functionalisation is limited to non-conjugated systems.  At this point, the 
benchmark reaction with methyl propiolate (122) was tested against various C-6 
functionalised 4-hydroxy-2-pyrones (Table 2.9). 
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Table 2.9: Michael additions of C-6 functionalised 4-hydroxy-2-pyrones with 122. 
O
MeO
O
O
HO R
O
O
O
O
MeO R
+
122
DCM, TEA,
45 °C, 16 h
 
Entry Starting Material Product Yield (%) 
1 
O
O
HO
 
96 
O
O
O
O
MeO
 
135 
86 
2 
O
O
HO Ph
 
90 
O
O
O
O
MeO Ph
 
136 
68 
3 
O
O
HO
 
95 
O
O
O
O
MeO
 
137 
64 
4 
O
O
HO
TIPS
 
44 
O
O
O
O
MeO
TIPS
 
138 
82 
 
The reaction proceeded well with all of the variations, but particularly encouraging 
is the 82% yield of 135, which can be seen as an ethyl side chain deficient analogue of the 
advanced EAB fragment 126.  Now with the confirmation that C-6 modified 4-hydroxy-2-
pyrones will react in a similar fashion to the simpler system utilising 9, the incorporation of 
the ethyl side chain must be addressed. 
Preliminary investigations into the Michael addition of 9 onto an internal alkyne 
utilised a methyl side chain as opposed to the desired ethyl side chain in order to first 
generate conditions for the slightly simpler system. 
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Table 2.10: Optimisation of Michael addition between 9 and 139. 
O
O
HO
+ EtO
O
O
O
O
O
EtO
9 139 140
 
Entry Solvent Base 
Eq. 
Base 
Additive 
Mol % 
Additive 
Temp 
(ºC) 
Time 
(h) 
Yield 
(%) 
1 DCM TEA 1 - - 40 1 0 
2 DCM TEA 1 - - 80 (mw) 1 ~1 
3 DCM DBU 2 - - 90 (mw) 1 4 
4 THF DBU 1 BF3 20 90 (mw) 2 18* 
5 DCM DBU 1 BF3 20 80 (mw) 2 6* 
6 THF DBU 1 BF3 20 80 (mw) 2 24* 
7 THF TEA 1 BF3 20 80 (mw) 2 5* 
8 THF DBU 1 Yb(OTf)3 20 80 (mw) 2 13 
9 THF DBU 1 BF3 20 70 16 22* 
10 THF DBU 1 BF3 6 80 (mw) 2 19* 
11 THF DBU 1 BiPr3 20 80 (mw) 2 17 
12 DCM TEA 1 CuI 10 80 (mw) 1 29 
13 THF DBU 1 CuI 10 40 16 29 
14 THF DBU 1 CuI 10 80 (mw) 2 26 
15 THF DBU 0.1 CuI 10 80 (mw) 3 0 
16 THF DBU 0.2 CuI 10 80 (mw) 6 30 
17 THF DBU 0.66 CuI 10 80 (mw) 0.5 43 
18 THF DBU 0.66 CuI 10 40 16 7 
19 THF DBU 0.66 
CuI / 
BiPr3 
10 / 20 80 (mw) 0.5 9 
20 THF NaH 1 - - 20 5 0 
21 THF NaH 1 - - 40 5 0 
22 THF NaH 1 - - 70 5 0 
23 THF NaH 1 CuI 10 70 5 0 
*
 Large amounts of 2-pyrone degradation observed 
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As expected, the use of an internal alkyne severely affects the reactivity of the 4-
hydroxy-2-pyrone towards the alkyne.  Utilising the same conditions as previously used for 
the terminal alkyne yielded no product.  The rationale for the lack of reactivity was 
attributed to a combination of the restricted access to the alkyne, but also a poor 
nucleophilic character displayed by the 2-pyrone.  By altering the base to the stronger and 
more bulky DBU, the degree of charge formed on the 2-pyrone 9 is increased, due to the 
increased distance between itself and the counterion.  The nucleophilicity would now be 
enhanced, however this again proved to be too little to affect a substantial increase in yield 
(entry 3).   
The use of additives in Michael additions is well documented, most commonly 
using a Lewis acid to activate the carbonyl and subsequently withdraw electron density 
from the point of nucleophilic attack.98  The introduction of BF3 as a Lewis acid greatly 
improved the reaction yield, however large amounts of 2-pyrone degradation was also 
noticeable (entries 4-7, 9-10).  The use of weaker Lewis acids such as BiPr3 and Yb(OTf)3 
promoted the reaction to a lesser degree, although the amount of 2-pyrone degradation was 
noticeably smaller (entries 8 and 11).  The use of Lewis acids to remove electron density 
from the alkyne shows that this is a feasible way of increasing reactivity. Copper(I) iodide 
is known to bind to alkynes, and is used in the Sonogashira cross-coupling for this 
purpose.99  In binding to the alkyne the copper(I) removes electron density, thereby making 
it more susceptible to electrophilic attack.  The use of copper(I) iodide as an alternative to 
a Lewis acid was then tested and was shown to increase the yield under similar conditions 
(entries 12-14).  
The high polarity of 2-pyrone 9 means that it is often only partially soluble in 
organic solvents such as DCM and THF until an organic base is introduced.  On repetition 
of these reactions, it was noted that complete solubility occurred at precisely 0.66 
equivalents of base. The use of sub-stoichiometric quantities of base was then tested and 
proved that the observed solubility point was also the optimum amount of base, 
culminating in a yield of 43% (Entry 17).  
The yield of 43% represented a vast improvement, however for use in the natural 
product synthesis a yield above 60% would be desirable.  The introduction of the same 
vinyl ether motif is also accessible via a substitution reaction utilising a vinyl iodide or 
triflate such as 141.  
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O
EtO
AcOH, LiI, 70 oC, 5 h
(86%)
139
O
O
HOO
EtO I
O
O
OEtO
O9
141 140
DMF, NaH, 70 oC
(25-43%)
(See Appendix 1.4 for full details)
 
Scheme 2.31: Synthesis of 140 via vinyl iodide 141. 
 
The coupling of 2-pyrone 9 and organoiodide 141 proceeded poorly despite the use 
of a variety of solvents, bases, temperatures and extended reaction times (Scheme 2.31).  
The reaction would only proceed in the presence of an iodide trap such as AgNO3, 
affording the desired product in a variable yield.  The major problem with this reaction is 
the reversibility of each step, and the generation of a quaternary centred intermediate.  The 
quaternary intermediate can eliminate either the iodide or the 2-pyrone, however due to the 
large steric bulk of the 2-pyrone, the initial addition is unlikely to occur.  The 2-pyrone is 
also able to delocalise the charge throughout the molecule making it more stable and thus a 
better leaving group than the iodide (Scheme 2.32). 
O
O
O
O
EtO I
O
O
OEtO
OO
O
OEtO
O I
 
Scheme 2.32: Substitution reaction mechanism. 
 
The addition of silver nitrate to irreversibly bind any free iodide made it possible to 
slowly drive the reaction forwards and generate the desired product, however the reaction 
proved to be unreliable and results varied.  The best result obtained using this approach 
only matched the 43% achieved through the direct Michael addition to the alkynoate.  The 
more challenging ethyl 3-pentynoate (125) was subjected to the optimised Michael 
conditions in order to generate the required ethyl side chain present in the natural product.  
Unfortunately, this proved to further reduce the activity and no product formation was 
observed.  
O
O
HO
O
EtO
O
O
OEtO
O
+
CuI (0.1 eq.), DBU (0.66 eq.)
THF, 80 °C (mw), 0.5 h
X
125 9 142
 
Scheme 2.33: Michael addition of 9 into 125. 
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The inclusion of the ethyl side chain is seen to shut down all reactivity, most likely 
due to the inaccessibility of the alkyne towards the incoming nucleophilic 4-hydroxy-2-
pyrone (Scheme 2.33).  In order to try and increase the accessibility of the desired β-
carbon it was hypothesised that using an allenoate may provide a better platform for 
addition, with the β-carbon now at the centre of the more accessible allene and therefore 
more susceptible to nucleophilic attack.  The intermediate formed can be envisaged to then 
react in one of two ways; firstly by re-eliminating the 2-pyrone, or alternatively by 
rearrangement and subsequently abstracting the proton from the conjugate base at the γ-
carbon to generate the desired product (Scheme 2.34).  Despite the equilibrium for the first 
step, the formation of the product would likely be an irreversible reaction and therefore 
drive the reaction forwards.    
• Me
O
EtO
O
O
O
+
O
O
O
O
EtO
Base
H
H-Base
O
O
O
O
EtO
 
Scheme 2.34: Proposed reaction pathway for nucleophilic attack of an allenoate.  
 
 Allenoate 144 was prepared via a one pot-two step Wittig/elimination reaction of 
phosphorane 143 with propionyl chloride (117), to generate the desired product and also 
the alkynoate 125 in similar yield (Scheme 2.35). 
EtO
O
PPh3 +
Cl
O
EtO
O
+
• Me
O
EtO
TEA, DCM
 22 °C, 18 h
125
(27%)
143 144
(29%)
117
 
Scheme 2.35: Synthesis of 144. 
 
The subsequent reaction of 9 with allenoate 144 does not occur at all, with 
complete recovery of 9, despite the use of elevated temperatures and a Lewis acid additive 
to encourage the initial step of the reaction (Scheme 2.36). 
• Me
O
EtO
O
O
HO
O
O
OEtO
O+
9 144 142
Base
(See Appendix 1.5 
for full details)
X
 
Scheme 2.36: Michael Addition of 9 with allenoate 144. 
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At this point the synthesis of an ethyl side chain deficient analogue (145) of the 
natural product was considered to test the feasibility of the remaining steps in the proposed 
synthesis. 
O
O
O
145 (Analogue)
O
O
O
33 (Target)
 
Figure 2.3: Natural product 33 and modified analogue 145. 
 
The next step in the proposed synthesis involves the hydride reduction of the α,β-
unsaturated ester into the allylic alcohol.  The results of the hydride reduction of 123 are 
shown in Table 2.11. 
 
Table 2.11: Hydride reduction of 123. 
O
O
OMeO
O
121
O
O
OHO
"H  "  (2 eq.)
122
(See Table for details)
 
Entry Hydride Source Solvent Temperature Yield 
1 LiAlH4 Ether -78 °C 0* 
2 DIBAL-H DCM -78 °C 30* 
3 DIBAL-H Ether -78 °C 17* 
4 L-Selectride THF -78 °C 0† 
5 NaBH4 Ether -20 °C 0† 
*Complete consumption of 121 observed by TLC analysis. 
†Reaction yielded >95% 4-hydroxy-6-methyl-2-pyrone 9. 
 
The hydride reduction of 123 gave low yields with a number of hydride sources 
with varying degrees of strength.  It is noticeable that within the structure of 123 there are 
three positions at which hydride is able to attack (Fig. 2.4).  Firstly, when utilising softer 
sources of hydride such as selectride and borohydride, the desired product was not formed.  
 52 
Instead, the leaving group properties of the 2-pyrone encourage Michael substitution 
through hydride attack at the β-carbon and subsequent elimination of the 2-pyrone.  
O
O
OMeO
O
Soft hydride 
source e.g. NaBH4
Hard hydride 
source e.g. LiAlH4
 
Figure 2.4: Sites of hydride attack on 123. 
 
Alternatively, when using harder sources of hydride such as LiAlH4 and DIBAL-H 
the hydride attacks the carbonyl positions of both the unsaturated ester and the 2-pyrone. 
The subsequent 30% yield observed using can be attributed to a near statistical distribution 
of products where each equivalent of hydride has reacted unselectively . 
  In order to improve the selectivity of the reduction, the reactivity of the ester and 
2-pyrone carbonyls need to be better differentiated.  One way of approaching this is to 
provide a better leaving group than methoxide to encourage a more facile attack from a 
weaker hydride source.  The use of fluorinated esters is known to promote hydride 
reduction,100 and with this in mind, pentafluorophenyl (PFP) propiolate (146) was utilised 
in the Michael addition with both compounds 9 and 44 (Scheme 2.37).   
O
O
O
PFPO
O
O
O
O
PFPO
O
Si
HO
O
O
HO
O
O
Si
TEA, DCM, 45 °C, 16 h
(27%)
PFPO
O
As Above
(37%)
9
44 148
147
146
 
Scheme 2.37: Michael additions of 9 and 44 with fluorinated ester 146. 
  
The yields of the Michael addition appear to be heavily influenced by the ester.  In 
this case, the PFP ester proves to be a relatively poor match for the addition of 4-hydroxy-
6-methyl-2-pyrone derivatives.  However, despite the lower yields in the Michael addition, 
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it is important to test whether the variation of the ester affects the subsequent hydride 
reduction.  The PFP ester 147 was subjected to both DIBAL-H and NaBH4, though in each 
case the yields mimicked those seen previously with the methyl ester derivative 123 
(Scheme 2.38). 
9
123
147
O
O
O
PFPO
O
O
O
O
HO
DIBAL-H (2 eq.), DCM,
 -78 to 20 °C, 3 h
(30%)
O
O
O
PFPO
O
HO
O
O
NaBH4 (2 eq.), THF, 
-20 to 20 °C, 3 h
(15% + 82% RSM)
147
 
Scheme 2.38: Hydride reduction of 147. 
 
The continued poor selectivity for the reduction of the α,β-unsaturated ester versus 
the 2-pyrone suggest that this approach is not appropriate for this system.  In order to 
differentiate better it is feasible that a BH3 reduction of an acid would allow complete 
selectivity in the formation of the allyl alcohol.  The Michael addition was then performed 
using tert-butyl propiolate 149 with 9 to yield 150 in a respectable 61% yield.  Subsequent 
treatment of 150 with TFA to yield the desired acid 151, however the following BH3 
reduction of the acid failed to generate any allyl alcohol 123 (Scheme 2.39). 
O
O
O
O
O
O
O
O
HO O
O
O
HO
O
HO
O
O
O
O
+
X
TFA, THF, 
20 °C, 0.5 h
(86%)
BH3, THF, 
20 °C, 16 h
TEA, DCM, 
45 °C, 16 h
(61%)
149 9 150
151123
 
Scheme 2.39: Hydride free approach to 123. 
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The 1H NMR spectroscopic analysis of crude material from the borane reduction 
shows the absence of the alkene signals from the α,β-unsaturated ester, suggesting that 
hydroboration of the alkene has occurred in preference to the reduction of the acid. No 
conclusive proof was isolated from the crude reaction mixture. 
The continuing poor selectivity shown in generating a 2-pyrone bound allyl 
functionality suitable for cross-coupling indicates that the current synthetic strategy is 
flawed.  However, the possibility of cross-coupling vinylic and allylic groups to generate 
the skipped 1,4-diene motif allows two different approaches to be studied, with the pyronyl 
substrate able to provide the allylic or vinylic unit.  The current study has shown that the 2-
pyrone fragment does not easily provide access to the allylic fragment, however it is 
possible that the 2-pyrone can instead provide the vinylic substrate for cross-coupling 
(Scheme 2.40). 
O
O
O
X
B O
O
R
O
O
O
R+
O
O
O
O
O
O
R+
HO
cat. Pd
cat. Pd
B O
OR
 
Scheme 2.40: Two Pd-mediated approaches to a skipped 1,4-diene. 
 
In order to test the feasibility of using the 2-pyrone bound vinyl halide for cross-
coupling, a simple analogue was developed.  The earlier synthesised 113 was treated with 
bromine to generate a dibromide (152) which subsequently underwent an elimination 
reaction to generate the vinyl bromides E/Z-153 (Scheme 2.41). 
O
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O
Br
O
O
O
Br
Br
O
O
O
O
O
O
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+
Br2, DCM
-78 °C, 3 h
(80%)
(~60%) (17%)
113 152 E-153 Z-153
DBU, THF
80 °C, 16 h
 
Scheme 2.41 Synthesis of vinyl bromide 153. 
 
The synthesis of vinyl bromide 153 is not an efficient route due to the lack of 
stereo-selectivity observed.  The initial bromination works in good yield, however the C-3 
position of the 2-pyrone core is also susceptible to attack from bromine, and it was noted 
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(via 1H NMR) that some material was brominated at this position, although no isolation 
was possible due to the decomposition of all material on silica.  As a result, the impurity 
was carried forwards into the elimination reaction.  The elimination reaction works well 
with selective elimination of the secondary bromide to yield both cis and trans-isomers of 
the desired vinyl bromide.  Unfortunately, the desired bromide E-153 was never isolated 
cleanly, due to the presence of a second inseparable product.  The identity of this impurity 
has not been proven, although the mass spectrum of the mixture showed only one ion 
present (m/z = 231/233), indicating an elemental composition identical to that of E-153.  It 
is suspected that the impurity stems from the C-3 brominated material carried through from 
the initial bromination reaction. 
Although no tests could be run on E-153, the cis-bromide (Z-153) was isolated and 
subjected to Suzuki reaction conditions (Table 2.12). 
 
Table 2.12: Suzuki cross-couplings of vinyl bromide Z-153 with boronic acids. 
Z-153
O
O
O
Br
cat. Pd, Na2CO3(aq), 
THF, 70 °C
(see Table for details)
R B(OH)2+
O
O
O
R
 
Boronic acid 
Pd 
source 
Mol% 
Pd 
Product 
Time 
(h) 
Yield 
(%) 
 
B(OH)2
 
57 
Pd2(dba)3 
/ PPh3 
5 
O
O
O
Ph
 
154 
2 60 
 
B
O
O
 
155 
Pd2(dba)3 
/ PPh3 
5 
O
O
O
 
156 
4 10 
B
O
O
 
155 
CatCat 
E-27 
5 
O
O
O
 
156 
4 59 
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In each reaction it was noted that complete retention of stereochemistry occurred. 
The natural product 33 requires trans stereochemistry at the vinyl ether, however the 
retention of stereochemistry from the unfavoured cis-adduct Z-153 indicates that the 
reaction will always proceed with retention of stereochemistry. 
The success of utilising vinyl bromide Z-153 in Suzuki cross-couplings to generate 
skipped 1,4-dienes, particularly using the previously studied palladium complex E-27, now 
offers a second route to forming the problematic left hand side of the natural product. 
 
2.3 Further revised RSA and forward synthesis 
 
2.3.1 Revised RSA 
The new disconnection occurs adjacent to the vinyl ether, reversing the vinylic and 
allylic positions seen in the previous route and generates fragment G (158) and the 
advanced HAB (157) fragment. 
In addition to this RSA the alternative macrocycle forming disconnection can be 
made across a double bond to yield the two fragments HAB′ (159) and I (160), suitable for 
RCM.  Both of these routes can easily be followed in parallel (Scheme 2.42). 
+
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O
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BPin
X
Fragment G
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O
O
O 1. Suzuki-Miyaura
2. Sonogashira
O
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O
O
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2. RCM
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Route B
157
33
33
158
159
160
I
II
III
I
 
Scheme 2.42: Disconnections for routes A and B.  
(Note: Fragments containing B′ refer to the 1,4-enyne system) 
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The revised synthesis for route A requires the synthesis of novel fragment G (158) 
which can easily be accessed via a similar route to that of fragment F (133).  By utilising 
the intermediate 130, the reaction with propargyl alcohol in the presence of copper(I) 
iodide and base will generate 161 (Scheme 2.43).  The reaction of 161 with Lindlar 
catalyst will then generate allylic alcohol 162 which can be converted to the boronic acid 
pinacol ester via conversion to a halide or triflate followed by a Miyaura borylation to 
generate a silyl protected fragment G (163).101 
 
OTfTBDMSO CuI, K2CO3, NaI
OH
TBDMSO
OH
Lindlar / H2
TBDMSO OH
2. cat. Pd, PinB-BPin
Base
TBDMSO BPin
161
162163
130
46
1. Tf2O
 
Scheme 2.43: Proposed synthesis of fragment G. 
 
The revised synthesis for route B can utilise the previously synthesised AB′ 
fragment (95) thereby circumventing the requirement for a silyl protection of the terminal 
alkyne.  Conversion to the proposed HAB′ fragment (159) and subsequent reaction with 
fragment I (160) would rapidly generate a substrate suitable for ring closing metathesis.  
Fragment I (160) can be accessed utilising allylic borylation methodology, developed by 
Aggarwal and co-workers, with the previously synthesised compound 48 (Scheme 
2.44).102   
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Scheme 2.44: Proposed synthesis of HAB′ fragment. 
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The generation of the vinyl bromide will present the largest challenge for the 
synthesis via the new route, as fragment H is not available directly, but will be accessed 
via various transformations once bound to the 2-pyrone (Scheme 2.45).  The preliminary 
studies will focus on generating a 2-pyrone-bound aldehyde.  The aldehyde can then be 
converted to a 1,1-dibromide which will subsequently undergo an elimination reaction to 
generate the desired vinyl bromide. 
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X
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Scheme 2.45: RSA of vinyl halide. 
 
2.5.2 Synthesis of the HA fragment (176) 
 
The synthesis of the HAB fragment (157) will first rely on adequate methodology 
developed on the simpler HA fragment. 
The planned synthesis of the HA fragment requires the formation of an aldehyde 
bound to the 2-pyrone.  Once the aldehyde is incorporated, it is possible to convert the 
carbonyl to a dibromide, with subsequent elimination of one bromide to generate the 
desired vinyl bromide.  Alternatively, it is possible to use the conditions discussed by 
Spaggiari et al. to generate the vinyl bromide directly (Scheme 2.46).103 
O
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O
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PBr5 Base
P(OPh)3, Br2, NEt3
  
Scheme 2.46: Conversion of an aldehyde to a vinyl bromide. 
 
There is literature precedent for the introduction of alkyl groups onto the alcohol of 9 
through a simple substitution reaction with alkyl bromides.104  A substitution reaction of α-
halobutyraldehyde with 9 was attempted to create the desired aldehyde, although this 
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proved to be unsuccessful under various conditions, with none of the desired product 
formed (Scheme 2.47).  
 
O
O
HO
+ O
X
O
O
O
O
Base
9 165
(see Appendix 1.6 
for full details)
 
Scheme 2.47: Substitution reaction of 9 with α-halobutyraldehyde. 
 
Initial attempts focused on using organic bases to assist the substitution reaction, 
however a quantitative amount of 9 was always recovered.  The poor reactivity was 
attributed to an elimination reaction of the α-halobutyraldehyde occurring in preference to 
the substitution reaction. In order to prevent this side reaction, sodium hydride was used to 
pre-form a 2-pyrone salt which would be unable to act as a base to perform the elimination 
reaction.  Unfortunately, this proved ineffective and no product was formed despite 
extended reaction times.  
Previous work with 4-hydroxy-6-methyl-2-pyrone (9) had provided excellent yields 
when subjected to Mitsunobu conditions, and the introduction of the aldehyde was 
therefore planned via a Mitsunobu reaction of 1-penten-3-ol with 4-hydroxy-6-methyl-2-
pyrone, followed by an ozonolysis of the terminal alkene to generate the desired aldehyde.  
 
Table 2.13: Mitsunobu reactions of 9 and 164. 
O
O
HO
+
OH
O
O
O
DIAD, PPh3, THF
0 - 20 °C, 16 h
9 166 167
 
Eq. of 
PPh3/DIAD/164  
Yield (%) 
1.0 12 
1.5 17 – 32* 
2.0 28 
*Reaction yield varied across five runs. 
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1-Penten-3-ol (166) proved to be a poor substrate for the reaction with variable 
yields obtained, and no yields of an adequate level have been achieved.  In each case, large 
quantities of unreacted 9 were recovered. 
Previous work with 1,2-butanediol had shown it was possible to selectively protect 
the primary alcohol and then utilise the secondary alcohol for Mitsunobu coupling to 9 
(Scheme 2.19).  By utilising the same methodology, a new approach to the aldehyde was 
suggested (Scheme 2.48). 
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Scheme 2.48: Proposed route to 165. 
 
The first two steps of the reaction proceeded in excellent yields to generate a silyl 
protected alcohol (169).  It was then predicted that a simple deprotection and oxidation 
would lead directly to the desired aldehyde 165.  The initial deprotection strategy was to 
use TBAF as a source of fluoride.  The deprotection step gave excellent conversion, 
however upon isolation, two products had been generated.  The 1H NMR spectroscopic 
analysis confirmed that a rearrangement of the diol had occurred under the conditions used 
(Scheme 2.49). 
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TBAF, THF, 
20 °C, 2 h
(30%) (66%)
169 170 171
   
Scheme 2.49: TBAF deprotection of 169. 
 Figure 2.5: 1H NMR spectrum of 171 with emphasis of the diagnostic peaks. 
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Figure 2.6: Overlay of observed 1H NMR (top) and gNMR simulation (bottom) signals for 
diagnostic peaks of 171. 
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The 1H NMR spectra of the two products differ only very slightly, however the key 
diagnostic signals are those directly adjacent to the alcohols on the 1,2-butanediol.  The 
electron-withdrawing effect of the 2-pyrone means that the protons on the carbon adjacent 
to the 2-pyrone ring will be more deshielded than those adjacent to the hydroxyl group.  In 
the case of the TBAF deprotection, the major product showed two multiplet signals 
observed at δ ~3.7 and ~3.9 correlating to one and two protons, respectively.  This 
corresponds with the shifts expected for 171.  The multiplets can be explained due to the 
presence of the chiral centre adjacent to the alcohol.  The two protons in an adjacent CH2 
group are no longer equivalent, and as such will couple to each other and also the adjacent 
CH, thereby introducing increased complexity in the 1H NMR spectrum of 170.   
The minor product also produced an interesting 1H NMR spectrum.  The two 
diagnostic signals were observed at chemical shifts of δ 3.75 and δ 4.3 corresponding to 
two and one protons’ respectively.  The single proton is now the more deshielded proton 
and therefore adjacent to the 2-pyrone as in 170.  This proton is also discernible as an 
indistinct quartet of doublets, indicating that three of the four adjacent protons have 
equivalent coupling values.  The apparent multiplet corresponding to the ‘CH2OH’ group 
can be seen as an overlapping of the two diastereotopic protons, each a doublet of doublets, 
which as a result leads to the second order effects observed (Fig. 2.5). 
By utilising the NMR simulation program ‘gNMR’ developed by P. Budzelaar, it is 
possible to simulate the observed second order effects and designate the individual peaks 
and coupling constants with confidence.105  In this case, the signals observed for the two 
protons adjacent to the alcohol at δ3.75, correspond to 3JHH couplings of 4.1 and 5.9 Hz to 
the proton at the chiral centre, and also a 2JHH coupling of 12.1 Hz between each other.  
The gNMR simulation of these peaks supports this assignment (Fig. 2.6). 
The assigned structures of 170 and 171 were subsequently confirmed by oxidation, 
using Dess-Martin periodinane to generate the aldehyde and ketone, respectively (Scheme 
2.50). 
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Scheme 2.50: Oxidations of 170 and 171. 
 
The general mechanism for TBAF deprotection is for the insertion of fluoride to 
create a silyl fluoride and oxide counter ion which becomes protonated upon work-up. 
However, due to the strong electron-withdrawing effect of the 2-pyrone motif in 169, it is 
feasible that the oxide is able to eliminate the 2-pyrone to create an epoxide.  Upon 
nucleophilic attack of the 2-pyrone on the epoxide, the terminal carbon would now be the 
most accessible, resulting in the undesired 171 (Scheme 2.51). 
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Scheme 2.51: Deprotection/Rearrangement of 169 in presence of TBAF. 
 
The most surprising aspect of this rearrangement is that given the lack of 
nucleophilic character observed with 9 in previous experiments, none of the free 2-pyrone 
was isolated.  In order to probe this reaction mechanism, 1,2-epoxybutane (173) was 
treated with the sodium salt of 9 and subjected to prolonged reaction times and increased 
temperatures (Scheme 2.52). 
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Scheme 2.52: Attempted synthesis of 171 from nucleophilc reaction of 9 with 173. 
 
In each case no reaction was observed, indicating one of two scenarios. Either the 
proposed mechanism is incorrect, or the presence of the large sterically bulky tetrabutyl 
ammonium counter ion increases the nucleophilicity of the 2-pyrone.  
Alternatively, the alkoxide ion could undergo a conjugate addition into the 2-
pyrone ring to form an acetal intermediate.  The resulting ring opening would generate the 
two products in equilibrium, with the formation of the undesired secondary alcohol likely 
to be favoured (Scheme 2.53). 
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Scheme 2.53: Alternative rearrangement pathway. 
 
In order to avoid the rearrangement, acidic conditions were tested and quickly 
proved to be very effective, providing an efficient route to the free alcohol (Scheme 2.54).  
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Scheme 2.54: Acidic deprotection of 169. 
 
 The next step towards the synthesis of the vinyl halide was the oxidation to an 
aldehyde.  Using DMP has been shown to be an adequate method for the oxidation, 
however trace amounts of aromatic impurities were consistently found in the product, 
which proved to be unstable to silica gel chromatography.  Subsequent testing showed that 
a Swern oxidation gave quantitative yields of 165 in high purity (Scheme 2.55). 
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Scheme 2.55: Swern oxidation of 170. 
 
  The initially proposed two step synthesis of the vinyl halide via the synthesis of a 
1,1-dihalo-intermediate can potentially be circumvented using a suitable pseudo-halide 
such as a triflate.  The use of vinyl triflates in cross-coupling reactions is well documented, 
with the triflates often accessed through the reaction of a suitable carbonyl with base and a 
source of triflate such as triflic anhydride.106  Aldehyde 165 was subsequently treated with 
various bases and triflic anhydride to generate the desired vinyl triflate (174).   
 
165 174
O
O
O
O
Base, Tf2O
O
O
O
TfO
X
(Degradation of S.M.)
  
Scheme 2.56: Synthesis of vinyl triflate 172. 
 
The triflation of 165 proved to be unsuccessful with degradation of the 2-pyrone 
seen despite a variety of conditions (Scheme 2.56).  It is likely that trace amounts of triflic 
acid in the reaction could have mediated the degradation of the 2-pyrone. 
The alternative synthesis of the vinyl halide utilises methodology developed by 
Spaggiari et al. whereby an aldehyde can be converted into a 1,1-dihalide under relatively 
mild conditions.103  Treatment of the resulting dihalide with base will generate the desired 
vinyl halides suitable for cross-coupling.  Treatment of 165 under these conditions gave 
access to dibromo and dichloro adducts 175a and 175b, respectively, in relatively low 
yields (Scheme 2.57).  
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Scheme 2.57: Synthesis of dihalides 175a and 175b. 
 
 Dihalides 175a and 175b were subjected to a variety of elimination conditions, 
with the results shown in Table 2.14.   
 
Table 2.14: Elimination reactions of 175a and 175b. 
O
O
O
X
Base
O
O
O
X
X
O
O
O
+
X
E Z
X = Br (175a)
       Cl (175b)
X = Br (E/Z-176a)
      Cl (E/Z-176b)
(see Table for conditions)
 
*Ratio established from isolated yields. 
 
The initial elimination of HBr from 175a resulted in the formation of both isomers 
of 176a (entry 1), with the undesired Z-isomer favoured.  Reduction of the reaction 
temperature to promote formation of the kinetic product resulted in the ratio shifting 
Entry X Base Solvent Time Temperature 
Yield 
(%) 
E:Z 
Ratio* 
1 Br DBU
 
THF 24 h 80 °C 93 41 : 59 
2 Br DBU THF 24 h 70 °C >99 36 : 64 
3 Br DBU Dioxane 18 h 100 °C 68 31 : 69 
4 Br Ag2CO3 THF 24 h 70 °C 0 - 
5 Br Ag2CO3 THF 24 h 100 °C (µλ) 0 - 
6 Br KHMDS THF 18 h -78 - 20 °C 0 - 
7 Cl DBU THF 24 h 80 °C 0 - 
8 Cl DBU THF 24 h 90 °C 9 44 : 56 
  
 
 
 
Figure 2.7: Overlay of 1H NMR sprectra for Z and E isomers of 176a (a), with emphasis of 
the alkene (b) and CH2 (c) signals. 
 
 
 
 
 
 
 
E-176a 
Z-176a 
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slightly more towards the Z-isomer (entry 2), however when utilising a higher reaction 
temperature to promote formation of the thermodynamic product, it was observed that the 
ratio of products has now shifted dramatically in favour of the Z-isomer (entry 3).  It must 
be noted however that the yields drop towards higher temperatures, whilst no starting 
material is recovered, indicating that product degradation is a significant problem.  It is a 
distinct possibility that at higher temperatures formation of the E-isomer is preferred, 
however due to the high temperatures, degradation of the E-isomer occurs quicker 
resulting in a distorted isomeric ratio. The use of relatively weak organic bases, such as 
DBU, are likely to enforce an E2 pathway for the reaction, however, by using stronger 
bases to generate a deprotonated intermediate the reaction can be shifted towards an E1CB 
type mechanism which may affect the isomeric ratio obtained.  Unfortunately, the use of 
stronger inorganic bases such as KHMDS resulted in no observed reaction (entries 4,5 and 
6).  A possible explanation for this is the relatively acidic protons at C-7 of 175a.  In the 
presence of DBU, the elimination proceeds via a concerted deprotonation and elimination 
of bromide, whereby the strength of the base is insufficient to deprotonate any position of 
the molecule directly.  However, when using KHMDS, it is now sufficiently basic to 
deprotonate the most acidic position of the molecule.  On this occasion, the C-7 position 
would appear to be the most likely, forming the extended enolate and thereby shutting 
down the elimination pathway (Scheme 2.58). 
O
O
O
Br
O
O
O
Br
Br
H O
O
O
Br
Br
H X
KHMDS
 
Scheme 2.58: Possible explanation for lack of elimination when using KHMDS. 
 
 In the absence of any adjacent protons to the alkene in 174, it is not possible to 
determine stereochemistry through the magnitude of the alkene-alkene 3JHH values.  
However, study of the two isomers indicates that the longer 4JHH allylic couplings are only 
present in one of the isomeric forms, allowing distinction of the isomers through these 
differences (Fig. 2.7).  
Literature precedent suggests that the 4JHH allylic couplings are promoted when the 
alkene proton is located cis to the relevant allylic protons.107  Further to this, it was noted 
in the isolation papers of the phacelocarpus macrocycles that some derivatives exhibited 
the allylic coupling, however in the case of 33, no such coupling was observed.  Complete 
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assignment of the stereochemistry was confirmed through NOESY correlations which were 
observed between the alkene and CH2 in Z-176a, but were absent in E-176a (Fig. 2.9). 
O
O
O
Br
E-176a
O
O
O
Z-176aBr
Correlation
observedNo correlation
observed
 
Figure 2.8: Observed NOESY correlations of E/Z-174. 
 
2.4.3 Cross-coupling reactions involving the HA fragment (176a) 
  
The most important step in the current synthetic pathway is the synthesis of the 1,4-
skipped diene via a vinylic / allylic coupling reaction. The vinyl bromides E/Z-176a were 
subjected to Suzuki reactions utilising the previously described methodology. The results 
are shown in Table 2.15.  
The initial Suzuki reactions worked well on both isomers of 176a when using 
highly active organoboronic acids (177 and 57), proving the activity of the vinyl bromide 
is sufficient for palladium catalysed cross-coupling.  It is noticeable that as the stable aryl 
boronic acid partner is exchanged for a less active coupling partner, such as the allyl 
boronates, the reactivity declines rapidly.  The poor reactivity of allyl BPin (152) can be 
attributed to the rapid hydrolysis of the pinacol ester into the allyl boronic acid in the 
presence of aqueous base, which subsequently degrades due to the slow transmetalation 
step.  The use of stable BF3K salts instead of the boronic acids, pioneered by Molander,108 
allows for the reaction of more sensitive reagents which may be prone to degradation.  The 
use of 181 in the Suzuki reaction continues to show poor reactivity, despite changing to the 
stronger cesium carbonate base.  To avoid the problems associated with hydrolysis of allyl 
pinacolborane, the reaction was carried out in the absence of water, resulting in a 
respectable 41% yield of the desired 1,4-skipped diene product (E-180). 
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Table 2.15: Suzuki couplings of E/Z-176a with organoboronic acids. 
O
O
O
Br
R B(OH)2+
2 mol% CatCat
70 oC, THF, 12 h
O
O
O
R
 
Entry Vinyl bromide 
Boronic 
acid 
Base* Products 
Yield 
(%) 
1 
O
O
O
Br
 
Z-176a 
OMe
B(OH)2
 
177 
Na2CO3(aq) 
O
O
O
OMe
 
Z-178 
68 
2 O
O
O
Br
E-176a OMe
B(OH)2
 
177 
Na2CO3(aq) O
O
O
MeO
E-178 
98 
3 E-176a 
B(OH)2
 
57 
Na2CO3(aq) 
O
O
O
 
E-179 
61 
4 E-176a BPin152 
Na2CO3(aq) 
O
O
O
 
E-180 
0 
5 E-176a 
BF3K
181 
Na2CO3(aq) E-180 0 
6 E-176a 
BF3K
181 
Cs2CO3(aq) E-180 0 
7 E-176a 
BF3K
181 
Cs2CO3 E-180 0 
8 E-176a BPin152 
Cs2CO3 E-180 41 
*
 
2M aqueous solutions or 3 equivalents of anhydrous base were used in all cases   
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2.4.4 Synthesis of the HAB (157) and HAB′ (159) fragments 
 
The synthetic methodology developed towards the HA fragment (176a) was applied to 
the synthetic routes A (Scheme 2.59) and B (Scheme 2.60) suggested in Scheme 2.43.  
OH
OTBDMS
O
O
HO
DIAD, PPh3, DCM
20 oC, 16 h
AcOH/THF/H2O
20 oC, 3 h
(74%)Si
O
O
Si
O
TBDMSO
(75%)
O
O
Si
O
HO
(95%)
O
O
Si
O
O
O
O
Si
O
Br
Br
(COCl)2, DMSO, TEA
DCM, -78 oC, 3 h
P(OPh)3, Br2, TEA, DCM
-60 oC to reflux, 18 h
X
(Degradation of SM only)
44
182
183184
185
O
O
Si
O
Br
186
DBU
168
 
Scheme 2.59: Synthetic route A 
 
The initial incorporation of the protected alcohol 168, deprotection and oxidation to 
184 proceeded with a respectable 53% yield (over the three steps).  The subsequent 
dibromination failed with complete degradation of the starting material observed (TLC and 
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1H NMR).  The same synthetic pathway was applied to the synthesis of the HAB′ fragment 
(159) with a similar result. 
168
OH
OTBDMSO
O
HO
DIAD, PPh3, DCM
20 oC, 16 h
AcOH/THF/H2O
(50%)
O
O
O
TBDMSO
(98%)
O
O
O
HO
(69%)
O
O
O
O
O
O
O
Br
Br
(COCl)2, DMSO, TEA
DCM, -78 oC, 3 h
P(OPh)3, Br2, DCM
-60 oC to reflux, 18 h
X
95
187
188189
190
O
O
O
Br
159
DBU
 
Scheme 2.60: Synthetic route B 
 
The poor conversion to the dibromides in each of the real systems attempted was 
disappointing.  The only significant difference between the test substrate 165 and the real 
systems, 184 and 189, is the presence of the alkyne.   The use of bromine in the synthesis 
of the dibromides 185/190 could contribute to the degradation of the starting materials.  
 The mechanism involves an initial equilibrium forming between the bromine and 
phosphate to generate a bromophosphonium ion and the reactive bromide ion which 
attacks the carbonyl.  However, in the presence of non-aromatic alkenes/alkynes, a 
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competing reaction pathway is formed whereby the bromine can react rapidly with the 
points of unsaturation.  The dibromination of the aldehyde is a slow reaction, whereas C-3 
bromination of 2-pyrones is known to be extremely rapid,109  as is the bromination of 
alkynes.110  In this instance the equilibrium of the intitial step will drive the reaction away 
from the desired dibromide compound. 
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Scheme 2.61: Proposed mechanism for dibromination. 
 
2.5 Synthesis of macrocyclic 2-pyrones 
 
The proposed method of forming the macrocycle in route B is through ring closing 
alkene metathesis. In order to test the feasibility of this method a simple analogue was 
rapidly prepared through the reaction of 8-bromo-1-octene (191) with 95 under basic 
conditions to generate 192 (Scheme 2.62). 
191 192
O
O
HO
Br
+
O
O
O
DBU, MeCN, 
60 oC, 16 h
(73%)
95
 
Scheme 2.62: Synthesis of 192. 
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The analogue 192 was subsequently subjected to various metathesis conditions, 
however, no cyclised product was observed utilising a variety of conditions (Scheme 
2.63). 
193
192
O
O
O
O
O
OCat. Ru
(see appendix 1.7 
for full details)
X
 
Scheme 2.63: Ring closing metathesis of 192. 
 
The results from Scheme 2.63 suggest that RCM is not compatible with this 
system.  The likelihood is that the linearity of the alkyne is preventing the two alkenes 
being orientated in the correct manner for alkene metathesis to occur. 
Recent work by Young et al. has shown that in medium-sized ring systems it is 
possible to enhance RCM compatibility of 1,4-enynes through the protection of the alkyne 
with Co2(CO)8.111  The dicobalt hexacarbonyl protection enforces a significant change in 
the hybridisation of the alkyne.  As the unprotected alkyne the orbitals are in an sp-
hybridised state, allowing no rotation out of the plane.  However, upon formation of the 
dicobalt hexacarbonyl adduct, the alkyne now assumes a tetrahedral sp3-hybridised 
geometry about which there is a much greater degree of flexibility available (Fig. 2.9). 
OC
R
R'
Co
Co
CO
CO
OC
COOC
R'R
sp-hybridisation
sp3-hybridisation
Co(CO)8
-2 CO
 
Figure 2.9: Alkyne-dicobalt hexacarbonyl compound.  
 
 The same methodology was applied to 192 which facilitates a greater degree of 
rotation for the macrocyclisation. The protection of the alkyne proceeds well under mild 
conditions, with the following RCM now proceeding in excellent yield (Scheme 2.64). 
 Figure 2.10: 1H NMR spectra (500 MHz, CDCl3) of a) 192, b) 194, c) 195  
 
 
Figure 2.11: 1H NMR spectra (500 MHz, CDCl3) of a) 194 and b) 195 (Sine bell 
apodisation applied to raw FID) 
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Scheme 2.64: Synthesis of macrocycle 195. 
 
On inspection of the 1H NMR spectroscopic data for 195, the presence of two 2-
pyrone species are observed, indicating one of two possibilities. It is possible that both cis 
and trans-isomers of the alkene are present. Alternatively, it is equally plausible that 
decomposition of the dicobalt complex 195 is leading to the formation of the deprotected 
macrocycle 193. 
The 1H NMR spectra of 192 (Fig. 2.10-A) shows the presence of four terminal 
alkene protons and two overlapping internal C-H alkenes in addition to the two 2-pyrone 
signals. Upon formation of the dicobalt complex 194 (Fig. 2.10-B) the internal alkenes 
become distinct.  A downfield shift of the CH2 centred in the 1,4-enyne motif, observed as 
a doublet at δ 3.55.  Following macrocyclisation to 195 (Fig. 2.10-C), the four terminal 
alkenes have been removed, however two products in a 2:1 ratio are observed from the 
integrals of the two 2-pyrone signals and the CH2 doublet signal at δ 3.55. Interestingly, 
the alkene signals for the major and minor products do not differ sufficiently to interpret 
the signals separately using standard processing methods.  
Applying Sine bell apodisation to the raw NMR data obtained for 194 and 195 
generates spectra with increased resolution between overlapping signals (Fig. 2.11-A and 
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2.11-B, respectively), allowing for improved characterisation of the key alkene signals. 
The first alkene at δ 5.40 represents a doublet of triplets with 3JHH values of 15.0 Hz and 
7.5 Hz, respectively. Analysis of the second alkene at δ 5.55 is more difficult. However, it 
is possible to assign the signal as a doublet of triplets with 3JHH values of 15.0 Hz and 7.0 
Hz, respectively, with an additional impurity overlapping. The major component of 195 
can be assigned with confidence as E-195 (Fig. 2.12). 
O
O
O
Co2(CO)6
E-195
 
Figure 2.12: Major component of 195. 
  
 The interpretation of the 1H NMR spectra suggests that there is only one isomer (E-
195) present in the product, as a mixture would be expected to generate a complex 
multiplet or two additional signals corresponding to the cis-alkene protons. The most 
important factor in identifying the cis-isomer would be the identification of a suitable J 
value or alternatively an NOE correlation between the relevant protons. Unfortunately, a J 
value is not discernible due to the more prominent signals from E-195, and the NOESY 
spectra proved inconclusive.  The formation of mixed isomers in large ring sized 
macrocylisations formed through ring closing metathesis has been well documented, which 
supports the evidence for the cis-isomer.112  Of particular note are the selectivity problems 
encountered in the various syntheses of nakadomarin A 197, whereby the final RCM is 
noted to generate both E- and Z- isomers in a ratio of 2:1 in all cases (Scheme 2.66).113  
N
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Grubbs I/II/Hoveyda
196 197(-)-Nakadomarin A
 (2:1 E/Z)
 
Scheme 2.65: RCM approach to Nakadomarin A 
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The alternative explanation for the minor product as a deprotection of the dicobalt 
complex would also appear inaccurate. Upon complexation of dicobalt hexacarbonyl to 
192, the signals for the CH2 group centred in the 1,4-enyne motif shifted further downfield. 
It can be assumed that a similar shift upfield would be expected upon removal of the 
protecting group, however the minor product clearly indicates the CH2 signal remains close 
to the major product, and thus the cobalt complex must still be intact.  Mass spectrometry 
supports this interpretation due to the absence of the correct mass for the deprotected 
macrocycle. 
The degradation of dicobalt hexacarbonyl complexes has been well documented, 
with the loss of CO as a key fragment in their degradation.114 The mass spectrum of 195 
shows the presence of degradation peaks whereby loss of 1, 3 or 4 CO units has occurred. 
Whilst the presence of these peaks would be expected from pure product, it is possible that 
partial degradation of the dicobalt complex accounts for the minor product observed. The 
co-ordination of alkynyl dicobalt hexacarbonyl complexes to alkenes via the loss of CO 
has been widely shown to be a key step in the Pauson-Khand reaction. 115  It is therefore 
conceivable that the minor product could contain the alkene and alkyne linked cobalt 
complex 198. This assignment would account for the small change in the chemical shifts 
observed for the C-3-H and C-5-H 2-pyrone signals. The two possibilities for the minor 
component in the RCM of 194 have been suggested as Z-195 and 198 (Fig. 2.13), however 
upon inspection of the IR data for E-195, only three bands are observed in CO region 
(2086, 2043 and 2012 cm-1), consistent with the presence of an alkyne bound Co2(CO)6.  
The IR spectrum of 198 would be expected to exhibit additional bands due to the 
unsymmetrical nature of the cobalt complex, whereas Z-195 should exhibit the same bands 
as E-195.   
Whilst definitive proof has yet to be obtained, the identity of the minor compenent 
from the RCM of 194 is attributed to Z-195.  The key details in the assignment are the 
presence of only three distinct bands in the IR data and the minimal shifts in the NMR 
signals.  
 76 
O
O
O
Z-195 198
O
O
O
Co2(CO)6 (OC)3Co
Co(CO)2
 
Figure 2.13: Possible minor components from RCM of 194. 
 
The desired macrocycles can now be acquired through the oxidative deprotection of 
the dicobalt hexacarbonyl group.  The choice of oxidant needs careful consideration for a 
number of reasons.  The use of strong oxidants, such as CAN, may jeopardise the 1,4-
enyne motif which could be converted into the 1,3-enyne in the event of radical formation, 
or alternatively, in the presence of elevated temperatures, an inter/intra-molecular Pauson-
Khand reaction may occur.  
The formation of macrocycle 195 is an important result as it shows RCM is a 
suitable means of macrocycle formation, however it is also important that the ring closing 
methodology is able to accommodate further complexity in the left hand chain which 
would require two additional alkenes for the formation of 33.  Prior work towards the vinyl 
ether has shown it to be unreactive towards metathesis, although the additional alkene 
within the chain could potentially become involved in the metathesis and disrupt the 
formation of the desired product.  However, the presence of the two terminal alkenes 
should dictate that the ruthenium catalyst reacts preferentially at these positions.  The 
competitive RCM reaction was subsequently tested (Scheme 2.66).  
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Scheme 2.66: Synthesis and RCM of 201. 
  
The synthesis of triene 201 was achieved in modest yield through the Mitsunobu 
reaction of 95 with diene 199 and alkyne protection of the resulting triene 200.  The RCM 
reaction failed to yield the desired macrocycle 202 indicating that the internal alkene unit 
must be masked in order for the reaction to become a suitable means of macrocycle 
formation in the real system. 
 There are a number of methods available to mask alkenes, with perhaps the most 
widely utilised method being the alkyne, allowing stereoselective hydrogenation to give 
the formation of the desired alkene isomer.  The presence of an alkyne has already been 
shown to inhibit macrocyclisation, yet further protection of the alkyne enabled the ensuing 
macrocyclisation to occur.  In order to test the viability of a doubly protected diyne system, 
a simple test substrate was synthesised (Scheme 2.66).  
 78 
O
O
O
O
O
O
Co2(CO)6
Grubbs II (10 mol %)
DCM, 40 oC, 16 h
Co2(CO)8, THF,
20 oC, 2 h
(95%)
O
O
HO+
DIAD, PPh3, DCM, 
20 oC, 16 h
(61%)
X
OH
Co2(CO)6
O
O
O
Co2(CO)6(OC)6Co2
203
95 204
205206
 
Scheme 2.67: Synthesis and RCM of 205. 
 
 The RCM of doubly alkyne protected diyne system 205 proved to be unsuccessful. 
Although the reaction failed, it is not a definitive failure towards the natural product 
formation.  The presence of dicobalt hexacarbonyl units in close vicinity to the terminal 
alkynes on both arms could be providing too much steric bulk to allow the formation of the 
metathesis intermediate required for the formation of the desired product (Scheme 2.68). 
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Scheme 2.68: Proposed reaction intermediates in the RCM of 203. 
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2.6 Conclusions and Future work 
 
2.6.1 Conclusions 
  
Throughout the course of the studies towards 33, the important features required for 
the synthesis have been identified.  The most important factor that has been addressed is 
the synthesis of the novel vinyl ether motif.  Whilst the originally proposed Buchwald-
Hartwig etherification strategy proved to be inadequate, alternative methods proved to be 
effective at installing the motif.  The use of 4-hydroxy-2-pyrones as nucleophilic partners 
has been of key importance to the installation of functionalised side chains through 
Mitsunobu and Michael addition reactions. The stability of the vinyl ether motif has also 
been observed to be relatively poor, with degradation occurring above 100 °C. 
The most important results from the studies towards 33 are: a) the successful 
synthesis 44 and 95 as suitable fragments for future syntheses; b) the synthesis of vinyl 
bromide 176a and the subsequent successful Suzuki reactions of both isomers; and c) the 
utilisation of a dicobalt hexacarbonyl protected alkyne to enable the formation of the 19 
membered macrocycle 195. 
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Figure 2.14: Key structures from studies towards 33. 
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2.6.2 Future Work 
 
 The unsuccessful attempt to generate the advanced 1,1-dibromides 184 and 189 
presents a problem in the planned synthesis, however future studies can contemplate one of 
two solutions to this problem.  The elimination reaction of dibromide 175a to generate the 
vinyl bromide 176a did not occur in the presence of strong inorganic bases, such as 
KHMDS.  The low reactivity was attributed to deprotonation at the C-7 position, which is 
desirable for alkylation at this position.  This would allow formation of the previously 
synthesised dibromide 172 followed by the subsequent lithiation/ potassiation and 
alkylation with a suitable alkyl iodide (Scheme 2.69).  
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Scheme 2.69: Metallation strategy to advanced dibromides. 
 
Alternatively, the problem of the alkyne can be circumvented via the introduction 
of an alkyne protecting group such as, Co2(CO)6 prior to the dibromination reaction.  The 
protecting Co2(CO)6 group may then be carried forward into the potential RCM reactions 
(Scheme 2.70). 
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Scheme 2.70: Alkyne protection strategy to vinyl bromides. 
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The ring-closing methodology developed so far is still at an early stage.  Despite 
the successful macrocycle formation in the presence of a dicobalt protected alkyne, further 
work is necessary to assess the full capability of this reaction.  The failure of the triene and 
doubly protected alkyne derivatives suggest that the desired macrocycle substrate can only 
accommodate the presence of one bulky dicobalt complex, and yet the additional alkene 
will require accessing at a later stage.  A possible solution to this is the incorporation of a 
masked alkene which would allow macrocyclisation to occur and subsequent alkene 
formation to generate the natural product. 
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Scheme 2.71: Masked alkene strategy to promote RCM. 
 
 The formation of the desired cis-alkene as one of the final steps creates problems 
with selectivity.  In Scheme 2.71 it is suggested that a phenyl selenide would act as a 
suitable masked alkene, however the resulting elimination would generate two possible 
regioisomers, each with stereoisomers likely.  
 As a result of the poor selectivity these strategies suggest, the previously suggested 
route A would appear to be the more logical choice for selective ring-closing methodology.  
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Scheme 2.71: Sonogashira focused disconnections. 
 
The formation of the macrocycle would now be reliant upon Sonogashira or copper 
mediated allylation reactions.  The suitability of this macrocycle formation strategy will 
require ample testing, and the required fragment G will require synthesis.  The proposed 
forward synthesis now requires the Suzuki coupling of 185 with 159, removal of both silyl 
protecting groups and suitable functionalisation of the ensuing allyl alcohol, which would 
present an advanced intermediate suitable for macrocyclisation.  The natural product would 
then be completed via the relevant alkynyl-allyl coupling reaction. 
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Scheme 2.72: Proposed forward synthesis of 33. 
 83 
3. Intramolecular C-H arylation of 2-Pyrones 
 
3.1 Reaction discovery and optimisation  
 
 In the course of the studies towards phacelocarpus-2-pyrone A an integral reaction 
in the desired route focused on a proposed Suzuki cross-coupling of allyl boronate 155 
with vinyl bromide 175a.  In the course of reaction screening it was noted that the Suzuki 
cross-coupling of Z-175a led to the identification of a second reaction product, namely 
furopyrone 213 formed in 25% yield (Scheme 3.1). 
O
O
O
Br
O
O
O
+
BPin CatCat (2 mol%), Cs2CO3,
THF, 80 ºC, 18 h
+ O
O
O
(40%) (25%)Z-175a 155 Z-180
213
 
Scheme 3.1: Intramolecular C-H functionalisation-initial discovery. 
 
The low yield of 180 was attributed to the low stability and reactivity of the allyl 
pinacolborane 155.  Recent work by Molander and co-workers has shown that the more 
stable potassium trifluoroborate salts of boronic acids are adequate substitutes for boronic 
acids.108  The Suzuki cross-coupling of Z-175a was subsequently attempted utilising 
potassium allyltrifluoroborate 181 as an alternative to allyl pinacol borane. 
Z-175a 181 213
O
O
O
Br
+
BF3K
CatCat (2 mol%), Cs2CO3,
THF, 80 ºC, 18 h O
O
O
(44%)
(only)
 
Scheme 3.2: Selective intramolecular C-H functionalisation of Z-175a.  
  
 The use of 181 as an alternative source of allyl boronic acid resulted in a complete 
shut-down of the Suzuki reaction pathway giving an improved 44% yield of 213. The 
reason for this is likely to be in part due to the absence of water.  Molander and co-workers 
have recently shown that the presence of trace water is needed for the potassium 
trifluoroborate salts to be an effective boronic acid substitute.116 The synthesis of 213 
represents the first Pd-catalysed C-H functionalisation of a 2-pyrone. 
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 The synthesis of furopyrones has been well documented, with two reported 
syntheses (Scheme 3.3) as good examples.  The first was reported by Cadierno et al.,117 
which utilises the reaction of a propargylic alcohol with 4-hydroxy-6-methyl-2-pyrone (9) 
in the presence of a cationic ruthenium catalyst.  The reaction utilises 9 in a propargylic 
substitution-cyclisation process.  The second example, highlighted from the work of 
Cabarès et al.,118 requires the prior formation of a tetra-substituted furan derivative and 
subsequent formation of the furopyrone.  The reaction is limited by the accessibility of the 
substituted furans, however the direct product of the reaction provides a carboxylic acid as 
a useful handle for further manipulation. 
O
O
HO
R
OH
R'
+
[Ru(eta3-2-C3H4Me)-
(CO)(dppf)][SbF6] 
TFA, THF,
 70 °C, 20 h
O
O
O
R'
R
O
O
O
O
O
O
O
O
R
O
HO
R
O
O
1. NaOH
2. HCl
3. Ac2O
9
 
Scheme 3.3: Known synthetic routes to furopyrones. 
 
The routes highlighted in Scheme 3.3 are limited however, as they do not allow the 
incorporation of an additional fused ring into the system to create a benzofuropyrone.  The 
synthesis of benzofuropyrones has received little attention, with only one reported pathway 
to date.  Majumdar and co-workers have synthesised a variety of structures featuring a 
tricyclic system containing the benzofuran motif, including benzofuropyrone 216.  
However, the reaction is limited as the final step requires very high temperatures (250 °C) 
to affect elimination and subsequent dehydrogenation to the benzene ring (Scheme 3.4).119  
O
O
HO
O
O
O
10% Pd/C, 250 °C
Ph2O, 2 h
O
O
OI
SnCl4, I2
DCM, RT
214 215 216
 
Scheme 3.4: Majumdar’s synthesis of 216. 
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In order to further develop the unique transformation observed in Scheme 3.2, a 
model aromatic analogue was synthesised in two steps from 4-hydroxy-6-methyl-2-pyrone 
9 (Scheme 3.5).  
O
O
HO
TBAB, P2O5,
Toluene, 110 ºC, 6 h
(71%)
O
O
Br
I
OH
K2CO3, Acetone, 60 ºC, 6 h
(85%)
O
O
O
I
9 106
217
218
 
Scheme 3.5: Synthesis of 216. 
  
The cyclisation of 218 was screened with a variety of Pd sources, bases and 
additives to optimise the formation of cyclised product 216.  The results of the 
optimisation of the intramolecular cyclisation are shown in Table 3.1. 
 
Table 3.1: Optimisation of cyclisation conditions. 
216218
O
O
O
cat. Pd (2 mol%), Cs2CO3 (3 eq.)
THF, 70 ºC, 18 h
(See Table for other conditions)
O
O
O
I
 
Entry Catalyst Additive Yield (%) 
1 CatCat 155 (2 eq.) 49* 
2 CatCat 181 (1 eq.) 57 
3 CatCat 181 (0.1 eq.) 69 
4 CatCat AgBF4 (1 eq.) 6† 
5 CatCat PivOH (0.3 eq.) 41 
6 Pd(OAc)2 PivOH (0.3 eq.) 31 
7 Pd2(dba)3 PPh3 (4 mol%) 74 
8 Pd2(dba-4,4′-OMe)3 PPh3 (4 mol%) 79 
9 Pd2(dba-4,4′-OMe)3 PPh3 (4 mol%) 77‡ 
10 Pd2(dba-4,4′-OMe)3 
PPh3 (4 mol%)/ 
PivOH (0.3 eq.) 
45 
*A 42% yield of the Suzuki product is also observed. 
† Reaction left for 72 h in the dark.  
‡ Using K3PO4 instead of Cs2CO3. 
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Initial studies with CatCat and the two allyl boronate reagents correlate well with 
the original observations detailed in Scheme 3.2 where more stable boronates resulted in a 
higher yield for the intramolecular cyclisation (entries 1 and 2) under anhydrous 
conditions.  It was suggested that the boronate could be acting in one of two ways. Firstly, 
it could act as a reducing agent for the palladium(II) precatalyst generating the active 
palladium(0) species, or alternatively, the boronate could be influencing the reaction in 
another capacity. 
Catalytic quantities of 181 proved to further increase the yield of 216, whereas utilising 
AgBF4 as a boron alternative limited the reaction, indicating that 181 is acting as a 
reductant (entries 3 and 4).  Recent work by Fagnou and co-workers has shown that a 
combination of Pd(OAc)2, pivalic acid and caesium carbonate proves to be an efficient 
catalytic system for C-H functionalisation of various heteroaromatic systems,120 however 
the inclusion of pivalic acid with either CatCat or Pd(OAc)2 proved ineffective for the 
synthesis of 216 (entries 5 and 6).   
The results so far point to the formation of Pd0(PPh3)2 which is sufficiently active to 
perform the cyclisation. A common route to access Pd0(PPh3)2 is through the reaction of 
Pd2dba3 with PPh3 (Ratio Pd:PPh3 = 1:2). The application of this methodology towards 216 
proves to be effective, with an improved 74% yield obtained (entries 7).  Work by Jutand 
and co-workers has shown that the presence of dba in the reaction has a profound effect on 
the formation of the active catalyst, with the dba forming a dynamic equilibrium between 
active catalyst and a stabilised form whereby the alkene from dba binds η2 to the 
palladium(0) centre.121  This interaction limits the amount of active catalyst found within 
the reaction, while also stabilising the highly reactive catalyst to prevent rapid catalyst 
degradation. 
Pd0
Ph3P
Ph3P
Ph
O
Ph
Pd2dba3 + 4 PPh3 Pd0
Ph3P
Ph3P
S
-S
+S
(S = Solvent)
Inactive form Active form
 
Scheme 3.6: dba stabilisation of palladium (0). 
 
 Work by Fairlamb and co-workers has shown that by influencing the electronic 
nature of the dba alkene, through functionalisation of the aryl group, it is possible to alter 
the equilibrium and therefore affect the quantity of active catalyst formed in the 
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reaction.122,123 The most useful catalyst from this work, Pd2(dba-4,4′-MeO)3, proved to be 
effective in the intramolecular cyclisation of 218 yielding an improved 79% of 216 (entry 
8), conditions which will be utilised in all further reactions to assess the substrate scope. 
 The intramolecular cyclisation reactions can functionalise two positions of the 2-
pyrone, with C-3 and C-5 being equidistant from the aryl iodide and both being available 
for attack.  The 1H-NMR spectroscopic data suggests that the reaction occurs exclusively at 
the C-3 position, with an observable 4JHH coupling observed between protons at C-5 and C-
7.  Conclusive proof of this assignment was obtained through a single crystal X-ray 
diffraction study of 216 (Fig. 3.1). 
 
Figure 3.1: Crystal structure of 216 (Arbitrary numbering used). Selected bond lengths 
(Å): C(2)-C(3) 1.443, C(2)-C(9) 1.374, C(3)-C(8) 1.398. Selected bond angles: C(1)-C(2)-
C(3) 133.18, C(2)-C(3)-C(4) 136.20, C(1)-C(2)-C(9) 120.00, C(2)-C(9)-O(3) 111.95.  
  
The intramolecular reaction utilises an aryl halide and reacts at the C-3 position of 
the 2-pyrone, however it is also conceivable that the reaction may utilise a 4-halo-2-pyrone 
and react with an aryl C-H to generate the same product. 
O
O
Br
O
O
O
Br
O
O
O
Pd2(dba-4,4'-OMe)3 (1 mol%), 
PPh3 (4 mol%), Cs2CO3 (3 eq.)
 
THF, 70 ºC, 18 h
X
1. PhOH (1.1 eq.), K2CO3, 
acetone, 40 ºC, 18 h 
2. Br2 (1 eq.), DCM, 
20 ºC, 2 h (59%)
216219106
Scheme 3.7: Alternative intramolecular cyclisation. 
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The intramolecular reaction with 219 fails to generate any of the desired cyclisation 
product 216, with starting material degradation the only notable pathway (Scheme 3.7).  
The reaction pathway is therefore highly dependant upon the inherent activity of the 2-
pyrone. 
 
3.2 Reaction scope 
 
 Previous work with 6-alkyl-2-pyrones (Chapter 2) has shown that the protons at C-
7 are commonly the most acidic.  The presence of base in the reaction media therefore 
point towards deprotonation at C-7 playing a crucial role in the reaction mechanism, from 
which a suitable mechanistic pathway can be proposed (Scheme 3.8). 
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Scheme 3.8: Preliminary proposed catalytic cycle. 
 
The proposed mechanism (Scheme 3.8) is dependant upon proton transfer between 
C-7 and C-3 under the reaction conditions.  To test the suspected acidity of C-7 and the 
ensuing proton transfer required for the proposed mechanism, the starting material 218 was 
subjected to basic conditions in the presence of a deuterium transfer agent (acetone-d6). 1H 
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NMR spectroscopic analysis of the resulting product showed total incorporation of 
deuterium at the C-7 position.  Upon treatment of the deuterated starting material 218 with 
Cs2CO3 in anhydrous THF, it was noted that the deuterium equilibrates between C-3 and 
C-7, thereby confirming that proton transfer is possible under the reaction conditions 
(Scheme 3.9).  The reaction also confirms the requirement of a palladium catalyst for 
cyclisation to occur.  The outcome is also consistent with Dr. L. R. Marrison in his PhD 
studies on the Sonogashira cross-couplings of 3-bromo-4-alkoxy-6-methyl-2-pyrones.124 
  
O
O
CD3O
Ar
O
O
O
Ar
Cs2CO3, D6-acetone, 
THF, 70 ºC, 1 h
(3 cycles)
Cs2CO3, THF, 
70 ºC, 18 h
O
O
CD2HO
Ar
H0.33D0.67C
 
Scheme 3.9: Deuterium transfer study of 218.  
 
The proposed mechanism (Scheme 3.8) also suggests that in the absence of any 
acidic protons at C-7 then the reaction would either cease entirely or require higher 
temperatures to attain comparable yields.  In order to test the importance of the C-7 
protons, a number of C-6 functionalised analogues were synthesised (Scheme 3.10). 
Firstly, a proto-C-6 derivative (221) was synthesised through a C-6 selective zinc reduction 
of 220, followed by a conjugated nucleophilic displacement with 217 to afford 221 in 49% 
over the two steps. The second analogue, phenyl-C-6 derivative 223, was synthesised 
through a low temperature Kumada coupling of 220 with PhMgCl, followed by a 
conjugated nucleophilic displacement with 217 to afford 223 in 11% over the two steps. 
The final analogue was synthesised via bromination of 90 and a conjugated nucleophilic 
displacement of the resulting bromide with 215 to afford 225 in 23% over the two steps.  
 
 90 
O
O
ClCl
1. Zn, AcOH, 
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Scheme 3.10: Synthesis and cyclisation of 221, 223 and 225. 
 
 Subjecting the parent system 221 to the intramolecular cyclisations yielded 222 in a 
74% yield, with regioselectively confirmed through a single crystal X-ray diffraction study 
(Fig. 3.2).  The subsequent cyclisations of 223 and 225 proved to be very efficient yielding 
224 and 226 in yields of 59% and 68%, respectively.  These findings suggest that although 
the presence of the acidic C-7 proton may be affecting the mechanistic pathway, the 
reaction is not entirely dependant upon their presence.  The reaction mechanism will be 
further discussed later in this chapter. 
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Figure 3.2: X-ray structure of 222 (Arbitrary numbering used). Selected bond lengths (Å): 
C(5)-C(6) 1.441, C(5)-C(1) 1.371, C(6)-C(11) 1.398. Selected bond angles: C(4)-C(5)-
C(6) 132.45, C(4)-C(5)-C(1) 120.67, C(5)-C(6)-C(7) 135.78, C(5)-C(1)-O(1) 111.94. 
 
Following the optimisation of relatively mild conditions for the cyclisation, and 
subsequent testing of various C-6 substituted analogues, the influence of the aromatic 
component was explored. This was tested through the synthesis and subsequent cyclisation 
of various analogues derived from 2-bromo-phenols. The results are collected in Table 4.2. 
The reaction appears to be sensitive to the nature of the electronic effects of the 
aromatic substituents. Steric effects appear less important, as good yields are observed with 
substituents present in the 6-position (entries 2, 4 and 8).  The most important contribution 
to the reaction yield appears to be the stability of the starting material under the reaction 
conditions.  In most examples, the yields after 18 hours appear to be limited by how 
rapidly 2-pyrone degradation has occurred, as no additional starting material or products 
are observed.   
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Table 3.2: Intramolecular cyclisations 
O
O
O
Br
8
9
O 12
O
O
7
34
5
6
Pd2(dba-4,4'-OMe)3 
(1 mol%), PPh3 (4 mol%), 
Cs2CO3 (3 eq.)
 
THF, 70 ºC, 18 hR
ROH
Br
R
106, K2CO3, acetone
45 ºC, 18 h
Step 1
Step 2
227(a-n) 229(a-n)228(a-n)
 
Entry R 
Yield Step 1 (%) 
(228 a-n) 
Yield Step 2 (%) 
(229 a-n) 
1 4-Me (a) 96 72 
2 4,6-(Me)2 (b) 37 79 
3 4-t-Bu (c) 66 71 
4 4,6-(t-Bu)2 (d) 28* 71 
5 4-Ph (e) 90 44 (56) † 
6 4-OMe (f) 90 65 (93) † 
7 5-OMe (g) 53 67 
8 5,6-(OMe)2 (h) 17 32 
9 4-O(C6H5O2) (i) 49 16 
10 4-F (j) 87 30 
11 5-F (k) 88 24 (31) † 
12 4-Cl (ℓ) 97 28 
13 4-Br (m) 71 0 
14 4-CF3 (n) 90 11 
*
 Reaction conditions: 106, NaH, THF, 70 °C, 18 h.  
†
 Numbers in brackets refer to the calculated yield based on recovered starting material 
following flash column chromatography. 
 
 It would be expected that with the methoxy functionality para to the bromide, as in 
228g (entry 7), reactivity would be enhanced, however the yield is limited due to the 
degradation of the starting material, whereas with the methoxy meta to the bromide we 
observe a comparable yield except with unreacted 228f also recovered (entry 6).  In this 
instance, the degradation is much slower and the yield is more reliant upon the receptivity 
of the substrate to cyclisation.  The reaction appears to be unreceptive towards the presence 
of additional aryl halide functionality, with limited reactivity for fluoride adducts 228j and 
228k (entries 10 and 11), chloride adduct 228ℓ (entry 12) and no reactivity for the 
  
 
 
 
 
 
 
 
 
Figure 3.3: Representative example to show the 1H-NMR (400 MHz, CDCl3) spectral 
changes observed from starting material to product (228ℓ→229ℓ)  
 
 
 
 
 
 
 
 
 
 
 
 
O
O
O
Cl
O
O
O
BrCl
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bromine adduct 228m (entry 13).  The low reactivity of the bromide can be attributed to 
competitive oxidative addition between the two aryl bromide bonds.  The intramolecular 
arylation appears to be a slow reaction, therefore in the presence of a second bromide the 
palladium is likely to be moving between positions and unable to cyclise as a result.  The 
poor reactivity of the fluoride/chloride adducts 228j, 228k and 228ℓ is a little more 
surprising.  It is well established that the oxidative addition of palladium into aryl 
chlorides/fluorides requires phosphines which are more electron rich than 
triphenylphosphine, so competitive oxidative addition should not be affecting the 
reactivity.  However, it is possible that in the presence of multiple C-X bonds, the 
palladium is able to migrate around the system once oxidative addition has occurred at the 
most active C-X bond. 125,126 
ClPd
R
L
Br
Cl
R
Br
PdL
Br Cl
PdL
R
Br Pd L
Cl
R
 
Scheme 3.11: Possible migration of Pd into C-Cl bond. 
 
Throughout the series of benzofuropyrones synthesised, there are notable changes 
in the NMR spectroscopic data, allowing for accurate identification of the products. The 
most important changes are those in the 2-pyrone C-H signals. The 1H-NMR spectra of the 
starting materials consistently show the C-3 and C-5 2-pyrone C-H signals at δ~5.1 and 
δ~6.0 respectively.  Following arylation, the 2-pyrone C-5 signal is shifted significantly to 
δ~6.5, indicating the 2-pyrone motif is now significantly more aromatic (Fig. 3.3).  The 
regioselectivity is subsequently determined through the presence of a 4JHH coupling 
between the CH3 and the C-5 protons from the 2-pyrone.  
Additionally, the IR spectroscopic data shows a 2-pyrone C=O stretching frequency 
at ~1700 cm-1 for the starting materials, whereas the cyclised products routinely show a 
shift of ~20 cm-1 to higher wavenumbers.  The change in frequency to a higher 
wavenumber is consistent for systems with increased conjugation.127 
Further X-ray diffraction studies have confirmed the regioselectivity for 
compounds 229j and 229k (Fig. 3.4). 
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Figure 3.4: X-ray structures of 229j and 229k (Arbitrary numbering used). Selected bond 
lengths 229j (Å): C(6)-C(7) 1.440, C(6)-C(1) 1.379, C(7)-C(12) 1.401. Selected bond 
angles 229j: C(5)-C(6)-C(7) 133.35°, C(5)-C(6)-C(1) 119.94°, C(6)-C(7)-C(8) 136.17°, 
C(6)-C(1)-O(1) 112.02°. Selected bond lengths 229k (Å): C(6)-C(7) 1.446, C(6)-C(1) 
1.367, C(7)-C(12) 1.396. Selected bond angles 229k: C(5)-C(6)-C(7) 133.34°, C(5)-C(6)-
C(1) 119.98°, C(6)-C(7)-C(8) 136.20°, C(6)-C(1)-O(1) 112.14°. 
 
Thus far, the importance of the 2-pyrone and aryl moieties has been tested.  The 
final area of importance is the link between the aryl group and the 2-pyrone, whereby all 
reactions so far have generated a furan ring.  It is conceivable that the same reaction 
methodology could be utilised to generate other 6:5:6 ring systems (e.g. 
benzothiophenylpyrones) or alternatively generate different sized ring systems (e.g. 6:6:6). 
O
O
X
O
O
On
X = S, N-R, C
6:5:6 ring systems 6:(5+n):6 ring systems
 
Figure 3.5: Alternative ring systems. 
 
 In order to probe the importance of the central ring, two suitable substrates were 
prepared.  
The reaction of the thiophene derivative 231 failed to deliver any of the cyclisation 
product 232.  The cause of this is potentially due to ligand effects from the sulphur. It is 
possible that following oxidative addition the sulphur coordinates to palladium in any 
subsequent steps, thereby shutting down the catalytic cycle.  This effect has not been 
investigated further. 
229j      229k 
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Scheme 3.11: Synthesis of alternative ring systems. 
   
 The synthesis of ester 234 was chosen as a cyclisation precursor due to the absence 
of any saturated positions, allowing a close mimic of the original system regarding a fully 
conjugated ring system.  However, upon treatment with the cyclisation conditions no 
product was observed with complete degradation of the starting material occurring.  The 
failure to form a 6:6:6 ring system mirrors the findings by Chang et al. whereby the 
formation of a coumarin derived 6:5:6:6 occurred in good yield when utilising their rather 
complex Pd precatalyst, whereas no product was observed when trying to form the 6:6:6:6 
system.128   Whilst the reactions performed by Chang et al. conform with the observations 
seen here; the authors offer no insight into the reasons they screened the reaction with the 
complex precatalyst 237 or the reason for the failure of the 6:6:6 system. The reaction was 
described as an intramolecular Heck reaction, although no proposed mechanism was put 
forward and no other reactions were performed. 
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n = 1: 0%
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Ph2
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Ph
CoCp Pd
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236 238
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Scheme 3.12: Chang’s ‘intramolecular Heck’ reaction. 
 
 The intramolecular cyclisation reaction methodology was subsequently applied to 
the synthesis of the natural product coumestan.129  The synthesis of coumestan has been 
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achieved on many occasions, most notably the rapid synthesis by Larock and co-workers, 
utilising a Pd-catalysed carbonylation to install the ‘2-pyrone’ motif (Scheme 3.13).130 
239 240
O
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K2CO3, DMF, 60 ºC
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O
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Scheme 3.13: Larock’s synthesis of coumestan. 
 
 The application of the intramolecular cyclisation to the synthesis of coumestan 
allowed rapid access to the natural product from the commercially available 4-hydroxy 
coumarin (241).  Bromination of the coumarin followed by a conjugated nucleophilic 
displacement reaction with 2-iodophenol (217) gave access to the cyclisation precursor 
242. Subsequent cyclisation of 242 gave rise to a respectable 44% yield of coumestan 
(240), with an overall unoptimised yield of 21% over three steps (Scheme 3.14). The three 
step synthesis of coumestan compares unfavourably with Larock’s synthesis which 
accessed the natural product with an overall yield of 90% from three linear steps. However, 
cost analysis of the key reagents used by the two routes indicates a much more favourable 
outcome for the intramolecular arylation with a cost of ~£4/g compared to Larock’s 
synthesis which costs ~£18/g.131 
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Scheme 3.14: Synthesis of coumestan (240). 
 
3.3 Stoichiometric studies 
 
 To gain further insight into the reaction mechanism, a series of stoichiometric 
studies were performed. 
 The complex [Pd0(PPh3)2(η2-dba-4,4′-OMe)] is presumed to be the initial Pd0 
species formed in the reaction.  Preparation and characterisation of this intermediate was 
performed in situ by the reaction of Pd2(dba-4,4′-OMe)3 and PPh3 (ratio Pd:P = 1:2) in D8-
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: 31P-NMR (700 MHz, THF-d8) spectra of 243 and 244. 
(Spectra shown at approx. same intensity) 
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THF (Scheme 3.15).  Addition of 2 equivalents of aryl iodide 218 resulted in quantitative 
conversion to the oxidative addition product 244 when monitored by 1H NMR.  Treatment 
of the oxidative addition product with Cs2CO3 at 70 °C for 2 hours results in quantitative 
conversion to the cyclised product 216. 
Ph3P
Pd0
PPh3
Ar
O
Ar
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Scheme 3.15: NMR scale synthesis of 216. 
 
  The 283 MHz 31P-NMR spectrum of 243 (Fig. 3.6-A) shows two broad signals at δ 
24.5 and 26.2 (∆ν1/2 = 60 Hz) corresponding to exchanging phosphines, as observed by 
Jutand and Fairlamb, and an additional peak at δ 23.4 corresponding to a small quantity of 
(O)PPh3.61 Following the addition of aryl iodide 218 the 283 Mhz 31P-NMR spectrum 
exhibits a sharp singlet at δ 22.4 indicitive of a trans-PdII complex (Fig. 3.6-B).  Additional 
peaks are seen at δ 23.4 and -5.5 corresponding to (O)PPh3 and free PPh3, respectively. 
The presence of (dba-4,4′-OMe) and PPh3 in stoichiometric quantities serves to 
complicate the aromatic region of the 1H-NMR spectrum.  However, PdII complexes are 
known to be air stable, and as such the oxidative addition product was isolated as both the 
proto- and deuteron- PPh3 adducts (Scheme 3.16).
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Figure 3.7: 1H-NMR (700 MHz, DCM-d2) of (a) 216, (b) 244 and (c) 244-d30. 
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Scheme 3.16: Preparative synthesis of 244 and 244-d30. 
 
The 1H-NMR spectrum of the intermediate shows a substantial shift of the aromatic 
signals, however 1H-1H COSY and 1H-31P HMQC were able to confirm the signals 
associated with the 2-pyrone as those at δ 4.72 and 5.65 (Fig 3.7). 
 
Crystals of 244 (obtained from DCM/Ether) were analysed by single crystal X-ray 
diffraction.  The X-ray diffraction data confirms the structure of 244 (Fig. 3.8), with a 
distorted square planar geometry observed at the palladium centre. The key angles between 
P-Pd-P and C-Pd-I are observed to be 169.0° and 169.2° respectively. The distorted 
geometry relieves any steric interference between the bulky phosphino and aryl 
components. The distortion of bulky [PdII(I)R(PPh3)2] complexes has been previously 
reported, but note in 244 are the near identical angles observed which is unique.132, 133, 134  
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Figure 3.8: X-ray structure of 244 (Arbitrary numbering used). Selected bond 
lengths (Å): C(37)-Pd(1) 2.014, I(1)-Pd(1) 2.664, P(1)-Pd(1) 2.316, P(2)-Pd(1) 2.326. 
Selected bond angles: C(37)-Pd(1)-I(1) 169.21°, P(1)-Pd(1)-P(2) 169.03°. 
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Scheme 3.17: Known intermediates in the catalytic cycle. 
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The initial step in the catalytic cycle has been shown to be the oxidative addition 
into the aryl iodide bond to give 244.  It can also be assumed that the final structure 
required for the catalytic cycle is the palladacycle III (Scheme 3.17) which can reductively 
eliminate to give the desired product 216 and regenerate the active Pd0 catalyst.  The 
intermediate steps (II) between these two crucial stages are however more difficult to 
envisage.  
It is known that 2-pyrones are capable of binding to metal centres and conceivably 
could coordinate to the PdII through the alkene adjacent to C-3 of the 2-pyrone in a similar 
manner to dba, thereby activating the C-H bond.135  Assuming this interaction, there are 
two possible routes through to III which can be taken. The first approach involves a 
neutral palladium centre which loses phosphine and co-ordinates the 2-pyrone, in 
conjunction with transmetallation of the iodide for the carbonate.  The ensuing 
intermediate then rapidly undergoes an intramolecular concerted metallation deprotonation 
(CMD), akin to the mechanisms reported independently by Fagnou and Echavarren 
(Scheme 3.18).120, 136 
  Alternatively the mechanism could involve a cationic PdII intermediate, 
whereby loss of CsI generates the palladium cation stabilised by the carbonate anion.  
Subsequent intermolecular deprotonation of the activated C3-H by the carbonate would 
lead to the reductive elimination precursor III.  
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Scheme 3.18: Potential reaction pathways.  
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Figure 3.9: 1H-NMR (700 MHz, DCM-d2) of (a) 244-d30 and (b) 248. 
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To try and elucidate the reactive pathway, 244 and 244-d30 were treated with a 
silver salt (AgPF6) containing a non-coordinating anion.  Subsequent removal of the silver 
iodide by filtration generated the palladium cations 245 and 245-d30 (Scheme 3.19). 
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244-d30: Ar = C6D5
 
Scheme 3.19: Synthesis of cationic PdII complexes 245 and 245-d30. 
 
 The 1H-NMR spectrum of 245-d30 shows a significant change in the chemical shifts 
of the 2-pyrone signals from δ 4.72 (C-3) and 5.65 (C-5) in 244-d30 to δ 4.41 (C-3) and 
4.73 (C-5) in the cationic complex 245-d30 (Fig. 3.9).  However, further spectroscopic 
techniques, including 13C, 1H-31P HMQC and 1H-13C HMQC, failed to show any 
significant evidence for the formation of 2-pyrone-Pd interactions (C=C or C-H agostic or 
anagostic137). 
The reaction was subsequently tested utilising Ag2CO3 in the reaction to generate 
the cation in the presence of the carbonate base, however monitoring the reaction via 1H-
NMR spectroscopy showed no reactivity.  The lack of reactivity under these conditions 
suggests that the mechanism does not follow a cationic pathway, an observation which was 
subsequently supported by the crystallisation of the PF6- derived intermediate 245.  Upon 
layering the NMR sample (in DCM-d2) of 245 with ether, the formation of white 
crystalline needles were observed following 24 hours in the dark.  Single crystal X-ray 
diffraction studies revealed that the cationic species formed has undergone a Pd to P 
transfer to generate 246 (Scheme 3.20/ Fig. 3.10).  Whilst this type of transformation has 
been reported,138,139 the formation of 246 under such mild conditions indicates that under 
the intramolecular arylation conditions, which require elevated temperatures to occur, this 
pathway will be kinetically and thermodynamically preferred to the cyclisation and thus 
the pathway is unlikely to involve cationic palladium(II) intermediates. 
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Scheme 2.20: Synthesis of 248. 
 
 
Figure 3.10: Crystal structure of 248. 
 
 Whilst further study is required at this stage to determine the mechanism, it seems 
likely that the mechanism involving neutral PdII intermediates and a CMD process is 
preferred (Scheme 3.21).  The key step in the mechanism is the concerted metallation and 
deprotonation between intermediates IV and V, which is promoted by solvation of the 
subsequent acid.   
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Scheme 3.21: Proposed mechanism for intramolecular arylation. 
 
Most of the reported CMD processes reported to date have utilised highly polar 
solvents, such as DMF and DMA, to promote this transition.120, 136  The use of THF in the 
intramolecular C-H functionalisation could partially solvate the intermediate VI, however 
not as much as DMF or DMA, and therefore it would be expected that if the reaction 
proceeds via the CMD pathway the change to one of these solvents would enhance the 
reaction yields.  The intramolecular C-H functionalisation of 218 was subsequently 
attempted in DMF (Scheme 3.22). 
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Scheme 3.22: Intramolecular arylation of 218 in DMF. 
 
 104 
 The intramolecular arylation fails to generate any of the desired product 216, when 
the more polar DMF is used as solvent instead of THF.  This result suggests that the actual 
reaction mechanism does not undergo a CMD pathway as previously suspected. It was 
earlier noted during optimisation conditions (Table 3.1), that the inclusion of pivalic acid 
as an additive restricted the formation of 216, which is also consistent with a non-CMD 
pathway. It therefore seems likely that the CMD process is not involved in the 
intramolecular arylation.  Previous work by Chang and co-workers suggested a ‘Heck-like’ 
mechanism in their synthesis of Coumestan (Scheme 3.12); however they offered no 
mechanism to support their rationale. The ‘Heck-like’ mechanism is so far still a 
possibility in the intramolecular arylation reaction, however there are also problems 
associated with this mechanism. 
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Scheme 3.23: ‘Heck-like’ mechanism for the intramolecular arylation. 
 
The ‘Heck-like’ mechanism, shown in Scheme 3.23, involves the same initial steps 
I-III as for the CMD mechanism. However, instead of forming a 6:6:6 palladacyclic 
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intermediate, loss of a phosphine leads to intermediate IV, where the PdII co-ordinates to 
the alkene of the 2-pyrone.  The PdII-Ar subsequently undergoes a syn-insertion into the 2-
pyrone alkene thereby generating the C-Ar bond in this process to form intermediate V.  
The desired product is subsequently formed via β-H elimination, however due to the syn-
insertion the β-H is located anti to the palladium and an internal rotation is impossible due 
to the rigid cyclic framework.  As a result, the palladium is likely to shift to the more stable 
π-allyl intermediate VI, before undergoing inter-molecular β-H elimination and R.E. to 
regenerate the active Pd0 catalyst II.  The mechanism proposed above requires base for the 
final regeneration of the Pd0 catalyst, it must also be noted that the solubility of Cs2CO3 in 
THF is very low, and therefore will not easily participate in the inter-molecular base 
assisted deprotonation.140 
 At this point neither the ‘Heck-like’ or CMD mechanisms is without problems. 
The most likely pathway based on the results obtained is the ‘Heck-like’ mechanism. It 
should be noted that halide-carbonate exchange may be required prior to the base-assisted 
deprotonation/ R.E. to facilitate product formation. Clearly further study is necessary to 
support the exact mechanism. 
The poor reactivity of electron-withdrawing substituents was further investigated 
by attempting the stoichiometric intramolecular arylation of the CF3-substituted derivative 
228n. 
 Initial preparative scale synthesis of the O.A. product (III) from 228n was 
performed in THF at 70 °C. As expected, the solution became a bright yellow colour 
indicative of the formation of a palladium(II) species.  Following removal of THF in vacuo 
and crystallisation from ether, the formation of dark purple crystals was observed.  Single 
crystal X-ray diffraction of the crystals confirmed the identity of the crystals to be Pd2dba3. 
Assuming the oxidative addition had occurred, the recovery of Pd2dba3 indicates that the 
O.A. step is reversible. 
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1. PPh3 (4 eq.), 228n (3 eq.)
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Scheme 3.22: Preparation of 247. 
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To assess whether O.A. had occurred, the reaction was subsequently performed on 
an NMR scale (Scheme 3.23).  The reaction is observed to undergo O.A. to generate a 
trans-palladium(II) complex, confirmed by 1H and 31P NMR spectroscopy.  Following 2 
hours at 70 °C in the presence of Cs2CO3 the reaction had not proceeded.  Moreover, the 
O.A. was observed to have reversed, regenerating the dba stabilised active catalyst 243, 
identifiable via two broad singlets in the 31P NMR spectrum at δ 26.8 and 25.2 (∆ν½ 42 
Hz).60  
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Scheme 3.23: NMR scale Synthesis of 229n. 
 
The poor yields for the more electron-withdrawing substituents can therefore be 
attributed to the poor conversion from the O.A. products through to the R.E. precursor, due 
to competitive reversal of the O.A. under reaction conditions.  It is important to note that 
the reversal of the O.A. is not the only limitation of the reaction, as in most cases no 
starting material is recovered after the reaction period.  Degradation pathways are therefore 
an important limitation in the intamolecular arylation reaction.  The synthesis of electron 
deficient systems was limited due to the poor nucleophilic character of other functionalised 
phenols containing substituents such as nitro and formyl groups.  The presence of electron 
deficient substituents therefore increases the leaving group potential of the phenoxy group. 
Following deprotonation at the C-7 position of the 2-pyrone, it is conceivable that loss of 
ArO- is a major step in the degradation pathway, consistent with the poor recovery of 
starting materials with electron deficient substituents.  A possible mechanism to enable the 
loss of ArO- involves the initial loss of CO2, and generates the highly unsaturated product 
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248 (Scheme 3.24).  The low molecular mass and high degree of unsaturation in 248 
would suggest that it is likely to be lost as a gas or undergo polymerisation under the 
reaction conditions. 
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Scheme 3.24: Possible degradation pathway of starting materials under basic conditions. 
 
3.4 Conclusion and Future work 
 
3.4.1 Conclusion 
 During the course of studies towards 33 the first catalytic C-H functionalisation of 
a 2-pyrone has been identified and the reaction developed further. Optimised conditions 
have been applied to a wide variety of substrates to yield 15 different benzofuropyrones in 
yields varying from 11-79%. Whilst good yields are observed with alkyl substrates, the 
reaction proceeds poorly with electron deficient functionality and appears to be limited by 
the rate of degradation of the starting materials. In addition, the catalytic cycle has been 
investigated and the initial step confirmed as oxidative addition from a Pd0 source to give a 
distorted square planar complex. The possibility of a cationic reaction pathway has also 
been disproved due to a competing Pd to P transfer at room temperature. 
 
3.4.2 Future work 
 The future work in this area can develop in a number of ways. Further mechanistic 
studies are required to determine an absolute mechanism for the intramolecular arylation. 
In addition to the mechanism, further study of the reaction scope is required. Although the 
formation of a thiophene derivative was unsuccessful, further development and testing 
could give rise to nitrogen and carbon containing derivatives, whilst the variation in the 
size of the central ring is also largely untested. Another potential area to develop is the 
application to 2-pyridinone analogues which should be analogous to the 2-pyrone systems 
so far studied. 
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Figure 3.11: Development potential for intramolecular arylation reaction. 
 
 Finally, the development of more vinyl halide systems such as E-175a, from which 
the reaction was discovered, need to be probed more extensively which could allow rapid 
access to a large series of compounds, such as 249, identified by Hua et al. to have 
excellent bio-activity and a potentially important role in the treatment and prevention of 
Alzheimer’s disease.141 
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Chapter 4: Natural product experimental 
 
4.1 General Details 
Reagents were purchased from either Sigma Aldrich or Alfa Aesar and used 
directly unless otherwise stated.  Dry THF, toluene and diethyl ether were distilled over 
sodium wire using benzophenone indicator and stored over a potassium mirror. Dry 
acetone was distilled over drierite®, MeOH was distilled over magnesium turnings and 
triethylamine was dried over KOH.  All other solvents were dried utilising a chromasolv® 
solvent column.  Nitrogen gas was oxygen free and dried immediately before use via 
passage through sodium hydroxide pellets and silica.  Argon and hydrogen were 
administered directly via balloon.  All carefully additions were performed using a syringe 
pump unless otherwise stated within the text. Filtrations were performed under gravity 
with fluted filter papers unless otherwise stated within the text. 
All TLC analysis was performed using Merck 5554 aluminium backed silica plates 
and visualised using UV light (254 nm), an aqueous solution of potassium permanganate, 
or an ethanol based solution of p-anisaldehyde.  1H NMR and 13C NMR spectra were 
recorded on a Jeol ECX400 or Jeol ECS400 spectrometer operating at 400 and 100 MHz 
respectively, a Bruker 500 spectrometer operating at 500 and 126 MHz respectively.  All 
column chromatography was performed using flash silica-gel with the solvent systems 
specified within the text. 
Mass spectrometry was performed on a Bruker daltronics micrOTOF spectrometer, 
with < 5 ppm error recorded for all HRMS samples.  IR was performed on a Jasco FTIR 
4100 spectrometer using an ATR attachment. Melting point analyses were performed on a 
Stuart SMP3 melting point apparatus, using a temperature ramp of 3 °C/minute. 
 
4.2 General procedures 
 
4.2.1 Suzuki cross-coupling reactions (General Procedure A) 
A solution of arylboronic acid (0.58 mmol, 1 eq.), organohalide (0.58 mmol, 1 eq.) 
and palladium precatalyst 27 (0.0058 mmol, 1 mol %) were stirred in THF (2 ml) under 
nitrogen at 60 °C for 10 minutes.  To this solution aqueous 2M Na2CO3 (1 ml) was added 
and the reaction stirred for up to 5 hours at 60 °C.  The solution was allowed to cool to 22 
°C, diluted with ether (3 ml), and the organic layer separated.  The aqueous layer was then 
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extracted with ether (3 × 3 ml) and the combined organic extracts washed with brine, dried 
over MgSO4, filtered and then concentrated in vacuo.  The product was then purified by 
flash column chromatography on silica gel eluting with hexanes/EtOAc.   
 
4.2.2 Lithiation/alkylations of 4-hydroxy-6-methyl-2-pyrone (General Procedure B) 
4-Hydroxy-6-methyl-2-pyrone 9 (1 mmol, 1 eq.) was heated under nitrogen in 
HMDS (3 ml) to 80 °C for 1 hour.  The solution was allowed to cool and the HMDS 
removed under vacuum.  THF (3 ml) was then added and the solution cooled to -78 °C at 
which point n-BuLi (2.5M in hexanes) (1.25 mmol, 1.25 eq.) was added carefully over 15 
minutes, and the solution stirred for 1 hour.  The alkyl halide (1.7-2.3 mmol, 1.7-2.3 eq.) 
was then added over 10 minutes and the solution allowed to warm gradually to 20 °C and 
stirred for 16h.  The reaction was quenched with 6M HCl until the pH ≈ 2 and the solvent 
removed in vacuo.  The residue was taken up in ethyl acetate (5 ml), washed twice in brine, 
dried over MgSO4, filtered and concentrated in vacuo to afford a crude brown residue 
which was purified by flash column chromatography on silica eluting with MeOH 3% in 
DCM. 
 
4.3 Characterisation data for known and novel compounds  
 
All known compounds are indicated with a reference following the compound title.  
Compounds without a reference are therefore novel and have been characterised 
accordingly. 
 
5-Triisopropylsilyl-4-pentyn-1-ol (42)82,142 
3
2
1
Si
6
7
7
6
6
7
7
7
OH7
 
Route A 
To a stirred solution of 4-pentyn-1-ol 41 (1.06 g, 12.6 mmol, 1 eq.) in THF (50 ml) under 
nitrogen at 0 °C was added n-BuLi (2.5M in hexanes) (0.596 ml, 1.26 mmol, 0.1 eq.) 
carefully over 30 minutes.  The solution was allowed to warm to 22 °C over 30 minutes, 
and chlorotrimethylsilane (1.36 g, 12.6 mmol, 1 eq.) added carefully over 1 hour.  The 
solution was stirred for one hour at 22 °C, then cooled to 0 °C and n-BuLi (2.5M in 
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hexanes) (5.96 ml, 12.6 mmol, 1 eq.) added carefully over 30 minutes.  The solution was 
stirred for 30 minutes at 0 °C then warmed to 22 °C and stirred for a further hour.  
Chlorotriisopropylsilane (2.48 g, 12.9 mmol, 1.02 eq.) was added and the solution stirred at 
22 °C for 16 hours.  The reaction was quenched with 2M HCl (20 ml) and the product 
extracted with ether (3 × 17 ml).  The combined organic extracts were then concentrated in 
vacuo and dissolved in methanol (50 ml).  Potassium hydroxide (0.504 g, 9.0 mmol, 0.74 
eq.) was then added and the solution stirred for 2 hours at 22 °C.  The solution was 
neutralized with drops of 2M HCl and the solvent removed in vacuo.  The residue was 
taken up in water (25 ml) and extracted with ether (3 × 20 ml), then the combined organic 
extracts washed with brine, dried over MgSO4, filtered and concentrated in vacuo.  The 
product was then distilled under reduced pressure (108 °C, 3 mmHg) to afford the title 
compound as a colourless oil (1.21 g, 40%). 
 
Route B 
To a solution of pentyn-1-ol 41 (8.6 mmol, 1 eq.) in THF (16 ml) under argon was added 
ethyl magnesium bromide (3M in ether) (6 ml, 18 mmol, 2.1 eq.) over 30 minutes.  The 
solution was refluxed for 16 hours then cooled to 22 °C and a solution of 
chlorotriisopropylsilane (1.66 g, 8.6 mmol, 1 eq.) in THF (8 ml) added slowly over 10 
minutes.  The reaction mixture was then refluxed for a further 6 hours, then quenched by 
slow addition into 2M HCl (15 ml) and the organic layer separated.  The aqueous layer was 
then washed with ether (3 × 25 ml) and the combined organic extracts washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo.  The product was then distilled 
under reduced pressure (b.p. 108 °C, 3 mmHg) to afford the title compound as a colourless 
oil (1.85 g, 90%). 
1H-NMR (400 MHz, CDCl3): 3.75 (t, J = 6.0 Hz, 2H, C1H2), 2.28-2.31 (m, 2H, C2H2), 
1.73-1.77 (m, 2H, C3H2), 0.98-1.01 (m, 21H, C6H/C7H3); 13C-NMR (100 MHz, CDCl3): 
108.4, 81.1, 61.9, 31.2, 18.3, 16.2, 10.9; MS (ESI) m/z (rel.%): 241 [MH+] (100), 215 (4), 
198 (12), 175 (5), 157 (19); HRMS (ESI) calculated for C14H29OSi [MH+]: 241.1982, 
found: 241.1985. 
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5-Trisopropylsilyl-1-methanesulfonyloxypent-4-yne (43a)76 
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To a solution of 42 (7.2 g, 30 mmol, 1 eq.) and triethylamine (4.55 g, 45 mmol, 1.5 eq.) in 
DCM (60 ml) under nitrogen at -10 °C, was added methanesulfonylchloride (6.87 g, 60 
mmol, 2 eq.).  The reaction was quenched with ice cold water (7.5 ml) and separated.  The 
organic layer was then washed with cold 2M HCl (45 ml), sat. NaHCO3 (45 ml) and brine 
(45 ml).  The organic extracts were then dried over Na2SO4, filtered and concentrated in 
vacuo to afford a pale yellow oil (10.2 g, quant.) which was used without further 
purification.  
1H-NMR (400 MHz, CDCl3): 4.38 (t, J = 6.4 Hz, 2H, C1H2), 3.02 (s, 3H, C8H3), 2.43 (t, J 
= 6.4 Hz, 2H, C3H2), 1.97 (p, J = 6.4 Hz, 2H, C2H2), 1.03-1.07 (m, 21H, C6H/C7H3); 13C-
NMR (100 MHz, CDCl3): 106.3, 82.2, 68.6, 37.3, 28.4, 18.7, 16.2, 11.3; MS (ESI) m/z 
(rel.%): 341 [MNa+] (100), 272 (4), 209 (76), 181 (36), 157 (30); HRMS (ESI) calculated 
for C15H30O3SSi [MNa+]: 341.1577, found: 341.1577.  
 
5-Triisopropylsilyl-1-iodopent-4-yne (43b)76 
3
2
1
Si
6
7
7
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6
7
7
7
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A solution of 43a (10.2 g, 30 mmol, 1 eq.) and NaI (13.5 g, 90 mmol, 3 eq.) in acetone 
(300 ml) were stirred for 16 hours under argon at 20 °C, then refluxed for 2 hours.  The 
solution was allowed to cool before being filtered, the filtrate was concentrated in vacuo 
taken up in pentane (5 × 5 ml), filtered and solvent removed in vacuo to afford the title 
compound as a pale yellow oil (8.2 g, 78.1%), which was used immediately without further 
purification.  
1H-NMR (400 MHz, CDCl3): 3.34 (t, J = 6.7 Hz, 2H, C1H2), 2.40 (t, J = 6.7 Hz, 2H, 
C3H2), 2.00 (p, J = 6.7 Hz, 2H, C2H2), 1.00-1.08 (m, 21H, C6H/C7H3); 13C-NMR (100 
MHz, CDCl3): 106.1, 81.5, 31.9, 20.6, 18.4, 11.0, 5.1; MS (ESI) m/z (rel.%): 351 [MH+] 
(100).  
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5-Triisopropylsilyl-1-bromopent-4-yne (43c) 
3
2
1
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6
7
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6
7
7
7
Br7
 
To a solution of 42 (500 mg, 2.1 mmol, 1 eq.) in THF (4 ml) under nitrogen at 0 °C, was 
added PBr3 (226 mg, 0.83 mmol, 0.4 eq.) carefully over 10 minutes.  The solution was 
stirred for 1 hour at 0 °C, then allowed to warm to 22 °C and stirred for a further 2 hours. 
The reaction was quenched with 1M NaHCO3 until pH ≈ 7 and the aqueous layer extracted 
with ether (3 × 3 ml) and the combined organic extracts washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo.  The product was then purified by column 
chromatography on silica-gel (using hexanes) and visualized by p-anisaldehyde stain, to 
afford a pale yellow oil (63 mg, 10%).  
1H-NMR (400 MHz, CDCl3): 3.77 (t, J = 5.8 Hz, 2H, C1H2), 2.37 (t, J = 6.8 Hz, 2H, 
C3H2), 1.73-1.82 (m, 2H, C2H2), 0.99-1.07 (m, 21H, C6H/ C7H3); 13C-NMR (100 MHz, 
CDCl3): 106.6, 99.9, 81.6, 32.5, 30.9, 18.6, 11.2; MS (ESI) m/z (rel.%): 223 (40), 209 (15), 
195 (8); HRMS: not available due to loss of Br under ESI conditions. 
 
5-Triisopropylsilyl-1-toluenesulfonyloxypent-4-yne (43d) 
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To a solution of 42 (240 mg, 1 mmol, 1 eq.) and triethylamine (151 mg, 1.5 mmol, 1.5 eq.) 
in DCM (2 ml) under nitrogen at -10 °C, was added toluenesulfonylchloride (381 mg, 2 
mmol, 2 eq.).  The reaction was quenched with ice cold water (1.5 ml) and separated.  The 
organic layer was then washed with cold 2M HCl (1.5 ml), sat. NaHCO3 (1.5 ml) and brine 
(1.5 ml).  The organic extracts were then dried over Na2SO4, filtered and concentrated in 
vacuo purified by flash column chromatography (pet. ether) to afford a pale yellow oil 
(857 mg, 43.5%). 
1H-NMR (400 MHz, CDCl3): 7.78 (d, J = 8.2 Hz, 2H, C9H), 7.33 (d, J = 8.2 Hz, 2H, 
C10H), 4.14 (t, J = 6.6 Hz, 2H, C1H2), 2.43 (s, 3H, C12H3), 2.31 (t, J = 6.6 Hz, 2H, C3H2), 
1.85 ( p, J = 6.6 Hz, 2H, C2H2), 0.96-1.00 (m, 21H, C6H/C7H3); 13C-NMR (100 MHz, 
CDCl3): 145.1, 133.2, 130.1, 128.1, 106.5, 81.6, 69.0, 28.0, 21.3, 18.2, 15.8, 10.8; MS 
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(ESI) m/z (rel.%): 417 [MNa+] (100), 395 (24), 329 (15), 285 (79), 257 (11), 157 (13); 
HRMS (ESI) calculated for C21H34NaO3SSi [MNa+]: 417.1890, found: 417.1888. 
 
3.5.6 4-Hydroxy-6-(6-triisopropylsilyl-hex-5-yne)-2-pyrone (44) 
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 43b (550 
mg, 1.6 mmol, 1.6 eq.) to afford the title compound as a yellow oil (239 mg, 69%). 
1H-NMR (400 MHz, CDCl3): 5.93 (d, J = 2.1 Hz, 1H, C5H), 5.54 (d, J = 2.1 Hz, 1H, 
C3H), 2.47 (t, J = 7.5 Hz, 2H, C7H), 2.24 (t, J = 6.9 Hz, 2H, C10H), 1.74-1.84 (m, 2H, 
C8H), 1.53-1.62 (m, 2H, C9H), 0.97-1.01 (m, 21H, C13H/ C14H3); 13C-NMR (100 MHz, 
CDCl3): 172.3, 167.9, 166.8, 107.9, 101.3, 89.9, 80.9, 53.4, 33.0, 27.9, 25.6, 18.6, 11.2; 
MS (ESI) m/z (rel.%): 349 [MH+] (100), 307 (8), 255 (3), 167 (4); HRMS (ESI) calculated 
for C20H33O3Si [MH+]: 349.2193, found: 349.2189; IR (DCM, cm-1): 3684, 2944, 2865, 
2169, 1693, 1613, 1572, 1462. 
 
4-Hydroxy-6-(hex-5-yne)-2-pyrone (45) 
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A solution of 44 (80 mg, 0.23 mmol, 1 eq.) and TBAF (1M in THF) (0.69 ml, 0.69 mmol, 
3 eq.) in THF (1 ml) was stirred under nitrogen at 22 °C for 16 hours.  The reaction was 
quenched with 2M HCl (1 ml) and the product extracted with ether (3 × 3 ml) then 
concentrated in vacuo.  The resulting product was purified by flash column 
chromatography on silica-gel, eluting with 1% MeOH in DCM, to afford the title 
compound as a waxy yellow solid (32.3 mg, 73%). 
1H-NMR (400 MHz, CDCl3): 5.97 (d, J = 1.9 Hz, 1H, C5H), 5.56 (d, J = 1.9 Hz, 1H, 
C3H), 2.50 (t, J = 7.57 Hz, 2H, C7H2), 2.21 (dt, J = 6.91 Hz, 2H, C10H2), 1.95 (t, J = 2.5 
Hz, 1H, C12H), 1.74 – 1.81 (m, 2H, C9H), 1.56 (p, J = 7.4 Hz, 2H, C8H); 13C- NMR (100 
MHz, CDCl3): 172.1, 167.8, 166.6, 101.3, 89.9, 83.6, 68.8, 33.1, 27.5, 25.6, 18.0; MS 
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(ESI) m/z (rel.%): 191 [MH+] (83), 147 (100); HRMS (ESI) calculated for C11H11O3 [M+]: 
191.0714, found: 191.0719; IR (DCM, cm-1): 3304, 2928, 1702, 1693, 1639, 1453, 1365. 
 
Hex-5-en-2-yn-1-ol (48)137, 72  
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Propargyl alcohol 47 (5.6 g, 100 mmol, 1 eq.) was stirred under nitrogen in acetone (400 
ml) at 22 °C.  Allyl bromide 46 (14.5 g, 120 mmol, 1.2 eq.) was then added, followed by 
CuI (19.1 g, 100 mmol, 1 eq.), NaI (30.0 g, 200 mmol, 2 eq.) and K2CO3 (27.6 g, 200 
mmol, 2 eq.).  The solution was stirred for 16 hours before being quenched with 1N HCl 
(120 ml), diluted with water (500 ml) and stirred for 10 minutes.  The mixture was then 
filtered through CeliteTM and the filtrate extracted with ether (5 × 120 ml).  The combined 
organic extracts were then dried over MgSO4, filtered and concentrated in vacuo to afford 
the crude product, which was purified by Kuhglrohr distillation under reduced pressure 
(b.p. 100 °C, 6 mmHg) to afford the title compound as a colourless oil (9.5 g, 99%). 
1H-NMR (400 MHz, CDCl3): 5.78 (ddt, J = 17.0, 10.0, 5.4 Hz, 1H, C5H), 5.28 (ddt, J = 
17.0, 1.7, 1.7 Hz, 1H, C6Hb), 5.09 (ddt, J = 10.0, 1.7, 1.7 Hz, 1H, C6Ha), 4.26 (t, J = 2.2 
Hz, 2H, C1H2), 2.95-3.00 (m, 2H, C4H2), 2.19 (s, 1H, OH); 13C-NMR (100 MHz, CDCl3): 
132.2, 116.2, 82.76, 80.6, 51.1, 23.0; MS (EI) m/z (rel.%): 95 [M+] (62), 81 (100), 77 (24), 
67 (32), 53 (22) 
 
(2Z)-Hexa-2,5-dien-1-ol (49)143 
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A stirred solution of 48 (480 mg, 5 mmol, 1 eq.), quinoline (32 mg, 0.25 mmol, 0.05 eq.) 
and Lindlar catalyst (520 mg, 5 mol % palladium) in methanol (5 ml) was stirred under a 
hydrogen atmosphere at 22 °C for 5 hours.  The solution was then filtered through CeliteTM 
and concentrated in vacuo, then the crude material was purified by flash column 
chromatography (15% EtOAc in hexanes) and visualized by p-anisaldehyde stain, to give 
an colourless oil (378mg, 77%). 
1H-NMR (400 MHz, CDCl3): 5.80 (ddt, J = 17.1, 10.1, 6.2 Hz, 1H, C5H), 5.66 (dtt, J = 
10.8, 6.6, 1.5 Hz, 1H, C3H), 5.57 (dtt, J = 10.8, 6.5, 1.3 Hz, 1H, C2H), 5.04 (ddt, 17.1, 1.7, 
1.7 Hz, 1H, C6Hb), 5.00 (ddt, 10.1, 1.7, 1.7 Hz, 1H, C6Ha), 4.21 (dd, J = 6.6, 1.5 Hz, 1H, 
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C1H2), 2.80-2.92 (m, 2H, C4H2); 13C-NMR (100 MHz, CDCl3): 136.41, 129.86, 129.69, 
115.26, 60.50, 31.67; MS (EI) m/z (rel.%): 97 [M+] (25), 83 (12), 80 (100), 70 (14), 67 
(42), 57 (93), 54 (41), 43 (17), 41 (73), 39 (73). 
 
(2Z)-1-Bromohexa-2,5-diene (50)144 
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To a stirred solution of CBr4 (1.99 g, 6 mmol, 1.2 eq.) and PPh3 (1.57 g, 6 mmol, 1.2 eq.) 
in DCM (10 ml), under nitrogen at 22 °C, was added 49 (490 mg, 5 mmol, 1 eq.) carefully.  
The solution was stirred for 4 hours then the solvent removed and the crude material 
passed through a silica plug, eluting with ether. Concentration in vacuo afforded the title 
compound as a yellow oil (403 mg, 50%). 
1H-NMR (400 MHz, CDCl3): 5.76-5.87 (m, 2H, C5H/ C2H), 5.63 (dtt, J = 10.5, 7.6, 0.8 
Hz, 1H, C3H), 5.08 (ddt, J = 17.1, 1.7, 1.7 Hz, 1H, C6Hb), 5.04 (ddt, J = 10.0, 1.7, 1.7 Hz, 
1H, C6Ha), 3.99 (d, J = 8.3 Hz, 2H, C1H2), 2.90 (m, 2H, C4H2); 13C-NMR (100 MHz, 
CDCl3): 135.3, 132.5, 126.3, 115.8, 31.0, 26.8; MS (EI) m/z (rel.%): 81 [MH+-Br] (100), 
53 (30), 41 (34). 
 
Diphenylmethane (58)145 
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 57 (50 
mg, 0.41 mmol, 1 eq.) to afford the title compound as a pale yellow oil (88 mg, 88%). 
1H-NMR (400 MHz, CDCl3): 7.32-7.28 (m, 4H), 7.23-7.19 (m, 6H), 4.00 (s, 2H); 13C-
NMR (100 MHz, CDCl3): 141.1, 128.9, 128.4, 126.0, 41.9; MS (EI) m/z (rel.%): 168 
[MH+] (100), 152 (19), 91 (22). 
 
2-Benzyl-5-acetylthiophene (60)146 
S O
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 59 (70 
mg, 0.41 mmol, 1 eq.) to afford the title compound as a pale yellow oil (103 mg, 82%).  
1H-NMR (400 MHz, CDCl3): 7.53 (d, J = 3.8 Hz, 1H), 7.33 (tt, J = 7.2, 1.4 Hz, 2H), 7.28-
7.23 (m, 3H), 6.83 (dt, J = 3.8, 0.8 Hz, 1H), 4.16 (s, 2H), 2.50 (s, 3H); 13C-NMR (100 
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MHz, CDCl3): 190.5, 153.9, 142.8, 138.9, 132.8, 128.7, 128.5, 126.8, 126.3, 36.6, 26.4; 
MS (EI) m/z (rel.%): 216 [MH+] (87), 201 (100), 173 (60), 129 (27). 
 
2-Benzyl-5-chlorothiophene (62)147 
S
Cl
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 61 
(66.4 mg, 0.41 mmol, 1 eq.) to afford the title compound as a pale yellow oil (102 mg, 
84%). 
1H-NMR (400 MHz, CDCl3): 7.36-7.30 (m, 2H), 7.28-7.22 (m, 3H), 6.73 (dd, J = 3.7, 1.8 
Hz, 1H), 6.58 (d, J = 3.7 Hz, 1H), 4.06 (s, 2H); 13C-NMR (100 MHz, CDCl3): 142.9, 
139.5, 128.6, 128.5, 127.9, 126.7, 125.7, 124.3, 36.4; MS (EI) m/z (rel.%): 208 [MH+] 
(67), 173 (100), 131 (25). 
 
3-Benzylthiophene (64)148 
S
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 63 
(52.5 mg, 0.41 mmol, 1 eq.) to afford the title compound as a pale yellow oil (99 mg, 
96%).  
1H-NMR (400 MHz, CDCl3): 7.33-7.29 (m, 2H), 7.26 (dd, J = 4.9, 3.1 Hz, 1H), 7.24-7.20 
(m, 3H), 6.94-6.91 (m, 2H), 4.00 (s, 2H); 13C-NMR (100 MHz, CDCl3):141.5, 140.6, 
128.7, 128.45, 128.43, 126.1, 125.6, 121.2, 36.5; MS (EI) m/z (rel.%): 174 [MH+] (100), 
97 (48). 
 
2-Benzyl-5-formylthiophene (66)149 
S
H
O
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 65 (64 
mg, 0.41 mmol, 1 eq.) to afford the title compound as a yellow oil (70 mg, 60%).  
1H-NMR (400 MHz, CDCl3): 9.81 (s, 1H), 7.61 (d, J = 3.8 Hz, 1H), 7.34 (tt, J = 8.0, 1.7 
Hz, 2H), 7.29-7.23 (m, 3H), 6.91 (dt, J = 3.7, 0.8 Hz, 1H), 4.19 (s, 2H); 13C-NMR (100 
MHz, CDCl3): 182.7, 155.8, 142.4, 138.7, 136.9, 128.8, 128.7, 127.1, 126.6, 36.9; MS (EI) 
m/z (rel.%): 202 [MH+] (100), 173 (92), 129 (20). 
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1-Benzyl-3,5-difluorobenzene (72) 
F
F
 
Prepared according to General Procedure A using 56 (100 mg, 0.58 mmol, 1 eq.) and 71 
(92.4 mg, 0.58 mmol, 1 eq.) to afford the title compound as a colourless oil (82 mg, 69%).  
1H-NMR (400 MHz, CDCl3): 7.33 (tt, J = 8.2, 1.6 Hz, 2H), 7.25 (tt, J = 6.2, 1.4 Hz, 1H), 
7.20-7.17 (m, 2H), 6.74-6.68 (m, 2H), 6.65 (tt, J = 9.0, 2.3 Hz, 1H), 3.96 (s, 2H); 13C-
NMR (100 MHz, CDCl3): 163.0 (dd, JC-F = 248.0, 12.9 Hz), 145.0 (t, JC-F = 8.9 Hz), 
139.4, 128.9, 128.7, 126.6, 111.6 (dd, JC-F = 18.4, 6.5 Hz), 101.6 (t, JC-F = 25.4 Hz), 
41.6 (t, JC-F = 1.9 Hz); 19F NMR (376 MHz, CDCl3): -110.3 (m, 2F); MS (EI) m/z 
(rel.%): 204 [MH+] (100), 183 (36), 127 (8), 91 (19); HRMS (EI) calculated for C13H10F2 
[MH+]: 204.0751, found: 204.0752; IR (neat, cm-1): 3086, 3063, 3030, 1624, 1596, 1495, 
1461, 1452, 1322, 1116, 991, 972, 844, 757, 701, 684. 
 
2-Benzylthiophene (74)153 
S
 
Prepared according to General Procedure A using 56 (70 mg, 0.41 mmol, 1 eq.) and 73 
(52.5 mg, 0.41 mmol, 1 eq.) to afford the title compound as a pale yellow oil (91 mg, 
90%).  
1H-NMR (400 MHz, CDCl3): 7.43-7.38 (m, 2H), 7.36-7.31 (m, 3H), 7.23 (dd, J = 5.1, 1.2 
Hz, 1H), 7.02 (dd, J = 5.1, 3.4 Hz, 1H), 6.90 (dd, J = 3.4, 1.2 Hz, 1H), 4.25 (s, 2H); 13C-
NMR (100 MHz, CDCl3): 144.0, 140.3, 128.53, 128.48, 126.7, 126.4, 125.1, 123.9, 36.0; 
MS (EI) m/z (rel.%): 174 [MH+] (100), 97 (44). 
 
4-Hydroxy-6-(hex-5-ene)-2-pyrone (87)150 
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 86 (342 
mg, 2.3 mmol, 2.3 eq.) to afford the title compound as a yellow oil (95 mg, 49%).  
1H-NMR (400 MHz, CDCl3): 5.98 (s, 1H, C5H), 5.76 (ddt, J = 17.0, 10.2, 7.1 Hz, 1H, 
C11H), 5.58 (s, 1H, C3H), 4.99 (ddt, J = 17.0, 2.0, 2.0 Hz, 1H, C12Ha), 4.94 (ddt, J = 10.2, 
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2.0, 1.2 Hz, 1H, C12Hb), 2.48 (t, J = 7.5 Hz, 2H, C7H2), 2.02-2.08 (m ,2H, C8H2), 1.60-1.69 
(m, 2H, C10H2), 1.39-1.48 (m, 2H, C9H2); 13C-NMR (100 MHz, CDCl3): 172.49, 168.21, 
167.10, 138.11, 114.92, 101.32, 89.81, 33.46, 33.25, 28.07, 26.06; MS (ESI) m/z (rel.%): 
195 [MH+] (100); HRMS (ESI) calculated for C11H15O3 [M+]: 195.1016, found: 195.1011. 
 
4-Hydroxy-6-(2-phenylethyl)-2-pyrone (90)17  
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 56 (373 
mg, 2.3 mmol, 2.3 eq.) to afford the title compound as a yellow solid (85 mg, 40%). 
Mpt: 134-135 °C (lit. 137-138 °C); 1H-NMR (400 MHz, CDCl3): 7.32-7.14 (m, 5H, C10H/ 
C11H/ C12H), 5.92 (d, J = 2.1 Hz, 1H, C5H), 5.57 (d, J = 2.1 Hz, 1H, C3H), 2.96 (dd, J = 
8.8, 6.8 Hz, 2H, C7H2), 2.78 (dd, J = 8.8, 6.8 Hz, 2H, C8H2); 13C-NMR (100 MHz, 
CDCl3): 172.24, 167.94, 165.87, 139.50, 128.54, 128.15, 126.43, 101.72,89.94, 35.36, 
32.70; MS (ESI) m/z (rel.%): 217 [MH+] (100); HRMS (ESI) calculated for C13H13O3 
[M+]: 217.0859, found: 217.0865. 
 
4-Methoxy-6-methyl-2-pyrone (91)151 
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To a stirred suspension of 4-hydroxy-6-methyl-2-pyrone 9 (5.29 g, 42 mmol, 1 eq.) and 
potassium carbonate (17.4 g, 126 mmol, 3 eq.) in acetone (80 ml), was added dimethyl 
sulphate (5.29 g, 42 mmol, 1 eq.).  The solution was then refluxed (48 °C) for 48 hours, 
allowed to cool and filtered through CeliteTM.  The filtrate was concentrated in vacuo and 
recrystallised from pet. ether to afford a white crystalline powder (4.75 mg, 81%). 
Mpt: 87-88 °C (lit. 87-88 °C); 1H-NMR (400 MHz, CDCl3): 5.76 (d, J = 2.2 Hz, 1H, 
C5H), 5.39 (d, J = 2.2 Hz, 1H, C3H), 3.77 (s, 3H, C8H3), 2.18 (s, 3H, C7H3); 13C-NMR 
(100 MHz, CDCl3): 171.4, 165.1, 162.1, 100.4, 87.4, 55.9, 19.9; MS (ESI) m/z (rel.%): 141 
[MH+] (100) 
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4-Isopropyloxy-6-methyl-2-pyrone (92) 
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To a stirred solution of 4-hydroxy-6-methyl-2-pyrone 9 (1.89 g, 15 mmol, 1 eq.), 
triphenylphosphine (5.89 g, 22.5 mmol, 1.5 eq.) and isopropyl alcohol (1.35 g, 22.5 mmol, 
1.5 eq.), in THF (90 ml) under nitrogen at ambient temperature, was added DIAD (4.54 g, 
22.5 mmol, 1.5 eq.) carefully.  The solution was then stirred for 16 hours and the solvent 
removed in vacuo, then the product purified by flash column chromatography (20% EtOAc 
in hexanes) to afford a white crystalline solid (1.76 g, 70%). 
Mpt: 49-51 °C; 1H-NMR (400 MHz, CDCl3): 5.71 (m, 1H, C5H), 5.35 (d, J = 2.2 Hz, 1H, 
C3H), 4.49 (sept., J = 6.1 Hz, 1H, C8H), 2.18 (s, 3H, C7H3), 1.32 (d, J = 6.1 Hz, 6H, 
C9H3); 13C-NMR (100 MHz, CDCl3): 169.41, 165.15, 161.85, 100.96, 87.81, 71.37, 21.23; 
MS (ESI) m/z (rel.%): 169 [MH+] (100). HRMS (ESI) calculated for C9H12O3Na [M+]: 
191.0679, found: 191.0682; IR (DCM, cm-1): 2984, 2937, 1733, 1651, 1562, 1467, 1376, 
1321. 
 
1-Iodooct-7-en-4-yne (94) (via 1-(methanesulfonyloxy)oct-7-en-4-yne)137 
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To a solution of oct-7-en-5-yn-1-ol (203) (12.4 g, 100 mmol, 1 eq.) and TEA (20.8 g, 150 
mmol, 1.5 eq.) in DCM (800 ml) under nitrogen at 20 °C, was added 
methanesulfonylchloride (22.9 g, 200 mmol, 2 eq.).  The reaction was quenched with ice 
cold water (150 ml) and separated.  The organic layer was then washed with cold 2M HCl 
(150 ml), sat. NaHCO3 (150 ml) and brine (150 ml).  The organic extracts were then dried 
over MgSO4, filtered and concentrated in vacuo to afford a pale yellow oil (20.2 g, >99%) 
which was used without further purification.  
1H- NMR (400 MHz, CDCl3): 5.81 (ddt, J = 16.9, 10.0, 5.3 Hz, 1H, C7H), 5.23 (dd, J 
=16.9, 1.7  Hz, 1H, C8Ha), 5.10 (dd, J =10.0, 1.7 Hz, 1H, C8Hb), 4.35 (t, J = 6.4 Hz, 2H, 
C1H2), 3.02 (s, 3H, C9H3),  2.91-2.95 (m, 2H, C6H2), 2.36 (tt, J =6.4, 2.5 Hz, 2H, C3H2), 
1.94 (p, J = 6.4 Hz, 2H, C2H2); 13C-NMR (100 MHz, CDCl3): 133.4, 116.2, 80.7, 78.7, 
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69.1, 37.6, 28.7, 23.4, 15.4; MS (ESI) m/z (rel.%): 203 [MH+] (100); IR (neat, cm-1): 2943, 
2866, 2172, 1464, 1427, 1360, 1185, 971. 
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A solution of 1-(methanesulfonyloxy)oct-7-en-4-yne (20.2 g, 100 mmol, 1 eq.) and NaI (45 
g, 300 mmol, 3 eq.) was stirred in acetone (300 ml) for 72 hours under nitrogen, and then 
refluxed for 2 hours.  The solution was allowed to cool then filtered and the filtrate 
concentrated in vacuo.  The crude product was then taken up in hexane (3 × 40 ml) filtered 
and reduced in vacuo to afford a pale yellow oil (17.4 g, 74.5%), which was used 
immediately without further purification.  
1H- NMR (400 MHz, CDCl3): 5.81 (ddt, J = 16.9, 10.0, 5.3 Hz, 1H, C7H), 5.30 (ddt, J 
=16.9, 1.7, 1.7 Hz, 1H, C8Ha), 5.10 (ddt, J = 10.0, 1.7, 1.7 Hz, 1H, C8Hb),  3.31 (t, J = 6.7 
Hz, 2H, C1H2), 2.93 (m, 2H, C6H2), 2.34 (tt, J = 6.7, 2.4 Hz, 2H, C3H2), 1.99 (p, J = 6.7 
Hz, 2H, C2H2); 13C-NMR (100 MHz, CDCl3): 133.50, 116.15, 80.77, 78.35, 32.86, 23.49, 
20.25, 5.90; MS (EI) m/z (rel.%): 234 [MH+] (33), 206 (21), 155 (10), 127 (8), 105 (9), 91 
(45), 79 (100), 65 (10), 51 (25), 39 (23); IR (neat, cm-1): 2945, 2865, 2173, 1463, 1427, 
1364, 1220, 1177. 
 
4-Hydroxy-6-(non-8-en-5-ynyl)-2-pyrone (95) 
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 94 (330 
mg, 1.4 mmol, 1.4 eq.) to afford the title compound as a yellow oil (74 mg, 32%). 
1H- NMR (400 MHz, CDCl3): 6.00 (d, J= 2.1 Hz, 1H, C5H), 5.83 (ddt, J = 17.0, 10.0, 5.3 
Hz, 1H, C14H), 5.58 (d, J= 2.1 Hz, 1H, C3H), 5.28 (ddt, J = 17.0, 1.8, 1.8 Hz, 1H, C15Hb), 
5.08 (ddt, J = 10.0, 1.8, 1.8 Hz, 1H, C15Ha), 2.91-2.94 (m, 2H, C13H2), 2.51 (t, J = 7.6, 2H, 
C7H2), 2.22 (tt, J = 7.0, 2.4 Hz, 2H, C10H2), 1.72-1.80 (m, 2H, C8H2) 1.51-1.58 (m, 2H, 
C9H2); 13C- NMR (100 MHz, CDCl3) 172.6, 168.2, 166.9, 133.2, 133.2, 115.7, 115.7, 
101.5, 89.9, 81.8, 33.2, 28.1, 25.7, 23.1, 18.4; MS (ESI) m/z (rel.%):233 [MH+] (100), 255 
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[MNa+] (19); HRMS (ESI) calculated for C14H17O3 [M+]: 233.1172, found: 233.1178; IR 
(neat, cm-1): 3083, 2939, 2619, 1694, 1568, 1492, 1445, 1364, 1250, 1142, 993. 
 
4-Hydroxy-6-(but-3-en)-2-pyrone (96)147 
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 45 (363 
mg, 2.3 mmol, 2.3 eq.) to afford the title compound as a waxy yellow solid (88 mg, 50%).  
1H-NMR (400 MHz, CDCl3): 6.01 (d, J = 1.9 Hz, 1H, C5H), 5.77 (ddt, J = 17.1, 10.1, 6.8 
Hz, 1H, C9H), 5.58 (d, J = 1.9 Hz, 1H, C3H), 5.05 (ddt, J = 17.1, 1.5, 1.5 Hz, 1H, C10Ha), 
5.01 (dtd, J = 10.1, 3.3, 1.5 Hz, 1H, C10Hb), 2.57 (t, J = 7.5 Hz, 2H, C7H2), 2.35-2.41 (m, 
2H, C8H); 13C-NMR (100 MHz, CDCl3): 172.70, 168.38, 166.28, 135.94, 116.45, 101.85, 
90.02, 33.04, 30.62; MS (ESI) m/z (rel.%): 167 [MH+] (100); HRMS (ESI) calculated for 
C9H11O3 [MH+]: 167.0703, found: 167.0704. 
 
4-Hydroxy-6-(4,8-dimethylnona-3,7-dien)-2-pyrone (97) 
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Prepared according to General Procedure B using 9 (126 mg, 1 mmol, 1 eq.) and 81 (395 
mg, 2.3 mmol, 2.3 eq.) to afford the title compound as a dark yellow oil (95 mg, 36%). 
1H-NMR (400 MHz, CDCl3): 5.95 (d, J = 2.1 Hz, 1H, C5H), 5.57 (d, J = 2.1 Hz, 1H, 
C3H), 5.06 (m, 2H, C9H/ C13H), 2.49 (t, J = 7.4 Hz, 2H, C7H), 2.33 (dd, J = 14.6, 6.7 Hz, 
2H, C12H2), 2.04 (dd, J = 14.6, 6.7 Hz, 2H, C11H2), 1.95 (d, J = 7.4 Hz, 2H, C8H2), 1.66 (d, 
J = 0.9 Hz, 3H, C17H3), 1.58 (s, 6H, C15H3/ C16H3); 13C-NMR (100 MHz, CDCl3): 172.03, 
167.71, 166.70, 137.39, 131.52, 124.02, 121.52, 101.23, 99.89, 89.84, 39.58, 33.80, 26.56, 
25.66, 17.67, 16.00; MS (ESI) m/z (rel.%): 263 [MH+] (100); HRMS (ESI) calculated for 
C16H23O3 [MH+]: 263.1642, found: 263.1632; IR (neat, cm-1): 3373, 2968, 2927, 2621, 
1673, 1574, 1439, 1376, 1254, 1150, 997. 
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4-Hydroxy-6-(undec-10-en)-2-pyrone (99)152 
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Prepared according to General Procedure B using 9 (504 mg, 4 mmol, 1 eq.) and 98 (876 
mg, 4 mmol, 1 eq.) to afford the title compound as a yellow oil (45 mg, 17%). 
1H-NMR (400 MHz, CDCl3): 5.95 (d, J = 1.8 Hz, 1H, C5H), 5.73 (ddt, J = 16.9, 10.2, 6.7 
Hz, 1H, C16H), 5.58 (d, J = 1.8 Hz, 1H, C3H), 4.92 (m, 2H, C17H2), 2.38 (tt, J = 9.00, 5.50 
Hz, 2H), 2.01 (m, 4H), 1.58 (m, 6H), 1.31 (m, 6H); 13C-NMR (100 MHz, CDCl3): 178.41, 
172.07, 167.23, 138.96, 113.90, 99.23, 89.60, 81.39, 33.55, 29.17, 29.14, 28.97, 28.84, 
28.69, 28.66, 26.42; MS (EI) m/z (rel.%): 265 [MH+] (100). 
 
1-Toluenesulfonyloxypent-4-yne (100)153 
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To a solution of 4-pentyn-1-ol (0.42 g, 5 mmol, 1 eq.) and TEA (0.75 g, 7.5 mmol, 1.5 eq.) 
in DCM (20 ml) under nitrogen at -10 °C, was added toluenesulfonylchloride (1.9 g, 10 
mmol, 2 eq.).  The reaction was quenched with ice cold water (7.5 ml) and separated.  The 
organic layer was then washed with cold 2M HCl (7.5 ml), sat. NaHCO3 (7.5 ml) and brine 
(7.5 ml).  The organic extracts were then dried over Na2SO4, filtered, concentrated in 
vacuo purified via flash column chromatography (hexanes) to afford a pale yellow oil 
(1.07g, 90%). 
1H-NMR (400 MHz, CDCl3): 7.79 (d, J = 8.4 Hz, 2H, C7H), 7.35 (d, J = 8.4 Hz, 2H, 
C8H), 4.14 (t, J = 6.1 Hz, 2H, C1H2), 2.45 (s, 3H, C10H3), 2.26 (dt, J = 6.7, 2.7 Hz, 2H, 
C3H2), 2.04 (s, 1H, C5H), 1.85 (t, J = 6.7 Hz, 2H, C2H2); 13C-NMR (100 MHz, CDCl3): 
144.91, 133.01, 129.95, 128.03, 82.20, 69.52, 68.82, 27.80, 21.74, 14.79; MS (ESI) m/z 
(rel.%): 261 [MNa+] (100), 228 (8), 173 (9), 157 (9); HRMS (ESI) calculated for 
C12H14NaO3S [MNa+]: 261.0556, found: 261.0566. 
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4,4'-Bis-trifluoromethyl-biphenyl (102)154 
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A solution of 9 (152 mg, 1.2 mmol, 1.2 eq.), 101 (225 mg, 1 mmol, 1 eq.), Pd(OAc)2 (4.5 
mg, 0.02 mmol, 2 mol%), K3PO4 (424 mg, 2 mmol, 2 eq.) and 28 (8.9 mg, 0.03 mmol, 3 
mol%) in toluene (2 ml) was heated at 100 °C under nitrogen for 24 hours.  The solution 
was allowed to cool and filtered through CeliteTM, then concentrated in vacuo to afford the 
crude product which was purified by flash column chromatography (hexanes) to afford a 
white powder (218 mg, 70%).  
1H-NMR (400 MHz, CDCl3): 7.63 (dd, J = 8.8, 0.7 Hz, 4H), 7.49 (dd, J = 8.8, 0.7 Hz, 
4H): MS (ESI) m/z (rel.%): 313 [MNa+] (100). 
 
4,4'-Dimethoxy-biphenyl (104)1540 
OO
 
A solution of 9 (152 mg, 1.2 mmol, 1.2 eq.), 103 (187 mg, 1 mmol, 1 eq.), Pd(OAc)2 (4.5 
mg, 0.02 mmol, 2 mol%), K3PO4 (424 mg, 2 mmol, 2 eq.) and 28 (8.9 mg, 0.03 mmol, 3 
mol%) in toluene (2 ml) was heated at 100 °C under nitrogen for 24 hours.  The solution 
was allowed to cool and filtered through CeliteTM, then concentrated in vacuo to afford the 
crude product which was purified by flash column chromatography (hexanes) to afford a 
white powder (200 mg, 85%). 
1H-NMR (400 MHz, CDCl3): 7.38 (d, J = 9.1 Hz, 4H), 6.78 (d, J = 9.1 Hz, 4H), 3.37 (s, 
6H); MS (ESI) m/z (rel.%): 237 [MNa+] (100). 
 
1-Toluenesulfonyloxybutan-1-ol (108)137, 155 
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A solution of toluenesulfonyl chloride (51.5 g, 270 mmol, 1 eq.), TEA (54.6 g, 405 mmol, 
1.5 eq.) and butane-1,2-diol (36.5 g, 540 mmol, 2 eq.) under nitrogen in DCM (800 ml), 
was stirred at 20 °C for 16 h.  The reaction was then quenched with ice cold water (550 ml) 
and the aqueous layer removed.  The organic layer was then washed sequentially with ice 
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cold 2M HCl (550 ml), sat. NaHCO3 (550 ml) and brine (550 ml).  The organic phase was 
then dried over MgSO4, filtered and concentrated in vacuo to afford the crude material. 
The product was purified via flash column chromatography (10% EtOAc in toluene) to 
afford a white crystalline powder (53g, 80%). 
Mpt: 59-61 °C (lit. 59-60 °C); 1H- NMR (400 MHz, CDCl3): 7.80 (d, J = 8.1 Hz, 2H, 
C8H), 7.35 (d, J = 8.1 Hz, 2H, C9H), 4.05 (dd, J = 10.1, 3.1 Hz, 1H, C4H), 3.90 (dd, J 
=7.1, 10.1 Hz, 1H, C4H), 3.77 (qd, J = 7.1, 3.1 Hz, 1H, C3H), 2.45 (s, 3H, C11H3), 1.51-
1.44 (m, 2H, C2H2), 0.93 (t, J = 7.5 Hz, 3H, C1H3); 13C-NMR (100 MHz, CDCl3): 145.02, 
132.78, 129.92, 127.94, 73.62, 70.79, 25.75, 21.62, 9.56; MS (ESI) m/z (rel.%): 245 [MH+] 
(72), 227 (13), 173 (21); IR (neat, cm-1): 3536, 2968, 2881, 1598, 1456, 1359, 1161, 1097, 
963. 
 
4-(1-Toluenesulfonyloxybutyl-2-oxy)-6-methyl-2-pyrone (109)137 
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4-Hydroxy-6-methyl-2-pyrone 9 (13.87 g, 110 mmol, 1 eq.), 108 (40.3 g, 165 mmol, 1.5 
eq.) and triphenylphosphine (43.3 g, 165 mmol, 1.5 eq.) were dissolved in THF (380 ml) 
under nitrogen at 0 °C.  DIAD (33.4 g, 165 mmol, 1.5 eq.) was then added carefully over 
30-40 minutes to prevent the generation of excess heat.  The reaction was stirred for 16 h at 
20 °C and then the solvent removed in vacuo.  Phosphine oxide was removed from the 
product by dissolving the product in ether (200 ml), and vacuum filtration to remove the 
solid oxide.  The ether was then removed in vacuo and the crude product purified by flash 
column chromatography (10-40% EtOAc in heptane), to afford the title compound as a 
white crystalline solid. 
Mpt: 96-98 °C; 1H-NMR (400 MHz, CDCl3): 7.73 (d, J = 7.5 Hz, 2H, C15H), 7.31 (d, J = 
7.5 Hz, 2H, C16H), 5.64 (m, 1H, C5H), 5.22 (d, J = 2.1 Hz, 1H, C3H) 4.33-4.28 (m, 1H, 
C10H), 4.16-4.07 (m, 2H, C11H2), 2.42 (s, 3H, C18H3), 2.15 (s, 3H, C7H3), 1.68 (p, J = 7.5 
Hz, 2H, C9H2), 0.93 (t, J = 7.5 Hz, 3H, C8H3); 13C-NMR (100 MHz, CDCl3): 169.2, 164.6, 
162.4, 145.3, 130.0, 127.9, 100.5, 88.4, 68.8, 60.4, 23.1, 21.7, 19.8, 14.2, 9.0; MS (ESI) 
m/z (rel.%): 375 [MNa+] (100), 353 [MH+] (80), 281 (7), 227 (20); HRMS (ESI) 
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calculated for C17H21O6S [MH+]: 353.1053, found: 353.1062; IR (DCM, cm-1): 3062, 
2979, 2883, 1713, 1652, 1598, 1436, 1365, 1243, 1178, 1096. 
 
4-(But-1-en-2-yloxy)-6-methyl-2-pyrone (110)137 
O
3
5
O
O
7
9
11
8
 
A solution of 109 (26.1 g, 74 mmol, 1 eq.), NaI (33.3 g, 222 mmol, 3 eq.) and DBU (22.5 
g, 148 mmol, 2 eq.) in DME (720 ml) was refluxed under argon for 16 hours.  The reaction 
was allowed to cool then quenched by addition of water (800 ml) and the product extracted 
with ether (3 × 800 ml).  The combined organic extracts were dried over MgSO4, filtered, 
concentrated in vacuo and purified by flash column chromatography (20-40% Ether in pet. 
ether) to afford the title compound as a a colourless oil (13.3g, 89%).  
Rf = 0.3 (40% Ether); 1H- NMR (400 MHz, CDCl3): 5.87 (dq, J = 2.0, 0.9 Hz, 1H, C5H), 
5.52 (dq, J = 2.0, 0.6 Hz, 1H, C3H), 4.80 (dt, J = 2.0, 1.3 Hz, 1H, C11H), 4.70 (dt, J = 2.0, 
0.6 Hz, 1H, C11H), 2.22 (dd, J = 0.9, 0.6 Hz, 3H, C7H3), 2.19 (qdd, J = 7.4, 0.9, 0.6 Hz, 
2H, C9H2), 0.98 (t, J = 7.4 Hz, 3H, C8H3); 13C-NMR (100 MHz, CDCl3): 168.9, 164.4, 
162.8, 159.18, 100.2, 99.86, 90.3, 25.3, 19.6, 10.7; MS (ESI) m/z (rel.%): 181 [MH+] 
(100), 127 (31); HRMS (ESI) calculated for C10H13O3 [MH+]: 181.0859, found: 181.0864; 
IR (neat, cm-1): 3093, 2974, 2941, 2923, 2884, 1739, 1648, 1566, 1448, 1406, 1320, 1230, 
1188, 1136, 1033, 997. 
 
4-(2-Bromoethoxy)-6-methyl-2-pyrone (112)137 
O
3
5
O
O
7
8
9
Br
 
4-Hydroxy-6-methyl-2-pyrone 9 (12.6 g, 100 mmol, 1 eq.), 2-bromoethanol (18.7 g, 150 
mmol, 1.5 eq.) and triphenylphosphine (39.3 g, 150 mmol, 1.5 eq.) were dissolved in THF 
(380 ml) under nitrogen at 0 °C.  DIAD (30.3 g, 150 mmol, 1.5 eq.) was then added 
carefully over 30-40 minutes to prevent the formation of excess heat.  The reaction was 
stirred for 16 h at 20 °C and then the solvent removed in vacuo.  Phosphine oxide was 
removed from the product by dissolving the product in ether (200 ml), and vacuum 
filtration to remove the solid oxide.  The ether was then removed in vacuo and the crude 
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product purified via flash column chromatography (10-40% EtOAc in heptane) to afford 
the title compound as a pale yellow crystalline solid (19.1 g, 82%). 
Mpt: 66-68 °C; 1H- NMR (400 MHz, CDCl3): 5.83 (m, 1H, C5H), 5.37 (d, J = 2.0 Hz, 1H, 
C3H), 4.26 (t, J = 6.0 Hz, 2H, C8H2), 3.61 (t, J = 6.0 Hz, 2H, C9H2), 2.21 (s, 3H, C7H3); 
13C-NMR (100 MHz, CDCl3): 169.7, 164.5, 162.5, 100.1, 88.1, 77.3, 77.0, 76.7, 68.0, 
27.1, 19.8; MS (ESI) m/z (rel.%): 235 [81Br-MH+] (84), 233 [79Br-MH+] (100); HRMS 
(ESI) calculated for C8H979BrO3Na: 254.9627, found: 254.9622; IR (DCM, cm-1): 3059, 
1716, 1653, 1571, 1448, 1418, 1377, 1251, 1184, 1145 cm-1. 
 
4-(Vinyloxy)-6-methyl-2-pyrone (113)137 
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A solution of 112 (18.0 g, 77 mmol, 1 eq.), NaI (34.7 g, 232 mmol, 3 eq.) and DBU (23.5 
g, 154 mmol, 2 eq.) in DME (720 ml) was refluxed under argon for 16 hours. The reaction 
was allowed to cool then quenched by addition of water (800 ml) and the product extracted 
with ether (3 × 800 ml). The combined organic extracts were dried over MgSO4, 
concentrated in vacuo and purified via flash column chromatography (20-40% Ether in pet 
ether) to afford the title compound as a crystalline white powder (5.5 g, 46.6%).  
Mpt: 43-45 °C; 1H-NMR (400 MHz, CDCl3): 6.53 (dd, J = 13.5, 5.9 Hz, 1H, C8H),  5.84 
(d, J = 2.0 Hz, 1H, C3H), 5.49 (d, J = 1.9 Hz, 1H, C5H), 5.03 (dd, J = 13.5, 2.0 Hz, 2H, 
C9Hb), 4.77 (dd, J = 5.9, 2.0 Hz, 2H, C9Ha), 2.23 (s, 3H, C7H3); 13C-NMR (100 MHz, 
CDCl3): 168.2, 164.0, 163.1, 143.6, 101.4, 99.5, 89.9, 19.8; MS (ESI) m/z (rel.%): 175 
[MNa+] (100), 153 [MH+] (2); HRMS (ESI) calculated for C8H8O3Na [M+]: 175.0366, 
found: 175.0373; IR (DCM, cm-1): 3672, 3060, 1731, 1641, 1573, 1448, 1411, 1235, 1185, 
1142.  
 
6-Methyl-4-propionyl-2-pyrone (118)137 
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To a stirred solution of 4-hydroxy-6-methy-2-pyrone 9 (1.01 g, 8 mmol, 1 eq.) and TEA 
(3.34 g, 24 mmol, 3 eq.) in DCM (24 ml), was added propionyl chloride (0.81 g, 8.8 mmol, 
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1.1 eq.) at 20 °C.  The solution was stirred for 2 hours then quenched by addition of water 
(15 ml) and the DCM separated and concentrated in vacuo.  The crude product was then 
purified via flash column chromatography (20% EtOAc in pet ether) to afford the title 
compound as a colourless oil (1.3 g, 89%). 
1H-NMR (400 MHz, CDCl3): 5.91 (d, J = 1.1 Hz, 1H, C5H), 5.86 (d, J = 1.1 Hz, 1H, 
C3H), 2.45 (q, J = 7.5 Hz, 2H, C9H2), 2.14 (s, 3H, C7H3), 2.14 (t, J = 7.5 Hz, 3H, C10H3); 
13C-NMR (100 MHz, CDCl3): 170.86, 164.02, 163.59, 101.67, 101.01, 53.90,  28.12, 
20.28, 8.89; MS (ESI) m/z (rel.%): 183 [MH+] (100); HRMS (ESI) calculated for 
C9H10O4Na [M+]: 205.0471, found: 205.0478; IR (neat, cm-1): 3097, 2986, 2945, 1772, 
1739, 1648, 1571, 1447, 1398, 1352, 1317, 1218, 1110.   
 
Methyl 3-(6-methyl-2-pyronyl-4-oxy)-acrylate (123)137 
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4-Hydroxy-6-methyl-2-pyrone 9 (9.45 g, 75 mmol, 1 eq.), TEA (7.58 g, 75 mmol, 1 eq.) 
and methyl propiolate (7.57 g, 90 mmol, 1.2 eq) were refluxed in DCM (250 ml) for 16 
hours.  The solvent was then removed in vacuo and the product purified by column 
chromatography (20% EtOAc in hexanes) to afford a yellow crystalline powder (12.85 g, 
82%). 
Mpt: 129-130 °C; 1H-NMR (400 MHz, CDCl3): 7.67 (d, J = 12.0 Hz, 1H, C8H), 5.91 (d, J 
= 2.2 Hz, 1H, C5H), 5.85 (d, J = 12.0 Hz, 1H, C9H), 5.65 (d, J = 2.2 Hz, 1H, C3H), 3.78 (s, 
3H, C11H3), 2.27 (s, 3H, C7H3); 13C- NMR (100 MHz, CDCl3); 167.2, 165.9, 164.2, 163.3, 
152.5, 107.7, 99.1, 92.1, 48.8, 20.1; MS (ESI) m/z (rel.%): 233 [MNa+] (100), 177 (5); 
HRMS (ESI) calculated for C10H10O5Na [M+]: 233.0420, found: 233.0429; IR (DCM, cm-
1): 3061, 2953, 1723, 1644, 1576, 1447, 1406, 1258, 1186, 1101. 
 
4-(3-Hydroxy-propenyloxy)-6-methyl-2-pyrone (124) 
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A solution of 123 (210 mg, 1 mmol, 1 eq.) was dissolved in DCM (3 ml) under nitrogen.  
DIBAL (1M in DCM) (2 ml, 2 mmol, 2 eq.) was then added at -40 °C, and the solution 
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allowed to warm up to -20 °C over 1 hour.  The solution was then transferred to a flask 
containing aqueous Rochelle’s salt (15 ml, 20% w/w) and stirred for 3 hours.  The aqueous 
layer was then separated and washed with DCM (3 × 5 ml) and the combined organic 
extracts dried over MgSO4, filtered and then concentrated in vacuo.  The crude product 
was then purified via flash column chromatography (50% EtOAc in hexanes) to afford a 
yellow powder (49 mg, 27%).   
1H- NMR (400 MHz, CDCl3): 6.63 (dt, J = 12.0, 1.5 Hz, 1H, C8H), 5.85 (dq, J = 2.2, 0.7 
Hz, 1H, C5H), 5.75 (dt, J = 12.0, 6.4 Hz, 1H, C9H), 5.53 (d, J =2.2 Hz, 1H, C3H), 4.22 (dd, 
J = 6.4, 1.5 Hz, 2H, C10H2), 2.23 (d, J = 0.7 Hz, 3H, C7H3); 13C- NMR (100 MHz, 
CDCl3); 168.6, 164.5, 163.2, 140.0, 117.5, 99.8, 90.1, 59.0, 20.0; MS (ESI) m/z (rel.%): 
205 [MNa+] (100), 133 (9); HRMS (ESI) calculated for C9H10O4Na [M+]: 205.0471, 
found: 205.0478; IR (DCM, cm-1): 3683, 3603, 3056, 2927, 1716, 1650, 1570, 1448, 1409. 
 
Methyl 3-(6-(but-3-enyl)-2-pyronyl-4-oxy)-acrylate (135) 
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2-pyrone 96 (14 mg, 84 µmol, 1 eq.), TEA (8 mg, 84 µmol, 1 eq.) and methyl propiolate (7 
mg, 84 µmol, 1 eq.) were stirred in DCM (1 ml) for at 45 °C for 16 hours.  The solvent was 
then removed in vacuo and the product purified via flash column chromatography (20% 
EtOAc in hexanes) to afford a yellow crystalline powder (18.1 mg, 86%). 
1H-NMR (500 MHz, CDCl3): 7.67 (d, J = 12.1 Hz, 1H, C12H), 5.90 (d, J = 2.1 Hz, 1H, 
C5H), 5.84 (d, J = 12.1 Hz, 1H, C13H), 5.78 (ddt, J = 17.0, 10.1, 6.7 Hz, 1H, C9H), 5.65 (d, 
J = 2.1 Hz, 1H, C3H), 5.08 (ddt, J = 17.0, 1.5, 1.5 Hz, 1H, C10Ha), 5.05 (ddt, J = 10.1, 1.5, 
1.5 Hz, 1H, C10Hb), 3.77 (s, 3H, C16H3), 2.60 (t, J = 7.9 Hz, 2H, C7H2), 2.41-2.45 (m, 2H, 
C8H2); 13C-NMR (101 MHz, CDCl3): 167.1, 166.8, 165.9, 163.3, 152.5, 135.7, 116.6, 
107.7, 98.8, 92.3, 51.8, 33.2, 30.5; MS (ESI) m/z (rel.%): 251 [MH+] (100); HRMS (ESI) 
calculated for C13H15O5: 251.0914, found: 251.0917; IR (CHCl3, cm-1): 3077, 2955, 2362, 
1722, 1639, 1574, 1415, 1325, 1223, 1163, 1099. 
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Methyl 3-(6-(2-phenylethyl)-2-pyronyl-4-oxy)-acrylate (136) 
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2-pyrone 90 (20.4 mg, 94 µmol, 1 eq.), TEA (9.4 mg, 94 µmol, 1 eq.) and methyl 
propiolate (8.7 mg, 100 µmol, 1.1 eq.) were stirred in DCM (1 ml) for at 45 °C for 16 
hours.  The solvent was then removed in vacuo and the product purified via flash column 
chromatography (20% EtOAc in hexanes) to afford a yellow crystalline powder (19.3 mg, 
68%). 
1H-NMR (400 MHz, CDCl3): 7.65 (d, J = 12.1 Hz, 1H), 7.33 – 7.28 (m, 2H), 7.25 – 7.20 
(m, 1H), 7.19 – 7.15 (m, 2H), 5.84 (dt, J = 2.3, 0.7 Hz, 1H), 5.82 (d, J = 12.1 Hz, 1H), 5.66 
(d, J = 2.3 Hz, 1H), 3.77 (s, 3H), 2.99 (t, J = 7.8 Hz, 2H), 2.81 (td, J = 7.7, 0.7 Hz, 2H); 
13C-NMR (101 MHz, CDCl3): 167.1, 166.5, 166.0, 163.5, 152.5, 139.6, 128.8, 128.4, 
126.7, 107.8, 99.2, 92.5, 52.0, 35.8, 32.9; MS (ESI) m/z (rel.%): 301 [MH+] (100); HRMS 
(ESI) calculated for C17H17O5: 301.1071, found: 301.1069; IR (CHCl3, cm-1): 3019, 2363, 
1721, 1641, 1573, 1416, 1101, 670. 
 
Methyl 3-(6-(non-8-en-5-ynyl)-2-pyronyl-4-oxy)-acrylate (137) 
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2-pyrone 95 (33.3 mg, 143 µmol, 1 eq.), TEA (15 mg, 143 µmol, 1 eq.) and methyl 
propiolate (12.1 mg, 144 µmol, 1.01 eq.) were stirred in DCM (1 ml) for at 45 °C for 16 
hours.  The solvent was then removed in vacuo and the product purified via flash column 
chromatography (20% EtOAc in hexanes) to afford a waxy yellow powder (28.9 mg, 
64%). 
1H-NMR (400 MHz, CDCl3): 7.68 (d, J = 12.0 Hz, 1H, C17H), 5.92 (dt, J = 2.3, 0.7 Hz, 
1H, C5H), 5.85 (d, J = 12.0 Hz, 1H, C18H), 5.82 (ddt, J =16.9, 10.0, 5.3 Hz, 1H, C14H), 
5.66 (d, J = 2.3 Hz, 1H, C3H), 5.29 (ddt, J = 16.9, 1.8, 1.8 Hz, 1H, C15Hb), 5.09 (ddt, J = 
10.0, 1.8, 1.8 Hz, 1H, C15Ha), 3.77 (s, 3H, C21H3), 2.91 – 2.96 (m, 2H, C13H2), 2.53 (dt, J = 
7.6, 0.7 Hz, 2H, C7H2), 2.24 (tt, J = 2.4, 6.9 Hz, 2H, C10H2), 1.74 – 1.83 (m, 2H, C8H2), 
1.51 – 1.62 (m, 2H, C9H2); 13C-NMR (101 MHz, CDCl3): 167.5, 167.1, 166.0, 163.5, 
 131 
152.4, 133.2, 115.7, 107.7, 99.9, 98.6, 92.1, 81.7, 51.9, 33.4, 28.1, 25.7, 23.1, 18.4; MS 
(ESI) m/z (rel.%): 339 [MNa+] (63), 317 [MH+] (100), 210 (7), 180 (7); HRMS (ESI) 
calculated for C18H21O5 [MH+]: 317.1384, found: 317.1379; IR (neat, cm-1): 3091, 2947, 
2160, 1710, 1636, 1567, 1415, 1221, 1098, 823. 
 
Methyl 3-(6-(6-triisopropylsilyl-hex-5-ynyl)-2-pyronyl-4-oxy)-acrylate (138) 
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2-pyrone 44 (100 mg, 287 µmol, 1 eq.), TEA (29 mg, 287 µmol, 1 eq.) and methyl 
propiolate (24.2 mg, 288 µmol, 1.01 eq.) were stirred in DCM (1 ml) for at 45 °C for 16 
hours.  The solvent was then removed in vacuo and the product purified via flash column 
chromatography (20% EtOAc in hexanes) to afford a waxy yellow powder (102 mg, 82%). 
1H-NMR (400 MHz, CDCl3): 7.68 (d, J = 12.0 Hz, 1H, C17H), 5.90 (d, J = 2.3 Hz, 1H, 
C5H), 5.84 (d, J = 12.0 Hz, 1H, C18H), 5.65 (d, J = 2.3 Hz, 1H, C3H), 3.77 (s, 3H, C21H3), 
2.53 (t, J = 7.5 Hz, 2H, C7H2), 2.30 (t, J = 6.9 Hz, 2H, C10H2), 1.77 – 1.86 (m, 2H, C8H2), 
1.54 – 1.63 (m, 2H, C9H2), 1.00 – 1.08 (m, 21H, C14H/C15H3); 13C-NMR (101 MHz, 
CDCl3): 167.5, 167.1, 165.9, 163.4, 152.4, 107.8, 107.7, 98.5, 92.1, 81.0, 51.8, 33.2, 27.8, 
25.5, 19.4, 18.6, 11.2; MS (ESI) m/z (rel.%): 455 [MNa+] (100), 433 [MH+] (51), 399 (5), 
377 (3), 326 (4), 289 (12), 267 (8), 242 (10), 217 (7), 180 (4); HRMS (ESI) calculated for 
C24H36NaO5Si [MNa+]: 455.2224, found: 455.2213; IR (CHCl3, cm-1): 3023, 2956, 2866, 
2362, 1721, 1641, 1574, 1418, 1215, 1101. 
 
Ethyl 3-(6-methyl-2-pyronyl-4-oxy)-but-2-enoate (140) 
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A solution of 4-hydroxy-6-methyl-2-pyrone 9 (126 mg, 1 mmol, 1 eq.), ethyl 3-butynoate 
137 (134 mg, 1.2 mmol, 1.2 eq.), DBU (100 mg, 0.66 mmol, 0.66 eq.), and CuI (19 mg, 0.1 
mmol, 10 mol%) in THF (2 ml) was heated under nitrogen at 80 °C in a microwave for 30 
minutes.  The solvent was removed in vacuo and the product purified by column 
chromatography (30% EtOAc in hexanes) to afford a waxy yellow solid (102 mg, 42.8%). 
 132 
Rf = 0.43 (40% EtOAc in hexanes); 1H-NMR (400 MHz, CDCl3): 5.87 (dq, J = 2.0, 0.8 
Hz, 1H, C5H), 5.57 (dq, J = 2.0, 0.6 Hz, 1H, C3H), 5.52 (q, J = 0.9 Hz, 1H, C10H), 4.19 (q, 
J = 7.1 Hz, 2H, C12H2), 2.38 (d, J = 0.9 Hz, 3H, C8H3), 2.26 (dd, J = 0.8, 0.6 Hz, 3H, 
C7H3), 1.29 (t, J = 7.1 Hz, 3H, C13H3); 13C-NMR (100 MHz, CDCl3): 167.2, 165.8, 165.6, 
163.9, 107.5, 100.1, 94.4, 79.9, 60.4, 20.1, 17.4, 14.2; MS (ESI) m/z (rel.%): 261 [MNa+] 
(100), 177 (2), 153 (4); HRMS (ESI) calculated for C12H14O5Na [M+]: 261.0733, found: 
261.0738; IR (DCM, cm-1): 3018, 2919, 2871, 2774, 1729, 1643, 1556, 1384, 1335, 1168. 
 
Ethyl 3-iodobut-2-enoate (141)156 
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 A solution of ethyl 3-butynoate 139 (2.24 g, 20 mmol, 1 eq.) and LiI (2.95 g, 22 
mmol, 1.1 eq.) in AcOH (3 ml) was heated to 70 °C for 5 hours then allowed to cool to 20 
°C.  Water (10 ml) and EtOAc (15 ml) were added and the organic layer separated then 
washed with water (10 ml), sat. NaHCO3 (10 ml), and brine (10 ml).  The organic layer 
was concentrated in vacuo and flushed through a silica plug (5% EtOAc in hexanes) then 
concentrated in vacuo to afford a red oil (4.14 g, 86%). 
1H-NMR (400 MHz, CDCl3): 6.26 (s, 1H, C3H), 4.21 (q, J = 7.1 Hz, 2H, C5H2) , 2.71 (s, 
3H, C1H3), 1.28 (t, J = 7.1 Hz, 3H, C7H3); 13C-NMR (100 MHz, CDCl3): 164.3, 125.5, 
113.2, 60.2, 21.0, 14.1; MS (ESI) m/z (rel.%): 262 [MNa+] (100), 135 (8). 
 
Ethyl penta-2,3-dienoate (144)157 
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To a stirred solution of ethyl (triphenylphosphoranylidene) acetate 143 (3.48 g, 10 mmol, 1 
eq.) in DCM (35 ml) at 22 °C was added TEA (1.11 g, 11 mmol, 1.1 eq.) and the solution 
stirred for 10 minutes.  Propionyl chloride (925 mg, 10 mmol, 1 eq.) was added carefully 
over 15 minutes and the reaction stirred at 22 °C for 18 h.  The solvent was removed in 
vacuo and the residue taken up in ether (20 ml) then filtered.  The filtrate was concentrated 
in vacuo and purified by column chromatography (0-5% EtOAc in hexanes). 
1H-NMR (400 MHz, CDCl3): 5.60 – 5.48 (m, 2H, C4H/C2H), 4.15 (q, J = 7.1 Hz, 2H, 
C6H2), 1.74 (dd, J = 7.2, 3.3 Hz, 3H, C1H3), 1.24 (t, J = 7.1 Hz, 3H, C7H3); 13C-NMR (100 
 133 
MHz, CDCl3): 212.8, 168.9, 90.1, 87.6, 60.7, 25.9, 14.1; MS (ESI) m/z (rel.%): 127 [MH+] 
(100). 
 
Pentafluorophenyl 3-(6-methyl-2-pyronyl-4-oxy)-acrylate (147) 
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2-pyrone 9 (54.5 mg, 430 µmol, 1 eq.), TEA (43.4 mg, 430 µmol, 1 eq.) and 
pentafluorophenyl propiolate 146 (204 mg, 860 µmol, 2 eq.) were stirred in DCM (1 ml) at 
45 °C for 16 hours.  The solvent was then removed in vacuo and the product purified via 
flash column chromatography (20% EtOAc in hexanes) to afford a yellow crystalline 
powder (102 mg, 82%). 
Mpt: 102-105 °C; 1H-NMR (400 MHz, CDCl3): 7.93 (d, J = 12.0 Hz, 1H, C9H), 6.05 (d, J 
= 12.0 Hz, 1H, C9H), 5.96 (dq, J = 2.2, 0.9 Hz, 1H, C5H), 5.74 (d, J = 2.2 Hz, 1H, C3H), 
2.29 (t, J = 0.9 Hz, 3H, C5H3); 13C-NMR (101 MHz, CDCl3): 166.7, 164.7, 163.1, 161.5, 
155.9, 104.3, 98.9, 92.9, 20.2; 19F-NMR (376 MHz, CDCl3): -152.30 – -152.41 (m, 2F), -
157.31 (t, J = 21.7, 1F), -161.82 – -161.99 (m, 2F); MS (ESI) m/z (rel.%): 380 [MNa+] 
(52), 363 [MH+] (100), 301 (14), 279 (26); HRMS (ESI) calculated for C15H8F5O5 [MH+]: 
363.0286, found: 363.0299; IR (neat, cm-1): 3106, 2916, 2160, 1731, 1641, 1577, 1516, 
1280, 1227, 1185, 997. 
 
Pentafluorophenyl 3-(6-(6-triisopropylsilyl-hex-5-ynyl)-2-pyronyl-4-oxy)-acrylate 
(148) 
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2-pyrone 44 (105 mg, 301 µmol, 1 eq.), TEA (30 mg, 301 µmol, 1 eq.) and 
pentafluorophenyl propiolate 146 (71.2 mg, 301 µmol, 1 eq.) were stirred in DCM (1 ml) 
for at 45 °C for 16 hours.  The solvent was then removed in vacuo and the product purified 
via flash column chromatography (20% EtOAc in hexanes) to afford a waxy yellow 
powder (65.7 mg, 37%). 
 134 
1H-NMR (400 MHz, CDCl3): 7.94 (d, J = 12.0 Hz, 1H, C17H), 6.06 (d, J = 12.0 Hz, 1H, 
C18H), 5.97 (d, J = 2.3 Hz, 1H, C5H), 5.75 (d, J = 2.3 Hz, 1H, C3H), 2.57 (t, J = 7.6 Hz, 
2H, C7H2), 2.32 (t, J = 6.9 Hz, 2H, C10H2), 1.79 – 1.89 (m, 2H, C8H2), 1.55 – 1.66 (m, 2H, 
C9H2), 1.01 – 1.09 (m, 21H, C14H/C15H3); 13C-NMR (101 MHz, CDCl3): 168.1, 166.8, 
163.2, 161.5, 155.8, 107.8, 104.3, 98.3, 93.0, 81.1, 33.3, 27.8, 25.5, 19.4, 18.6, 11.2; 19F-
NMR (376 MHz, CDCl3): -152.22 – -152.50 (m, 2F), -157.29 (t, J = 21.7, 1F), -161.75 – -
162.06 (m, 2F); MS (ESI) m/z (rel.%): 607 [MNa+] (79), 471 (53), 284 (74), 247 (100), 
225 (20); HRMS (ESI) calculated for C29H33F5NaO5Si [MNa+]: 607.1910, found: 
607.1925; IR (neat, cm-1): 3093, 2946, 2865, 2167, 1717, 1637, 1571, 1517, 1181, 1005. 
 
tert-Butyl 3-(6-methyl-2-pyronyl-4-oxy)-acrylate (150) 
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2-pyrone 9 (100 mg, 0.79 mmol, 1.25 eq.), TEA (101 mg, 1 mmol, 1.6 eq.) and tert-butyl 
propiolate 149 (80 mg, 0.63 mmol, 1 eq.) were stirred in DCM (1 ml) for at 45 °C for 16 
hours.  The solvent was then removed in vacuo and the product purified via flash column 
chromatography (20% EtOAc in hexanes) to afford a yellow crystalline powder (98 mg, 
61%). 
Mpt: 60-62 °C; 1H-NMR (400 MHz, CDCl3): 7.54 (d, J = 12.0 Hz, 1H), 5.90 (d, J = 2.2 
Hz, 1H), 5.74 (d, J = 12.0 Hz, 1H), 5.63 (d, J = 2.2 Hz, 1H), 2.25 (s, 3H), 1.48 (s, 9H); 
13C-NMR (101 MHz, CDCl3): 167.3, 164.7, 164.0, 163.6, 151.5, 110.0, 99.3, 91.8, 81.3, 
28.1, 20.1; MS (ESI) m/z (rel.%): 275 [MNa+] (34), 253 [MH+] (100), 197 (8); HRMS 
(ESI) calculated for C13H17O5: 253.1071, found: 253.1068; IR (neat, cm-1): 3082, 2980, 
2160, 1720, 1696, 1658, 1623, 1561, 1235, 1149, 1091, 845. 
 
 135 
3-(6-Methyl-2-pyronyl-4-oxy)-acrylic acid (151) 
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A solution of 150 (46 mg, 0.18 mmol, 1 eq.) in THF (1 ml) and TFA (1 ml) was stirred at 
22 °C for 30 minutes.  The solution was filtered and the solid washed with DCM (3 ml) to 
afford the desired product as a white powder (30 mg, 86%). 
Mpt: degrades > 142 °C; 1H-NMR (500 MHz, CDCl3/MeOD): 7.63 (d, J = 12.0 Hz, 1H), 
5.91 (d, J = 2.2 Hz, 1H), 5.74 (d, J = 12.0 Hz, 1H), 5.62 (d, J = 2.2 Hz, 1H), 2.21 (s, 3H); 
MS (ESI) m/z (rel.%): 219 [MNa+] (33), 197 [MH+] (100), 141 (15), 102 (13); HRMS 
(ESI) calculated for C9H9O5: 197.0444, found: 197.0449; IR (neat, cm-1): 3093, 2161, 
2025, 1977, 1722, 1644, 1575, 1324, 1236, 1191, 1166, 1142, 1096, 982, 832. 
 
4-(1,2-Dibromoethoxy)-6-methyl-2-pyrone (152) 
3
5 7
O
O
8
9
O
Br
Br
 
To a solution of 113 (1.52 g, 10 mmol, 1 eq.) in DCM (10 ml) under nitrogen at -78 °C, 
was added Br2 (1.6 g, 10 mmol, 1 eq.) in DCM (5 ml) over 15 minutes.  The solution was 
allowed to warm to 20 °C over 3 hours, the solvent and unreacted bromine was 
subsequently removed in vacuo to afford the crude product as a light brown powder (2.96 
g, 95%).  The crude material was used without further purification due to degradation upon 
silica. 
1H-NMR (400 MHz, CDCl3): 5.88 (m, 1H, C5H),  5.72 (d, J = 2.0 Hz, 1H, C3H), 4.07-
4.01 (m, 1H, C8H), 3.93-4.00 (m, 2H, C9H), 2.26 (s, 3H, C7H3); MS (ESI) m/z (rel.%): 315 
[81Br/81Br-MH+] (41), 313 [81Br/79Br-MH+] (92), 311 [79Br/79Br-MH+]  (45); HRMS (ESI) 
calculated for C8H879Br2O3Na: 332.87, found: 332.9; IR (DCM, cm-1): 3103, 3059, 2926, 
1726, 1650, 1631, 1542, 1444, 1388, 1231, 1172, 1069. 
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(Z)-4-(1-bromovinyloxy)-6-methyl-2-pyrone (Z-153) 
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A solution of 152 (3.12 g, 10 mmol, 1 eq.) and DBU (1.68 g, 20 mmol, 2 eq.) in THF (40 
ml) was refluxed under argon for 16 hours.  The reaction allowed to cool then quenched by 
addition of water (80 ml) and the product extracted from ether (3 × 80 ml).  The combined 
organic extracts were dried over MgSO4, concentrated in vacuo and purified via flash 
column chromatography (20-40 % Ether in pet ether) to afford a brown powder (401 mg, 
17.4%). 
Rf = 0.3 (40% Ether); 1H-NMR (400 MHz, CDCl3): (400 MHz, CDCl3): 7.03 (d, J = 4.4 
Hz, 1H, C8H), 5.97 (m, 1H, C5H), 5.91 (d, J = 4.4 Hz, 1H, C9H), 5.72 (d, J = 2.0 Hz, 1H, 
C3H), 2.26 (s, 3H, C7H3); 13C-NMR (100 MHz, CDCl3): 167.5, 163.8, 163.7, 139.9, 99.5, 
95.1, 90.7, 20.0; MS (ESI) m/z (rel.%): 231 [MH+] (63), 233 (61); HRMS (ESI) calculated 
for C8H779BrO3Na [MNa+]: 252.9471, found: 252.9472; IR (DCM, cm-1): 2960, 2928, 
1717, 1640, 1572, 1447, 1408, 1317, 1234, 1139, 1055. 
 
(Z)-6-Methyl-4-(styrenyloxy)-2-pyrone (154) 
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A solution of Pd2dba3 (22.9 mg, 0.025 mmol, 5 mol%) and triphenylphosphine (13.1 mg, 
0.05 mmol, 10 mol%) in dry THF(1.2ml) was stirred at 40 °C under argon for 20 minutes.  
A solution of phenylboronic acid (122 mg, 1 mmol, 2 eq.) and organohalide Z-153 (116 
mg, 0.5 mmol, 1 eq.) in THF (0.4ml) was then added and the mixture heated to 70 °C for 
15 minutes.  2M Na2CO3 (0.8 ml) was then added and the mixture stirred at 70 °C for 2 
hours.  The reaction was allowed to cool then diluted with ether (3ml) and the organic 
layer removed.  The aqueous layer was then washed with ether (2 x 3 ml) and the 
combined organic extracts dried over MgSO4, filtered and concentrated in vacuo.  The 
crude material was then purified via flash column chromatography (20% EtOAc in 
heptane) to afford an orange crystalline solid (68 mg, 59.6%).   
 137 
Rf = 0.12 (20% EtOAc in heptane); 1H-NMR (400 MHz, CDCl3): 7.53 (d, J = 7.6 Hz, 2H, 
C11H), 7.35 (t, J = 7.6 Hz, 2H, C12H), 7.30 (d, J = 7.6 Hz, 1H, C13H), 6.54 (d, J = 6.8 Hz, 
1H, C8H), 5.99 (m, 1H, C5H), 5.89 (d, J = 6.8 Hz, 1H, C9H), 5.64 (d, J = 1.7 Hz, 1H, C3H), 
2.23 (s, 3H, C7H3); 13C-NMR (100 MHz, CDCl3): 168.1, 164.1, 163.4, 136.6, 133.1, 
129.1, 128.5, 127.9, 115.7, 99.7, 90.5, 20.0; MS (ESI) m/z (rel.%): 229 [MH+] (100); 
HRMS (ESI) calculated for C14H12O3Na [MNa+]: 251.0679, found: 251.0685; IR (DCM, 
cm-1): 3064, 3027, 2926, 2854, 1718, 1648, 1571, 1447, 1391, 1320, 1235, 1174, 1140, 
1050.   
 
(Z)-6-Methyl-4-(penta-Z-1,4-dienyloxy)-2-pyrone (155) 
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A solution of allylboronic acid pinacol ester (168 mg, 1.0 mmol, 2 eq.), organohalide Z-
153 (116 mg, 0.5 mmol, 1 eq.) and palladium complex 27 (20 mg, 0.025 mmol, 5 mol %) 
were stirred in THF (1.6 ml) under nitrogen at 70 °C for 10 minutes.  To this solution 
aqueous 2M Na2CO3 (0.8 ml) was added and the reaction stirred for up to 5 hours at 70 °C.  
The solution was allowed to cool to 20 °C diluted with ether (3 ml), and the organic layer 
separated.  The aqueous layer was then extracted with ether (3 × 3 ml) and the combined 
organic extracts washed with brine, dried over MgSO4, filtered and then concentrated in 
vacuo.  The product was then purified via flash column chromatography (20% EtOAc in 
hexanes) to afford an orange oil (53.8 mg, 56%).   
1H-NMR (400 MHz, CDCl3): 6.37 (dt, J = 6.8, 1.4 Hz, 1H, C8H), 5.88 (m, 1H, C5H), 5.80 
(ddt, J = 17.0, 10.2, 6.2 Hz, 1H, C11H), 5.50 (d, J = 1.9 Hz, 1H, C3H), 5.15 (td, J = 7.5, 
6.0 Hz, 1H, C9H), 5.07 (dq, J = 17.0, 1.6 Hz, 1H, C12Hb), 5.02 (dd, J = 10.2, 1.6 Hz, 1H, 
C12Ha), 2.92-2.87 (m, 2H, C10H2), 2.24 (s, 3H, C7H3); 13C-NMR (100 MHz, CDCl3): 168. 
6, 164.4, 163.1, 137.1, 135.2, 115.6, 115.6, 99.8, 89.9, 28.2, 19.9; MS (ESI) m/z (rel.%): 
193 [MH+] (100); HRMS (ESI) calculated for C11H12O3Na [MNa+]: 215.0679, found: 
215.0680; IR (neat, cm-1): 3082, 2962, 2925, 1699, 1645, 1566, 1450, 1413, 1324, 1254, 
1146, 1054, 998. 
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2-(6-Methyl-2-pyron-4-yloxy)-butyraldehyde (165) 
3
5
O
O
7O
10
11
9
8
O
 
To a solution of oxalyl chloride (826 mg, 6.5 mmol, 1.3 eq.) in DCM (15 ml) at -78 °C was 
added DMSO (1.01 g, 13 mmol, 2.6 eq.) in DCM (15 ml) carefully over 15 minutes.  The 
reaction was stirred for 30 minutes at -78 °C then a solution of 170 (990 mg, 5 mmol, 1 
eq.) in DCM (15 ml) was added carefully over 20 minutes and the reaction stirred for a 
further 30 minutes at -78 °C.  Triethylamine (1.80 g, 18 mmol, 3.6 eq.) was added over 15 
minutes and the reaction stirred for 1 h at -78 °C then allowed to warm to ambient 
temperature.  The solvent was removed in vacuo and the residue taken up in ether then 
passed through a silica plug, eluting with ether.  The solvent was then removed in vacuo to 
afford the desired product as a colourless oil (978 mg, >99%). 
1H-NMR (400 MHz, CDCl3): 9.57 (d, J = 1.2 Hz, 1H, C11H), 5.88 (d, J= 2.1 Hz, 1H, 
C5H), 5.23 (d, J = 2.1 Hz, 1H, C3H), 4.47 (ddd, J = 7.0, 5.4, 1.2 Hz, 1H, C10H), 2.22 (s, 
3H, C7H3), 1.85-2.00 (m, 2H, C9H2), 1.03 (t, J = 7.4 Hz, 3H, C8H3); 13C-NMR (100 MHz, 
CDCl3); 198.4, 169.4, 164.4, 163.0, 100.3, 89.1, 82.9, 23.0, 20.0, 9.1; IR (DCM, cm-1): 
3608, 3376, 3061, 2965, 1710, 1650, 1566, 1450, 1413, 1322, 1244, 1146, 1093. 
 
6-Methyl-4-(pent-1-en-3-yloxy)-2-pyrone (167) 
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4-hydroxy-6-methyl-2-pyrone 9 (504 mg, 4 mmol, 1 eq.), 3-hydroxypent-1-ene (516 mg, 6 
mmol, 1.5 eq.) and triphenylphosphine (1.57 g, 6 mmol, 1.5 eq.) were dissolved in THF (8 
ml) under nitrogen at 0 °C.  DIAD (1.21 g, 6 mmol, 1.5 eq.) was then added carefully over 
15 minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in 
vacuo.  The crude product was purified via flash column chromatography (10-40% EtOAc 
in hexanes) to afford a pale yellow oil (130 mg, 17%). 
1H-NMR (400 MHz, CDCl3): 5.77 (m, 1H, C5H), 5.70 (ddd, J = 17.3, 10.7, 6.5 Hz, 1H, 
C11H), 5.35 (d, J = 2.2 Hz, 1H, C3H), 5.26 (dt, J = 10.7, 1.0 Hz, 1H, C12Ha), 5.22 (dt, J = 
17.4, 1.0 Hz, 1H, C12Hb), 4.50 (q, J = 6.5 Hz, 1H, C10H), 2.17 (s, 3H, C7H3), 1.72 (m, 2H, 
C9H2), 0.93 (t, J = 7.44 Hz, 3H, C8H3); 13C-NMR (100 MHz, CDCl3): 169.9, 165.3, 162.2, 
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135.3, 118.3, 101.1, 89.4, 81.3, 28.1, 20.0, 9.4; MS (ESI) m/z (rel.%): 217 [MNa+] (100), 
157 (4), 122 (2); HRMS (ESI) calculated for C11H14O3Na [MNa+]: 217.0835, found: 
217.0844; IR (neat, cm-1): 3086, 2971, 2936, 2879, 1731, 1650, 1563, 1450, 1319, 1243. 
 
1-(tert-Butyl-dimethyl-silanyloxy)-butan-2-ol (168) 
O
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A solution of tert-butyl-dimethylsilyl chloride (3.01 g, 20 mmol, 1 eq.), TEA (4.04 g, 40 
mmol, 2 eq.) and butane-1,2-diol (2.70 g, 30 mmol, 1.5 eq.) under nitrogen in DCM (25 
ml), was stirred at 20 °C for 16 h.  The reaction was then quenched with ice cold water (15 
ml) and the aqueous layer removed.  The organic layer was then washed with brine (15 ml) 
and dried over MgSO4 then concentrated in vacuo to afford the crude material.  The 
product was purified via flash column chromatography (40% EtOAc in toluene) to afford a 
colourless oil (3.43 g, 84.1%). 
1H-NMR (400 MHz, CDCl3): 3.63 (dd, J = 9.7, 3.3 Hz, 1H, C4H), 3.55 (ddt, J = 10.5, 7.2, 
3.3 Hz, 1H, C4H), 3.39 (dd, J = 9.7, 7.2 Hz, 1H, C3H), 1.40-1.48 (m, 2H, C2H2), 0.95 (t, J 
= 7.5 Hz, 3H, C1H3), 0.89 (s, 9H, C6H3), 0.07 (s, 6H, C5H3); 13C-NMR (100 MHz, 
CDCl3); 73.3, 67.0, 26.0, 21.7, 18.4, 10.0, -5.3, -5.3; MS (ESI) m/z (rel.%): 205 [MH+] 
(100); IR (neat, cm-1): 3406, 2955, 2929, 2858, 1462, 1253, 1092, 834, 774. 
 
4-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propoxy]-6-methyl-2-pyrone (169) 
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4-Hydroxy-6-methyl-2-pyrone (504 mg, 4 mmol, 1 eq.), alcohol 168 (1.22 g, 6 mmol, 1.5 
eq.) and triphenylphosphine (1.57 g, 6 mmol, 1.5 eq.) were dissolved in DCM (8 ml) under 
nitrogen at 0 °C.  DIAD (1.21 g, 6 mmol, 1.5 eq.) was then added carefully over 15 
minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in vacuo.  
The crude product was purified via flash column chromatography (20% EtOAc in hexanes) 
to afford a colourless oil (1.23 g, 98.4%). 
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 Rf = 0.56 (20% EtOAc); 1H-NMR (400 MHz, CDCl3): 5.71 (dq, J= 1.9, 0.8 Hz, 1H, 
C5H), 5.36 (d, J = 1.9 Hz, 1H, C3H), 4.17 (p, J = 5.4 Hz, 1H, C10H), 3.66 (s, 1H, C11H), 
3.64 (d, J = 1.3 Hz, 1H, C11H), 2.11-2.15 (m, 3H, C7H3), 1.53-1.69 (m, 2H, C9H2), 0.87 (t, 
J = 7.5 Hz, 3H, C8H3), 0.79 (s, 9H, C16H3), -0.03 (s, 3H, C14H3), -0.04 (s, 3H, C14H3); 13C-
NMR (100 MHz, CDCl3): 170.5, 165.3, 162.1, 100.9, 88.4, 80.9, 63.8, 25.8, 23.4, 19.8, 
18.2, 9.5, -5.4, -5.4; MS (ESI) m/z (rel.%): 335 [MNa+] (100), 313 [MH+] (2); HRMS 
(ESI) calculated for C16H28O4NaSi [M+]: 335.1649, found: 335.1640; IR (neat, cm-1): 
2929, 2883, 2857, 1736, 1651, 1563, 1450, 1414, 1320, 1249, 1139, 1036, 1001. 
 
4-(1-Hydroxymethyl-propoxy)-6-methyl-2-pyrone (170) 
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A solution of 169 (11.0 g, 35.3 mmol, 1 eq.) in THF (20 ml), water (20 ml) and acetic acid 
(60 ml) was stirred for 16 hours at 20 °C.  The solution was concentrated in vacuo and the 
resulting product was purified via flash column chromatography (2-4% MeOH in DCM) to 
afford a pale yellow oil (6.98 g, >99%). 
Rf = 0.21 (5% MeOH in DCM); 1H-NMR (400 MHz, CDCl3): 5.80 (dq, J = 2.2, 0.8 Hz, 
1H, C5H), 5.46 (d, J = 2.2 Hz, 1H, C3H), 4.28 (tdd, J = 5.9, 5.9, 4.1 Hz, 1H, C10H), 3.81 
(dd, J = 12.1, 4.1 Hz, 1H, C11H), 3.68 (dd, J = 12.1, 5.9 Hz, 1H, C11H), 2.18 (q, J =  0.8 
Hz, 3H, C7H3), 2.07 (s, 1H, OH), 1.66-1.74 (m, 2H, C9H2), 0.93 (t, J = 7.5 Hz, 3H, C8H3); 
13C-NMR (100 MHz, CDCl3) 170.5, 165.6, 162.5, 101.2, 88.7, 81.2, 63.4, 23.2, 20.0, 9.6; 
MS (ESI) m/z (rel.%): 221 [MNa+] (100), 199 [MH+] (6), 133; HRMS (ESI) calculated for 
C10H14O4Na [M+]: 221.0784, found: 221.0790; 
 
4-(2-Hydroxy-butoxy)-6-methyl-2-pyrone (171) 
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To a solution of 169 (936 mg, 3 mmol, 1 eq.) in THF (10 ml) was added TBAF (1M in 
THF) (3 ml, 3 mmol, 1 eq.) at 20 °C.  The solution was stirred for 2 hours then quenched 
with 2M HCl (3 ml) and the product extracted with ether (3 × 10 ml).  The combined 
organic extracts were then concentrated in vacuo and the resulting product was purified via 
 141 
flash column chromatography (5% MeOH in DCM) to afford a colourless oil (392 mg, 
66%). 
Rf = 0.35 (5% MeOH in DCM); 1H-NMR (400 MHz, CDCl3): 5.80 (d, J = 2.2 Hz, 1H, 
C5H), 5.39 (d, J = 2.2 Hz, 1H, C3H), 3.82-3.93 (m, 2H, C8H), 3.71-3.74 (m, 1H, C9H), 
2.19 (s, 3H, C7H3), 1.53-1.61 (m, 2H, C10H2), 1.00 (t, J = 7.5 Hz, 3H, C11H3); 13C-NMR 
(100 MHz, CDCl3): 170.5, 165.1, 162.4, 100.5, 88.2, 72.5, 70.8, 26.2, 22.0, 19.9, 9.8: MS 
(ESI) m/z (rel.%): 221 [MNa+] (100), 199 [MH+] (6), 133; HRMS (ESI) calculated for 
C10H14O4Na [MNa+]: 221.0784, found: 221.0790; IR (neat, cm-1): 3325, 2928, 2884, 2857, 
1705, 1651, 1565, 1463, 1361, 1253, 1049, 835, cm-1. 
 
6-Methyl-4-(2-oxo-butoxy)-2-pyrone (172) 
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A solution of 171 (99 mmg, 0.5 mmol, 1 eq.) and Dess-Martin periodinane (212 mg, 0.5 
mmol, 1 eq.) in DCM (1 ml) was stirred at 20 °C under nitrogen for 2 hours.  The reaction 
was quenched by addition of sat. NaHCO3 solution (10 ml) and sodium thiosulfate (120 
mg) and stirred until the precipitate had disappeared (ca. 10 mins).  The organic layer was 
separated and the aqueous layer extracted with DCM (5 ml).  The combined organic 
extracts were washed with brine (5 ml) and dried over MgSO4, then concentrated in vacuo.  
The crude product was then flushed through a silica plug eluting with 5% MeOH in DCM 
to afford a yellow oil (34 mg, 34.7%).    
Rf = 0.61 (5% MeOH in DCM);  1H-NMR (400 MHz, CDCl3): 5.87 (d, J = 2.2 Hz, 1H, 
C5H), 5.24 (d, J = 2.2 Hz, 1H, C3H), 4.55 (s, 2H, C8H), 2.49 (q, J = 7.3 Hz, 1H, C10H), 
2.20 (s, 3H, C7H3), 1.10 (t, J = 7.3 Hz, 3H, C11H3); 13C-NMR (100 MHz, CDCl3): 204.0, 
169.5, 164.5, 162.8, 100.1, 88.4, 71.8, 32.4, 19.9, 7.0; MS (ESI) m/z (rel.%): 219 [MNa+] 
(100), 197 [MH+] (5), 172 (3); HRMS (ESI) calculated for C10H12O4Na [MNa+]: 
219.0628, found: 219.0636; IR (DCM, cm-1): 3666, 2956, 2930, 2856, 1713, 1650, 1570, 
1453, 1411, 1321, 1250, 1096. 
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4-(1-Dibromomethyl-propoxy)-6-methyl-2-pyrone (175a) 
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To a stirred solution of triphenyl phosphite (748 mg, 2.4 mmol, 1.1 eq.) in DCM (10 ml) 
under argon at -60 °C, was added Br2 (405 mg, 2.53 mmol, 1.15 eq.) carefully over 10 
minutes.  Anhydrous TEA (267 mg, 2.64 mmol, 1.2 eq.) was then added carefully over 10 
minutes, followed by the carefully addition aldehyde 165 (430 mg, 2.2 mmol, 1 eq.) in 
DCM (1 ml) over 5 minutes.  The reaction was maintained at -60 °C for 30 minutes then 
allowed to warm slowly to ambient temperature over 18 hours, followed by heating to 
reflux for a further 2 hours.  The solvent was removed in vacuo and the reaction mixture 
purified via flash column chromatography (20% EtOAc in pet ether) to afford a white 
crystalline solid (265 mg, 36%). 
Rf = 0.16 (20% EtOAc in pet ether); Mpt: 99-100 °C; 1H-NMR (500 MHz, CDCl3): 5.86 
(dq, J = 2.3, 0.8 Hz, 1H, C5H), 5.83 (d, J = 4.1 Hz, 1H, C10H), 5.43 (d, J = 2.3, 1H, C3H), 
4.45 (td, J = 8.0, 4.1 Hz, 1H, C11H), 2.22 (app. s, 3H, C7H3), 2.07 – 1.86 (m, 2H, C9H2), 
1.01 (t, J = 7.5 Hz, 3H, C8H3); 13C-NMR (126 MHz, CDCl3): 169.5, 164.5, 163.0, 100.4, 
88.8, 82.4, 71.2, 22.9, 19.9, 9.3; MS (ESI) m/z (rel.%): 343 [81Br/81Br -MH+] (44), 341 
[79Br/81Br -MH+] (100), 339 [79Br/79Br -MH+] (45); HRMS (ESI) calculated for 
C10H1379Br2O3: 338.9226, found: 338.9223; IR (neat, cm-1): 3079, 3017, 2976, 2942, 2159, 
1703, 1646, 1558, 1443, 1409, 1248, 1230, 1145, 996, 829. 
 
4-(1-Dichloromethyl-propoxy)-6-methyl-2-pyrone (175b) 
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To a stirred solution of triphenyl phosphite (748 mg, 2.4 mmol, 1.1 eq.) in DCM (10 ml) 
under argon at -20 °C, was bubbled Cl2 until the solution turned yellow.  Additional 
triphenyl phosphite (~10 mg) was then added carefully until the yellow colouration 
disappeared.  Anhydrous TEA (267 mg, 2.64 mmol, 1.2 eq.) was then added carefully over 
10 minutes, followed by the carefully addition aldehyde 165 (430 mg, 2.2 mmol, 1 eq.) 
over 5 minutes.  The reaction was maintained at -20 °C for 30 minutes then allowed to 
warm slowly to ambient temperature over 18 hours, followed by heating to reflux for a 
 143 
further 2 hours.  The solvent was removed in vacuo and the reaction mixture purified via 
flash column chromatography (20% EtOAc in pet ether) to afford a white crystalline solid 
(228 mg, 41%). 
Mpt: 84-85 °C; 1H-NMR (400 MHz, CDCl3): 5.87 (qd, J = 2.2, 0.8 Hz, 1H, C5H), 5.79 (d, 
J = 3.8 Hz, 1H, C11H), 5.41 (d, J = 2.2 Hz, 1H, C3H), 4.40 (dt, J = 7.8, 3.8 Hz, 1H, C10H), 
2.23 (d, J = 0.8 Hz, 3H, C7H3), 1.89 – 2.10 (m, 2H, C9H2), 1.01 (t, J = 7.5 Hz, 3H, C8H3); 
13C-NMR (101 MHz, CDCl3): 169.4, 164.6, 163.0, 100.5, 88.8, 82.6, 43.7, 24.4, 19.9, 9.5; 
MS (ESI) m/z (rel.%): 255 [37Cl/37Cl-MH+] (10), 253 [37Cl/35Cl-MH+] (65), 251 [37Cl/37Cl-
MH+] (100); HRMS (ESI) calculated for C10H1335Cl2O3: 251.0236, found: 251.0239; IR 
(DCM, cm-1): 2978, 2883, 1714, 1652, 1568, 1448, 1411, 1322, 1257, 1241, 1181, 1145, 
1037, 1004.   
 
4-(E-1-Bromomethylene-propoxy)-6-methyl-2-pyrone (E-176a) 
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A solution of dibromide 175a (340 mg, 1 mmol, 1 eq.) and DBU (304 mg, 2 mmol, 2 eq.) 
in THF (3 ml) was stirred at 70 °C for 24 hours.  The solvent was then removed in vacuo 
and the reaction mixture purified via flash column chromatography (20% EtOAc in pet 
ether) to afford a pale yellow oil (94 mg, 36%). 
1H-NMR (500 MHz, CDCl3): 6.00 (s, 1H, C11H), 5.87 (dq, J = 2.2, 0.9 Hz, 1H, C5H), 5.49 
(d, J = 2.2 Hz, 1H, C3H), 2.48 (q, J = 7.5 Hz, 2H, C9H2), 2.25 (d, J = 0.8 Hz, 3H, C7H3), 
1.08 (t, J = 7.6 Hz, 3H, C8H3); 13C-NMR (126 MHz, CDCl3): 169.9, 168.5, 163.6, 163.5, 
100.1, 99.8, 89.9, 24.4, 20.0, 7.9; MS (ESI) m/z (rel.%): 283 [81Br-MNa+] (42), 281 [79Br-
MNa+] (42), 261 [81Br-MH+] (98), 259 [79Br-MH+] (100); HRMS (ESI) calculated for 
C10H1279BrO3: 258.9964, found: 258.9964; IR (CHCl3, cm-1): 2916, 2848, 2158, 1732, 
1716, 1652, 1568, 1456, 1226, 1172, 1128, 996, 818, 719. 
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4-(Z-1-Bromomethylene-propoxy)-6-methyl-2-pyrone (Z-176a) 
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A solution of dibromide 175a (340 mg, 1 mmol, 1 eq.) and DBU (304 mg, 2 mmol, 2 eq.) 
in THF (3 ml) was stirred at 70 °C for 24 hours.  The solvent was then removed in vacuo 
and the reaction mixture purified via flash column chromatography (20% EtOAc in pet 
ether) to afford a pale yellow oil (167 mg, 65%). 
1H-NMR (500 MHz, CDCl3): 5.95 (t, J = 1.3 Hz, 1H, C11H), 5.92 (dq, J = 2.2, 0.8 Hz, 1H, 
C5H), 5.40 (dq, J = 2.2, 0.5 Hz, 1H, C3H), 2.29 (qd, J = 7.5, 1.3 Hz, 2H, C9H2), 2.25 (dd, J 
= 0.8, 0.5 Hz, 3H, C7H3), 1.11 (t, J = 7.5 Hz, 3H, C8H3); 13C-NMR (126 MHz, CDCl3): 
169.0, 164.3, 163.5, 155.0, 99.5, 97.9, 91.0, 23.3, 20.0, 10.4; MS (ESI) m/z (rel.%): 283 
[81Br-MNa+] (42), 281 [79Br-MNa+] (42), 261 [81Br-MH+] (98), 259 [79Br-MH+] (100); 
HRMS (ESI) calculated for C10H1279BrO3: 258.9964, found: 258.9964; IR (neat, cm-1): 
3089, 2975, 2939, 1712, 1642, 1565, 1446, 1405, 1221, 1174, 1138, 998, 819. 
 
4-(E-1-Chloromethylene-propoxy)-6-methyl-2-pyrone (E-176b) 
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A solution of dichloride 175b (187 mg, 0.75 mmol, 1 eq.), NaI (337 mg, 2.25 mmol, 3 eq.) 
and DBU (227 mg, 1.5 mmol, 2 eq.) in DME (5 ml) was stirred at 90 °C for 24 hours.  The 
solvent was then removed in vacuo and the reaction mixture purified via flash column 
chromatography (20% EtOAc in pet ether) to afford a pale yellow oil (6 mg, 4%). 
1H-NMR (500 MHz, CDCl3): 5.98 (s, 1H, C11H), 5.88 (dq, J = 2.2, 0.9 Hz, 1H, C5H), 5.48 
(dq, J = 2.2, 0.5 Hz, 1H, C3H), 2.46 (q, J = 7.5 Hz, 2H, C9H2), 2.24 – 2.25 (m, 3H, C7H3), 
1.08 (t, J = 7.5 Hz, 3H, C8H3); 13C-NMR (126 MHz, CDCl3): 169.3, 164.3, 163.5, 154.2, 
110.6, 99.5, 90.8, 21.6, 20.0, 10.4; MS (ESI) m/z (rel.%): 217 [37Cl-MH+] (33), 215 [35Cl-
MH+] (100); HRMS (ESI) calculated for C10H1235ClO3: 215.0469, found: 215.0477. 
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4-(Z-1-Chloromethylene-propoxy)-6-methyl-2-pyrone (Z-176b) 
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A solution of dichloride 175b (187 mg, 0.75 mmol, 1 eq.), NaI (337 mg, 2.25 mmol, 3 eq.) 
and DBU (227 mg, 1.5 mmol, 2 eq.) in DME (5 ml) was stirred at 90 °C for 24 hours.  The 
solvent was then removed in vacuo and the reaction mixture purified via flash column 
chromatography (20% EtOAc in pet ether) to afford a pale yellow oil (8 mg, 5%). 
1H-NMR (400 MHz, CDCl3): 5.91 (dq, J = 2.1, 0.8 Hz, 1H, C5H), 5.86 (t, J = 1.4 Hz, 1H, 
C11H), 5.40 (d, J = 2.1 Hz, 1H, C3H), 2.27 (qd, J = 7.4, 1.4 Hz, 2H, C9H2), 2.25 (d, J = 0.8 
Hz, 3H, C7H3), 1.10 (t, J = 7.4 Hz, 3H, C8H3); 13C-NMR (126 MHz, CDCl3): 169.3, 164.3, 
163.5, 154.2, 110.6, 99.5, 90.8, 21.6, 20.0, 10.4; MS (ESI) m/z (rel.%): 217 [37Cl-MH+] 
(33), 215 [35Cl-MH+] (100); HRMS (ESI) calculated for C10H1235ClO3: 215.0469, found: 
215.0477; IR (CHCl3, cm-1): 2979, 2362, 1712, 1651, 1570, 1405, 1227, 1178, 907, 732. 
 
4-[1-(Z-4-Methoxy-benzylidene)-propoxy]-6-methyl-2-pyrone (Z-178) 
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Prepared according to General Procedure A using Z-176a (20 mg, 77 µmol, 1 eq.), 177 (24 
mg, 158 µmol, 2 eq.) and CatCat (27) (1.2 mg, 1.5 µmol, 2 mol%) to afford the title 
compound as a pale yellow oil (15 mg, 68%). 
1H-NMR (400 MHz, CDCl3): 7.23 – 7.27 (m, 2H, C13H), 6.77 – 6.82 (m, 2H, C14H), 5.97 
(t, J = 1.0 Hz, 1H, C11H), 5.93 (dq, J = 2.1, 0.9 Hz, 1H, C5H), 5.46 (dq, J = 2.1, 0.5 Hz, 
1H, C3H), 3.77 (s, 3H, C17H3), 2.31 (qd, J = 7.4, 1.0 Hz, 2H, C9H2), 2.23 (dd, J = 0.9, 0.5 
Hz, 3H, C7H3), 1.14 (t, J = 7.4 Hz, 3H, C8H3); 13C-NMR (101 MHz, CDCl3): 168.0, 164.7, 
163.3, 158.8, 149.6, 129.6, 126.0, 115.7, 113.9, 99.7, 90.4, 55.2, 26.4, 20.1, 11.5; MS 
(ESI) m/z (rel.%): 287 [MH+] (100); HRMS (ESI) calculated for C17H19O4: 287.1278, 
found: 287.1274; IR (neat, cm-1): 2967, 2935, 2838, 1721, 1647, 1606, 1564, 1510, 1446, 
1405, 1252, 1224, 1175, 1135, 1031, 820. 
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4-[E-1-(4-Methoxy-benzylidene)-propoxy]-6-methyl-2-pyrone (E-178) 
3
5
O
O
7O
10
9
11
8
13
14
14
13
O
17
 
Prepared according to General Procedure A using E-176a (20 mg, 77 µmol, 1 eq.), 177 (24 
mg, 158 µmol, 2 eq.) and CatCat (27) (1.2 mg, 1.5 µmol, 2 mol%) to afford the title 
compound as a pale yellow oil (21.5 mg, 98%). 
1H-NMR (400 MHz, CDCl3): 7.15 – 7.19 (m, 2H, C13H), 6.88 – 6.92 (m, 2H, C14H), 6.20 
(s, 1H, C11H), 5.93 (dq, J = 2.2, 0.9 Hz, 1H, C5H), 5.60 (d, J = 2.2 Hz, 1H, C3H), 3.82 (s, 
3H, C17H3), 2.48 (q, J = 7.5 Hz, 2H, C9H2), 2.25 (d, J = 0.9 Hz, 3H, C7H3), 1.12 (t, J = 7.5 
Hz, 3H, C8H3); 13C-NMR (101 MHz, CDCl3): 167.0, 164.9, 163.1, 158.9, 152.3, 129.6, 
126.3, 118.9, 114.0, 100.1, 90.3, 55.3, 22.6, 20.0, 11.5; MS (ESI) m/z (rel.%): 287 [MH+] 
(100); HRMS (ESI) calculated for C17H19O4: 287.1278, found: 287.1274; IR (neat, cm-1): 
2973, 2934, 2838, 1723, 1645, 1607, 1563, 1511, 1446, 1404, 1249, 1227, 1174, 1133, 
821. 
 
4-[E-1-benzylidene-propoxy]-6-methyl-2-pyrone (E-179) 
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Prepared according to General Procedure A using E-176a (15 mg, 57.7 µmol, 1 eq.), 57 
(19 mg, 158 µmol, 2.7 eq.) and CatCat (27) (1.2 mg, 1.5 µmol, 3 mol%) to afford the title 
compound as a pale yellow oil (15 mg, 68%). 
1H-NMR (400 MHz, CDCl3): 7.37 (t, J = 7.2 Hz, 2H, C14H), 7.30 (t, J = 7.2 Hz, 1H, 
C15H), 7.24 (d, J = 7.2 Hz, 2H, C13H), 6.27 (s, 1H, C11H), 5.94 (m, 1H, C5H), 5.62 (d, J = 
2.2 Hz, 1H, C3H), 2.49 (q, J = 7.5, 2H, C9H2), 2.26 (s, 3H, C7H3), 1.13 (t, J = 7.5, 3H, 
C8H3); 13C-NMR (101 MHz, CDCl3): 169.8, 164.9, 163.2, 153.6, 134.0, 129.6, 128.6, 
128.4, 127.4, 124.6, 120.2, 120.2, 119.3, 100.1, 90.5, 22.6, 20.0, 11.5; MS (ESI) m/z 
(rel.%): 257 [MH+] (100); HRMS (ESI) calculated for C16H17O3: 257.1172, found: 
257.1180; IR (neat, cm-1): 3060, 2976, 2937, 1721, 1645, 1563, 1489, 1447, 1406, 1227, 
1190, 1133, 924, 692. 
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4-(1-Ethyl-penta-E-1,4-dienyloxy)-6-methyl-2-pyrone (E-180) 
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A solution of E-176a (23 mg, 89 µmol, 1 eq.), 152 (30 mg, 178 µmol, 2 eq.), Cs2CO3 (87 
mg, 266 µmol, 3 eq.) and CatCat (35)  (1.4 mg, 1.8 µmol, 2 mol%) in THF (1 ml) was 
stirred under nitrogen at 70 °C for 18 h, then quenched by the addition of water (1 ml) and 
EtOAc (1 ml).  The organic layer was separated and the organic layer extracted with 
EtOAc (3 × 1 ml), then the combined organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuo.  Flash column chromatography (20% EtOAc in pet ether) of the 
crude material afforded the title compound as a pale yellow oil (8 mg, 41%). 
1H-NMR (400 MHz, CDCl3): 5.87 (dq, J = 2.2, 0.8 Hz, 1H, C5H), 5.79 (ddt, J = 17.0, 
10.3, 6.0 Hz, 1H, C13H), 5.48 (d, J = 2.2 Hz, 1H, C3H), 5.20 (t, J = 7.8 Hz, 1H, C11H), 5.07 
(app. dq, J = 17.0, 1.6 Hz, 1H, C14Ha), 5.03 (app. dq, J = 10.3, 1.6 Hz, 1H, C14Hb), 2.81 
(m, 2H, C12H2), 2.26 (q, J = 7.5 Hz, 2H, C9H2), 2.23 (d, J = 0.8 Hz, 3H, C7H3), 1.04 (t, J = 
7.5 Hz, 3H, C8H3); 13C-NMR (101 MHz, CDCl3): 168.8, 164.9, 163.1, 151.3, 135.3, 114.1, 
99.8, 95.6, 89.5, 29.4, 25.3, 20.0, 11.1; MS (ESI) m/z (rel.%): 243 [MNa+] (28), 221[MH+] 
(100), 201 (6), 179 (28), 127 (4); HRMS (ESI) calculated for C13H17O3: 221.1172, found: 
221.1175. 
 
4-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propoxy]-6-(6-triisopropylsilyl-hex-5-
ynyl)-2-pyrone (182) 
3
5
O
O
7
O
18
17
19
16
O
8
9
10
Si
Si24
24
24 22
22
14
14
14
15
15 15
15
15
15
 
2-pyrone 44 (550 mg, 1.58 mmol, 1 eq.), alcohol 168 (484 mg, 2.37 mmol, 1.5 eq.) and 
triphenylphosphine (621 mg, 2.37 mmol, 1.5 eq.) were dissolved in DCM (5 ml) under 
nitrogen at 0 °C.  DIAD (479 mg, 2.37 mmol, 1.5 eq.) was then added carefully over 15 
minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in vacuo.  
The crude product was purified via flash column chromatography (20% EtOAc in hexanes) 
to afford a colourless oil (628 mg, 75%). 
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1H-NMR (500 MHz, CDCl3): 5.77 (d, J = 2.3 Hz, 1H, C5H), 5.44 (d, J = 2.3 Hz, 1H, C3H), 
4.23 (p, J = 5.5 Hz, 1H, C18H), 3.68-3.74 (m, 2H, C19H2), 2.47 (t, J = 7.5 Hz, 2H, C7H2), 
2.29 (t, J = 6.9 Hz, 2H, C10H2), 1.76-1.83 (m, 2H, C8H2), 1.62-1.75 (m, 2H, C17H2), 1.54-
1.61 (m, 2H, C9H2), 0.97-1.08 (m, 21H, C14H/ C15H2), 0.94 (t, J = 7.5 Hz, 3H, C16H3), 0.86 
(s, 9H, C24H3), 0.03 (s, 3H, C22H3), 0.02 (s, 3H, C22H3); 13C-NMR (126 MHz, CDCl3): 
170.4, 165.4, 165.4, 108.4, 100.3, 88.5, 80.8, 77.2, 63.7, 32.9, 27.9, 25.7, 25.6, 23.3, 19.5, 
18.6, 18.2, 11.2, 9.4, -5.4, -5.5; MS (ESI) m/z (rel.%): 557 [MNa+] (19), 535 [MH+] (100), 
413 (11), 391 (39); HRMS (ESI) calculated for C30H55O4Si2 [MH+]: 535.3633, found: 
535.3648.  
 
4-(1-Hydroxymethyl-propoxy)-6-(6-triisopropylsilyl-hex-5-ynyl)-2-pyrone (183) 
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A solution of 182 (584 mg, 1.09 mmol, 1 eq.) in THF (2 ml), water (1 ml) and acetic acid 
(3 ml) was stirred for 16 hours at 20 °C.  The solution was concentrated in vacuo and the 
resulting product was purified via flash column chromatography (2-4% MeOH in DCM) to 
afford a pale yellow oil (343 mg, 75%). 
1H-NMR (500 MHz, CDCl3): 5.79 (d, J = 2.0 Hz, 1H, C5H), 5.44 (d, J = 2.0 Hz, 1H, C3H), 
4.28 (app.qd, J = 6.0, 3.5  Hz, 1H, C18H), 3.81 (dd, J = 12.0, 3.5 Hz, 1H, C19H2), 3.76 (dd, 
J = 12.0, 6.0 Hz, 1H, C19H2), 2.48 (t, J = 7.5 Hz, 2H, C7H2), 2.29 (t, J = 6.9 Hz, 2H, 
C10H2), 1.77-1.84 (m, 2H, C8H2), 1.70-1.76 (m, 2H, C17H2), 1.55-1.63 (m, 2H, C9H2), 0.99 
– 1.09 (m, 21H, C14H/ C15H3), 0.96 (t, J = 7.5 Hz, 3H, C16H3): 13C-NMR (126 MHz, 
CDCl3): 169.9, 165.7, 165.0, 108.1, 100.1, 88.7, 80.9, 80.8, 63.3, 33.0, 27.9, 25.6, 22.8, 
19.5, 18.6, 11.3, 9.4; MS (ESI) m/z (rel.%): 443 [MNa+] (15), 535 [MH+] (100); HRMS 
(ESI) calculated for C24H41O4Si [MH+]: 421.2769, found: 421.2771; IR (neat, cm-1): 3405, 
2941, 2864, 2171, 1696, 1645, 1560, 1462, 1426, 1244, 1140, 1061, 995, 882, 818. 
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2-(6-(6-triisopropylsilanyl-hex-5-ynyl)-2-pyron-4-yloxy)-butyraldehyde (184) 
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To a solution of oxalyl chloride (826 mg, 6.5 mmol, 1.3 eq.) in DCM (15 ml) at -78 °C was 
added DMSO (1.01 g, 13 mmol, 2.6 eq.) in DCM (15 ml) carefully over 15 minutes.  The 
reaction was stirred for 30 minutes at -78 °C then a solution of 183 (990 mg, 5 mmol, 1 
eq.) in DCM (15 ml) was added carefully over 20 minutes and the reaction stirred for a 
further 30 minutes at -78 °C.  TEA (1.80 g, 18 mmol, 3.6 eq.) was added over 15 minutes 
and the reaction stirred for 1 h at -78 °C then allowed to warm to ambient temperature.  
The solvent was removed in vacuo and the residue taken up in ether then passed through a 
silica plug, eluting with ether.  The solvent was then removed in vacuo to afford the 
desired product as a colourless oil (978 mg, >99%) 
1H-NMR (400 MHz, D2-DCM): 9.57 (d, J = 1.4 Hz, 1H, C19H), 5.89 (dt, J = 2.3, 0.7 Hz, 
1H, C5H), 5.19 (d, J = 2.2 Hz, 1H, C3H), 4.51 (ddd, J = 6.9, 5.4, 1.3 Hz, 1H, C18H), 2.50 
(td, J = 7.4, 0.7 Hz, 2H, C7H2), 2.30 (t, J = 6.9 Hz, 2H, C10H2), 2.00 – 1.85 (m, 2H, C8H2), 
1.84 – 1.75 (m, 2H, C17H2), 1.64 – 1.56 (m, 2H, C9H2), 1.27 – 1.22 (m, 3H, C14H), 1.11 – 
0.99 (m, 21H, C16H3/ C15H3); 13C-NMR (101 MHz, D2-DCM): 199.0, 169.8, 166.8, 164.4, 
108.9, 99.9, 89.5, 83.4, 81.2, 41.6, 33.6, 28.5, 26.2, 23.4, 19.9, 18.9, 11.8, 9.3; MS (ESI) 
m/z (rel.%): 419 [MH+] (100): HRMS (ESI) calculated for C24H39O4Si: 419.2612, found: 
419.2618.   
 
4-[1-(tert-Butyl-dimethyl-silanyloxymethyl)-propoxy]-6-(non-8-en-5-ynyl)-2-pyrone 
(187) 
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2-pyrone 95 (105 mg, 0.45 mmol, 1 eq.), alcohol 168 (212 mg, 0.68 mmol, 1.5 eq.) and 
triphenylphosphine (178 mg, 0.68 mmol, 1.5 eq.) were dissolved in DCM (2 ml) under 
nitrogen at 0 °C.  DIAD (137 mg, 0.68 mmol, 1.5 eq.) was then added carefully over 15 
minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in vacuo.  
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The crude product was purified via flash column chromatography (20% EtOAc in hexanes) 
to afford a colourless oil (93 mg, 49.5%). 
1H-NMR (500 MHz, CDCl3): 5.81 (ddt, J = 16.9, 10.0, 5.3 Hz, 1H, C14H), 5.76 (d, J = 2.2 
Hz, 1H, C5H), 5.42 (d, J = 2.2 Hz, 1H, C3H), 5.28 (ddt, J = 16.9, 1.8, 1.8 Hz, 1H, C15Hb), 
5.08 (ddt, J = 10.0, 1.8, 1.8 Hz, 1H, C15Ha), 4.22 (p, J = 5.5 Hz, 1H, C18H), 3.69-3.72 (m, 
2H, C19H2), 2.90-2.94 (m, 2H, C13H2), 2.45 (t, J = 5.5 Hz, 2H, C7H2), 2.22 (tt, J = 7.0, 2.4 
Hz, 2H, C10H2), 1.72-1.80 (m, 2H, C8H2), 1.62-1.71 (m, 2H, C17H2), 1.51-1.58 (m, 2H, 
C9H2), 0.94 (t, J = 7.5 Hz, 3H, C16H3), 0.86 (s, 9H, C24H3), 0.03 (s, 3H, C22H3), 0.02 (s, 
3H, C22H3); 13C-NMR (126 MHz, CDCl3): 170.3, 165.3, 165.2, 133.2, 115.6, 100.3, 88.6, 
81.8, 80.8, 63.7, 33.1, 28.1, 25.7, 23.4, 23.1, 21.9, 20.4, 18.5, 18.2, 9.4, -5.4, -5.5; MS 
(ESI) m/z (rel.%): 441 [MNa+] (60), 419 [MH+] (100), 391 (9); HRMS (ESI) calculated for 
C24H39O4Si [MH+]: 419.2612, found: 419.2620; IR (neat, cm-1): 2930, 2857, 1733, 1652, 
1559, 1472, 1419, 1241, 1107, 1005, 837. 
 
4-(1-Hydroxymethyl-propoxy)-6-(non-8-en-5-ynyl)-2-pyrone (188)  
3
5
O
O
7
O
18
17
19
16
HO 8
9
10
13
14
15
H
Ha
b
HH
 
A solution of 187 (30 mg, 71 µmol, 1 eq.) in THF (1 ml), water (0.5 ml) and acetic acid (2 
ml) was stirred for 16 hours at 20 °C.  The solution was concentrated in vacuo and the 
resulting product was purified via flash column chromatography (2-4% MeOH in DCM) to 
afford a pale yellow oil (15 mg, 69%). 
1H-NMR (500 MHz, CDCl3): 5.77-5.85 (m, 2H, C14H/ C5H), 5.46 (d, J = 2.2 Hz, 1H, 
C3H), 5.28 (ddt, J = 16.9, 1.8, 1.8 Hz, 1H, C15Hb), 5.08 (ddt, J = 10.0, 1.8, 1.8 Hz, 1H, 
C15Ha), 4.22 (tdd, J = 6.0, 6.0, 3.7  Hz, 1H, C18H), 3.80 (dd, J = 12.1, 3.7 Hz, 1H, C19H2), 
3.75 (dd, J = 12.1, 6.0 Hz, 1H, C19H2), 2.91-2.95 (m, 2H, C13H2), 2.46 (t, J = 7.6 Hz, 2H, 
C7H2), 2.23 (tt, J = 7.0, 2.4 Hz, 2H, C10H2), 2.08 (s, 1H, OH), 1.70-1.80 (m, 4H, C8H2/ 
C17H2), 1.52-1.59 (m, 2H, C9H2), 0.96 (t, J = 7.5 Hz, 3H, C16H3); 13C-NMR (126 MHz, 
CDCl3): 170.2, 165.8, 165.4, 133.4, 115.8, 100.5, 88.9, 82.0, 81.1, 63.4, 33.3, 28.3, 25.9, 
23.3, 23.1, 18.7, 9.6, 1.2; MS (ESI) m/z (rel.%): 305[MH+] (100), 293 (8), 279 (5), 247 (8), 
101 (7); HRMS (ESI) calculated for C18H25O4 [MH+]: 305.1747, found: 305.1735; IR 
(neat, cm-1): 3419, 2937, 2880, 1700, 1645, 1560, 1433, 1335, 1246, 1143, 1061, 1020, 
916, 818, 668. 
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2-(6-(non-8-en-5-ynyl)-2-pyron-4-yloxy)-butyraldehyde (189) 
3
5
O
O
7
O
18
17
19
16
O 8
9
10
13H
14
15
H
Ha
b
 
To a solution of oxalyl chloride (16.3 mg, 129 µmol, 1.3 eq.) in DCM (1 ml) at -78 °C was 
added DMSO (20.1 mg, 258 µmol, 2.6 eq.) in DCM (1 ml) carefully over 15 minutes.  The 
reaction was stirred for 30 minutes at -78 °C then a solution of 188 (30.0 mg, 99 µmol, 1 
eq.) in DCM (1 ml) was added carefully over 20 minutes and the reaction stirred for a 
further 30 minutes at -78 °C.  TEA (36 mg, 357 µmol, 3.6 eq.) was added over 15 minutes 
and the reaction stirred for 1 h at -78 °C then allowed to warm to ambient temperature.  
The solvent was removed in vacuo and the residue taken up in ether then passed through a 
silica plug, eluting with ether.  The solvent was then removed in vacuo to afford the 
desired product as a colourless oil (29.2 mg, 98%). 
1H-NMR (400 MHz, CDCl3):  9.59 (d, J = 1.5 Hz, 1H, C19H), 5.90 (d, J = 2.3 Hz, 1H, 
C5H), 5.82 (ddt, J = 17.0, 10.0, 5.4 Hz, 1H, C14H), 5.30 (ddt, J = 17.0, 1.8, 1.8 Hz, 1H, 
C15Hb), 5.23 (d, J = 2.3 Hz, 1H, C3H), 5.10 (ddt, J = 10.0, 1.8, 1.8 Hz, 1H, C15Ha), 4.48 
(ddd, J = 7.1, 5.4, 1.5 Hz, 1H, C18H), 2.96 – 2.93 (m, 2H, C13H2), 2.50 (t, J = 7.5 Hz, 2H, 
C7H2), 2.30 – 2.20 (m, 2H, C10H2), 2.00 – 1.89 (m, 2H, C17H2), 1.84 – 1.71 (m, 2H, C8H2), 
1.61 – 1.53 (m, 2H, C9H2), 1.05 (t, J = 7.4 Hz, 3H, C16H3); MS (ESI) m/z (rel.%): 303 
[MH+] (100); HRMS (ESI) calculated for C18H23O4: 303.1591, found: 303.1585. 
 
6-(Non-8-en-5-ynyl)-4-(oct-7-enyloxy)-2-pyrone (192) 
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A solution of 2-pyrone 95 (11.0 mg, 47 µmol, 1 eq.), 8-bromo-1-octene (18.1 mg, 95 µmol, 
2 eq.) and DBU (14.4 mg, 95 µmol, 2 eq.) in MeCN (1 ml), was stirred at 80 °C for 16 
hours.  The reaction mixture was cooled and the solvent removed in vacuo, and the crude 
product purified via flash column chromatography (40% ether in pet ether) to afford the 
title compound as a pale yellow oil (11.8 mg, 72.8%). 
1H-NMR (500 MHz, CDCl3): 5.75 – 5.86 (m, 3H), 5.37 (d, J = 2.2 Hz, 1H), 5.29 (ddt, J = 
17.0, 1.9, 1.9 Hz, 1H), 5.09 (ddt, J = 10.0, 1.7, 1.7 Hz, 1H), 5.00 (ddt, J = 17.1, 2.1, 1.6 Hz, 
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1H), 4.94 (ddt, J = 10.2, 2.1, 1.2 Hz, 1H), 3.92 (t, J = 6.5 Hz, 2H), 2.91 – 2.95 (m, 2H), 
2.46 (t, J = 7.5 Hz, 2H), 2.23 (tt, J = 7.0, 2.4 Hz, 2H), 2.02 – 2.09 (m, 2H), 1.72 – 1.80 (m, 
4H), 1.51 – 1.59 (m, 2H), 1.33 – 1.45 (m, 6H); 13C-NMR (126 MHz, CDCl3): 170.6, 165.2, 
165.1, 138.8, 133.2, 115.7, 114.4, 100.0, 87.9, 81.9, 77.2, 68.8, 33.6, 33.1, 28.7, 28.6, 28.4, 
28.1, 25.7, 25.7, 23.1, 18.5; MS (ESI) m/z (rel.%): 365 [MNa+] (50), 343 [MH+] (60), 301 
(17), 259 (100), 237 (75); HRMS (ESI) calculated for C22H31O3: 343.2268, found: 
343.2272; IR (DCM, cm-1): 2930, 1717, 1700, 1652, 1559, 1245, 810. 
 
Hexacarbonyl{µ2-[6-(non-8-en-5-ynyl)-4-(oct-7-enyloxy)-2-pyrone]} dicobalt (0) (194) 
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A solution of 192 (9.0 mg, 26.3 µmol, 1 eq.) and Co2(CO)6 (9.9 mg, 28.9 µmol, 1.1 eq.) in 
THF (1 ml) was stirred under argon at 20 °C for 2 hours.  The reaction mixture was then 
purified via flash column chromatography (30% ether in pet ether) to afford the title 
compound as a red/brown oil (9.0 mg, 57%).   
1H-NMR (400 MHz, CDCl3): 5.92 (ddt, J = 17.0, 10.0, 7.1 Hz, 1H), 5.81 (ddt, J = 17.0, 
10.1, 6.7 Hz, 1H), 5.77 (d, J = 2.2 Hz, 1H), 5.38 (d, J = 2.2 Hz, 1H), 5.20 (ddt, J = 17.0, 
1.2, 1.2 Hz, 1H), 5.14 (ddt, J = 10.0, 1.2, 1.2 Hz, 1H), 5.00 (ddt, J = 17.0, 1.8, 1.8 Hz, 1H), 
4.95 (ddt, J = 10.1, 1.8, 1.8 Hz, 1H), 3.92 (t, J = 6.5 Hz, 2H), 3.56 (d, J = 7.1 Hz, 2H), 2.84 
(dd, J = 8.0, 7.5 Hz, 2H), 2.51 (t, J = 7.5 Hz, 2H), 2.06 (q, J = 7.0 Hz, 2H), 1.79 – 1.86 (m, 
2H), 1.73 – 1.79 (m, 2H), 1.64 – 1.72 (m, 2H), 1.33 – 1.46 (m, 6H); 13C-NMR (101 MHz, 
CDCl3): 170.6, 165.0, 164.8, 138.8, 135.4, 117.3, 114.4, 110.0, 100.2, 98.4, 88.0, 68.9, 
38.2, 33.6, 33.4, 30.8, 29.7, 28.7, 28.6, 28.4, 26.5, 25.6; MS (ESI) m/z (rel.%): 651 [MNa+] 
(60), 629 [MH+] (55), 580 (17), 545 (100), 517 (47), 489 (19), 461 (20), 413 (56), 391 
(54), 365 (56), 343 (98); HRMS (ESI) calculated for C28H31Co2O9: 629.0627, found: 
629.0628. 
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Hexacarbonyl{µ2-[2,19-Dioxa-bicyclo[16.3.1]docosa-1(21),9,18(22)-trien-12-yn-20-
one]} dicobalt (0) (195) 
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A solution of 194 (4.0 mg, 8.0 µmol, 1 eq.) and Grubbs (2nd Gen.) catalyst (1.4 mg, 1.6 
µmol, 20 mol%) in DCM (5 ml) were stirred under nitrogen at 40 °C for 24 hours.  The 
excess solvent was removed in vacuo and the crude material purified via flash column 
chromatography (DCM) to afford the title compound as a red/brown oil (3.8 mg, 79.6%) 
with a 70:30 mixture of isomers. 
1H-NMR (500 MHz, CDCl3): 5.83 (d, J = 1.7 Hz, 0.7H), 5.79 (d, J = 1.6 Hz, 0.3H), 5.55 
(dt, J = 15.0, 7.0 Hz, 1H), 5.44 (d, J = 1.7 Hz, 0.7H), 5.43 (d, J = 1.6 Hz, 0.3H), 5.40 (dt, J 
= 15.0, 7.5 Hz, 1H), 4.09 – 4.03 (m, 2H), 3.55 (d, J = 7.5 Hz, 1.4H), 3.52 (d, J = 5.8 Hz, 
0.6H), 2.91 (dd, J = 16.6, 9.2 Hz, 2H), 2.63 – 2.51 (m, 2H), 1.98 (q, J = 6.1 Hz, 2H), 1.89 – 
1.81 (m, 2H), 1.78 – 1.71 (m, 2H), 1.65 – 1.60 (m, 2H), 1.51 – 1.38 (m, 4H); 13C-NMR 
(126 MHz, CDCl3): 170.5, 170.3, 165.2, 132.9, 128.2, 100.9, 100.8, 88.9, 88.2, 88.1, 38.6, 
35.3, 33.0, 31.1, 30.5, 29.9, 27.5, 26.5, 24.5, 22.9; MS (ESI) m/z (rel.%): 601 [MH+] (12), 
491 (8), 413 (36), 391 (45), 297 (100), 281 (12); HRMS (ESI) calculated for C26H27Co2O9: 
601.0314, found: 601.0313; IR (DCM, cm-1): 2916, 2849, 2086, 2043, 2012, 1734, 1559, 
1243, 1132. 
 
Octa-Z-4,7-dien-1-ol (199)158 
OH 
To a 100 ml flask containing PdCl2 (14 mg, 0.08 mmol, 8 mol%) and NaBH4 (304 mg, 8 
mmol, 8 eq.) under argon, was added PEG-200 (19.9 g) over 15 minutes.  DCM (12 ml) 
was added followed by 203 (124 mg, 1 mmol, 1 eq.) in one portion.  The solution was 
subsequently cooled to -10 °C and allowed to warm to ambient temperature over 2 hours.  
The reaction was quenched by the addition of water (30 ml) and the organic layer 
separated.  The aqueous layer was then extracted with DCM (3 × 12 ml) and the combined 
organic extracts concentrated in vacuo, then purified via flash column chromatography 
(15% EtOAc in pet ether) to afford the title compound as a colourless oil (66 mg, 52.3%). 
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1H-NMR (500 MHz, CDCl3): 5.81 (ddt, J = 17.1, 10.1, 6.2 Hz, 1H), 5.49 – 5.36 (m, 2H), 
5.03 (ddd, J = 17.1, 3.6, 1.7 Hz, 1H), 4.97 (ddd, J = 10.1, 3.4, 1.7 Hz, 1H), 3.63 (t, J = 6.5 
Hz, 2H), 2.81 (dd, J = 13.0, 7.2 Hz, 2H), 2.16 – 2.08 (m, 2H), 1.67 – 1.58 (m, 2H); 13C-
NMR (126 MHz, CDCl3): 136.9, 130.2, 127.4, 114.6, 62.4, 32.4, 31.4, 23.4; MS (ESI) m/z 
(rel.%): 127 [MH+] (40), 109  (29), 101 (62), 79 (100); HRMS (ESI) calculated for 
C8H15O: 127.1117, found: 127.1115; IR (neat, cm-1): 3342, 2931, 2870, 1434, 1347, 1057, 
909. 
 
6-(Non-8-en-5-ynyl)-4-(octa-Z-4,7-dienyloxy)-2-pyrone (200) 
O
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2-pyrone 92 (33 mg, 142 µmol, 1 eq.), alcohol 199 (27 mg, 213 µmol, 1.5 eq.) and 
triphenylphosphine (56 mg, 213 µmol, 1.5 eq.) were dissolved in DCM (1 ml) under 
nitrogen at 0 °C.  DIAD (43 mg, 213 µmol, 1.5 eq.) was then added carefully over 15 
minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in vacuo.  
The crude product was purified via flash column chromatography (20% EtOAc in hexanes) 
to afford a colourless oil (25 mg, 52%). 
1H-NMR (500 MHz, CDCl3): 5.94 (d, J = 2.1 Hz, 1H), 5.74 – 5.86 (m, 2H), 5.52 – 5.41 
(m, 2H), 5.40 (d, J = 2.1 Hz, 1H), 5.29 (ddt, J = 17.0, 1.7, 1.7 Hz, 1H), 5.09 (ddt, J = 10.0, 
1.7, 1.7 Hz, 1H), 5.02 (ddt, J = 17.1, 3.4, 1.7 Hz, 1H), 4.98 (ddt, J = 10.2, 3.4, 1.6 Hz, 1H), 
3.94 (t, J = 6.4 Hz, 2H), 2.91 – 2.96 (m, 2H), 2.74 – 2.83 (m, 2H), 2.15 – 2.27 (m, 4H), 
1.89 – 2.06 (m, 2H), 1.80 – 1.88 (m, 2H), 1.56 – 1.71 (m, 4H); 13C-NMR (126 MHz, 
CDCl3): 170.2, 166.1, 164.2, 136.6, 128.9, 128.8, 128.5, 115.7, 114.9, 100.1, 88.7, 81.6, 
77.5, 68.2, 48.0, 33.1, 31.4, 31.1, 28.2, 23.2, 23.1, 14.4; MS (ESI) m/z (rel.%): 363 [MNa+] 
(23), 341 [MH+] (36), 329 (69), 307 (100); HRMS (ESI) calculated for C22H29O3: 
341.2111, found: 341.2114. 
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Hexacarbonyl{µ2-[6-(non-8-en-5-ynyl)-4-(octa-Z-4,7-dienyloxy)-2-pyrone]} dicobalt 
(0) (201) 
O
O
O
Co2(CO)6
 
A solution of 200 (10.0 mg, 29 µmol, 1 eq.) and Co2(CO)6 (15 mg, 44 µmol, 1.5 eq.) in 
THF (1 ml) was stirred under argon at 20 °C for 2 hours.  The reaction mixture was then 
purified via flash column chromatography (30% ether in pet ether) to afford the title 
compound as a red/brown oil (5.0 mg, 27.8%).   
1H-NMR (500 MHz, CDCl3): 5.97 (d, J = 2.1 Hz, 1H), 5.96 – 5.87 (m, 1H), 5.83 – 5.74 
(m, 1H), 5.53 – 5.42 (m, 2H), 5.40 (d, J = 2.2 Hz, 1H), 5.20 (d, J = 16.9 Hz, 1H), 5.14 (d, J 
= 9.9 Hz, 1H), 5.06 – 5.00 (m, 1H), 5.00 – 4.96 (m, 1H), 3.96 – 3.90 (m, 4H), 3.55 (d, J = 
7.1 Hz, 2H), 2.84 (t, J = 8.0 Hz, 2H), 2.79 (t, J = 5.7 Hz, 1H), 2.25 – 2.15 (m, 4H), 1.87 – 
1.81 (m, 4H); MS (ESI) m/z (rel.%): 627 [MH+] (3), 589 (12), 533 (6), 505 (5), 409 (19), 
387 (23), 329 (53), 307 (100), 282 (41), 235 (42); HRMS (ESI) calculated for 
C28H29Co2O9: 627.0470, found: 627.0465; IR (DCM, cm-1): 2930, 2087, 2046, 2014, 1733, 
1717, 1700, 1652, 1559.   
 
Oct-7-en-4-yn-1-ol (203)159 
6
7
8
3
2
1
OH
H
H
a
b
 
In a 3 L round bottom flask was added pent-4-yn-1-ol (14.97 g, 178 mmol, 1 eq.), allyl 
bromide (25.9 g, 214 mmol, 1.2 eq.), NaI (53.4 g, 356 mmol, 2 eq.), CuI (34.0 g, 178 
mmol, 1 eq.) and K2CO3 (49.1 g, 356 mmol, 2 eq.) in acetone (700 ml).  The flask was 
flushed with nitrogen and the mixture stirred for 16 hours at 20 °C, then filtered through 
celite and further quenched by the addition of 1N HCl (200 ml).  Ether (200 ml) was added 
and the phases separated.  The aqueous phase was then extracted using ether (4 x 200 ml) 
and the combined organic extracts washed with sat. brine solution (400 ml), dried over 
MgSO4 and concentrated in vacuo.  This afforded a dark orange oil and a white solid (NaI).  
These were separated via filtration with pet ether as eluent, and the solution once again 
concentrated in vacuo to afford the crude product which was purified via flash column 
chromatography (20% EtOAc in Heptane) to give a colourless oil (15.1 g, 68.5%). 
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1H- NMR (400 MHz, CDCl3): 5.81 (ddt, J = 16.9, 10.0, 5.3Hz, 1H, C7H), 5.29 (ddt, J 
=16.9, 1.7, 1.7 Hz, 1H, C8Ha), 5.09 (ddt, J =10.0, 1.7, 1.7 Hz, 1H, C8Hb),  3.76 (t, J = 6.4 
Hz, 2H, C1H2), 2.93 (m, 2H, C6H2), 2.32 (tt, J = 6.4, 2.4 Hz, 2H, C3H2), 1.76 (p, J = 6.4 
Hz, 2H, C2H2); 13C- NMR (100 MHz, CDCl3): 133.2, 115.7, 96.4, 81.8, 62.0, 31.6, 23.1, 
15.4; MS (ESI) m/z (rel.%): 125 [MH+] (100); IR (neat, cm-1): 3359, 2946, 1641, 1421, 
1056, 991, 915. 
 
6-(Non-8-en-5-ynyl)-4-(oct-7-en-4-ynyloxy)-2-pyrone (204) 
O
O
O
 
2-pyrone 95 (55 mg, 237 µmol, 1 eq.), alcohol 203 (44 mg, 355 µmol, 1.5 eq.) and 
triphenylphosphine (93 mg, 355 µmol, 1.5 eq.) were dissolved in DCM (1 ml) under 
nitrogen at 0 °C.  DIAD (72 mg, 355 µmol, 1.5 eq.) was then added carefully over 15 
minutes.  The reaction was stirred for 16 h at 20 °C and then the solvent removed in vacuo.  
The crude product was purified via flash column chromatography (20% EtOAc in hexanes) 
to afford a colourless oil (59.3 mg, 61%). 
1H-NMR (500 MHz, CDCl3): 5.76 – 5.87 (m, 3H), 5.41 (d, J = 2.2 Hz, 1H), 5.29 (ddt, J = 
16.9, 1.8, 1.8 Hz, 1H), 5.28 (ddt, J = 16.9, 1.8, 1.8 Hz, 1H), 5.09 (app. dp, J = 10.0, 1.8 Hz, 
2H), 4.05 (t, J = 6.2 Hz, 2H), 2.91 – 2.95 (m, 4H), 2.46 (t, J = 7.5 Hz, 2H), 2.37 (tt, J = 6.8, 
2.4 Hz, 2H), 2.23 (tt, J = 7.0, 2.4 Hz, 2H), 1.96 (p, J = 6.6 Hz, 2H), 1.72 – 1.80 (m, 2H), 
1.51 – 1.59 (m, 2H); 13C-NMR (126 MHz, CDCl3): 170.5, 165.3, 165.1, 133.2, 133.0, 
115.8, 115.77, 100.0, 88.1, 81.9, 80.5, 78.0, 67.2, 62.0, 33.1, 28.1, 27.8, 25.7, 23.1, 23.0, 
18.5, 15.3; MS (ESI) m/z (rel.%): 339 [MH+] (48), 333 (69), 313 (100); HRMS (ESI) 
calculated for C22H27O3: 339.1955, found: 339.1949; IR (neat, cm-1): 2939, 1700, 1642, 
1564, 1436, 1249, 914, 733. 
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Bis[hexacarbonyl{µ2-[6-(non-8-en-5-ynyl)-4-(oct-7-en-4-ynyloxy)-2-pyrone]} 
dicobalt(0)] (205) 
O
O
O
Co2(CO)6
Co2(CO)6
 
A solution of 204 (15.0 mg, 44 µmol, 1 eq.) and Co2(CO)6 (33.4 mg, 97 µmol, 2.2 eq.) in 
THF (1 ml) was stirred under argon at 20 °C for 2 hours.  The reaction mixture was then 
purified via flash column chromatography (20% EtOAc in pet ether) to afford the title 
compound as a red/brown oil (38.0 mg, 95%).   
1H-NMR (400 MHz, CDCl3): 5.93 (br. s, 2H), 5.81 (s, 1H), 5.41 (s, 1H), 5.15 (br. s, 4H), 
4.07 (br. s, 2H), 3.57 (br. s, 4H), 2.96 (br. s, 2H), 2.84 (br. s, 2H), 2.53 (br. s, 2H), 2.12 (br. 
s, 2H), 1.83 (br. s, 2H), 1.68 (br. s, 2H); 13C-NMR (101 MHz, CDCl3): 170.5, 165.2, 
165.0, 135.6, 135.4, 117.6, 117.5, 106.8, 100.3, 98.5, 97.4, 97.3, 88.3, 68.1, 38.3, 38.3, 
33.5, 33.5, 30.9, 30.6, 30.3, 26.6; MS (ESI) m/z (rel.%): 933 [MNa+] (100), 911 [MH+] 
(12); HRMS (ESI) calculated for C34H26Co4NaO15: 932.8492, found: 932.8484; IR (neat, 
cm-1): 2933, 2088, 2044, 2013, 1734, 1700, 1653, 1569, 1437, 1248. 
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Chapter 5: Intramolecular arylation characterisation 
 
5.1 General Details 
 
Reagents were purchased from either Sigma Aldrich or Alfa Aesar and used 
directly unless otherwise stated. Solvents were dried according to standard procedures 
prior to use and stored under nitrogen. Nitrogen gas was oxygen free and dried 
immediately before use via passage through sodium hydroxide pellets and silica. Argon 
and hydrogen were administered directly via balloon. The substructure 2H-pyran-2-one is 
henceforth referred to in the text as 2-pyrone. 
Where commercially unavailable, 2-bromophenols were synthesised from the 
reaction of the corresponding phenol with Br2.160  
All TLC analysis was performed using Merck 5554 aluminium backed silica plates 
and visualised using UV light (254 nm), an aqueous solution of potassium permanganate, 
or an ethanol based solution of p-anisaldehyde. 1H NMR and 13C NMR spectra were 
recorded on a Jeol ECX400 spectrometer operating at 400 and 100 MHz respectively, a 
Bruker 500 spectrometer operating at 500 and 126 MHz respectively, or a Bruker 700 
MHz spectrometer operating at 700 and 176 MHz respectively. All column 
chromatography was performed using flash silica-gel with the solvent systems specified 
within the text. 
 
5.2 General procedures 
 
5.2.1 Synthesis of 4-(2-haloaryloxy)-2-pyrones (General Procedure A)  
A solution of 4-Bromo-6-methyl-2-pyrone (1 eq.), 2-halophenol (1.1 eq.), and K2CO3 (1.5 
eq.) in acetone (4 ml/mmol) was stirred at 60 °C for 16 hours. The reaction was quenched 
by addition of water and ethyl acetate, and the layers separated. The aqueous layer was 
extracted 3 times using ethyl acetate and the combined organic extracts dried over MgSO4, 
concentrated in vacuo and purified by flash column chromatography (10-30 % EtOAc in 
hexanes).   
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5.2.2  Intramolecular C-H arylation (General Procedure B) 
A solution of aryl halide (1 eq.), Cs2CO3 (3 eq.), PPh3 (4 mol%) and Pd2(dba-4,4′-OMe)3 
(1 mol%) in THF (4 ml/mmol) was stirred under nitrogen at 70 °C for 18 hours. The 
reaction was allowed to cool to ambient temperature and quenched by addition of water 
and ethyl acetate, and the layers separated. The aqueous layer was extracted 3 times using 
ethyl acetate and the combined organic extracts dried over MgSO4, concentrated in vacuo 
and purified by flash column chromatography (10-30 % EtOAc in hexanes). 
 
5.3 Characterisation data 
 
4-Bromo-6-methyl-2-pyrone (106)161 
O
O
Br
 
A 2 L 3 neck flask containing 9 (14.9 g, 119 mmol, 1 eq.), P2O5 (40.4 g, 284 mmol, 2.4 
eq.) and TBAB (42.0 g, 130 mmol, 1.1 eq.) in toluene (1 L) was equipped with a condenser 
and a mechanical stirrer. The reaction mixture was then heated to reflux for 8 hours whilst 
stirring then allowed to cool to ambient temperature. The toluene was decanted off, and the 
viscous black residue was extracted with toluene (3 × 400 ml). The combined organic 
fractions were concentrated in vacuo and recrystallisation (toluene) afforded the title 
compound as pale orange crystals (15.9 g, 70.7%).  
Mpt: 73-74 °C (lit. 73-74 °C)167; 1H-NMR (400 MHz, CDCl3): 6.43 (dq, J = 1.7, 0.8 Hz, 
1H), 6.18 (dq, J = 1.7, 0.8 Hz, 1H), 2.23 (t, J = 0.8 Hz, 1H); 13C-NMR (101 MHz, CDCl3): 
162.0, 160.6, 141.1, 114.6, 108.4, 19.7; MS (ESI) m/z (rel.%): 191 [81Br-MH+] (100), 189 
[79Br-MH+] (98). 
 
4-{[(1Z)-1-Ethyl-1,4-pentadienyl]oxy}-6-methyl-2-pyrone (180) 
O
O
O
 
 
A solution of 4-{[(Z)-2-Bromo-1-ethyl-1-ethenyl]oxy}-6-methyl-2-pyrone Z-176a (20 mg, 
0.077 mmol, 1 eq.), Cs2CO3 (75.3 mg, 0.231 mmol, 3 eq.), Allyl boronic acid pinacol ester 
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(25.9 mg, 0.154 mmol, 2 eq.) and 27 (1.2 mg, 0.0015 mmol, 2 mol%) in THF (1 ml) was 
stirred under nitrogen at 70 °C for 18 hours. The reaction was allowed to cool to ambient 
temperature and quenched by addition of water (1 ml) and ethyl acetate (2 ml), and the 
layers separated. The aqueous layer was extracted using ethyl acetate (3 × 2 ml) and the 
combined organic extracts dried over MgSO4, concentrated in vacuo and purified by flash 
column chromatography (10-20 % EtOAc in hexanes) to afford the product as a colourless 
oil (6.8 mg, 40.0%). 
Rf = 0.42 (20% EtOAc in hexanes); 1H-NMR (500 MHz, CDCl3): 5.87 (s, 1H), 5.73 (ddt, 
J = 17.0, 10.1, 6.3 Hz, 1H), 5.40 (s, 1H), 5.14 (t, J = 7.3 Hz, 1H), 5.01 (dd, J = 17.0, 1.2 
Hz, 1H), 4.99 (dd, J = 10.1, 1.2 Hz, 1H), 2.66 (dd, J = 6.3, 7.3 Hz, 2H), 2.23 (s, 3H), 2.18 
(q, J = 7.3 Hz, 2H), 1.06 (t, J = 7.3 Hz, 3H); 13C-NMR (126 MHz, CDCl3): 168.8, 164.9, 
163.1, 151.3, 135.3, 114.1, 99.8, 95.6, 89.5, 29.4, 25.3, 20.0, 11.1; MS (ESI) m/z (rel.%): 
243 [MNa+] (28), 221[MH+] (100), 201 (6), 179 (28), 127 (4); HRMS (ESI) calculated for 
C13H17O3: 221.1172, found: 221.1175; IR (neat): 3084, 2975, 2938, 1700, 1643, 1560, 
1448, 1407, 1225, 1177, 1139, 1037, 994, 917, 822 cm-1. 
 
4-Ethyl-7-methyl-furo[3,2-c]-2-pyrone (213) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.108 mmol 
scale, to afford the product as a yellow oil (9.2 mg, 47.9%).  
Rf = 0.42 (20% EtOAc in hexanes); 1H-NMR (500 MHz, CDCl3): 6.43 (q, J = 0.9 Hz, 
1H), 6.36 (t, J = 1.1 Hz, 1H), 2.72 (dq, J = 7.5, 1.1 Hz, 2H), 2.32 (d, J = 0.9 Hz, 3H), 1.28 
(t, J = 7.5 Hz, 3H); 13C-NMR (126 MHz, CDCl3): 161.0, 160.1, 159.6, 158.8, 115.6, 
109.2, 101.3, 21.3, 20.1, 11.8; MS (ESI) m/z (rel.%): 201 [MNa+] (22), 179 [MH+] (100); 
HRMS (ESI) calculated for C10H11O3: 179.0703, found: 179.0700; IR (neat): 3099, 2976, 
2922, 1734, 1622, 1593, 1574, 1459, 1381, 1258, 1027, 966, 918, 814, 764 cm-1. 
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9-Methyl-benzofuro[3,2-c]-2-pyrone (216)119 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (39.6 mg, 79.2%).  
Mpt: 188-190 °C (lit. 226-228°C)114; 1H-NMR (400 MHz, CDCl3): 8.01 – 8.06 (m, 1H), 
7.52 – 7.58 (m, 1H), 7.39 – 7.44 (m, 2H), 6.54 (q, J = 0.9 Hz, 1H), 2.43 (d, J = 0.9 Hz, 
3H); 13C-NMR (101 MHz, CDCl3): 164.5, 162.9, 159.5, 154.9, 126.1, 124.9, 122.9, 121.4, 
111.5, 103.7, 95.9, 20.6; MS (ESI) m/z (rel.%): 223 [MNa+] (16), 201 [MH+] (100); 
HRMS (ESI) calculated for C12H9O3: 201.0546, found: 201.0549; IR (neat): 3101, 2919, 
1719, 1614, 1572, 1445, 1251, 1187, 971, 934, 816, 748 cm-1 
 
4-(2-Iodophenoxy)-6-methyl-2-pyrone (218) 
O
O
O
I
 
The title compound was prepared according to General Procedure A, on a 10 mmol scale, 
to afford the product as a white solid (2.77g, 84.5%).  
Mpt: 71-73 °C; 1H-NMR (400 MHz, CDCl3): 7.86 (dd, J = 7.9, 1.5 Hz, 1H), 7.40 (td, J = 
7.9, 1.5 Hz, 1H), 7.09 (dd, J = 7.9, 1.5 Hz, 1H), 7.03 (td, J = 7.9, 1.5 Hz, 1H), 6.02 (dq, J = 
2.3, 1.0 Hz, C5H, 1H), 5.05 (d, J = 2.3, C3H, 1H), 2.26 (d, J = 1.0 Hz, C7H3, 3H); 13C-
NMR (101 MHz, CDCl3): 169.5, 164.3, 163.6, 152.2, 140.3, 130.1, 128.3, 122.3, 99.7, 
91.2, 89.6, 20.1; MS (ESI) m/z (rel.%): 351 [MNa+] (100), 329 [MH+] (97); HRMS (ESI) 
calculated for C12H9INaO3: 350.9489, found: 350.9484; IR (neat): 3806, 1697, 1636, 1559, 
1437, 1398, 1223, 820, 764 cm-1. 
 
4-(2-Allyl-phenoxy)-6-methyl-2-pyrone 
O
O
O
 
A solution of 4-(2-iodophenoxy)-6-methyl-2-pyrone  (82 mg, 0.25 mmol, 1 eq.), Cs2CO3 
(244 mg, 0.75 mmol, 3 eq.), Allyl boronic acid pinacol ester (84 mg, 0.5 mmol, 2 eq.) and 
(E)-PdBr(PPh3)2(N-succ) (4 mg, 0.005 mmol, 2 mol%) in THF (2 ml) was stirred under 
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nitrogen at 70 °C for 18 hours. The reaction was allowed to cool to ambient temperature 
and quenched by addition of water (1 ml) and ethyl acetate (2 ml), and the layers separated. 
The aqueous layer was extracted using ethyl acetate (3 × 2 ml) and the combined organic 
extracts dried over MgSO4, concentrated in vacuo and purified by flash column 
chromatography (10-20 % EtOAc in hexanes) to afford the product as a colourless oil 
(25.6mg, 42.3%). 
1H-NMR (400 MHz, CDCl3): 7.14 – 7.25 (m, 3H), 6.93 (m, 1H), 5.92 (d, 2.2 Hz, 1H), 
5.79 (ddt, J = 16.8, 10.1, 6.6 Hz, 1H), 5.04 (d, J = 2.2 Hz, 1H), 4.93 – 5.02 (m, 2H), 3.19 
(d, J = 6.6 Hz, 2H), 2.20 (s, 3H); 13C-NMR (101 MHz, CDCl3): 170.5, 164.6, 163.4, 
150.2, 135.4, 132.2, 131.1, 128.1, 126.8, 121.5, 116.7, 99.7, 90.6, 33.9, 20.0; MS (ESI) m/z 
(rel.%): 265 [MNa+] (14), 243 [MH+] (100); HRMS (ESI) calculated for C15H15O3: 
243.1016, found: 243.1014; IR (neat): 3078, 2921, 1725, 1641, 1565, 1487, 1445, 1402, 
1320, 1227, 1178, 1134, 982, 820, 768 cm-1. 
 
3-Bromo-6-methyl-4-phenoxy-2-pyrone (219) 
O
O
O
Br
 
A solution of 106 (189 mg, 1 mmol, 1 eq.), PhOH (103 mg, 1.1 mmol, 1.1 eq) and K2CO3 
(207 mg, 1.5 mmol, 1.5 eq.) in acetone (3 ml) was heated to 60 °C for 16 h. The reaction 
was quenched by addition of water (2 ml) and ethyl acetate (3 ml), and the layers 
separated. The aqueous layer was extracted with ethyl acetate (3 × 3 ml) and the combined 
organic extracts dried over MgSO4, filtered and concentrated in vacuo. The residue was 
taken up in CHCl3 (10 ml) and Br2 (160 mg, 1 mmol, 1 eq.) was added carefully. The 
solution was stirred at 20 °C for 2 h then quenched by the addition of sat. Na2SO2(aq) (5 ml) 
and the solution stirred for a further 10 minutes. The organic layer was separated, dried 
over Na2SO4, then filtered and concentrated in vacuo. Purification via column 
chromatography (20% EtOAc in pet ether) afforded the title compound as a white 
crystalline solid (166 mg, 59%). 
Mpt: 122-123 °C; 1H-NMR (400 MHz, CDCl3): 7.47 – 7.41 (m, 2H), 7.33 – 7.28 (m, 1H), 
7.10 – 7.05 (m, 2H), 5.60 (q, J = 0.9 Hz, 1H), 2.15 (d, J = 0.9 Hz, 3H); 13C-NMR (101 
MHz, CDCl3): 165.5, 162.3, 160.9, 152.8, 130.3, 126.5, 120.8, 97.5, 90.8, 20.0; MS (ESI) 
m/z (rel.%): 283 [81Br-MH+] (100), 281 [79Br-MH+] (96), 182 (5), 180 (5); HRMS (ESI) 
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calculated for C12H1079BrO3: 280.9808, found: 280.9809; IR (neat): 3051, 2159, 1725, 
1640, 1534, 1487, 1379, 1315, 1228, 993, 927 766 cm-1. 
 
4,6-Dichloro-2-pyrone (220)162 
O
O
ClCl
 
A 3-neck flask (100 ml) was fitted with a magnetic stirrer, a condenser with bubbler, gas 
inlet adapter and a funnel. PCl5 (6.44 g, 30.9 mmol, 1.03 eq.) was added followed by 
dimethyl 1,3-acetonedicarboxylate (5.22 g, 30 mmol, 1 eq.). Nitrogen gas was bubbled 
through the solution and the solution heated to 50 °C for 30 minutes. The reaction was 
quenched by pouring the cooled reaction mixture onto ice (30 g). The flask was rinsed with 
a DCM/Water mix (30 ml, 1:1) and the combined solutions separated. The aqueous layer 
was extracted with DCM (3 × 10 ml) and the combined organic extracts concentrated in 
vacuo. An aqueous solution of 20% HCl (31 ml) was then added and the reaction heated to 
reflux for 2.5 h. The water was removed in vacuo and the residue taken up in ether (30 ml) 
then dried over calcium chloride. Filtration of the solution and concentration in vacuo gave 
a dark orange solid. A round bottom flask was charged with PCl5 (6.44 g, 30.9 mmol, 1.03 
eq.) and the orange solid added in one portion. The mixture was maintainerd at 0 °C until 
the solid mixture liquefied. The red solution was then stirred at ambient temperature (20 
°C) for 1 hour and a further 15 minutes at 100 °C. The solution was allowed to cool to 
ambient temperature and DCM (30 ml) added. The solution was subsequently washed with 
water (2 × 30 ml) and organic portion filtered through celite. The filtrate was neutralised 
by slow addition of sat. NaHCO3(aq.) (~10 ml) with vigorous stirring. The organic layer was 
separated and dried over Na2SO4, then filtered and concentrated in vacuo. Purification via 
column chromatography (DCM) afforded the title compound as a white crystalline solid 
(0.99 g, 20%).  
Mpt: 43-44 °C (lit. 43-45 °C)169; 1H-NMR (400 MHz, CDCl3): 6.30 (d, J = 1.7 Hz, 1H), 
6.30 (d, J = 1.7 Hz, 1H); 13C-NMR (101 MHz, CDCl3): 158.4, 152.1, 150.3, 111.1, 106.6; 
MS (ESI) m/z (rel.%): 169 [37Cl/37Cl-MH+] (11), 167 [37Cl/35Cl-MH+] (66), 165 [35Cl/35Cl-
MH+] (100). 
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4-(2-iodophenoxy)-2-pyrone (221) via 4-Chloro-2-pyrone 162 
O
O
Cl
 
To a solution of 219 (330 mg, 2 mmol, 1 eq.) in AcOH (2 ml) was added Zn dust (156 mg, 
2.4 mmol, 1.2 eq.) and the reaction stirred for 48 h at 20°C. The solution was filtered and 
the excess AcOH removed in vacuo. The residue was taken up in DCM (10 ml) and water 
(3 ml), then neutralised by the addition of solid K2CO3 (100 mg). The layers were 
separated and the aqueous layer extracted with DCM (3 × 3 ml). The combined organic 
extracts were dried over Na2SO4, then filtered and concentrated in vacuo to afford the title 
compound as an off white powder (145 mg, 56%). 
1H-NMR (400 MHz, CDCl3): 7.44 (dd, J = 5.6, 0.9 Hz, 1H), 6.40 (dd, J = 2.0, 0.9 Hz, 
1H), 6.28 (dd, J = 5.6, 2.0 Hz, 1H); 13C-NMR (101 MHz, CDCl3): 160.1, 151.3, 150.8, 
114.7, 109.0; MS (ESI) m/z (rel.%): 133 [37Cl-MH+] (31), 131 [35Cl-MH+] (100); HRMS 
(ESI) calculated for C5H435ClO2: 130.9894, found: 130.9894. 
O
O
O
I
 
A solution of 4-chloro-2-pyrone (125 mg, 0.96 mmol, 1 eq.), 2-iodophenol (253 mg, 1.15 
mmol, 1.2 eq.), and K2CO3 (264 mg, 1.9 mmol, 2 eq.) in acetone (5 mL) was stirred at 60 
°C for 16 hours. The reaction was quenched by addition of water (2 mL)  and ethyl acetate 
(5 mL), and the layers separated. The aqueous layer was extracted using ethyl acetate (3 × 
5 mL) and the combined organic extracts dried over MgSO4, filtered  and concentrated in 
vacuo. Purification by flash column chromatography (20% EtOAc in hexanes) afforded the 
title compound as a white solid (260.2 mg, 86.5%).   
Mpt: 92-93 °C; 1H-NMR (400 MHz, CDCl3): 7.89 (dd, J = 7.9, 1.5 Hz, 1H), 7.50 (dd, J = 
5.8, 0.7 Hz, 1H), 7.42 (ddd, J = 8.1, 7.5, 1.5 Hz, 1H), 7.12 (dd, J = 8.1, 1.5, 1H), 7.05 (ddd, 
J = 7.9, 7.5, 1.5 Hz, 1H), 6.27 (dd, J = 5.8, 2.4 Hz, 1H), 5.20 (dd, J = 2.4, 0.7 Hz, 1H); 13C-
NMR (101 MHz, CDCl3): 168.4, 163.5, 152.5, 152.1, 140.4, 130.2, 128.4, 122.3, 102.8, 
94.2, 89.5; MS (ESI) m/z (rel.%): 337 [MNa+] (15), 315 [MH+] (100); HRMS (ESI) 
calculated for C11H8IO3: 314.9513, found: 314.9516; IR (neat): 3087, 1700, 1633, 1556, 
1434, 1328, 1218, 1195, 1158, 1054, 881, 821, 770 cm-1. 
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Benzofuro[3,2-c]-2-pyrone (222) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a white solid (34.6 mg, 74.4%).  
Rf = 0.33 (20% EtOAc in hexanes); Mpt: 149-150 °C; 1H-NMR (400 MHz, CDCl3): 8.09 
(m, 1H), 7.65 (d, J = 5.7 Hz, 1H), 7.60 (m, 1H), 7.42 – 7.49 (m, 2H), 6.81 (d, J = 5.7 Hz, 
1H); 13C-NMR (101 MHz, CDCl3): 162.7, 159.1, 155.0, 151.5, 126.7, 125.1, 122.7, 121.7, 
111.6, 106.5, 98.9; MS (ESI) m/z (rel.%): 209 [MNa+] (39), 187 [MH+] (100); HRMS 
(ESI) calculated for C11H7O3: 187.0390, found: 187.0389; IR (neat): 3102, 1717, 1607,  
1558, 1448, 1431, 1219, 1171, 1012, 926, 844, 783, 746 cm-1. 
 
4-(2-iodophenoxy)-6-phenyl-2-pyrone (223) via 4-Chloro-6-phenyl-2-pyrone 
Cl
O
O
 
To a solution of 4,6-dichloro-2-pyrone 220 (330 mg, 2 mmol, 1 eq.) and NiCl2(PPh3)2 
(21.7 mg, 0.04 mmol, 2 mol%) in THF (4 mL) under nitrogen at 20 °C, was added 2.0 M 
PhMgBr in THF (1 mL, 2 mmol, 1 eq.). The reaction was then stirred at 20 °C for 24 hours 
then quenched by the addition of water (2 mL) and EtOAc (5 mL). The organic layer was 
separated and the aqueous layer extracted with EtOAc (2 × 5 mL). The combined organic 
extracts were concentrated in vacuo and purified by flash column chromatography (10% 
EtOAc in hexanes) to afford a white crystalline solid (62.7 mg, 15.2%). 
Mpt: 103-105 °C; 1H-NMR (400 MHz, CDCl3): 7.79 – 7.86 (m, 2H), 7.44 – 7.54 (m, 3H), 
6.70 (d, J = 1.7 Hz, 1H), 6.35 (d, J = 1.7 Hz, 1H); 13C-NMR (101 MHz, CDCl3): 160.6, 
160.5, 151.9, 131.7, 130.2, 129.1, 125.9, 111.8, 103.6; MS (ESI) m/z (rel.%): 231 [37Cl-
MNa+] (14), 229 [35Cl-MNa+] (49), 209 [37Cl-MH+] (31), 207 [35Cl-MH+] (100); HRMS 
(ESI) calculated for C11H835ClO2:207.0207, found: 207.0209; IR (neat): 3079, 1721, 1706, 
1612, 1537, 1494, 1451, 1364, 1328, 1235, 1149, 1088, 1050, 859, 813, 776 cm-1. 
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O
O
O
I
 
A solution of 4-Chloro-6-phenyl-2-pyrone (50.0 mg, 0.24 mmol, 1 eq.), 2-iodophenol (64 
mg, 0.29 mmol, 1.2 eq.), and K2CO3 (50 mg, 0.36 mmol, 1.5 eq.) in acetone (1 mL) was 
stirred at 60 °C for 16 hours. The reaction was quenched by addition of water (1 mL) and 
ethyl acetate (3 mL), and the layers separated. The aqueous layer was extracted using ethyl 
acetate (3 × 3 mL) and the combined organic extracts dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc in 
hexanes) afforded the title compound as a white solid (77.6 mg, 82.9%).   
Mpt: 155-157 °C; 1H-NMR (400 MHz, CDCl3): 7.91 (dd, J = 8.0, 1.5 Hz, 1H), 7.84 – 7.89 
(m, 2H), 7.47 – 7.52 (m, 3H), 7.44 (ddd, J = 8.1, 7.4, 1.5 Hz, 1H), 7.17 (dd, J = 8.1, 1.5 
Hz, 1H), 7.07 (ddd, J = 8.0, 7.4, 1.5 Hz, 1H), 6.70 (d, J = 2.1 Hz, 1H), 5.20 (d, J = 2.1 Hz, 
1H); 13C-NMR (101 MHz, CDCl3): 169.6, 163.7, 161.5, 152.4, 140.4, 131.3, 130.9, 130.2, 
128.0, 128.4, 125.8, 122.4, 97.3, 92.2, 89.7; MS (ESI) m/z (rel.%): 413 [MNa+] (34), 391 
[MH+] (100); HRMS (ESI) calculated for C17H12IO3:390.9826, found: 390.9820; IR 
(neat): 3093, 2962, 1698, 1629, 1555, 1402, 1257, 1218, 1173, 1020, 808, 766 cm-1. 
 
9-Phenyl-benzofuro[3,2-c]-2-pyrone (224) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.13 mmol scale, 
to afford the product as a yellow solid (20.0 mg, 58.8%).  
1H-NMR (400 MHz, CDCl3): 8.09 (m, 1H), 7.93 – 7.98 (m, 2H), 7.60 (m, 1H), 7.49 – 7.53 
(m, 3H), 7.43 – 7.47 (m, 2H), 7.18 (s, 1H); 13C-NMR (101 MHz, CDCl3): 164.4, 160.8, 
158.7, 155.3, 131.4, 131.1, 129.1, 126.4, 125.9, 125.1, 122.9, 121.6, 111.5, 104.7, 93.2; 
MS (ESI) m/z (rel.%): 263 [MH+] (100), 251 (28), 159 (26), 149 (15); HRMS (ESI) 
calculated for C17H11O3:263.0703, found: 263.0706; IR (neat): 3090, 2161, 1721, 1560, 
1537, 1446, 1382, 1021, 746, 687 cm-1. 
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4-(2-iodophenoxy)-6-phenethyl-2-pyrone (225) via 4-Bromo-6-phenethyl-2-pyrone 
Br
O
O
 
To a solution of 4-hydroxy-6-phenethyl-2-pyrone 90 (100 mg, 0.46 mmol, 1 eq.) in DMF 
(1 ml) under nitrogen, was added carefully PBr3 (502 mg, 1.85 mmol, 4 eq.) over 10 
minutes. The reaction was then stirred at 80 °C for 18 hours and allowed to cool to ambient 
temperature, then DMF was removed under high vacuum and water (2 ml) and Et2O (5 ml) 
added. The organic layer was separated and the aqueous layer extracted with Et2O (5 × 5 
ml) then the combined organic extracts dried over MgSO4 and concentrated in vacuo to 
give the crude product. Purification via flash column chromatography (10% EtOAc in 
hexanes) gave the title compound as a yellow oil. (50.3 mg, 39.2%). 
1H-NMR (400 MHz, CDCl3): 7.20 – 7.26 (m, 2H), 7.17 (m, 1H), 7.07 – 7.11 (m, 2H), 6.39 
(d, J = 1.6 Hz, 1H), 6.05 (d, J = 1.6 Hz, 1H), 2.90 (t, J =7.9 Hz, 2H), 2.70 (t, J = 7.9 Hz, 
2H); 13C-NMR (101 MHz, CDCl3): 164.3, 160.6, 141.0, 139.4, 128.6, 128.2, 126.6, 115.1, 
108.2, 35.4, 32.8; MS (ESI) m/z (rel.%): 303 [81Br-MNa+] (57), 301 [79Br-MNa+] (58), 281 
[81Br-MH+] (96), 279 [79Br-MH+] (100); HRMS (ESI) calculated for C13H1279BrO2: 
279.0015, found: 279.0010;  
O
O
O
I
 
A solution of 4-Bromo-6-phenethyl-2-pyrone (45.0 mg, 0.16 mmol, 1 eq.), 2-iodophenol 
(40 mg, 0.18 mmol, 1.1 eq.), and K2CO3 (33 mg, 0.24 mmol, 1.5 eq.) in acetone (1 mL) 
was stirred at 60 °C for 16 hours. The reaction was quenched by addition of water (1 mL) 
and ethyl acetate (3 mL), and the layers separated. The aqueous layer was extracted using 
ethyl acetate (3 × 3 mL) and the combined organic extracts dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash column chromatography (20% EtOAc in 
hexanes) afforded the product as a yellow solid (39.4 mg, 58.9%). 
1H-NMR (400 MHz, CDCl3): 7.87 (dd, J = 7.9, 1.5 Hz, 1H), 7.40 (ddd, J = 8.1, 7.4, 1.5 
Hz, 1H), 7.27– 7.34 (m, 2H), 7.23 (m, 1H), 7.17– 7.21 (m, 2H), 7.08 (dd, J = 8.1, 1.5 Hz, 
1H), 7.04 (td, J = 1.5, 7.8, 1H), 5.95 (d, J = 2.2 Hz, 1H), 5.08 (d, J = 2.2 Hz, 1H), 2.98– 
3.06 (m, 2H), 2.79– 2.88 (m, 2H); 13C-NMR (101 MHz, CDCl3): 169.3, 165.9, 164.3, 
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152.3, 140.3, 139.7, 130.1, 128.6, 128.3, 128.3, 126.5, 122.3, 99.7, 91.6, 89.6, 35.7, 32.9; 
MS (ESI) m/z (rel.%): 441 [MNa+] (16), 419 [MH+] (100); HRMS (ESI) calculated for 
C19H16IO3: 419.0139, found: 419.0130; IR (DCM): 3065, 3030, 2932, 1724, 1643, 1571, 
1497, 1329, 1269, 1262, 1227, 1131, 1022 cm-1. 
 
9-Phenethyl-benzofuro[3,2-c]-2-pyrone (226) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.071 mmol 
scale, to afford the product as a yellow solid (16.3 mg, 68.2%).  
Rf = 0.58 (20% EtOAc in hexanes); Mpt: 130-132 °C; 1H-NMR (400 MHz, CDCl3): 8.01 
– 8.08 (m, 1H), 7.51 – 7.58 (m, 1H), 7.38 – 7.45 (m, 2H), 7.27 – 7.33 (m, 2H), 7.25 – 7.18 
(m, 3H), 6.46 (t, J = 0.7 Hz, 1H), 3.09 (dd, J = 8.5, 6.4 Hz, 2H), 2.94 – 2.99 (m, 2H); 13C-
NMR (101 MHz, CDCl3): 165.2, 164.2, 155.0, 139.7, 128.7, 128.3, 126.5, 126.2, 125.0, 
122.9, 121.4, 111.5, 104.0, 99.9, 95.9, 36.3, 33.3; MS (ESI) m/z (rel.%): 313 [MNa+] (44), 
291 [MH+] (100); HRMS (ESI) calculated for C19H15O3: 291.1016, found: 291.1011; IR 
(neat): 3085, 3057, 2921, 1727, 1612, 1571, 1447, 1186, 1029, 970, 937, 817, 750, 701 cm-
1
. 
 
4-(2-bromo-4-methyl-phenoxy)-6-methyl-2-pyrone (228a) 
O
O
O
Br
 
The title compound was prepared according to General Procedure A, on a 1 mmol scale, to 
afford the product as a white solid (283.5 mg, 96.1%).  
Mpt: 64-65 °C; 1H-NMR (400 MHz, CDCl3): 7.46 (d, J = 1.5 Hz, 1H), 7.15 (dd, J = 1.5, 
8.1 Hz, 1H), 7.00 (d, J = 8.1 Hz, 1H), 6.00 (dq, J = 2.2, 0.9 Hz, 1H), 5.08 (d, J = 2.2, 1H), 
2.36 (s, 3H), 2.26 (d, J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.8, 164.4, 163.5, 
147.0, 138.3, 134.4, 129.7, 122.6, 115.4, 99.6, 90.9, 20.6, 20.0; MS (ESI) m/z (rel.%): 297 
[81Br-MH+] (98), 295 [79Br-MH+] (100); HRMS (ESI) calculated for C13H1279BrO3: 
294.9964, found: 294.9972; IR (neat): 3072, 1726, 1648, 1561, 1488, 1449, 1395, 1316, 
1239, 1128, 850, 830 cm-1. 
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4-(2-bromo-4,6-dimethyl-phenoxy)-6-methyl-2-pyrone (228b) 
O
O
O
Br
 
The title compound was prepared according to General Procedure A, on a 4 mmol scale, to 
afford the product as a white solid (454 mg, 36.8%).  
Mpt: 138-142 °C; 1H-NMR (400 MHz, CDCl3): 7.27 (m, 1H), 7.00 (m, 1H), 6.02 (dq, J = 
2.0, 0.9 Hz, 1H), 5.02 (d, J = 2.0 Hz, 1H), 2.31 (app. t, J = 0.7 Hz, 3H), 2.27 (d, J = 0.9, 
3H), 2.14 (app. t, J = 0.6 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.0, 164.6, 163.6, 
145.3, 137.9, 132.0, 131.8, 131.4, 115.7, 99.4, 90.1, 20.6, 20.1, 16.4; MS (ESI) m/z 
(rel.%): 333 [81Br-MNa+] (17), 331 [79Br-MNa+] (18), 311 [81Br-MH+] (97), 309 [79Br-
MH+] (100); HRMS (ESI) calculated for C14H1479BrO3: 309.0121, found: 309.0119; IR 
(neat): 3074, 2922, 1699, 1640, 1563, 1445, 1400, 1220, 1203, 1134, 981, 828 cm-1. 
 
4-(2-bromo-4-tert-butyl-phenoxy)-6-methyl-2-pyrone (228c) 
O
O
O
Br
 
The title compound was prepared according to General Procedure A, on a 2 mmol scale, to 
afford the product as a white solid (442 mg, 65.6%).  
Mpt: 148-149 °C; 1H-NMR (400 MHz, CDCl3): 7.60 (d, J = 2.2 Hz, 1H), 7.35 (dd, J = 8.5, 
2.2 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H), 6.00 (d, J = 2.0 Hz, 1H), 5.06 (d, J = 2.0 Hz, 1H), 
2.25 (s, 3H), 1.30 (s, 9H); 13C-NMR (101 MHz, CDCl3): 169.8, 164.4, 163.4, 151.7, 146.8, 
131.0, 126.2, 122.4, 115.3, 99.6, 90.7, 34.7, 31.1, 20.0; MS (ESI) m/z (rel.%): 361 [81Br-
MNa+] (20), 359 [79Br-MNa+] (22), 339 [81Br-MH+] (96), 337 [79Br-MH+] (100); HRMS 
(ESI) calculated for C16H1879BrO3: 337.0434, found: 337.0425; IR (neat): 3089, 2955, 
1707, 1644, 1567, 1491, 1440, 1403, 1225, 1132, 1047, 979, 858, 822 cm-1. 
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4-(2-bromo-4,6-di-tert-butyl-phenoxy)-6-methyl-2-pyrone (228d) 
O
O
O
Br
 
To a solution of 2-bromo-4,6-di-tert-butylphenol (285 mg, 1 mmol, 1 eq.) under nitrogen 
in THF (2 ml) was added NaH (24 mg, 1 mmol, 1eq.) in one portion. The solution was 
stirred at 25 °C for 1 hour then 4-bromo-6-methyl-2-pyrone (189 mg, 1 mmol, 1 eq.) was 
added and the solution stirred at 60 °C for 16 hours. The reaction was allowed to cool to 
ambient temperature and quenched by the addition of water (1 ml). The solution was then 
extracted by EtOAc (3 × 3 ml) and the combined organic extracts dried over MgSO4, 
concentrated in vacuo to afford the crude product. Purification by flash column 
chromatography (15% EtOAc in hexanes) afforded the title compound as a white solid 
(108.4mg, 27.6%). 
Mpt: 108-110 °C; 1H-NMR (400 MHz, CDCl3): 7.45 (d, J = 2.3 Hz, 1H), 7.38 (d, J = 2.3 
Hz, 1H), 5.99 (s, 1H), 5.05 (s, 1H), 2.27 (s, 3H), 1.31 (s, 9H), 1.30 (s, 9H); 13C-NMR (101 
MHz, CDCl3): 169.7, 164.6, 163.5, 150.5, 145.2, 143.5, 129.1, 124.3, 117.2, 99.7, 91.7, 
35.6, 34.8, 31.2, 30.6, 20.1; MS (ESI) m/z (rel.%): 417 [81Br-MNa+] (17), 415 [79Br-MNa+] 
(17), 395 [81Br-MH+] (100), 393 [79Br-MH+] (98); HRMS (ESI) calculated for 
C20H2679BrO3: 393.1060, found: 393.1055; IR (neat): 2959, 1719, 1649, 1566, 1438, 1401, 
1223, 1128, 979, 852, 826 cm-1. 
 
4-(2-bromo-4-phenyl-phenoxy)-6-methyl-2-pyrone (228e) 
O
O
O
Br
 
The title compound was prepared according to General Procedure A, on a 2 mmol scale, to 
afford the product as a white solid (646 mg, 90.4%).  
Mpt: 125-127 °C; 1H-NMR (400 MHz, CDCl3): 7.86 (d, J = 2.2 Hz, 1H), 7.57 (dd, J = 8.4, 
2.2 Hz, 1H), 7.53 – 7.56 (m, 2H), 7.44 – 7.49 (m, 2H), 7.40 (m, 1H), 7.20 (d, J = 8.4 Hz, 
1H), 6.05 (dq, J = 2.2, 0.8 Hz, 1H), 5.17 (dd, J = 2.2, 0.5 Hz, 1H), 2.29 (dd, J = 0.8, 0.5 
Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.6, 164.4, 163.6, 148.5, 141.6, 138.5, 132.6, 
129.0, 128.2, 127.8, 127.1, 123.2, 116.2, 99.5, 91.1, 20.1; MS (ESI) m/z (rel.%): 381 [81Br-
MNa+] (14), 379 [79Br-MNa+] (14), 359 [81Br-MH+] (98), 357 [79Br-MH+] (100); HRMS 
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(ESI) calculated for C18H1479BrO3: 357.0121, found: 357.0117; IR (neat): 3060, 1717, 
1692, 1644, 1566, 1474, 1402, 1227, 1132, 1044, 982, 858, 817, 769, 738, 698 cm-1.  
 
4-(2-bromo-4-methoxy-phenoxy)-6-methyl-2-pyrone (228f) 
O
O
O
BrO
 
The title compound was prepared according to General Procedure A, on a 1 mmol scale, to 
afford the product as a white solid (279.3 mg, 89.8%).  
Mpt: 98-99 °C; 1H-NMR (400 MHz, CDCl3): 7.15 (d, J = 2.9 Hz, 1H), 7.04 (d, J = 8.9 Hz, 
1H), 6.88 (dd, J = 8.9, 2.9 Hz, 1H), 6.00 (d, J = 2.2 Hz, 1H), 5.08 (d, J = 2.2 Hz, 1H), 3.81 
(s, 3H), 2.26 (s, 3H); 13C-NMR (101 MHz, CDCl3): 170.1, 164.5, 163.4, 158.2, 142.9, 
123.3, 118.8, 116.1, 114.8, 99.5, 90.8, 55.9, 20.0; MS (ESI) m/z (rel.%): 335 [81Br-MNa+] 
(99), 333 [79Br-MNa+] (100), 313 [81Br-MH+] (93), 311 [79Br-MH+] (311); HRMS (ESI) 
calculated for C13H1279BrO4: 310.9913, found: 310.9909; IR (neat): 3193, 3087, 1726, 
1647, 1569, 1491, 1446, 1403, 1211, 1133, 1018, 982, 841, 805, 779 cm-1. 
 
4-(2-bromo-5-methoxy-phenoxy)-6-methyl-2-pyrone (228g) 
O
O
O
Br
O
 
The title compound was prepared according to General Procedure A, on a 3 mmol scale, to 
afford the product as a white solid (492 mg, 52.7%).  
Mpt: 103-106 °C; 1H-NMR (400 MHz, CDCl3): 7.15 (d, J = 2.9 Hz, 1H), 7.04 (d, J = 8.9 
Hz, 1H), 6.88 (dd, J = 8.9, 2.9 Hz, 1H), 6.00 (d, J = 2.2 Hz, 1H), 5.08 (d, J = 2.2 Hz, 1H), 
3.81 (s, 3H), 2.26 (s, 3H); 13C-NMR (101 MHz, CDCl3): 170.1, 164.5, 163.4, 158.2, 142.9, 
123.3, 118.8, 116.1, 114.8, 99.5, 90.8, 55.9, 20.0; MS (ESI) m/z (rel.%): 335 [81Br-MNa+] 
(68), 333 [79Br-MNa+] (70), 313 [81Br-MH+] (100), 311 [79Br-MH+] (100); HRMS (ESI) 
calculated for C13H1279BrO4: 310.9913, found: 310.9909; IR (neat): 3066, 1709, 1645, 
1566, 1483, 1441, 1399, 1314, 1236, 1199, 1137, 1018, 991, 858, 836 cm-1. 
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4-(6-bromo-2,3-dimethoxy-phenoxy)-6-methyl-2-pyrone (228h) 
O
O
O
Br
O
O
 
The title compound was prepared according to General Procedure A, on a 2 mmol scale, to 
afford the product as a white solid (116 mg, 17.0%).  
Mpt: 127-129 °C; 1H-NMR (400 MHz, CDCl3): 7.29 (d, J = 9.0 Hz, 1H), 6.78 (d, J = 9.0 
Hz, 1H), 6.01 (dq, J = 2.2, 0.9 Hz, 1H), 5.14 (dq, J = 0.4, 2.2 Hz, 1H), 3.88 (s, 3H), 3.81 (s, 
3H), 2.27 (dd, J = 0.9, 0.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.2, 164.5, 163.5, 
153.4, 143.2, 142.7, 127.3, 111.5, 107.1, 99.3, 90.8, 61.3, 56.3, 20.1; MS (ESI) m/z 
(rel.%): 365 [81Br-MNa+] (17), 363 [79Br-MNa+] (18), 343 [81Br-MH+] (97), 341 [79Br-
MH+] (100); HRMS (ESI) calculated for C14H1479BrO5: 341.0019, found: 341.0012; IR 
(neat): 3095, 2945, 1702, 1623, 1561, 1529, 1443, 1219, 1137, 1081, 983, 841, 818 cm-1. 
 
1-Bromo-2,4-bis(6-methyl-2-pyronyl-4-oxy)-benzene (228i) 
O
O
OO
Br
O
O
 
A solution of 4-Bromo-6-methyl-2-pyrone (756 mg, 4 mmol, 2 eq.), 2-bromoresorcinol 
(378 mg, 2 mmol, 1 eq.), and K2CO3 (690 mg, 5 mmol, 2.5 eq.) in acetone (4 ml/mmol) 
was stirred at 60 °C for 16 hours. The reaction was quenched by addition of water and 
ethyl acetate, and the layers separated. The aqueous layer was extracted 3 times using ethyl 
acetate and the combined organic extracts dried over MgSO4, concentrated in vacuo and 
purified by flash column chromatography (10-30 % EtOAc in hexanes) to afford the title 
compound as a white crystalline solid (395 mg, 48.8%). 
Mpt: 143-146 °C; 1H-NMR (400 MHz, CDCl3): 7.72 (d, J = 8.7 Hz, 1H), 6.97 (dd, J = 8.7, 
2.7 Hz, 1H), 6.93 (d, J = 2.7 Hz, 1H), 6.02 (dq, J = 2.2, 0.9 Hz, 1H), 5.95 (dq, J = 2.2, 0.9 
Hz, 1H), 5.27 (d, J = 2.2 Hz, 1H), 5.11 (d, J = 2.2 Hz, 1H), 2.28 (d, J = 0.9 Hz, 3H), 2.27 
(d, J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.5, 168.9, 164.0, 164.0, 163.9, 
152.4, 150.4, 135.3, 120.8, 116.4, 113.3, 99.4, 99.3, 91.7, 91.3, 30.9, 20.1, 20.1; MS (ESI) 
m/z (rel.%): 429 [81Br-MNa+] (97), 427 [79Br-MNa+] (100), 407 [81Br-MH+] (90), 405 
[79Br-MH+] (90); HRMS (ESI) calculated for C18H1379BrNaO6: 426.9788, found: 
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426.9794; IR (neat): 3058, 1722, 1644, 1584, 1565, 1473, 1444, 1399, 1315, 1264, 1227, 
1179, 1140, 982, 856, 812 cm-1. 
 
4-(2-Bromo-4-fluoro-phenoxy)-6-methyl-2-pyrone (228j) 
O
O
O
BrF
 
The title compound was prepared according to General Procedure A, on a 1 mmol scale, to 
afford the product as a white solid (260 mg, 87.1%).  
Mpt: 112-113 °C; 1H-NMR (400 MHz, CDCl3): 7.41 (ddd, J = 7.5, 2.5, 0.7 Hz, 1H), 7.15 
– 7.08 (m, 2H), 6.01 (dq, J = 0.8, 2.1 Hz, 1H), 5.06 (d, J = 2.1 Hz, 1H), 2.28 (d, J = 0.8 Hz, 
3H); 13C-NMR (101 MHz, CDCl3): 169.53, 163.75, 162.8 (d, J = 273.1 Hz), 158.97, 145.7 
(d, J = 3.6 Hz), 123.9 (d, J = 9.0 Hz), 121.3 (d, J = 26.0 Hz), 116.5 (d, J = 10.2 Hz), 116.1 
(d, J = 23.3 Hz), 99.40, 90.98, 20.09; 19F-NMR (376 MHz, CDCl3): -112.45 (td, J = 7.5, 
5.4 Hz); MS (ESI) m/z (rel.%): 301 [81Br-MH+] (97), 299 [79Br-MH+] (100); HRMS (ESI) 
calculated for C12H979BrFO3: 298.9714, found: 298.9714; IR (neat): 3065, 1731, 1651, 
1568, 1480, 1443, 1402, 1246, 1182, 1134, 980, 851, 827, 783 cm-1. 
 
4-(2-Bromo-5-fluoro-phenoxy)-6-methyl-2-pyrone (228k) 
O
O
O
Br
F
 
The title compound was prepared according to General Procedure A, on a 1 mmol scale, to 
afford the product as a white solid (262 mg, 87.7%).  
Mpt: 120-122 °C; 1H-NMR (400 MHz, CDCl3): 7.62 (dd, J = 8.9, 5.7 Hz, 1H), 6.97 (ddd, 
J = 8.9, 7.7, 2.9, 1H), 6.92 (dd, J = 8.4, 2.9 Hz, 1H), 6.01 (dq, J = 2.1, 0.8 Hz, 1H), 5.10 (d, 
J = 2.1 Hz, 1H), 2.28 (d, J = 0.7 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.0, 164.1, 
163.9,162.2 (d, J = 251.2 Hz), 150.0 (d, J = 10.6 Hz), 134.8 (d, J = 9.0 Hz), 115.5 (d, J = 
22.2 Hz), 111.2 (d, J = 24.9 Hz), 110.59 (d, J = 4.2 Hz), 99.3, 91.3, 20.1; 19F-NMR (376 
MHz, CDCl3): -110.01 (td, J = 8.0, 5.7 Hz); MS (ESI) m/z (rel.%): 301 [81Br-MH+] (97), 
299 [79Br-MH+] (100); HRMS (ESI) calculated for C12H9BrFO3: 298.9714, found: 
298.9711; IR (neat): 3063, 2923, 2855, 1726, 1644, 1563, 1453, 1401, 1233, 1166, 1134, 
995, 947, 851, 808 cm-1. 
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4-(2-Bromo-4-chloro-phenoxy)-6-methyl-2-pyrone (228ℓ) 
O
O
O
BrCl
 
The title compound was prepared according to General Procedure A, on a 2 mmol scale, to 
afford the product as a white solid (611 mg, 96.8%).  
Mpt: 114-115 °C; 1H-NMR (400 MHz, CDCl3): 7.67 (d, J = 2.4 Hz, 1H), 7.36 (dd, J = 8.6, 
2.4 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.00 (d, J = 2.2 Hz, 1H), 5.08 (d, J = 2.2 Hz, 1H), 
2.28 (s, 3H); 13C-NMR (101 MHz, CDCl3): 169.2, 164.1, 163.8, 148.1, 133.8, 132.9, 
129.3, 123.9, 116.7, 99.3, 91.1, 20.1; MS (ESI) m/z (rel.%): 319 [37Cl/81Br -MH+] (23), 
317 [35Cl/81Br, 37Cl/79Br-MH+] (100), 315 [35Cl/79Br -MH+] (77); HRMS (ESI) calculated 
for C12H979Br35ClO3: 314.9418, found: 314.9414; IR (neat): 3091, 3063, 1726, 1647, 1564, 
1470, 1446, 1401, 1234, 1131, 1090, 979, 849, 813 cm-1. 
 
4-(2,4-Dibromo-phenoxy)-6-methyl-2-pyrone (228m) 
O
O
O
BrBr
 
The title compound was prepared according to General Procedure A, on a 2 mmol scale, to 
afford the product as a white solid (514 mg, 71.4%).  
Mpt: 114-115 °C; 1H-NMR (400 MHz, CDCl3): 7.81 (d, J = 2.3 Hz, 1H), 7.51 (dd, J = 8.6, 
2.3 Hz, 1H), 7.03 (d, J = 8.6 Hz, 1H), 6.00 (dq, J = 2.2, 0.9 Hz, 1H), 5.08 (d, J = 2.2 Hz, 
1H), 2.28 (d, J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 169.1, 164.1, 163.8, 148.6, 
136.6, 132.3, 124.3, 120.33, 117.0, 99.3, 91.1, 20.1; MS (ESI) m/z (rel.%): 363 [81Br /81Br 
-MH+] (45), 361 [79Br /81Br,] (100), 359 [79Br /79Br-MH+] (46); HRMS (ESI) calculated 
for C12H979Br2O3: 358.8913, found: 358.8911; IR (neat): 3204, 1731, 1647, 1566, 1535, 
1468, 1445, 1402, 1235, 1194, 1132, 982, 852, 814 cm-1. 
 
4-(2-Bromo-4-(trifluoromethyl)-phenoxy)-6-methyl-2-pyrone (228n) 
O
O
O
BrF3C
 
The title compound was prepared according to General Procedure A, on a 0.5 mmol scale, 
to afford the product as a white solid (166.4 mg, 95.3%).  
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Mpt: 91-93 °C; 1H-NMR (400 MHz, CDCl3): 7.93 (dq, J = 2.2, 0.7 Hz, 1H), 7.65 (ddq, J = 
8.4, 2.2, 0.7 Hz, 1H), 7.26 (dq, J =8.4, 0.8 Hz, 1H), 6.02 (dq, J = 2.3, 0.9 Hz, 1H), 5.07 
(dq, J = 2.3, 0.6 Hz, 1H), 2.27 (dd, J = 0.9, 0.6 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 
168.8, 164.1, 163.9, 152.1, 131.6 (q, J = 3.7 Hz), 130.3 (q, J = 33.9 Hz), 127.7 (q, J = 3.6 
Hz), 126.4 (q, J = 3.5 Hz), 123.6, 116.6, 99.3, 91.4, 20.1; 19F-NMR (376 MHz, CDCl3): -
62.38 (s); MS (ESI) m/z (rel.%): 351 [81Br-MH+] (96), 349 [79Br-MH+] (100), 282 (7), 271 
(12); HRMS (ESI) calculated for C13H979BrF3O3: 348.9682, found: 348.9685; IR (neat): 
3086, 2960, 2159, 1721, 1646, 1607, 1568, 1511, 1446, 1405, 1320, 1245, 1119, 1075, 
982, 818 cm-1. 
 
4,9-Dimethyl-benzofuro[3,2-c]-2-pyrone (229a) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (38.4 mg, 71.8%).  
1H-NMR (400 MHz, CDCl3): 7.82 (dq, J = 1.9, 0.7 Hz, 1H), 7.41 (d, J = 8.4, 1H), 7.20 
(ddq, J = 8.4, 1.9, 0.7 Hz, 1H), 6.51 (q, J = 0.9, 1H), 2.47 (app. t, J = 0.7 Hz, 3H), 2.41 (d, 
J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.6, 162.6, 159.7, 153.3, 134.8, 127.2, 
122.8, 121.2, 110.9, 103.5, 96.0, 21.3, 20.6; MS (ESI) m/z (rel.%): 237 [MNa+] (40), 215 
[MH+] (100); HRMS (ESI) calculated for C13H11O3 [MH+]: 215.0703, found: 215.0706; IR 
(neat): 3088, 2921, 1727, 1615, 1571, 1450, 1190, 1037, 971, 941, 821, 795, 773 cm-1. 
 
4,6,9-Trimethyl-benzofuro[3,2-c]-2-pyrone (229b) 
 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (44.8 mg, 78.6%).  
Rf = 0.43 (20% EtOAc in hexanes); Mpt: 149-150 °C; 1H-NMR (400 MHz, CDCl3): 7.65 
(s, 1H), 7.02 (s, 1H), 6.52 (s, 1H), 2.50 (s, 3H), 2.44 (s, 3H), 2.41 (s, 3H); 13C-NMR (101 
MHz, CDCl3): 164.3, 162.4, 159.8, 152.4, 134.8, 128.5, 122.4, 121.1, 118.6, 103.8, 96.0, 
21.2, 20.6, 14.9; MS (ESI) m/z (rel.%): 251 [MNa+] (16), 229 [MH+] (100); HRMS (ESI) 
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calculated for C14H13O3: 229.0859, found: 229.0858; IR (neat): 3097, 2924, 1731, 1621, 
1572, 1446, 1287, 1222, 1180, 1033, 970, 939, 842, 798, 736 cm-1. 
 
4-tert-Butyl-9-methyl-benzofuro[3,2-c]-2-pyrone (229c) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (44.9 mg, 70.2%).  
Rf = 0.50 (20% EtOAc in hexanes); Mpt: 119-120 °C; 1H-NMR (400 MHz, CDCl3): 8.03 
(app. t, J = 1.3 Hz, 1H), 7.46 (app. d, J = 1.3 Hz, 2H), 6.52 (q, J = 0.8 Hz, 1H), 2.42 (d, J = 
0.8 Hz, 3H), 1.40 (s, 9H); 13C-NMR (101 MHz, CDCl3): 164.7, 162.6, 159.7, 153.1, 148.4, 
123.9, 122.6, 117.8, 110.7, 103.8, 96.0, 35.0, 31.8, 20.6; MS (ESI) m/z (rel.%): 279 
[MNa+] (6), 257 [MH+] (100); HRMS (ESI) calculated for C16H17O3: 257.1172, found: 
257.1176; IR (neat): 2964, 1732, 1626, 1570, 1459, 1192, 1030, 968, 932, 889, 824, 787 
cm-1. 
 
4,6-Di-tert-butyl-9-methyl-benzofuro[3,2-c]-2-pyrone (229d) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.16 mmol scale, 
to afford the product as a yellow solid (35.4 mg, 70.9%).  
Rf = 0.64 (20% EtOAc in hexanes); Mpt: 144-147 °C; 1H-NMR (400 MHz, CDCl3): 7.90 
(d, J = 2.0 Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 6.56 (q, J = 0.9 Hz, 1H), 2.42 (d, J = 0.9 Hz, 
3H), 1.51 (s, 9H), 1.40 (s, 9H); 13C-NMR (101 MHz, CDCl3): 163.9, 162.1, 159.8, 151.5, 
148.1, 134.1, 123.0, 120.8, 115.6, 103.7, 96.1, 35.1, 34.5, 31.8, 29.9, 20.6; MS (ESI) m/z 
(rel.%): 335 [MNa+] (18), 313 [MH+] (100); HRMS (ESI) calculated for C20H23O3: 
313.1798, found: 313.1791; IR (neat): 2954, 1737, 1619, 1569, 1365, 1243, 1226, 1064, 
971, 874, 815, 752 cm-1. 
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4-Phenyl-9-methyl-benzofuro[3,2-c]-2-pyrone (229e) 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford recovered starting material (19.5 mg, 21.8%) and the product as a yellow solid 
(30.0 mg, 43.5% [55.6% b.r.s.m]).  
Rf = 0.36 (20% EtOAc in hexanes); Mpt: 211-213 °C; 1H-NMR (400 MHz, CDCl3): 8.24 
(dd, J = 1.9, 0.7 Hz, 1H), 7.68 – 7.65 (m, 2H), 7.65 (dd, J = 8.6, 1.9 Hz, 1H), 7.60 (dd, J = 
8.6, 0.7 Hz, 1H), 7.44 – 7.49 (m, 2H), 7.38 (m, 1H), 6.56 (q, J = 0.8 Hz, 1H), 2.44 (d, J = 
0.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 165.0, 163.1, 154.5, 140.6, 138.7, 128.8, 
127.5, 127.4, 125.6, 123.5, 119.7, 111.6, 103.8, 99.9, 95.9, 20.7; MS (ESI) m/z (rel.%): 
299 [MNa+] (8), 277 [MH+] (100); HRMS (ESI) calculated for C18H13O3: 277.0859, 
found: 277.0862;
 
IR (neat): 3055, 2921, 1733, 1625, 1575, 1443, 1242, 1196, 1030, 968, 
930, 887, 829, 805, 775, 762, 703, 682 cm-1.
 
 
4-Methoxy-9-methyl-benzofuro[3,2-c]-2-pyrone (229f) 
O
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford recovered starting material (24 mg, 30.8%) and the product as a yellow solid 
(37.1 mg, 64.5% [93% b.r.s.m]).  
Rf = 0.31 (20% EtOAc in hexanes); Mpt: 155-157 °C; 1H-NMR (400 MHz, CDCl3): 7.48 
(d, J = 2.6 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 6.98 (dd, J = 9.0, 2.6 Hz, 1H), 6.51 (q, J = 0.9 
Hz, 1H), 3.90 (s, 3H), 2.42 (d, J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.9, 
162.6, 159.7, 157.5, 149.6, 123.6, 115.1, 112.1, 103.9, 103.2, 96.0, 56.0, 20.6; MS (ESI) 
m/z (rel.%): 253 [MNa+] (45), 231 [MH+] (100); HRMS (ESI) calculated for C13H11O4 
[MH+]: 231.0652, found: 231.0651; IR (neat): 3095, 2958, 1728, 1631, 1619 1572, 1461, 
1436, 1274, 1226, 1177, 1023, 965, 937, 848, 813, 786, 771 cm-1. 
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5-Methoxy-9-methyl-benzofuro[3,2-c]-2-pyrone (229g) 
O
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.5 mmol scale, 
to afford the product as a yellow solid (76.7 mg, 66.7%).  
Rf = 0.29 (20% EtOAc in hexanes); Mpt: 172-173 °C; 1H-NMR (400 MHz, CDCl3): 7.88 
(d, J = 8.6 Hz, 1H), 7.07 (d, J = 2.2 Hz, 1H), 7.01 (dd, J = 8.6, 2.2 Hz, 1H), 6.51 (q, J = 
0.9, 1H), 3.88 (s, 3H), 2.41 (d, J = 0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.0, 
161.7, 159.7, 159.2, 156.1, 121.5, 115.9, 113.0, 103.8, 96.7, 95.9, 55.8, 20.5; MS (ESI) m/z 
(rel.%): 253 [MNa+] (100), 231 [MH+] (87); HRMS (ESI) calculated for C13H10NaO4 
[MNa+]: 253.0471, found: 253.0469; IR (neat): 3095, 1715, 1569, 1496, 1270, 1137, 1110, 
1036, 973, 939, 834, 801 cm-1. 
 
5,6-Dimethoxy-9-methyl-benzofuro[3,2-c]-2-pyrone (229h) 
 
O
O
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (20.5 mg, 31.5%).  
Rf = 0.19 (20% EtOAc in hexanes); 1H-NMR (400 MHz, CDCl3): 7.61 (d, J = 8.5 Hz, 1H), 
7.03 (d, J = 8.5 Hz, 1H), 6.53 (q, J = 0.8 Hz, 1H), 4.15 (s, 3H), 3.95 (s, 3H), 2.41 (d, J = 
0.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.3, 162.2, 159.6, 150.5, 147.1, 147.0, 
118.0, 114.7, 110.8, 103.8, 95.9, 61.3, 57.0, 20.6; MS (ESI) m/z (rel.%): 283 [MNa+] (8), 
261 [MH+] (100); HRMS (ESI) calculated for C14H13O5: 261.0757, found: 261.0753; IR 
(neat): 3104, 2947, 1731, 1623, 1574, 1504, 1444, 1403, 1269, 1229, 1074, 1001, 971, 950, 
801 cm-1.  
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5-(6-methyl-2-pyronyl-4-oxy)-9-methyl-benzofuro[3,2-c]-2-pyrone (229i) 
O
O
O
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.5 mmol scale, 
to afford the product as a yellow solid (26 mg, 16%).  
Mpt: degrades > 215 °C; 1H-NMR (400 MHz, CDCl3): 8.05 (d, J = 8.4 Hz, 1H), 7.31 (d, J 
= 2.1 Hz, 1H), 7.16 (dd, J = 8.4, 2.1 Hz, 1H), 6.57 (d, J = 0.9 Hz, 1H), 6.00 (dd, J = 2.2, 
0.9 Hz, 1H), 5.23 (d, J = 2.2 Hz, 1H), 2.45 (d, J = 0.9 Hz, 3H), 2.28 (d, J = 0.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): 170.7, 165.5, 163.6, 163.5, 159.1, 157.9, 155.0, 150.6, 
122.3, 121.4, 118.5, 105.3, 103.4, 99.9, 99.7, 95.8, 91.3, 20.7, 20.1; MS (ESI) m/z (rel.%): 
347 [MNa+] (98), 325 [MH+] (100); HRMS (ESI) calculated for C18H13O6: 325.0707, 
found: 325.0701; IR (neat): 3100, 1726, 1649, 1615, 1570, 1445, 1400, 1319, 1255, 1168, 
1135, 1032, 982, 944, 819 cm-1. 
 
4-Fluoro -9-methyl-benzofuro[3,2-c]-2-pyrone (229j) 
O
O
O
F
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale 
using 2.5 mol% Pd2(dba-4,4′-OMe)3 and 10 mol% PPh3, to afford the product as a yellow 
solid (22.5 mg, 41.3%).  
Rf = 0.37 (20% EtOAc in hexanes); Mpt: 207-208 °C; 1H-NMR (400 MHz, CDCl3): 7.70 
(dd, J = 8.1, 2.7 Hz, 1H), 7.48 (dd, J = 9.0, 3.9 Hz, 1H), 7.12 (app. td, J = 9.0, 2.7 Hz, 1H), 
6.53 (q, J = 0.8 Hz, 1H), 2.43 (d, J = 0.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 165.71, 
163.54, 160.3 (d, J = 242.1 Hz), 159.08, 151.0 (d, J = 1.3 Hz), 124.10 (d, J = 11.6 Hz), 
113.65 (d, J = 26.4 Hz), 112.27 (d, J = 9.6 Hz), 107.49 (d, J = 26.5 Hz), 103.76 (d, J = 3.6 
Hz), 95.85, 20.69; 19F-NMR (376 MHz, CDCl3): -117.03 (ddd, J = 9.0, 8.1, 3.9 Hz); MS 
(ESI) m/z (rel.%): 241 [MNa+] (67), 219 [MH+] (100); HRMS (ESI) calculated for 
C12H8FO3:219.0452, found: 241.0449; IR (neat): 3090, 2922, 1728, 1613, 1571, 1449, 
1243, 1211, 1130, 1031, 972, 856, 797, 769 cm-1.
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5-Fluoro -9-methyl-benzofuro[3,2-c]-2-pyrone (229k) 
O
O
O
F
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford recovered starting material (13.2 mg) and the product as a yellow solid (13.2 mg, 
24.2%) 
1H-NMR (400 MHz, CDCl3): 7.96 (dd, J = 8.6, 5.4 Hz, 1H), 7.28 (dd, J = 8.5, 2.3 Hz, 
1H), 7.17 (ddd, J = 9.4, 8.6, 2.3 Hz, 1H), 6.54 (q, J = 0.8 Hz, 1H), 2.43 (d, J = 0.8 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): 165.1, 163.87 (d, J = 233.1 Hz), 162.8, 159.3, 154.93 (d, J 
= 13.5 Hz), 121.77 (d, J = 10.0 Hz), 119.10 (d, J = 2.0 Hz), 113.11 (d, J = 23.8 Hz), 99.78 
(d, J = 27.4 Hz) 99.4, 95.8, 20.6; 19F-NMR (376 MHz, CDCl3): -113.48 (td, J = 9.0, 5.4 
Hz); MS (ESI) m/z (rel.%): 241 [MNa+] (77), 219 [MH+] (100); HRMS (ESI) calculated 
for C12H8FO3: 298.9714, found: 298.9711; IR (CHCl3): 1731, 1615, 1573, 1496, 1276, 
947, 651 cm-1. 
 
4-Chloro-9-methyl-benzofuro[3,2-c]-2-pyrone (229ℓ) 
O
O
O
Cl
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (19.5 mg, 33.3%).  
Rf = 0.33 (20% EtOAc in hexanes); Mpt: 191-193 °C; 1H-NMR (400 MHz, CDCl3): 8.01 
(dd, J = 2.2, 0.5 Hz, 1H), 7.47 (dd, J = 8.8, 0.5 Hz, 1H), 7.36 (dd, J = 8.8, 2.2 Hz, 1H), 
6.53 (q, J = 0.8 Hz, 1H), 2.43 (d, J = 0.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 165.4, 
163.7, 158.9, 153.2, 130.8, 126.3, 124.3, 121.0, 112.4, 103.2, 95.8, 20.7; MS (ESI) m/z 
(rel.%): 259 [37Cl-MNa+] (10), 257 [35Cl-MNa+] (38), 237 [37Cl-MH+] (31), 235 [35Cl-
MH+] (100); HRMS (ESI) calculated for C12H835ClO3: 235.0156, found: 235.0156; IR 
(neat): 3093, 2923, 1737, 1627, 1570, 1438, 1258, 1194, 1030, 967, 928, 811, 797 cm-1. 
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4-(Trifluoromethyl)-9-methyl-benzofuro[3,2-c]-2-pyrone (229n) 
O
O
O
F3C
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford the product as a yellow solid (7.1 mg, 10.6%).  
1H-NMR (400 MHz, CDCl3): 8.34 (dt, J = 1.5, 0.7 Hz, 1H), 7.70 – 7.63 (m, 2H), 6.59 (d, J 
= 0.8 Hz, 1H), 2.46 (d, J = 0.8 Hz, 3H); 19F-NMR (376 MHz, CDCl3): -61.11 (d, J = 5.2 
Hz); MS (ESI) m/z (rel.%): 269 [MH+] (100), 249 (24), 215 (15), 126 (82), 84 (44); 
HRMS (ESI) calculated for C13H8F3O3: 269.0420, found: 269.0430; IR (neat): 2953, 2923, 
2853, 1743, 1575, 1458, 1319, 1266, 1164, 1119, 1050, 970, 818 cm-1. 
 
4-(2-Bromo-phenylsulfanyl)-6-methyl-2-pyrone (231) 
S
O
O
Br
 
The title compound was prepared according to General Procedure A, on a 1 mmol scale, to 
afford the product as a yellow solid (296 mg, >99%).  
Mpt: 75-79 °C; 1H-NMR (400 MHz, CDCl3): 7.76 (dd, J = 7.6, 1.7 Hz, 1H), 7.64 (dd, J = 
7.6, 2.0, 1H), 7.41 (td, J = 7.6, 1.7 Hz, 1H), 7.36 (td, J = 7.6, 2.0 Hz, 1H), 5.86 (dq, J = 1.6, 
0.9 Hz, 1H), 5.36 (d, J = 1.6, 1H), 2.21 (app. s, 3H); 13C-NMR (101 MHz, CDCl3): 161.5, 
160.9, 158.2, 137.9, 134.4, 132.3, 130.7, 128.8, 128.3, 103.9, 102.6, 19.9; MS (ESI) m/z 
(rel.%): 299 [81Br-MH+] (100), 297 [79Br-MH+] (98); HRMS (ESI) calculated for 
C12H1079BrO2S: 296.9579, found: 296.9583; IR (neat): 3096, 1702, 1623, 1529, 1442, 
1313, 1218, 1027, 981, 822, 749 cm-1. 
 
2-Bromo-benzoic acid (6-methyl-2-pyron-4-yl) ester (234) 
O O
O
O
Br
 
To a solution of 9 (252 mg, 2 mmol, 2 eq.), 2-Bromo-benzoic acid (201 mg, 1 mmol, 1 eq.) 
and DMAP (6.6 mg, 0.05 mmol, 5 mol%) in DCM (3 ml) at 22 °C was added DIC (139 
mg, 1.1 mmol, 1.1 eq.) carefully over 15 minutes. The reaction was stirred at 22 °C for 24 
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h and the solvent removed in vacuo. Purification via column chromatography (20% EtOAc 
in pet ether) afforded the title compound as a white crystalline solid (260 mg, 84.1%). 
Mpt: 99-100 °C; 1H-NMR (400 MHz, CDCl3): 7.95 (m, 1H), 7.75 (m, 1H), 7.43 – 7.48 (m, 
2H), 6.18 (d, J = 2.0 Hz, 1H), 6.13 (dq, J = 2.0, 0.8 Hz, 1H), 2.31 (d, J = 0.8 Hz, 2H); 13C-
NMR (101 MHz, CDCl3): 163.5, 163.1, 161.9, 154.2, 135.0, 134.1, 132.2, 129.5, 127.5, 
122.8, 101.4, 101.2, 20.2; MS (ESI) m/z (rel.%): 311 [81Br-MH+] (93), 309 [79Br-MH+] 
(100); HRMS (ESI) calculated for C12H1079BrO2S: 308.9757, found: 308.9755; IR (neat): 
3093, 1726, 1638, 1565, 1432, 1234, 1208, 1143, 1124, 1069, 1011, 962, 849, 732 cm-1. 
 
Benzofuro[3,2-c]coumarin (Coumestan)(240)130 
O
O
O
 
The title compound was prepared according to General Procedure B, on a 0.25 mmol scale, 
to afford recovered starting material (19.6 mg, 21.5%) and the product as a yellow solid 
(26.0 mg, 44.1% [56% b.r.s.m]).  
Mpt: 178-180 °C (lit. 179-180°C)125; 1H-NMR (400 MHz, CDCl3):  8.14 (m, 1H), 8.03 
(ddd, J = 7.8, 1.6, 0.4 Hz, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.51 (m, 1H), 7.46 – 7.49 (m, 
2H), 7.42 (m, 1H); 13C-NMR (101 MHz, CDCl3): 156.0, 158.1, 155.5, 153.7, 131.9, 126.8, 
125.2, 124.6, 123.4, 121.9, 117.5, 112.6, 111.7, 105.9; MS (ESI) m/z (rel.%): 237 [MH+] 
(100), 211 (24); HRMS (ESI) calculated for C15H9O3: 237.0546, found: 237.0543; 
 
4-(2-Iodophenoxy)-coumarin (242) via 4-Bromo-coumarin161 
Br
O
O
 
A 250 ml 3 neck flask containing 4-hydroxycoumarin 241 (1.49 g, 9.2 mmol, 1 eq.), P2O5 
(3.13 g, 22.1 mmol, 2.4 eq.) and TBAB (3.26 g, 10.1 mmol, 1.1 eq.) in toluene (100 ml) 
was equipped with a condenser and a mechanical stirrer. The reaction mixture was then 
heated to reflux for 8 hours whilst stirring then allowed to cool to ambient temperature. 
The toluene was decanted off, and the viscous black residue was extracted with toluene (3 
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× 40 ml). The combined organic fractions were concentrated in vacuo and recrystallisation 
(toluene) afforded the title compound as pale orange crystals (1.16 g, 56%).  
Mpt: 92-93 °C (lit. 87-89 °C)161; 1H-NMR (400 MHz, CDCl3): 7.83 (dd, J = 8.0, 1.5 Hz, 
1H), 7.59 (ddd, J = 8.3, 7.4, 1.6 Hz, 1H), 7.38 – 7.30 (m, 2H), 6.85 (s, 1H); 13C-NMR (101 
MHz, CDCl3): 158.6, 152.4, 141.4, 133.1, 128.0, 124.9, 119.5, 118.9, 116.9; MS (ESI) m/z 
(rel.%): 227 [81Br-MH+] (100), 225 [79Br-MH+] (98); HRMS (ESI) calculated for 
C9H679BrO2: 224.9546, found: 224.9550. 
O
O
O
I
 
A solution of 4-Bromo-coumarin (225 mg, 1 mmol, 1 eq.), 2-iodophenol (220 mg, 1 mmol, 
1 eq.), and K2CO3 (276 mg, 2 mmol, 2 eq.) in acetone (3 ml) was stirred at 60 °C for 16 
hours. The reaction was allowed to cool to ambient temperature and quenched by addition 
of water (2 ml) and ethyl acetate (4 ml), and the layers separated. The aqueous layer was 
extracted using ethyl acetate (3 × 4 ml) and the combined organic extracts dried over 
MgSO4, concentrated in vacuo and purified by flash column chromatography (10-20 % 
EtOAc in hexanes) to afford the product as a white solid (310 mg, 85.1%). 
Mpt: 154-155 °C; 1H-NMR (400 MHz, CDCl3): 8.09 (d, J = 7.5 Hz, 1H), 7.94 (d, J = 7.5 
Hz, 1H), 7.64 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.40 (d, J = 7.5 Hz, 2H), 7.22 (d, 
J = 7.5 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 5.31 (s, 1H); 13C-NMR (126 MHz, CDCl3): 
164.9, 162.4, 153.7, 152.3, 140.5, 132.9, 130.3 128.5, 124.3, 123.3, 122.4, 116.9, 115.1, 
93.8, 89.7; MS (ESI) m/z (rel.%): 387 [MNa+] (16), 365 [MH+] (100); HRMS (ESI) 
calculated for C15H10IO3: 364.9669, found: 364.9678; IR (neat): 3067, 1714, 1623, 1608, 
1568, 1380, 1227, 1177, 1088, 929, 752 cm-1. 
 
trans-[Pd{C6H4O-2-(C6H5O2)}I(PPh3)2] (244) 
O
O
O
PdII
I
PPh3Ph3P
 
A solution of Pd2dba3 (30 mg, 33 µmol, 1eq.), and PPh3 (34 mg, 132 µmol, 4 eq.) in DCM 
(20 ml) was stirred under nitrogen at ambient temperature for 15 minutes, followed by the 
addition of 4-(2-iodophenoxy)-6-methyl-2-pyrone (32.8 mg, 99 µmol, 3 eq.). The solution 
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was then allowed to stir for 1 hour at ambient temperature. The DCM was removed in 
vacuo to afford an orange oil which was subsequently taken up in Et2O (5 ml) and allowed 
to crystallise for 16 hours. The solution was then filtered and the crystals washed with Et2O 
(5 ml), then dried under high vacuum to afford a yellow crystalline solid (63 mg, 65.6%). 
1H-NMR (700 MHz, CD2Cl2): 7.52 (dd, J = 12.4, 5.5 Hz, 12H), 7.37 (t, J = 7.5 Hz, 6H), 
7.28 (t, J = 7.5 Hz, 12H), 6.92 (ddd, J = 7.5, 3.5, 1.9 Hz, 1H), 6.48 (t, J = 7.5 Hz, 1H), 6.32 
(t, J = 7.5 Hz, 1H), 6.04 (ddd, J = 7.5, 2.4, 1.2 Hz, 1H), 5.65 (dd, J = 1.0, 2.0, 1H), 4.72 (d, 
J = 1.9, 1H), 2.26 (app. s, 3H); 13C-NMR (176 MHz, CD2Cl2): 169.1, 164.4, 163.3, 153.4, 
149.9, 138.8, 135.5, 132.7, 130.6, 128.3, 125.5, 124.2, 119.7, 100.4, 91.4, 20.6; 31P-NMR 
(283 MHz, CD2Cl2): 21.23; MS (LIFDI) m/z (rel.%): 958 [M+] (100);  
 
trans-[Pd{C6H4O-2-(C6H5O2)}I{P(C6D5)3}2] (244-d30) 
O
O
O
PdII
I
P(C6D5)3(C6D5)3P
 
A solution of Pd2dba3 (30 mg, 33 µmol, 1 eq.), and D15- PPh3 (36 mg, 132 µmol, 4 eq.) 
in CH2Cl2 (20 mL) was stirred under nitrogen at ambient temperature for 15 minutes, 
followed by the addition of 4-(2-iodophenoxy)-6-methyl-2-pyrone (32.8 mg, 99 µmol, 
3 eq.). The solution was then allowed to stir for 1 hour at ambient temperature. The 
CH2Cl2 was removed in vacuo to afford an orange oil which was subsequently taken up 
in Et2O (5 mL) and allowed to crystallise for 16 hours. The solution was then filtered 
and the crystals washed with Et2O (5 mL), then dried under high vacuum to afford a 
yellow crystalline solid (23 mg, 35.3%). 1H-NMR (700 MHz, CD2Cl2): 6.92 (ddd, J = 
7.5, 3.5, 1.9 Hz, 1H), 6.48 (t, J = 7.5 Hz, 1H), 6.32 (t, J = 7.5 Hz, 1H), 6.04 (ddd, J = 
7.5, 2.4, 1.2 Hz, 1H), 5.65 (dd, J = 1.0, 2.0, 1H), 4.72 (d, J = 1.9, 1H), 2.26 (app. s, 
3H); 31P-NMR (283 MHz, CD2Cl2): 21.23; 31P-NMR (283 MHz, D8-THF): 22.44. 
 
Attempted synthesis of a cationic derivative of 245 
The neutral PdII complex 244 (41.3 mg, 43 µmol, 1 eq.) was reacted with AgPF6 (10.9 
mg, 43 µmol, 1 eq.) in CD2Cl2 (1 mL) at ambient temperature in a dry box for 1 hour in 
the dark. The reaction was then filtered through a pad of CeliteTM, and  NMR 
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spectroscopy showed that a new cationic complex was formed along with an additional 
new species (presumed to be 246). (Selected data) 1H NMR (700 MHz, CD2Cl2): 7.93 
(t, J = 7.9 Hz, 1H), 7.52 (td, J = 7.4, 2.2 Hz, 1H), 7.38 (dd, J = 8.1, 5.5 Hz, 1H), 7.33 
(ddd, J = 14.3, 7.9, 1.4 Hz, 1H), 5.20 (d, J = 2.0 Hz, 1H), 4.92 (d, J = 2.0 Hz, 1H), 1.98 
(s, 3H); 31P NMR (162 MHz, CD2Cl2): 39.02 (br. s, ∆ν ½ 46 Hz), 22.09 (s), -143.88 
(hept, J = 710 Hz). Layering the CH2Cl2 solution with Et2O and storing room 
temperature in the dark for two weeks gave crystals suitable for X-ray diffraction 
study.  Rather curiously, it was found that the “C6H4O-2-(C6H5O2)” group from the 
cationic PdII species had undergone Pd→P transfer forming [P{C6H4O-2-
(C6H5O2)}Ph3]PF6 (248), which was accompanied by significant Pd black formation. 
 
Reaction of 244 with Cs2CO3 to give product 216 
A solution of Pd2 (dba-4,4′-OMe)3 (3.6 mg, 3.3 µmol, 1 eq.), and PPh3 (3.4 mg, 13.2 
µmol, 4 eq.) in D8-THF (1 mL) was stirred in a dry box at ambient temperature for 15 
minutes, followed by the addition of 4-(2-iodophenoxy)-6-methyl-2-pyrone 218 (4.2 
mg, 13.2 µmol, 4 eq.). The solution was then allowed to stir for 1 hour at ambient 
temperature and the PdII intermediate confirmed by NMR. Cs2CO3 (6.6 mg, 20 µmol, 6 
eq.) was added and the solution heated to 70 °C for 2 hours. The solution was cooled to 
ambient temperature and filtered. The 1H NMR spectrum showed quantitative 
formation of 218a. 
 
Synthesis of trans-[Pd{C6H3-5-CF3-O-2-(C6H5O2)}Br(PPh3)2] (247) and attempted 
reaction with Cs2CO3 
From Pd2(dba-H)3: A solution of Pd2(dba)3 (30 mg, 33 µmol, 1 eq.), and PPh3 (34 mg, 
132 µmol, 4 eq.) in THF (20 mL) was stirred under a N2 atmosphere for 15 minutes, 
giving an orange solution which is Pd(η2-dba-H)(PPh3)2.  4-(2-Bromo-4-
(trifluoromethyl)-phenoxy)-6-methyl-2-pyrone 228n (46.0 mg, 132 µmol, 2 eq.) was 
then added and the solution was allowed to stir for 1 hour at 70 °C. The THF was 
removed in vacuo to afford an orange oil which was subsequently taken up in Et2O (5 
mL), and allowed to slowly crystallize over 16 hours.  A mixture of purple, orange and 
yellow crystals were formed.  X-ray crystallographic analysis identified the purple 
crystals as Pd2(dba-H)3 (as disordered isomers). The orange and yellow crystals were 
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not identified. From Pd2(dba-4,4′-OMe)3: In a dry box, a solution of Pd2 (dba-4,4′-
OMe)3 (3.6 mg, 3.3 µmol, 1 eq.), and PPh3 (3.4 mg, 13.2 µmol, 4 eq.) in D8-THF (1 
mL) was stirred at ambient temperature for 15 minutes, giving an dark orange solution 
which is Pd(η2-dba-4,4′-OMe)(PPh3)2. 4-(2-Bromo-4-(trifluoromethyl)-phenoxy)-6-
methyl-2-pyrone 228n (2.3 mg, 6.6 µmol, 2 eq.) was then added.  The solution was 
then allowed to stir for 1 hour at 70 °C and the PdII complex characterized by NMR 
spectroscopy. Selected Data: 1H-NMR (400 MHz, D8-THF): 7.59 – 7.54 (m, 12H), 7.35 
– 7.30 (m, 6H), 7.26 – 7.22 (m, 12H), 6.67 (d, J = 8.5 Hz, 1H), 6.15 (d, J = 8.5 Hz, 
1H), 6.03 (s, 1H), 5.69 (d, J = 2.2 Hz, 1H), 4.65 (d, J = 2.2 Hz, 1H), 2.24 (s, 3H); 31P-
NMR (162 MHz, D8-THF): 24.46 (s). Cs2CO3 (13.2 mg, 40 µmol, 12 eq.) was then 
added to the yellow/orange solution, which was heated to 70 °C for 2 hours.  The 
solution was allowed to cool to ambient temperature and filtered through CeliteTM.  1H 
NMR spectroscopic analysis of the filtrate showed no formation of the cyclised product 
229n.  The 31P NMR spectrum showed degradation of the PdII complex at δ 24.46 (s), 
and a new species, identified as [Pd0(η2-dba-4-OMe)(PPh3)2] 9.  31P-NMR (162 MHz, 
D8-THF): 26.8 (br. s, ∆ν½ 42 Hz), 25.2 (br. s, ∆ν½ 42 Hz). 
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Chapter 6- Appendices 
 
Appendix 1: Reaction optimisation tables 
 
Appendix 1.1: Silylation of 4-hydroxy-6-methyl-2-pyrone (9). 
O
O
HO
O
O
O
Si
R
Base
RMe2Si-Cl
 
 
Entry R Base Temp (°C) Yield (%) 
1 Me TEA 22 No Reaction 
2 Me NaH 22 No Reaction 
3 Me K2CO3 22 No Reaction 
4 tBu K2CO3 22 No Reaction 
5 tBu K2CO3 60 No Reaction 
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Appendix 1.2: Cross metathesis reaction of 110 and 113. 
O
O
O
R
Br
Br
O
O
O
R
+
Ru Catalyst (1-6 mol%)
Eq. of bromopentene (1-2)
 
Entry R Solvent 
Temperature 
(°C) 
eq. Of 
alkene 
Catalyst 
Mol% 
catalyst 
Yield 
(%)† 
1 Et DCM 30 1.5 Grubbs II 3 0 
2 Et DCM 20 1 Grubbs II 1 0 
3 Et DCM 20 2 Grubbs II 1 0 
4 Et DCM 20 1 Grubbs II 5 0 
5 Et DCM 20 2 Grubbs II 5 0 
6 Et DCM 40 1 Grubbs II 1 0 
7 Et DCM 40 2 Grubbs II 1 0 
8 Et DCM 40 1 Grubbs II 5 0 
9 Et DCM 40 2 Grubbs II 5 0 
10 H DCM 20 2 Grubbs II 6 0 
11 H DCM 40 2 Grubbs II 6 0 
12 H CHCl3 55 2* Grubbs II 6 Trace 
13 
H CHCl3 55 2* 
Hoveyda-
Grubbs 
6 0 
14 H Toluene 80 2* Grubbs II 6 0 
* Alkene changed to 6-hydroxyhex-1-ene 
†
 Recovered starting material observed in all cases 
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Appendix 1.3: Screening of conditions for the synthesis of 121. 
O
O
HO
Ph
O
O
O
Ph
+
Base
9 120 121
 
Entry Base 
eq. 
Base 
eq. Phenyl 
acetylene 
Solvent 
Temperature  
(°C) Yield (%) 
1 DMAP 0.2 1.0 DCM 20 SM recovered 
2 DMAP 0.2 1.1 DCM 40 SM recovered 
3 KOH 2 1.1 DCM 40 SM recovered 
4 DIPEA 2 1.1 DCM 40 SM recovered 
5 TEA 2 1.1 DCM 40 SM recovered 
6 K2CO3 2 1.1 DCM 40 SM recovered 
7 DMAP 0.2 1.1 THF 75 SM recovered 
8 KOH 2 1.1 THF 75 SM recovered 
9 DIPEA 2 1.1 THF 75 SM recovered 
10 TEA 2 1.1 THF 75 SM recovered 
11 K2CO3 2 1.1 THF 75 SM recovered 
12 TEA 2 2.2 DCM 100 (µwave) 
Degradation 
of SM 
13 TEA 2 2.2 DCM 140 (µwave) 
Degradation 
of SM 
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Appendix 1.4: Substitution reactions of 9 and 141. 
O
O
HO
O
EtO I
O
O
OEtO
O+
9 141 140
 
Entry Solvent Base 
Eq. 
Base 
Temperature 
(°C) 
Additive Yield 139 (%) 
1 DCM TEA 1 20 - SM Recovered 
2 DCM TEA 1 40 - SM Recovered 
3 DCM TEA 1.5 40 - SM Recovered 
4 DCM LiH 1 20 - SM Recovered 
5 DCM LiH 1 40 - SM Recovered 
6 THF NaH 1 25 - SM Recovered 
7 THF NaH 1 70 - SM Recovered 
8 Acetone K2CO3 1 25 - SM Recovered 
9 Acetone K2CO3 1 45 - SM Recovered 
10 THF NaH 1 70 AgNO3 SM Recovered 
11 DMF* NaH 1 25 AgNO3 SM Recovered 
12 DMF* NaH 1 50 AgNO3 25 – 43 
*
 Pyrone-Sodium salt preformed in THF prior to solvation in DMF 
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Appendix 1.5: Michael addition reactions of 9 and 142. 
•
Me
HO
EtO
O
O
HO
O
O
OEtO
O+
9 144 142
Base
 
Entry Solvent Base 
Eq. of 
Base 
Temperature 
(°C) 
Additive Yield 144 (%) 
1 DCM TEA 1 20 - SM Recovered 
2 DCM TEA 1 40 - SM Recovered 
3 DCM TEA 1 80 (µwave) - SM Recovered 
4 DCM DBU 1 40 - SM Recovered 
5 DCM DBU 1 80 (µwave) - SM Recovered 
6 DCM DBU 1 40 
Yb(OTf)3 
(10 mol%) 
SM Recovered 
7 DCM DBU 1 80 (µwave) 
Yb(OTf)3 
(10 mol%) SM Recovered 
 
Appendix 1.6: Substitution reactions of α-halobutyraldehydes with 9. 
O
O
HO
+ O
X
O
O
O
O
Base
9 165
 
Entry X Base Solvent Yield (%) 
1 Br TEA THF - 
2 Br DBU THF - 
3 Cl TEA THF - 
4 Cl DBU THF - 
5 Cl NaH THF - 
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Appendix 1.7: Ring Closing metathesis of 192. 
193
192
O
O
O
O
O
ORu Cat.
 
Entry Catalyst Solvent† Temperature Time Yield 
1 Grubbs I DCM 40 °C 48 h 0%
* 
2 DCM 40 °C 48 h 0%* 
3 Chloroform 60 °C 48 h 0%* 
4 
Grubbs II 
Toluene 100 °C 48 h 0% 
5 DCM 40 °C 48 h 0%* 
6 Chloroform 60 °C 48 h 0%* 
7 
Hoveyda-Grubbs II 
Toluene 100 °C 48 h 0% 
* Starting material recovered. 
† Reactions run at a concentration of 0.0016 M. 
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Appendix 2: X-ray diffraction details for all compounds. 
Compound reference ijf0925m 
(216) 
ijf0934m 
(222) 
ijf0930 
(229j) 
ijf0931 
(229k) 
ijf0936m 
(244) 
ijf1002m 
(248) 
Chemical formula C12H8O3 C11H6O3 C12H7FO3 C12H7FO3 C48H39IO3P2Pd C30H24O3P•(F6P1)0.98•(I)0.02 
Formula Mass 200.18 186.16 218.18 218.18 959.03 608.43 
Crystal system Triclinic Monoclinic Triclinic Triclinic Monoclinic Triclinic 
a/Å 7.1467(5) 11.1190(16) 3.7437(3) 3.7597(2) 10.2109(5) 7.8107(8) 
b/Å 7.3546(5) 8.2091(12) 6.3700(7) 6.1644(4) 11.8937(6) 13.2530(14) 
c/Å 9.3252(6) 18.856(3) 19.0219(19) 19.6660(11) 34.1332(17) 14.2579(15) 
α/° 69.7600(10) 90.00 91.665(9) 92.543(5) 90.00 97.040(2) 
β/° 81.8920(10) 105.787(2) 90.858(7) 90.715(5) 93.0340(10) 104.389(2) 
γ/° 75.2200(10) 90.00 93.699(8) 90.125(5) 90.00 104.932(2) 
Unit cell volume/Å3 443.91(5) 1656.2(4) 452.42(8) 455.30(5) 4139.5(4) 1353.6(2) 
Temperature/K 120(2) 110(2) 120(2) 120(2) 110(2) 110(2) 
Space group P1¯  C2/c P1¯  P1¯  P2(1)/n P1¯  
No. of formula units per unit cell, Z 2 8 2 2 4 2 
No. of reflections measured 6084 8041 7806 4447 55989 13874 
No. of independent reflections 2211 2057 1688 1706 10290 6661 
Rint 0.0124 0.0175 0.0390 0.0286 0.0494 0.0235 
Final R1 values (I > 2σ(I)) 0.0352 0.0373 0.0480 0.0477 0.0330 0.0490 
Final wR(F2) values (I > 2σ(I)) 0.1005 0.0970 0.1249 0.1335 0.0684 0.1227 
Final R1 values (all data) 0.0366 0.0443 0.0574 0.0514 0.0456 0.0719 
Final wR(F2) values (all data) 0.1023 0.1024 0.1316 0.1382 0.0730 0.1367 
CCDC number 764708 764709 773153 773154 764710 764711 
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ABSTRACT
trans-PdBr(N-Succ)(PPh3)2 (1) is a universally effective precatalyst for Suzuki−Miyaura cross-couplings of benzylic halides with aryl- or
heteroarylboronic acids. Substituted aryl halides and halogenated cyclic enones can be cross-coupled with aryl- or vinylboronic acids in
excellent yields. Catalyst recycling is also demonstrated.
Pd0-catalyzed C-C bond-forming processes have attracted
considerable attention in many applied research fields,
including target-directed synthesis.1,2 Significant effort has
been placed on the development of new catalyst systems for
a diverse array of coupling partners, particularly aryl
components. The majority of new catalysts possess an
electron-rich donor ligand, e.g., X-Phos,3 or an N-heterocyclic
carbene ligand,4 including the excellent PEPPSI catalysts,5
or utilize palladacycles.6 While such catalysts are extremely
versatile for many substrates, especially aryl/heteroaryl
chlorides and alkyl halides, the coupling of benzylic halides
with organoboronic acids has been little studied7 and has
unexplored potential.8 Their generic use in Suzuki-Miyaura
cross-couplings, to give diarylmethanes, is relatively rare,
particularly compared to aryl halides. In the 1990s, it was
reported that successful benzylic halide couplings were reliant
on the use of excess organoboronic acid (1.5-2 equiv).9
Molander and co-workers10 recently developed a valuable
synthetic protocol using potassium organotrifluoroborates as
the nucleophilic boron coupling partner. The precatalyst,
PdCl2(dppf)âCH2Cl2 (2 mol %), exhibited the highest cata-
lytic performance (S-Phos and X-Phos, more activated
(1) Metal-catalyzed Cross-coupling Reactions, 2nd ed.; de Meijere, A.,
Diederich, F., Eds.; Wiley-VCH: New York, 2004.
(2) Transition Metals for Organic Synthesis, 2nd ed.; Beller, M., Bolm,
C., Eds.; Wiley-VCH: Weinheim, 2004; Vol. 1.
(3) Nguyen, H.; Huang, X.; Buchwald, S. L. J. Am. Chem. Soc. 2003,
125, 11818 and references cited therein.
(4) Zapf, A.; Beller, M. Chem. Commun. 2005, 431.
(5) O’Brien, C. J.; Kantchev, E. A. B.; Hadei, N.; Valente, C.; Chass,
G. A.; Nasielski, J. C.; Lough, A.; Hopkinson, A. C.; Organ, M. G. Chem.-
Eur. J. 2006, 12, 4743, and references cited therein.
(6) Bedford, R. B. Chem. Commun. 2003, 1787.
(7) For use of palladacycles, with n-Bu4NBr as a stoichiometric additive,
in reactions of benzylic halides and arylboronic acids, see: (a) Botella, L.;
Na´jera, C. J. Organomet. Chem. 2002, 663, 46. (b) Alonso, D. A.; Na´jera,
C.; Pacheco, M. C. J. Org. Chem. 2002, 67, 5588.
(8) Two other approaches to diarylmethanes have been reported. See:
(a) Vanier, C.; Lorge´, F.; Wagner, A.; Mioskowski, C. Angew. Chem., Int.
Ed. 2000, 39, 1679. (b) Nakao, Y.; Ebata, S.; Chen, J.; Imanaka, H.; Hiyama,
T. Chem. Lett. 2007, 36, 606. For cross-coupling of an in situ generated
organoborane with a substituted benzyl chloride, see: Maddaford, S. P.;
Keay, B. A. J. Org. Chem. 1994, 59, 6501.
(9) (a) Nobre, S. M.; Monteiro, A. L. Tetrahedron Lett. 2004, 45, 8225.
(b) Chahen, L.; Doucet, H.; Santelli, M. Synlett 2003, 11, 1668. (c)
Chodhury, S.; Georghiou, P. Tetrahedron Lett. 1999, 40, 7599.
(10) Molander, G. A.; Elia, M. D. J. Org. Chem. 2006, 71, 9198.
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ligands, were not as good for this specific transformation);
a THF/H2O solvent mixture and Cs2CO3 (3 equiv) base were
preferred. Kuwano and Yokogi reported that benzylic
acetates can be used in Suzuki-Miyaura cross-couplings
using a catalyst system composed of DPEphos-[Pd(Ł3-
C3H5)Cl]2.11 Given the considerable interest in diarylmethanes
in medicinal chemistry12 and in view of the efficiency of
the PdII complex PdBr(N-Succ)(PPh3)2 (1) (Sigma-Aldrich;
Cat. No. 643742) in Stille cross-couplings of allylic and
benzylic halides with organostannanes, we envisaged that
efficient Suzuki-Miyaura cross-couplings of benzylic sub-
strates13 could be achieved using this simple Pd source.14
PPh3 is a strong enough activating ligand for benzylic
substrates. The imidate anion15 is also likely to play an
important role in the global catalyst efficacy. Our findings
using precatalyst 116 in Suzuki-Miyaura cross-couplings of
benzylic halides with organoboronic acids are thus reported
herein. Other tricky cross-couplings are presented, in addition
to a valuable recycling protocol.
The initial benchmark was the reaction of substituted
benzylic halides with an equivalent amount of substituted
arylboronic acids using 1 mol % of 1, in a mixture of 2 M
Na2CO3 and THF (1:2, v/v) at 60 °C (Scheme 1). Under
these simple conditions, a library of cross-coupled products
could be formed efficiently. For example, benzyl bromide
effectively reacted with phenylboronic acid to give diphe-
nylmethane 2 in 88% yield after 2 h. The catalyst loading
may be lowered to 0.01 mol %, which after 20 h gave an
81% yield (turnover number of 8100). The incorporation of
substituents onto the aryl group of the boronic acid (Z )
4-OMe, 4-F, and 3,5-F) was also possible, giving high yields
of the corresponding cross-coupled products (3-5, respec-
tively). Where the yield dropped slightly for 3, it could be
improved by heating to 80 °C. Benzyl chlorides can also be
used (at 80 °C). 3-Nitrobenzyl bromide reacts with various
organoboronic acids to give cross-coupled products in very
good yields (Z ) H, 4-F, and 4-OMe, 6-8). In a reaction
with PhB(OH)2, the catalyst loading was once again lowered
to 0.01 mol % (>99% conversion in 20 h; TON ) 10 000),
exemplifying the stability and longevity of the catalyst
system.17
Heteroarylboronic acids are also coupled effectively with
benzylic halides (Scheme 2). For example, thiophene-2-
boronic acid couples with BnBr to give 9 in 91% yield. Other
thiopheneboronic acids (Z ) 5-Cl, 5-acetyl) participate well
in these reactions affording 10 and 11 in 80% yields for
both BnBr and BnCl. For 5-formylthiophene-2-boronic acid,
a small amount of protodeborylation was observed (10%).
Thiophene-3-boronic acid reacts equally well with BnBr and
BnCl to give 13 in 93% and 91% yields, respectively.
Coupling of furan-2-boronic acid18 with BnBr and 3-meth-
oxybenzyl bromide was possible, giving the coupled products
14 and 15 in excellent yields (94% and >99%, respectively).
Organotrifluoroborates19 can be used as replacements for the
organoboronic acid coupling components. However, under
our reaction conditions, there is no real advantage over
related organoboronic acids in terms of yields and reaction
times.
(11) Kuwano, R.; Yokogi, M. Chem. Commun. 2005, 5899.
(12) (a) McPhail, K. L.; Rivett, D. E. A.; Lack, D. E.; Davies-Coleman,
M. T. Tetrahedron 2000, 56, 9391. (b) Long, Y.-Q.; Jiang, X.-H.; Dayam,
R.; Sachez, T.; Shoemaker, R.; Sei, S.; Neamati, N. J. Med. Chem. 2004,
47, 2561.
(13) Benzylic carbonates have been employed in Suzuki-Miyaura cross-
couplings. See: Kuwano, R.; Yokogi, M. Org. Lett. 2005, 7, 945.
(14) (a) Crawforth, C. M.; Burling, S.; Fairlamb, I. J. S.; Taylor, R. J.
K.; Whitwood, A. C. Chem. Commun. 2003, 2194. (b) Crawforth, C. M.;
Fairlamb, I. J. S.; Taylor, R. J. K. Tetrahedron Lett. 2004, 45, 461. (c)
Burling, S.; Crawforth, C. M.; Fairlamb, I. J. S.; Kapdi, A. R.; Taylor, R.
J. K.; Whitwood, A. C. Tetrahedron 2005, 61, 9736. Note that cis-1 was
used in these studies. The commerical source of PdBr(N-Succ)(PPh3)2 has
a trans-geometry. This material was used in all of the examples presented
in this paper.
(15) (a) Fairlamb, I. J. S.; Kapdi, A. R.; Lynam, J. M.; Taylor, R. J. K.;
Whitwood, A. C. Tetrahedron 2004, 60, 5711. (b) Chaignon, N. M.;
Fairlamb, I. J. S.; Kapdi, A. R.; Taylor, R. J. K.; Whitwood, A. C. J. Mol.
Catal. A: Chem. 2004, 219, 191. (c) Serrano, J. L.; Fairlamb, I. J. S.;
Sa´nchez, G.; Garcı´a, L.; Pe´rez, J.; Vives, J.; Lo´pez, G.; Crawforth, C. M.;
Taylor, R. J. K. Eur. J. Inorg. Chem. 2004, 2706. (d) Crawforth, C. M.;
Fairlamb, I. J. S.; Kapdi, A. R.; Serrano, J. L.; Taylor, R. J. K.; Sanchez,
G. AdV. Synth. Catal. 2006, 348, 405. (e) Young, G. L.; Smith, S. A.; Taylor,
R. J. K. Tetrahedron Lett. 2004, 45, 3797. (f) Fairlamb, I. J. S.; Taylor, R.
J. K.; Serrano, J. L.; Sanchez, G. New J. Chem. 2006, 30, 1685.
(16) In ref 15a, we reported that Pd(N-Succ)2(PPh3)2 is an effective
precatalyst for Suzuki-Miyaura cross-couplings of aryl halides with
arylboronic acids. The coupling of 4-nitrobromobenzene with phenylboronic
acid was tested with cis-1 as the precatalyst in this paper. For this specific
example, cis-1 was less effective than Pd(N-Succ)2(PPh3)2. Since this report,
it has emerged that couplings of this aryl halide, and related compounds,
can be complicated by electron-transfer processes, making it a poor
benchmark substrate for screening catalysts/precatalysts.
(17) For selected examples given in Schemes 1 and 2, Pd(N-Succ)2(PPh3)2
has been tested (see Supporting Information). Precatalyst 1 compares well
with Pd(N-Succ)2(PPh3)2; it is clear that both are useful precatalysts for
coupling benzylic halide components in this reaction.
(18) Commercial sources of furan-2-boronic acid and thiophene-2-boronic
acid were found to degrade at 25 °C in the presence of moisture.
(19) Molander, G. A.; Figueroa, R. Aldrichimica Acta 2005, 38, 49.
Scheme 1. Cross-Coupling of Benzyl Halides and Arylboronic
Acids (Isolated Yields Given)c
a Using 0.01 mol % of 1, 81% (20 h). b Using 0.01 mol % of
1, >99% (20 h). cAll BnCl couplings were run at 80 °C.
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In contrast to benzylic halides, allylic halides do not react
so readily with organoboronic acids under the standard
reaction conditions.20 Only where an activated arylboronic
acid is used was any coupled product detected (see Sup-
porting Information). Interestingly, E-1,4-dibromo-but-2-ene
can be used as an oxidant in homocoupling reactions of the
organoboronic acids affording biaryls in high yield (Scheme
3). For example, PhB(OH)2 and 4-methoxyphenylboronic
acid gave homocoupled products 16 and 17 in 88% and 87%
yields, respectively. Thiophene-2-boronic acid homocouples
more effectively, affording 18 in quantitative yield. The
product selectivity and yields compare favorably against
equivalent reactions using air as the oxidant.21
In view of the versatility of 1 with benzylic substrates, its
reactivity toward awkward aryl coupling partners was also
explored.22 More demanding arylboron reagents (19 and 22),
susceptible to protodeborylation, effectively cross-couple
with aryl bromides (Scheme 4, reactions 1 and 2). For
example, in eq 1, the sterically cumbersome arylboronic acid
19 couples well with two aryl bromides (Y ) C(O)Me, 20
in 84% yield; Z ) OMe, 21 in 72% yield). The less-hindered,
but as electron-releasing, 2,4,5-trimethoxyphenylboronic acid
22 is also a useful nucleophilic coupling partner (eq 2),
revealing the highly oxygenated biaryl product 23 (X-ray
structure determined). Furthermore, both 2-iodocyclopent-
2-enone and 2-iodocyclohex-2-enone react with 4-methox-
yphenylboronic acid to give 24 and 25 in 94% and 87%
yields, respectively (eq 3). Finally, Z-prop-1-enylboronic acid
reacts well with 2-iodocyclohex-2-enone to give 26 in 91%
yield, providing a useful synthon for further manipulation.
Catalyst recycling has been evaluated using a procedure
modified from that originally reported by Monteiro and co-
workers for Pd(OAc)2/PPh323 and used by our group with
palladacycles,24 using a poly(ethylene oxide) (PEO) solid
(20) For Suzuki-Miyaura cross-couplings using allylic halides, see: (a)
Miyaura, N.; Suzuki, A. Chem. ReV. 1995, 95, 2457. (b) Suzuki, A. J.
Organomet. Chem. 1998, 576, 147, and references cited therein.
(21) For use of O2 (air) as an oxidant in homocoupling of organoboronic
acids, see: (a) Smith, C. A.; Campi, E. M.; Jackson, R.; Marcuccio, S.;
Naeslund, C. G. M.; Deacon, G. B. Synlett 1997, 131. (b) Wong, M. S.;
Zhang, X. L. Tetrahedron Lett. 2001, 42, 4087. (c) Adamo, C.; Amatore,
C.; Ciofini, I.; Jutand, A.; Lakmini, H. J. Am. Chem. Soc. 2006, 128, 6829.
(22) Many monosubstituted aryl bromides and arylboronic acids ef-
fectively cross couple in good yields using the generic reaction conditions.
Scheme 2. Heteroaryl Couplings (Isolated Yields Given)
a 1.5 equiv of the organoboronic acid required.
Scheme 3. Facile Homocoupling Using
E-1,4-Dibromo-but-2-ene as the Oxidant (Isolated Yields Given)
Scheme 4. Other Cross-Coupling Reactions (Isolated Yields
Given)
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support25 in methanol. At the end of the reaction, the product
is extracted into a nonpolar phase, with the Pd catalyst
remaining in the polar phase. The polar phase is then
recharged with new reactants, allowing the Pd source to be
reused (Scheme 5).
For example, coupling of 4-methoxyphenyl bromide with
PhB(OH)2 leads to good yields of 27, in short reaction times,
over several runs (reaction 1). No appreciable loss of catalytic
activity is seen over four runs for an activated aryl substrate
(to give 28, reaction 2). For BnBr and PhB(OH)2 cross-
coupling, to give 2, recycling is possible, but the conversions
slowly deteriorate over three runs (reaction 3). However, the
yields are consistently higher using 1 than for PdBr2(PPh3)2
(reaction 4). The recycling study demonstrates that catalyst
stability and longevity are assisted by the succinimidate anion
in 1.
In summary, 1 is shown to be a universal precatalyst for
the Suzuki-Miyaura cross-coupling of benzylic bromides
with aryl and heteroarylboronic acids. For the examples
tested, catalyst loading can be significantly reduced (from 1
mol % to 0.01 mol %), allowing high TONs to be attained.
The synthetic protocol reported in this paper complements
the report by Molander and co-workers.10 For the examples
listed here, lower palladium loadings may be employed using
the inexpensive base, Na2CO3. Moreover, the ratio of benzyl
halide to organoboronic acid is 1:1 (in the majority of cases),
improving substantially on previous protocols using excess
organoboronic acid.9 Also, 1 is an effective but simple
precatalyst for aryl cross-couplings and offers good catalyst
recyclability on a PEO solid support. Mechanistic studies
on cross-coupling processes mediated by 1, and related
precatalysts, will be reported in due course.
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(23) Nobre, S. M.; Wolke, S. I.; da Rosa, R. G.; Monteiro, A. L.
Tetrahedron Lett. 2004, 45, 6527. PEO with a molecular weight of 100 000
was employed in this study.
(24) Fairlamb, I. J. S.; Kapdi, A. R.; Lee, A. F.; Sa´nchez, G.; Lo´pez,
G.; Serrano, J. L.; Garcı´a, L.; Pe´rez, J.; Pe´rez, E. Dalton Trans. 2004, 3970.
(25) PEO acts as an organic stabilizer for in situ formed palladium
colloids/nanoparticles (formed by degradation of the palladium(II) precata-
lyst), produced by aggregation of palladium(0).
Scheme 5. Catalyst Recycling (Conversions by GC)
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A new synthetic methodology for the catalytic C-H functionalisation of 2-pyrones is described 
which proceeds regioselectively at the C3 position, mirroring the observed regioselectivity in 6pi-
electocyclisation / oxidative aromatisation reactions of related compounds.  Insight into the 
reaction mechanism is provided, with support for a neutral palladium(II) pathway.  Cationic 10 
palladium(II) complexes possessing 2-pyrones are unstable and readily undergo PdII→P transfer at 
ambient temperature resulting in phosphonium salt formation (and Pd0Ln species).   
Introduction 
Functionalised 2-pyrones (2H-pyran-2-ones) have attracted 
considerable interest as medicinal agents, natural products, 15 
fluorescent derivatives, and synthetic intermediates.1 Classical 
cross-coupling reactions (e.g. Negishi,2 Stille3 and Suzuki-
Miyaura4 and others5) provide convenient access to these 
targets.  However, there is strict requirement for the 2-pyrone 
to be appropriately prefunctionalised, either as the 20 
organometallic ‘nucleophilic’ component or the 
halide/pseudohalide ‘electrophilic’ component.  It has been 
argued6 that a more efficient process would involve the union 
of two reaction components possessing C-H and C-X bonds, 
respectively. For several heteroaromatic compounds, this has 25 
been possible, and indeed some very efficient methods have 
been developed.7  However, surprisingly there are no reported 
catalytic methods involving the C-H functionalisation of 2-
pyrones.8  We are engaged in the development of innovative 
synthetic methods geared towards 2-pyrones and their metal 30 
complexes.9  We report herein the intramolecular Pd-catalysed 
C-H functionalisation of 2-pyrones, which is regioselective. 
Results and Discussion 
During synthetic studies toward phacelocarpus pyrone A10 we 
were interested in the Suzuki-Miyaura cross-coupling of 1 35 
with allylborane reagents 2a-b to give 3 using trans-Pd(Br)N-
Succ(PPh3)2 as the catalytic Pd source (Scheme 1), a 
precatalyst that has been previously developed by our research 
groups for use in Stille and Suzuki cross-couplings.11 
 40 
 
 
Scheme 1  Suzuki-Miyaura cross-couplings of 1. 
 
As expected the reaction of 1 with pinacol allylboronate 2a 45 
gave 3 in 40% yield.  However, we were very surprised to 
observe the regioselective formation of cyclised product 4 was 
also found to occur.  An otherwise identical reaction of 
potassium allyltrifluoroborate 2b gave 4 exclusively in 47% 
yield.  The absence of 3 in this reaction is attributed to a 50 
slower transmetallation step (2a is more reactive than 2b 
under the anhydrous reaction conditions used).  The trans-
Pd(Br)N-Succ(PPh3)2 is likely acting as a precatalyst under 
the reaction conditions (PdII→Pd0 mediated by 2a-b and/or 
Cs2CO3).  Further support for a Pd0-mediated reaction was 55 
gained by substituting trans-Pd(Br)N-Succ(PPh3)2 with an 
active Pd0 catalyst system {Pd2(dba-4-OMe)3/PPh3 (Pd:P = 
1:2)}, in the absence of 2a-b, which gave 4 in 48% yield.12    
 Additional experiments on model substrate 5a to give 6a, a 
compound which is of medicinal and synthetic interest,13 60 
highlight that trans-Pd(Br)N-Succ(PPh3)2 is a precatalyst, 
requiring a sub-stoichiometric amount of 2b (relative to 5a) to 
facilitate PdII reduction (Table 1; compare entries 1-3).  The 
best yield for cyclised product 6a using allylBF3K was 69% 
yield (entry 3).  Other additives such as AgBF4 or pivalic acid 65 
(PivOH) proved ineffective (entries 4 and 5). For the latter, a 
lower yield was obtainined with Pd(OAc)2 as the catalytic 
source of Pd (entry 6). Using Pd2(dba)3/PPh3 as the catalyst 
system with no additive gave 6a in 74% yield (entry 7).  
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Table 1 Other reaction conditions screened in the regioselective C-H 
functionalisation  of 5a.a  
 
 
Entry Catalyst Additive Yield / %b 
    
1 trans-Pd(Br)N-Succ(PPh3)2 AllylBPin (2 eq.) 49c 
2 " AllylBF3K (1 eq.) 57 
3 " AllylBF3K  (0.1 
eq.) 69 
4 " AgBF4 (1 eq.) 6† 
5 " PivOH (0.3 eq.) 41 
6 Pd(OAc)2 PivOH (0.3 eq.) 31 
7 Pd2(dba)3 PPh3 (4 mol%) 74 
8 Pd2(dba-4-OMe)3 " 79 
9 e " " 77 
10 " PPh3 (4 mol%)/ PivOH (0.3 eq.) 45 
a Other reaction conditions: THF, 70 ºC, 18 h (unless other stated).  5 
b Isolated yield following flash chromatography on silica gel. 
c A 42% yield of the Suzuki product is also observed. 
d
 Reaction left for 72 h in the dark.  
e Using K3PO4 as base instead of Cs2CO3. 
 10 
With the {Pd2(dba-4-OMe)3/PPh3} system a 79% yield was 
attained (entry 8).  This same reaction can be conducted using 
K3PO4 instead of Cs2CO3, giving a 77% yield of 6a (entry 9).  
Finally, addition of pivalic acid to the best catalyst system, 
resulted in a lowering of the reaction yield of 6a (entry 10).  15 
The regioselectivity (for C3-H) for products 4 and 6a was 
confirmed by 1H NMR spectroscopy (C5-H exhibiting a 4JHH 
coupling with the C6 methyl group).  However, conclusive 
evidence for the structure of 6a was gained by a single crystal X-
ray diffraction study (Fig. 1).  20 
 
 
Figure 1  Structure of 6a (X-ray diffraction; arbitrary numbering used). 
 
Control experiments confirm that catalytic Pd and Cs2CO3 base is 25 
required for C-H functionalisation.  In principle, the C6-methyl 
group could be playing a role, as previous studies14 have shown 
that the C6-methyl group and C3-H share similar acidities.  
Therefore we have evaluated three different 2-pyrones in addition 
to 5a (Table 1).  Subjecting a 2-pyrone without a C6-methyl 30 
group (5b) to the best conditions (entry 8, Table 1) gave 
compound 6b regioselectively (confirmed by X-ray studies, see 
ESI) in 74% yield (entry 2), comparing well with the yield for 6a 
(entry 1).  Other C6-substituted 2-pyrones 5c and 5d gave 6c and 
6d, respectively in 59% and 68% yields (entries 3 and 4).   35 
Table 2 On the importance of the C6-substituent.  
 
 
Entry R Yield / %a 
   
1 Me (6a) 79 
2 H (6b) 74 
3 Ph (6c) 59 
4 CH2CH2Ph (6d) 68 
a
 Isolated yield following flash chromatography on silica gel. 
 40 
These findings indicate that the C6-methyl could be affecting 
these reactions, but it is not essential for the reaction to take 
place. 
Having identified a mild set of reaction conditions and tested 
different C6-substituents, we next sought to understand how the 45 
reaction was affected by aromatic substituents.  The synthesis of 
the substrates for these reactions was generally achieved in two 
steps by a K2CO3-mediated reaction of the appropriately 
substituted 2-bromophenol with 4-bromo-6-methyl-2-pyrone to 
give 7a-j (see ESI for complete details).15  Due to the availability 50 
of 2-halophenols, we found it more convenient to prepare the 
bromides.  Pleasingly, the direct C-H functionalisation is feasible 
using bromide-containing substrates (7a-j → 8a-j, Table 3).  
Substrates possessing methoxy-, methyl- and t-butyl-substituents 
effectively participate well in these reactions (7a-f, entries 1-6).  55 
The yield is modest for 8g, possessing a 4-phenyl group (entry 7).  
Perhaps surprisingly, the presence of fluoro-substituents in 7h-i 
to give 8h-i, respectively, also leads to a lowering of the reaction 
yield (entries 8-9).‡  
The most dramatic effect was seen with a 4-trifluoromethyl-60 
substituent in 7j (entry 10) where the yield for 8j drops off 
significantly.  The following relative order is therefore 
established based on the yields16 of the reaction (H ≈ Me ≥ t-Bu > 
4- or 5-OMe > 4-Ph > 4-F ≈ 5-F > 4-CF3.  The issue for the 
electron-withdrawing substituents appears to be related to 2-65 
pyrone decomposition under the reaction conditions.  The 
‘arylalkoxide’ leaving group ability, from the initial oxidative 
addition intermediate (vide infra), could account for this outcome.  
The low yield for 8j is supported by a further example, where 
a substrate possessing an additional 2-pyrone moiety gives a low 70 
product yield (7k→8k, Scheme 3).  This 2-pyrone ‘substituent’ is 
electron-withdrawing and unlikely to interfere in the cyclisation. 
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Table 3 Aromatic substituent effects. 
 
 
Entry R Yield / %a 
1 4-OMe  (8a) 65 
 
2 5-OMe (8b) 67 
 
3 4-Me  (8c) 73 
 
4 4,6-(Me)2 (8d) 79 
 
5 4-t-Bu (8e) 71 
 
6 4,6-(t-Bu)2 (8f) 71 
 
7 4-Ph (8g) 44 
 
8 4-F (8h)b 30c 
 
9 5-F (8i)b 
 
24 
10 4-CF3 (8j) 11 
a
 Isolated yield following chromatography on silica gel. 
b
 Structures supported by X-ray diffraction analysis (See ESI).  5 
c
 A 41% yield was obtained using 5 mol% Pd. 
 
In a separate example, we were able to show that a coumarin-
derived substrate 7l cyclised under the reaction conditions to give 
benzofuro[3,2-c]coumarin 8l, which is better known as as the 10 
natural compound, coumestan (Scheme 2).17  
 
 
 
Scheme 2  Other substrates evaluated under the general reaction 15 
conditions (* yield is based on recovered 7l, after chromatography on 
silica gel).  
 
Stoichiometric studies.  To gain insight into the reaction 
mechanism a series of stoichiometric experiments were 20 
conducted.  The complex, [Pd0(η2-dba-4-OMe)(PPh3)2] 9, 
presumed to be the initial Pd0 species formed in the reaction, was 
prepared and characterized in situ by the reaction of Pd2(dba-4-
OMe)3 with PPh3 (ratio of Pd:P = 1:2) in d8-THF at 25 ºC 
(Scheme 3).   25 
 
 
Scheme 3  Stoichiometric NMR spectroscopic experiments. 
 
Two broad phosphorus signals corresponding to exchanging PPh3 30 
ligands in 9 were observed (δ 26.18 (s) and 24.52 (s), 283 
MHz).18  Addition of 2 equivalents of 5a to 9 (in a dry box at 22 
ºC) resulted in quantitative conversion into trans-[Pd{C6H4O-2-
(C6H5O2)}I(PPh3)2] 10 (the oxidative addition product).  The 31P 
NMR spectrum of 10 in d8-THF exhibits a singlet at δ 22.44.  The 35 
1H NMR spectrum (700 MHz) of 10 exhibits significant upfield 
chemical shifts for the 2-pyrone C3-H and C5-H protons when 
compared to 5a (in both CD2Cl2 and d8-THF).  By the same 
method (vide supra) [Pd0(η2-dba-4-OMe){P(C6D6)3}2] and 10-
{P(C6D5)3}2 were prepared and these showed that the upfield 40 
proton signals were associated with the 2-pyrone group 
(confirmed also by 2D 1H-1H COSY and 1H-31P HMQC 
experiments; see Supporting Information).  Crystals of 10 (from 
CD2Cl2) were analysed by X-ray diffraction (Fig. 2).  The X-ray 
data indicates that the complex exhibits a distorted square planar 45 
trans-geometry (P1-Pd-P2 angle = 169.03(2)º; I-Pd-C angle = 
169.21(7)º).  Whilst this type of distortion has been observed in 
previously reported X-ray diffraction studies involving 
PdII(I)R(PPh3)2 complexes,19 the angles P1-Pd-P2 (in the range 
172.39-174.41º) and I-Pd-C (in the range 166.03-176.50º) are 50 
significantly different.20  The finding that the P1-Pd-P2 and I-Pd-
C angles in 10 are near identical is unique. 
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Figure 2  Structure of trans-[Pd{C6H4O-2-(C6H5O2)}I(PPh3)2] 10 by X-
ray diffraction; arbitrary numbering used.  Selected bond lengths (Å): 
C(37)-Pd(1) 2.014(2), I(1)-Pd(1) 2.6641(3), P(1)-Pd(1) 2.3157(7), P(2)-
Pd(1) 2.3258(7). 5 
 
Treatment of 10 with Cs2CO3 (3 equiv.) (with 1.5 equiv. of dba-
4-OMe ligand) in d8-THF and heating to 70 ºC for 2 h gave 
product 6a in quantitative conversion (Scheme 4).  No other PdII 
intermediates were observed by NMR spectroscopy (note: the 10 
dba-OMe ligand was consumed under the reaction conditions – 
the -CH=CH- motif was no longer visible by 1H NMR 
spectroscopy, although the exact structure of the degraded dba-
OMe ligand remains unknown. 
The presence of electron-withdrawing groups has a profound 15 
effect on the catalytic reaction.  A further stoichiometric reaction, 
identical to that detailed above with 5a, shows that the reaction 
(oxidative addition) of 7j and [Pd0(η2-dba-4-OMe)(PPh3)2] 9 is a 
reversible process (see experimental section), both in the 
presence and absence of Cs2CO3.  Slow deposition of Pd0 black is 20 
observed.  Catalyst and substrate decomposition is thus an issue 
for substrates possessing electron-withdrawing substituents. 
We postulated cationic PdII species as potential reaction 
intermediates.  Thus, whilst 10 did not react with Ag2CO3 in 
CD2Cl2, the cationic PdII complex 11 was formed quantitatively 25 
(NMR) by reaction of 10 with AgPF6 in CD2Cl2 at ambient 
temperature (Scheme 4).  1H NMR spectra show no evidence of a 
2-pyrone secondary interaction (either a C=C21 or C-H agostic22 
or anagostic23).  Layering a CD2Cl2 solution of 11 with diethyl 
ether (in the dark at 18 ºC) gave crystals suitable for an X-ray 30 
diffraction study (Figure 3).  Rather curiously, it was found that 
the “C6H4O-2-(C6H5O2)” group from 11 had undergone Pd→P 
transfer forming [P{C6H4O-2-(C6H5O2)}Ph3]PF6 12, which was 
accompanied by Pd black formation.  Phosphonium salt 
formation has been observed previously by others, notably by 35 
Heck in early studies on the alkenylation of aryl halides.24 
 
 
 
 40 
Scheme 4  Decomposition of 11; R = {C6H4O-2-(C6H5O2)}. 
 
 
Figure 3  Structure of 12 by X-ray diffraction; arbitrary numbering used.  
Dotted lines show H-bonds between the CH3 and PF6 groups. 45 
 
Proposed mechanism.  The facile decomposition event (11→12) 
obviates a reaction mechanism involving cationic PdII species at 
elevated reaction temperatures.  Therefore based on our findings, 
we propose that the mechanism involves neutral Pd intermediates 50 
(Scheme 6).  There are two clear mechanistic possibilities – a 
Concerted Metallation Deprotonation (CMD) mechanism25 or 
Heck-like mechanism.26  For both, the first committed step is 
oxidative addition of the C-I bond in 5a (as a representative 
substrate) to Pd0 (I) to give II (complex 10).  It is important to 55 
point out that initially formed complex 9 will be in an 
endergonic/unfavourable equilibrium with the more reactive 
Pd0(S)(PPh3)2 species, releasing free dba-4-OMe (not shown in 
this scheme).18  This ligand is almost certainly consumed slowly 
under the reaction conditions, akin to the stoichiometric 60 
experiments detailed above.  Therefore, any controlling effect of 
dba-type ligands12 in this reaction is minimal {Pd2(dba-4-OMe)3 
was only marginally superior to Pd2(dba-H)3 in the catalytic 
reaction of 5a→6a}.   
For the CMD mechanism (catalytic cycle on the left, Scheme 65 
5), one needs to form intermediate IV, setting up reductive 
elimination to regenerate the Pd0 catalyst species and product 6a.  
Whilst it is conceivable that the Cs2CO3 can deprotonate the C3-
proton in 10 intermolecularly, we show here an iodide/carbonate 
metathesis followed by an intramolecular base-assisted CMD 70 
process (via III).  The formation of IV requires the loss of 
CsO(CO)OH (solvent-assisted?).  With 14-electron PdII 
intermediate V formed, reductive elimination to give both I and 
product 6a ought to be facile.  Going against this mechanism is 
the result given in Table 1 (entry 10).  If a CMD mechanism is 75 
operative, then we would anticipate that pivalic acid25a,27 would 
accelerate the step III→IV.  This is not the case. 
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Scheme 5 Possible reaction mechanisms for the C-H functionalisation reaction. 
 
The preferred C3-H over C5-H regioselectivity can be primarily 
explained by the significantly different acidities of these two 5 
positions.   However, one also needs to consider the Pd-C bond 
strengths of both the C3- and C5-products before drawing firm 
conclusions.  Of particular note is the finding that the 
regiochemical outcome mirrors 6pi-electrocyclisation/oxidative 
aromatic reactions of phenylethenyl-2-pyrone derivatives to give 10 
benzo[h]indeno[1,2-f]isochromenes.28  In that chemistry, 
unfavourable 6pi-electrocyclisation at C5-H results in ketene 
generation and 2-pyrone ring-opening. 
 In terms of the Heck-like mechanism (catalytic cycle on the 
right, Scheme 5), loss of PPh3 from II will generate 15 
intermediate VI (which is similar to III).  Migratory insertion 
(carbopalladation) then generates VII.  However, there is an 
apparent problem in the next step to give product 6a and 
“(PPh3)Pd(X)H”.  In the absence of other neighbouring β-
hydrogens, the anti-stereochemical relationship of the 20 
“PdII(X)PPh3” group and C3-H proton is a problem for β-
hydrogen elimination (syn-elimination being preferred).29  We 
believe that it is more likely that VII isomerises to the pi-allyl 
species VIII.30  Intermolecular base-assisted deprotonation 
can then take place at either C3-H or the C6-methyl group.  25 
For the latter, as the 2-pyrone can be considered semi-
aromatic, tautomerisation is facile.  Whilst other Heck-like 
mechanisms may be considered, e.g. involving cationic PdII or 
PdIV species,31a we believe they are ruled out because 
phosphonium salt formation is facile from the cationic 30 
complex derived from 5a (11).  An alternative mechanistic 
possibility is the SEAr type reaction pathway.31c The 
pronounced aromatic substituent effects, particularly the 
deliterous effect of electron-withdrawing groups on the 
aromatic moieties in substrates, 4-F (7h), 5-F (7i) and 4-CF3 35 
(7h), could indicate that positive charge is developed in the 
transition state intermediate(s), where the 4-oxygen would be 
expected to play a key stabilizing role.  However, extensive 
decomposition is observed for these substrates, so firm 
conclusions cannot be drawn.     40 
 Finally, a comment about the reaction solvent, THF.  
Whilst this solvent is sufficiently polar to stabilise charged / 
highly polar intermediates, previous studies32 which support a 
CMD mechanism involve highly polar solvents such as DMF 
or DMA. Furthermore, Cs2CO3 is only sparingly soluble in 45 
THF (0.023 mmols/L at 25 ºC) and its concentration is quasi-
constant and low.33  Finally, under the best conditions for 5a 
→6a (entry 8, Table 1) replacing THF with DMF results in no 
observable product formation.34  
Conclusions 50 
In summary, we have developed the first catalytic C-H 
functionalisation synthetic method for 2-pyrones35 which is 
completely regioselective for the C3 position.  The presence of a 
C6-methyl group could assist reactions of 7a-j.  However, the 
successful cyclisation of 6b-d confirms that the C-H 55 
functionalisation process is not dependent on it.  Our preliminary 
mechanistic studies show that cationic PdII species are unlikely 
intermediates and that characterised neutral PdII complex 10 gives 
organic product 6a quantitatively.  Further studies (both 
experimental and theoretical) to determine the mechanism of this 60 
C-H functionalisation reaction are ongoing in our laboratories. 
Experimental Section 
General details: 
Reagents were purchased from either Sigma Aldrich or Alfa 
Aesar and used directly unless otherwise stated. Solvents were 65 
dried according to standard procedures prior to use and stored 
under nitrogen. Nitrogen gas was oxygen free and dried 
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immediately before use via passage through sodium hydroxide 
pellets and silica. All TLC analysis was performed using 
Merck 5554 aluminium backed silica plates and visualised 
using UV light (254 nm), an aqueous solution of potassium 
permanganate, or an ethanol based solution of p-anisaldehyde. 5 
1H NMR and 13C NMR spectra were recorded on a Jeol 
ECX400 spectrometer operating at 400 and 100 MHz 
respectively, or a Bruker 500 spectrometer operating at 500 
and 126 MHz, respectively. All column chromatography was 
performed using flash silica gel eluting with an appropriate 10 
solvent system.  Preparative details and characterisation data 
for the starting materials detailed in this paper, in addition to 
representative NMR spectra of the cyclisation products, can 
be found in the E.S.I. file. 
General procedure for the direct C-H functionalisation  of 2-15 
pyrones:  
A solution of aryl halide (1 eq.), Cs2CO3 (3 eq.), PPh3 (4 
mol%) and Pd2(dba-4-OMe)3 (2 mol% Pd) in THF (4 
mL/mmol) was stirred under nitrogen at 70 ºC for 18 h. The 
reaction was allowed to cool to ambient temperature and 20 
quenched by water (8 mL per mmol) and ethyl acetate added 
(12 mL per mmol), and the layers separated. The aqueous 
layer was back-extracted with ethyl acetate (2x12mL) and the 
combined organic extracts dried over MgSO4, filtered and 
concentrated in vacuo. The crude products were purified by 25 
flash column chromatography on silica gel (10-30 % EtOAc in 
hexanes). 
 
4-{[(1Z)-1-Ethyl-1,4-pentadienyl]oxy}-6-methyl-2-pyrone (3) 
A solution of 4-{[(Z)-2-bromo-1-ethyl-1-ethenyl]oxy}-6-30 
methyl-2-pyrone (20 mg, 0.077 mmol, 1 eq.), Cs2CO3 (75.3 
mg, 0.231 mmol, 3 eq.), allyl boronic acid pinacol ester (25.9 
mg, 0.154 mmol, 2 eq.) and trans-Pd(Br)N-succ(PPh3)2 (1.2 
mg, 0.0015 mmol, 2 mol%) in THF (1 mL) was stirred under 
nitrogen at 70 °C for 18 hours. The reaction was allowed to 35 
cool to ambient temperature and quenched by addition of 
water (1 mL) and ethyl acetate (2 mL), and the layers 
separated. The aqueous layer was extracted using ethyl acetate 
(3 × 2 mL) and the combined organic extracts dried over 
MgSO4, concentrated in vacuo and purified by flash column 40 
chromatography (10-20 % EtOAc in hexanes) to afford the 
product as a colourless oil (6.8 mg, 40.0%). Rf = 0.42 (20% 
EtOAc in hexanes); 1H-NMR (500 MHz, CDCl3): 5.87 (s, 
1H), 5.73 (ddt, J = 17.0, 10.1, 6.3 Hz, 1H), 5.40 (s, 1H), 5.14 
(t, J = 7.3 Hz, 1H), 5.01 (dd, J = 17.0, 1.2 Hz, 1H), 4.99 (dd, J 45 
= 10.1, 1.2 Hz, 1H), 2.66 (dd, J = 6.3, 7.3 Hz, 2H), 2.23 (s, 
3H), 2.18 (q, J = 7.3 Hz, 2H), 1.06 (t, J = 7.3 Hz, 3H); 13C-
NMR (126 MHz, CDCl3): 168.8, 164.9, 163.1, 151.3, 135.3, 
114.1, 99.8, 95.6, 89.5, 29.4, 25.3, 20.0, 11.1; MS (ESI) m/z 
(rel.%): 243 [MNa+] (28), 221[MH+] (100), 201 (6), 179 (28), 50 
127 (4); HRMS (ESI) calculated for C13H17O3: 221.1172, 
found: 221.1175; IR (neat): 3084, 2975, 2938, 1700, 1643, 
1560, 1448, 1407, 1225, 1177, 1139, 1037, 994, 822 cm-1. 
4-Ethyl-7-methyl-furo[3,2-c]-2-pyrone (4) 
The title compound was prepared according to the General 55 
Procedure, on a 0.108 mmol scale, to afford the product as a 
yellow oil (9.2 mg, 47.9%). Rf = 0.42 (20% EtOAc in 
hexanes); 1H-NMR (500 MHz, CDCl3): 6.43 (q, J = 0.9 Hz, 
1H), 6.36 (t, J = 1.1 Hz, 1H), 2.72 (dq, J = 7.5, 1.1 Hz, 2H), 
2.32 (d, J = 0.9 Hz, 3H), 1.28 (t, J = 7.5 Hz, 3H); 13C-NMR 60 
(126 MHz, CDCl3): 161.0, 160.1, 159.6, 158.8, 115.6, 109.2, 
101.3, 21.3, 20.1, 11.8; MS (ESI) m/z (rel.%): 201 [MNa+] 
(22), 179 [MH+] (100); HRMS (ESI) calculated for C10H11O3: 
179.0703, found: 179.0700; IR (neat): 3099, 2976, 2922, 
1734, 1622, 1593, 1574, 1459, 1381, 1258, 1027, 966, 918, 65 
814, 764 cm-1. 
9-Methyl-benzofuro[3,2-c]-2-pyrone (6a) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford the product as a 
yellow solid (39.6 mg, 79.2%). M.p. 188-190 ºC; 1H-NMR 70 
(400 MHz, CDCl3): 8.01 – 8.06 (m, 1H), 7.52 – 7.58 (m, 1H), 
7.39 – 7.44 (m, 2H), 6.54 (q, J = 0.9 Hz, 1H), 2.43 (d, J = 0.9 
Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.5, 162.9, 159.5, 
154.9, 126.1, 124.9, 122.9, 121.4, 111.5, 103.7, 95.9, 20.6; 
MS (ESI) m/z (rel.%): 223 [MNa+] (16), 201 [MH+] (100); 75 
HRMS (ESI) calculated for C12H9O3: 201.0546, found: 
201.0549; IR (neat): 3101, 2919, 1719, 1614, 1572, 1445, 
1251, 1187, 971, 934, 816, 748 cm-1. 
Benzofuro[3,2-c]-2-pyrone (6b) 
The title compound was prepared according to the General 80 
Procedure, on a 0.25 mmol scale, to afford the product as a 
white solid (34.6 mg, 74.4%). Rf = 0.33 (20% EtOAc in 
hexanes). M.p. 149-150 ºC; 1H-NMR (400 MHz, CDCl3): 8.09 
(m, 1H), 7.65 (d, J = 5.7 Hz, 1H), 7.60 (m, 1H), 7.42 – 7.49 
(m, 2H), 6.81 (d, J = 5.7 Hz, 1H); 13C-NMR (101 MHz, 85 
CDCl3): 162.7, 159.1, 155.0, 151.5, 126.7, 125.1, 122.7, 
121.7, 111.6, 106.5, 98.9; MS (ESI) m/z (rel.%): 209 [MNa+] 
(39), 187 [MH+] (100); HRMS (ESI) calculated for C11H7O3: 
187.0390, found: 187.0389; IR (neat): 3102, 1717, 1607,  
1558, 1448, 1431, 1219, 1171, 1012, 926, 844, 783, 746 cm-1.  90 
9-Phenyl-benzofuro[3,2-c]-2-pyrone (6c) 
The title compound was prepared according to the General 
Procedure, on a 0.13 mmol scale, to afford the product as a 
yellow solid (20.0 mg, 58.8%). 1H-NMR (400 MHz, CDCl3): 
8.09 (m, 1H), 7.93 – 7.98 (m, 2H), 7.60 (m, 1H), 7.49 – 7.53 95 
(m, 3H), 7.43 – 7.47 (m, 2H), 7.18 (s, 1H); 13C-NMR (101 
MHz, CDCl3): 164.4, 160.8, 158.7, 155.3, 131.4, 131.1, 129.1, 
126.4, 125.9, 125.1, 122.9, 121.6, 111.5, 104.7, 93.2; MS 
(ESI) m/z (rel.%): 263 [MH+] (100), 251 (28), 159 (26), 149 
(15); HRMS (ESI) calculated for C17H11O3:263.0703, found: 100 
263.0706; IR (neat): 3090, 2161, 1721, 1560, 1537, 1446, 
1382, 1021, 746, 687 cm-1. 
9-Phenethyl-benzofuro[3,2-c]-2-pyrone (6d) 
The title compound was prepared according to the General 
Procedure, on a 0.071 mmol scale, to afford the product as a 105 
yellow solid (16.3 mg, 68.2%). Rf = 0.58 (20% EtOAc in 
hexanes). M.p. 130-132 ºC 1H-NMR (400 MHz, CDCl3): 8.01 
– 8.08 (m, 1H), 7.51 – 7.58 (m, 1H), 7.38 – 7.45 (m, 2H), 7.27 
– 7.33 (m, 2H), 7.25 – 7.18 (m, 3H), 6.46 (t, J = 0.7 Hz, 1H), 
3.09 (dd, J = 8.5, 6.4 Hz, 2H), 2.94 – 2.99 (m, 2H); 13C-NMR 110 
(101 MHz, CDCl3): 165.2, 164.2, 155.0, 139.7, 128.7, 128.3, 
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126.5, 126.2, 125.0, 122.9, 121.4, 111.5, 104.0, 99.9, 95.9, 
36.3, 33.3; MS (ESI) m/z (rel.%): 313 [MNa+] (44), 291 
[MH+] (100); HRMS (ESI) calculated for C19H15O3: 291.1016, 
found: 291.1011; IR (neat): 3085, 3057, 2921, 1727, 1612, 
1571, 1447, 1186, 1029, 970, 937, 817, 750, 701 cm-1. 5 
4-Methoxy-9-methyl-benzofuro[3,2-c]-2-pyrone (8a) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford recovered starting 
material (24 mg, 30.8%) and the product as a yellow solid 
(37.1 mg, 64.5% [93% based on recovery of halo-starting 10 
material]). Rf = 0.31 (20% EtOAc in hexanes); M.p. 155-157 
ºC;  1H-NMR (400 MHz, CDCl3): 7.48 (d, J = 2.6 Hz, 1H), 
7.43 (d, J = 9.0 Hz, 1H), 6.98 (dd, J = 9.0, 2.6 Hz, 1H), 6.51 
(q, J = 0.9 Hz, 1H), 3.90 (s, 3H), 2.42 (d, J = 0.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): 164.9, 162.6, 159.7, 157.5, 15 
149.6, 123.6, 115.1, 112.1, 103.9, 103.2, 96.0, 56.0, 20.6; MS 
(ESI) m/z (rel.%): 253 [MNa+] (45), 231 [MH+] (100); HRMS 
(ESI) calculated for C13H11O4 [MH+]: 231.0652, found: 
231.0651; IR (neat): 3095, 2958, 1728, 1631, 1619 1572, 
1461, 1436, 1274, 1226, 1177, 1023, 965, 937, 848, 813, 786, 20 
771 cm-1. 
5-Methoxy-9-methyl-benzofuro[3,2-c]-2-pyrone (8b) 
The title compound was prepared according to the General 
Procedure, on a 0.5 mmol scale, to afford the product as a 
yellow solid (76.7 mg, 66.7%). Rf = 0.29 (20% EtOAc in 25 
hexanes). M.p. 172-173 ºC; 1H-NMR (400 MHz, CDCl3): 7.88 
(d, J = 8.6 Hz, 1H), 7.07 (d, J = 2.2 Hz, 1H), 7.01 (dd, J = 8.6, 
2.2 Hz, 1H), 6.51 (q, J = 0.9, 1H), 3.88 (s, 3H), 2.41 (d, J = 
0.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 164.0, 161.7, 
159.7, 159.2, 156.1, 121.5, 115.9, 113.0, 103.8, 96.7, 95.9, 30 
55.8, 20.5; MS (ESI) m/z (rel.%): 253 [MNa+] (100), 231 
[MH+] (87); HRMS (ESI) calculated for C13H10NaO4 [MNa+]: 
253.0471, found: 253.0469; IR (neat): 3095, 1715, 1569, 
1496, 1270, 1137, 1110, 1036, 973, 939, 834, 801 cm-1. 
4,9-Dimethyl-benzofuro[3,2-c]-2-pyrone (8c) 35 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford the product as a 
yellow solid (38.4 mg, 71.8%). 1H-NMR (400 MHz, CDCl3): 
7.82 (dq, J = 1.9, 0.7 Hz, 1H), 7.41 (d, J = 8.4, 1H), 7.20 
(ddq, J = 8.4, 1.9, 0.7 Hz, 1H), 6.51 (q, J = 0.9, 1H), 2.47 40 
(app. t, J = 0.7 Hz, 3H), 2.41 (d, J = 0.9 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3): 164.6, 162.6, 159.7, 153.3, 134.8, 127.2, 
122.8, 121.2, 110.9, 103.5, 96.0, 21.3, 20.6; MS (ESI) m/z 
(rel.%): 237 [MNa+] (40), 215 [MH+] (100); HRMS (ESI) 
calculated for C13H11O3 [MH+]: 215.0703, found: 215.0706; 45 
IR (neat): 3088, 2921, 1727, 1615, 1571, 1450, 1190, 1037, 
971, 941, 821, 795, 773 cm-1. 
4,6,9-Trimethyl-benzofuro[3,2-c]-2-pyrone (8d) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford the product as a 50 
yellow solid (44.8 mg, 78.6%). Rf = 0.43 (20% EtOAc in 
hexanes); M.p. 149-150 ºC; 1H-NMR (400 MHz, CDCl3): 7.65 
(s, 1H), 7.02 (s, 1H), 6.52 (s, 1H), 2.50 (s, 3H), 2.44 (s, 3H), 
2.41 (s, 3H); 13C-NMR (101 MHz, CDCl3): 164.3, 162.4, 
159.8, 152.4, 134.8, 128.5, 122.4, 121.1, 118.6, 103.8, 96.0, 55 
21.2, 20.6, 14.9; MS (ESI) m/z (rel.%): 251 [MNa+] (16), 229 
[MH+] (100); HRMS (ESI) calculated for C14H13O3: 229.0859, 
found: 229.0858; IR (neat): 3097, 2924, 1731, 1621, 1572, 
1446, 1287, 1222, 1180, 1033, 970, 939, 842, 798, 736 cm-1. 
4-tert-Butyl-9-methyl-benzofuro[3,2-c]-2-pyrone (8e) 60 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford the product as a 
yellow solid (44.9 mg, 70.2%). Rf = 0.50 (20% EtOAc in 
hexanes); M.p. 119-120 ºC; 1H-NMR (400 MHz, CDCl3): 8.03 
(app. t, J = 1.3 Hz, 1H), 7.46 (app. d, J = 1.3 Hz, 2H), 6.52 (q, 65 
J = 0.8 Hz, 1H), 2.42 (d, J = 0.8 Hz, 3H), 1.40 (s, 9H); 13C-
NMR (101 MHz, CDCl3): 164.7, 162.6, 159.7, 153.1, 148.4, 
123.9, 122.6, 117.8, 110.7, 103.8, 96.0, 35.0, 31.8, 20.6; MS 
(ESI) m/z (rel.%): 279 [MNa+] (6), 257 [MH+] (100); HRMS 
(ESI) calculated for C16H17O3: 257.1172, found: 257.1176; IR 70 
(neat): 2964, 1732, 1626, 1570, 1459, 1192, 1030, 968, 932, 
889, 824, 787 cm-1. 
4,6-Di-tert-butyl-9-methyl-benzofuro[3,2-c]-2-pyrone (8f) 
The title compound was prepared according to the General 
Procedure, on a 0.16 mmol scale, to afford the product as a 75 
yellow solid (35.4 mg, 70.9%). Rf = 0.64 (20% EtOAc in 
hexanes); M.p. 144-147 ºC; 1H-NMR (400 MHz, CDCl3): 7.90 
(d, J = 2.0 Hz, 1H), 7.37 (d, J = 2.0 Hz, 1H), 6.56 (q, J = 0.9 
Hz, 1H), 2.42 (d, J = 0.9 Hz, 3H), 1.51 (s, 9H), 1.40 (s, 9H); 
13C-NMR (101 MHz, CDCl3): 163.9, 162.1, 159.8, 151.5, 80 
148.1, 134.1, 123.0, 120.8, 115.6, 103.7, 96.1, 35.1, 34.5, 
31.8, 29.9, 20.6; MS (ESI) m/z (rel.%): 335 [MNa+] (18), 313 
[MH+] (100); HRMS (ESI) calculated for C20H23O3: 313.1798, 
found: 313.1791; IR (neat): 2954, 1737, 1619, 1569, 1365, 
1243, 1226, 1064, 971, 874, 815, 752 cm-1. 85 
4-Phenyl-9-methyl-benzofuro[3,2-c]-2-pyrone (8g) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford recovered starting 
material (19.5 mg, 21.8%) and the product as a yellow solid 
(30.0 mg, 43.5% [55.6% based on recovery of halo-starting 90 
material]). Rf = 0.36 (20% EtOAc in hexanes); M.p. 211-213 
ºC; 1H-NMR (400 MHz, CDCl3): 8.24 (dd, J = 1.9, 0.7 Hz, 
1H), 7.68 – 7.65 (m, 2H), 7.65 (dd, J = 8.6, 1.9 Hz, 1H), 7.60 
(dd, J = 8.6, 0.7 Hz, 1H), 7.44 – 7.49 (m, 2H), 7.38 (m, 1H), 
6.56 (q, J = 0.8 Hz, 1H), 2.44 (d, J = 0.8 Hz, 3H); 13C-NMR 95 
(101 MHz, CDCl3): 165.0, 163.1, 154.5, 140.6, 138.7, 128.8, 
127.5, 127.4, 125.6, 123.5, 119.7, 111.6, 103.8, 99.9, 95.9, 
20.7; MS (ESI) m/z (rel.%): 299 [MNa+] (8), 277 [MH+] 
(100); HRMS (ESI) calculated for C18H13O3: 277.0859, found: 
277.0862;
 
IR (neat): 3055, 2921, 1733, 1625, 1575, 1443, 100 
1242, 1196, 1030, 968, 930, 887, 829, 805, 775, 762, 703, 682 
cm-1.
 
4-Fluoro-9-methyl-benzofuro[3,2-c]-2-pyrone (8h) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale using 2.5 mol% Pd2(dba-105 
4,4′-OMe)3 and 10 mol% PPh3, to afford the product as a 
yellow solid (22.5 mg, 41.3%). Rf = 0.37 (20% EtOAc in 
hexanes); M.p. 207-208 ºC; 1H-NMR (400 MHz, CDCl3): 7.70 
(dd, J = 8.1, 2.7 Hz, 1H), 7.48 (dd, J = 9.0, 3.9 Hz, 1H), 7.12 
(app. td, J = 9.0, 2.7 Hz, 1H), 6.53 (q, J = 0.8 Hz, 1H), 2.43 110 
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(d, J = 0.8 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 165.71, 
163.54, 160.3 (d, J = 242.1 Hz), 159.08, 151.0 (d, J = 1.3 Hz), 
124.10 (d, J = 11.6 Hz), 113.65 (d, J = 26.4 Hz), 112.27 (d, J 
= 9.6 Hz), 107.49 (d, J = 26.5 Hz), 103.76 (d, J = 3.6 Hz), 
95.85, 20.69; 19F-NMR (376 MHz, CDCl3): -117.03 (ddd, J = 5 
9.0, 8.1, 3.9 Hz); MS (ESI) m/z (rel.%): 241 [MNa+] (67), 219 
[MH+] (100); HRMS (ESI) calculated for C12H8FO3:219.0452, 
found: 241.0449;
 
IR (neat): 3090, 2922, 1728, 1613, 1571, 
1449, 1243, 1211, 1130, 1031, 972, 856, 797, 769 cm-1. 
5-Fluoro-9-methyl-benzofuro[3,2-c]-2-pyrone (8i) 10 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford recovered starting 
material (13.2 mg) and the product as a yellow solid (13.2 mg, 
24.2%). 1H-NMR (400 MHz, CDCl3): 7.96 (dd, J = 8.6, 5.4 
Hz, 1H), 7.28 (dd, J = 8.5, 2.3 Hz, 1H), 7.17 (ddd, J = 9.4, 15 
8.6, 2.3 Hz, 1H), 6.54 (q, J = 0.8 Hz, 1H), 2.43 (d, J = 0.8 Hz, 
3H); 13C-NMR (101 MHz, CDCl3): 165.1, 163.87 (d, J = 
233.1 Hz), 162.8, 159.3, 154.93 (d, J = 13.5 Hz), 121.77 (d, J 
= 10.0 Hz), 119.10 (d, J = 2.0 Hz), 113.11 (d, J = 23.8 Hz), 
99.78 (d, J = 27.4 Hz) 99.4, 95.8, 20.6; 19F-NMR (376 MHz, 20 
CDCl3): -113.48 (td, J = 9.0, 5.4 Hz); MS (ESI) m/z (rel.%): 
241 [MNa+] (77), 219 [MH+] (100); HRMS (ESI) calculated 
for C12H8FO3: 298.9714, found: 298.9711; IR (CHCl3): 1731, 
1615, 1573, 1496, 1276, 947, 651 cm-1. 
4-(Trifluoromethyl)-9-methyl-benzofuro[3,2-c]-2-pyrone (8j) 25 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford the product as a 
yellow solid (7.1 mg, 10.6%). 1H-NMR (400 MHz, CDCl3): 
8.34 (dt, J = 1.5, 0.7 Hz, 1H), 7.70 – 7.63 (m, 2H), 6.59 (d, J 
= 0.8 Hz, 1H), 2.46 (d, J = 0.8 Hz, 3H); 19F-NMR (376 MHz, 30 
CDCl3): -61.11 (d, J = 5.2 Hz); MS (ESI) m/z (rel.%): 269 
[MH+] (100), 249 (24), 215 (15), 126 (82), 84 (44); HRMS 
(ESI) calculated for C13H8F3O3: 269.0420, found: 269.0430; 
IR (neat): 2953, 2923, 2853, 1743, 1575, 1458, 1319, 1266, 
1164, 1119, 1050, 970, 818 cm-1. 35 
5-(6-Methyl-2-pyronyl-4-oxy)-9-methyl-benzofuro[3,2-c]-2-
pyrone (8k) 
The title compound was prepared according to the General 
Procedure, on a 0.5 mmol scale, to afford the product as a 
yellow solid (26 mg, 16%). M.p. >215 ºC (decomp.); 1H-NMR 40 
(400 MHz, CDCl3): 8.05 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 2.1 
Hz, 1H), 7.16 (dd, J = 8.4, 2.1 Hz, 1H), 6.57 (d, J = 0.9 Hz, 
1H), 6.00 (dd, J = 2.2, 0.9 Hz, 1H), 5.23 (d, J = 2.2 Hz, 1H), 
2.45 (d, J = 0.9 Hz, 3H), 2.28 (d, J = 0.9 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3): 170.7, 165.5, 163.6, 163.5, 159.1, 157.9, 45 
155.0, 150.6, 122.3, 121.4, 118.5, 105.3, 103.4, 99.9, 99.7, 
95.8, 91.3, 20.7, 20.1; MS (ESI) m/z (rel.%): 347 [MNa+] 
(98), 325 [MH+] (100); HRMS (ESI) calculated for C18H13O6: 
325.0707, found: 325.0701; IR (neat): 3100, 1726, 1649, 
1615, 1570, 1445, 1400, 1319, 1255, 1168, 1135, 1032, 982, 50 
944, 819 cm-1. 
Benzofuro[3,2-c]coumarin (Coumestan) (8l) 
The title compound was prepared according to the General 
Procedure, on a 0.25 mmol scale, to afford recovered starting 
material (19.6 mg, 21.5%) and the product as a yellow solid 55 
(26.0 mg, 44.1% [56% b.r.s.m]). M.p. 178-180 ºC; 1H-NMR 
(400 MHz, CDCl3): 8.14 (m, 1H), 8.03 (ddd, J = 7.8, 1.6, 0.4 
Hz, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.51 (m, 1H), 7.46 – 
7.49 (m, 2H), 7.42 (m, 1H); 13C-NMR (101 MHz, CDCl3): 
156.0, 158.1, 155.5, 153.7, 131.9, 126.8, 125.2, 124.6, 123.4, 60 
121.9, 117.5, 112.6, 111.7, 105.9; MS (ESI) m/z (rel.%): 237 
[MH+] (100), 211 (24); HRMS (ESI) calculated for C15H9O3: 
237.0546, found: 237.0543; 
trans-[Pd{C6H4O-2-(C6H5O2)}I(PPh3)2] (10) 
A solution of Pd2dba3 (30 mg, 33 µmol, 1 eq.), and PPh3 (34 65 
mg, 132 µmol, 4 eq.) in CH2Cl2 (20 mL) was stirred under 
nitrogen at ambient temperature for 15 minutes (giving 
complex 9) followed by the addition of 4-(2-iodophenoxy)-6-
methyl-2-pyrone (32.8 mg, 99 µmol, 3 eq.). The solution was 
then allowed to stir for 1 hour at ambient temperature. The 70 
CH2Cl2 was removed in vacuo to afford an orange oil which 
was subsequently dissolved in Et2O (5 mL) and stored at room 
temperature for 16 hours, affording yellow crystals.  The 
solution was then filtered and the crystals washed with Et2O 
(5 mL), then dried under high vacuum to afford a yellow 75 
crystalline solid (63 mg, 65.6%). 1H-NMR (700 MHz, 
CD2Cl2): 7.52 (dd, J = 12.4, 5.5 Hz, 12H), 7.37 (t, J = 7.5 Hz, 
6H), 7.28 (t, J = 7.5 Hz, 12H), 6.92 (ddd, J = 7.5, 3.5, 1.9 Hz, 
1H), 6.48 (t, J = 7.5 Hz, 1H), 6.32 (t, J = 7.5 Hz, 1H), 6.04 
(ddd, J = 7.5, 2.4, 1.2 Hz, 1H), 5.65 (dd, J = 1.0, 2.0, 1H), 80 
4.72 (d, J = 1.9, 1H), 2.26 (app. s, 3H); 13C-NMR (176 MHz, 
CD2Cl2): 169.1, 164.4, 163.3, 153.4, 149.9, 138.8, 135.5, 
132.7, 130.6, 128.3, 125.5, 124.2, 119.7, 100.4, 91.4, 20.6; 
31P-NMR (283 MHz, CD2Cl2): 21.23; MS (LIFDI) m/z 
(rel.%): 958 (100). Calculated for C48H39IO3P2Pd: C = 60.11, 85 
H = 4.10, Found: C = 59.90, H = 4.07. 
trans-[Pd{C6H4O-2-(C6H5O2)}I{P(C6D5)3}2]  
A solution of Pd2dba3 (30 mg, 33 µmol, 1 eq.), and D15- PPh3 
(36 mg, 132 µmol, 4 eq.) in CH2Cl2 (20 mL) was stirred under 
nitrogen at ambient temperature for 15 minutes, followed by 90 
the addition of 4-(2-iodophenoxy)-6-methyl-2-pyrone (32.8 
mg, 99 µmol, 3 eq.). The solution was then allowed to stir for 
1 hour at ambient temperature. The CH2Cl2 was removed in 
vacuo to afford an orange oil which was subsequently taken 
up in Et2O (5 mL) and allowed to crystallise for 16 hours. The 95 
solution was then filtered and the crystals washed with Et2O 
(5 mL), then dried under high vacuum to afford a yellow 
crystalline solid (23 mg, 35.3%). 1H-NMR (700 MHz, 
CD2Cl2): 6.92 (ddd, J = 7.5, 3.5, 1.9 Hz, 1H), 6.48 (t, J = 7.5 
Hz, 1H), 6.32 (t, J = 7.5 Hz, 1H), 6.04 (ddd, J = 7.5, 2.4, 1.2 100 
Hz, 1H), 5.65 (dd, J = 1.0, 2.0, 1H), 4.72 (d, J = 1.9, 1H), 2.26 
(app. s, 3H); 31P-NMR (283 MHz, CD2Cl2): 21.23; 31P-NMR 
(283 MHz, D8-THF): 22.44. 
Attempted synthesis of a cationic derivative of 10 
The neutral PdII complex 10 (41.3 mg, 43 µmol, 1 eq.) was 105 
reacted with AgPF6 (10.9 mg, 43 µmol, 1 eq.) in CD2Cl2 (1 
mL) at ambient temperature in a dry box for 1 hour in the 
dark. The reaction was then filtered through a pad of CeliteTM, 
and  NMR spectroscopy showed that a new cationic complex 
was formed along with an additional new species (presumed 110 
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to be 12). (Selected data) 1H NMR (700 MHz, CD2Cl2): 7.93 
(t, J = 7.9 Hz, 1H), 7.52 (td, J = 7.4, 2.2 Hz, 1H), 7.38 (dd, J 
= 8.1, 5.5 Hz, 1H), 7.33 (ddd, J = 14.3, 7.9, 1.4 Hz, 1H), 5.20 
(d, J = 2.0 Hz, 1H), 4.92 (d, J = 2.0 Hz, 1H), 1.98 (s, 3H); 31P 
NMR (162 MHz, CD2Cl2): 39.02 (br. s, ∆ν ½ 46 Hz), 22.09 5 
(s), -143.88 (hept, J = 710 Hz). Layering the CH2Cl2 solution 
with Et2O and storing room temperature in the dark for two 
weeks gave crystals suitable for X-ray diffraction study.  
Rather curiously, it was found that the “C6H4O-2-(C6H5O2)” 
group from the cationic PdII species had undergone Pd→P 10 
transfer forming [P{C6H4O-2-(C6H5O2)}Ph3]PF6 (12), which 
was accompanied by significant Pd black formation. 
Reaction of 10 with Cs2CO3 to give product 6a 
A solution of Pd2(dba-4,4′-OMe)3 (3.6 mg, 3.3 µmol, 1 eq.), 
and PPh3 (3.4 mg, 13.2 µmol, 4 eq.) in D8-THF (1 mL) was 15 
stirred in a dry box at ambient temperature for 15 minutes, 
followed by the addition of 4-(2-iodophenoxy)-6-methyl-2-
pyrone (4.2 mg, 13.2 µmol, 4 eq.). The solution was then 
allowed to stir for 1 hour at ambient temperature and the PdII 
intermediate confirmed by NMR spectroscopy. Cs2CO3 (6.6 20 
mg, 20 µmol, 6 eq.) was added and the solution heated to 70 
°C for 2 hours. The solution was cooled to ambient 
temperature and filtered. The 1H NMR spectrum showed 
quantitative formation of 6a. 
Synthesis of trans-[Pd{C6H3-5-CF3-O-2-(C6H5O2)}Br(PPh3)2] 25 
and attempted reaction with Cs2CO3 
From Pd2(dba-H)3: A solution of Pd2(dba)3 (30 mg, 33 µmol, 
1 eq.), and PPh3 (34 mg, 132 µmol, 4 eq.) in THF (20 mL) 
was stirred under a N2 atmosphere for 15 minutes, giving an 
orange solution which is Pd(η2-dba-H)(PPh3)2.  4-(2-Bromo-4-30 
(trifluoromethyl)-phenoxy)-6-methyl-2-pyrone (46.0 mg, 132 
µmol, 2 eq.) was then added and the solution was allowed to 
stir for 1 hour at 70 °C. The THF was removed in vacuo to 
afford an orange oil which was subsequently taken up in Et2O 
(5 mL), and allowed to slowly crystallize over 16 hours.  A 35 
mixture of purple, orange and yellow crystals were formed.  
X-ray crystallographic analysis identified the purple crystals 
as Pd2(dba-H)3 (as disordered isomers). The orange and 
yellow crystals were not identified. From Pd2(dba-4,4′-OMe)3: 
In a dry box, a solution of Pd2 (dba-4,4′-OMe)3 (3.6 mg, 3.3 40 
µmol, 1 eq.), and PPh3 (3.4 mg, 13.2 µmol, 4 eq.) in D8-THF 
(1 mL) was stirred at ambient temperature for 15 minutes, 
giving an dark orange solution which is Pd(η2-dba-4,4′-
OMe)(PPh3)2. 4-(2-Bromo-4-(trifluoromethyl)-phenoxy)-6-
methyl-2-pyrone 7j (2.3 mg, 6.6 µmol, 2 eq.) was then added.  45 
The solution was then allowed to stir for 1 hour at 70 °C and 
the PdII complex characterized by NMR spectroscopy. 
Selected Data: 1H-NMR (400 MHz, D8-THF): 7.59 – 7.54 (m, 
12H), 7.35 – 7.30 (m, 6H), 7.26 – 7.22 (m, 12H), 6.67 (d, J = 
8.5 Hz, 1H), 6.15 (d, J = 8.5 Hz, 1H), 6.03 (s, 1H), 5.69 (d, J 50 
= 2.2 Hz, 1H), 4.65 (d, J = 2.2 Hz, 1H), 2.24 (s, 3H); 31P-
NMR (162 MHz, D8-THF): 24.46 (s). Cs2CO3 (13.2 mg, 40 
µmol, 12 eq.) was then added to the yellow/orange solution, 
which was heated to 70 °C for 2 hours.  The solution was 
allowed to cool to ambient temperature and filtered through 55 
CeliteTM.  1H NMR spectroscopic analysis of the filtrate 
showed no formation of the cyclised product 8j.  The 31P 
NMR spectrum showed degradation of the PdII complex at δ 
24.46 (s), and a new species, identified as [Pd0(η2-dba-4-
OMe)(PPh3)2] 9.  31P-NMR (162 MHz, D8-THF): 26.8 (br. s, 60 
∆ν½ 42 Hz), 25.2 (br. s, ∆ν½ 42 Hz). 
 
Details of Crystallographic Analysis Diffraction data were 
collected at 110 K on a Bruker Smart Apex diffractometer 
with Mo-Kα radiation (λ = 0.71073 Å) using a SMART CCD 65 
camera. Diffractometer control, data collection and initial unit 
cell determination was performed using “SMART”.36 Frame 
integration and unit-cell refinement software was carried out 
with “SAINT+”.37 Absorption corrections were applied by 
SADABS (v2.10, Sheldrick).  Structures were solved by direct 70 
methods using SHELXS-973 and refined by full-matrix least 
squares using SHELXL-97. All non-hydrogen atoms were 
refined anisotropically.  Hydrogen atoms were placed using a 
“riding model” and included in the refinement at calculated 
positions.  Important X-ray details are collected in Table 4 75 
(shown below), including CCDC numbers.  
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Table 4 X-ray diffraction details for all compounds. 
Compound reference ijf0925m (6a) ijf0934m (6b) ijf0930 (8h) ijf0931 (8i) ijf0936m (10) ijf1002m (12) 
Chemical formula C12H8O3 C11H6O3 C12H7FO3 C12H7FO3 C48H39IO3P2Pd C30H24O3P•(F6P1)0.98•(I)0.02
Formula Mass 200.18 186.16 218.18 218.18 959.03 608.43 
Crystal system Triclinic Monoclinic Triclinic Triclinic Monoclinic Triclinic 
a/Å 7.1467(5) 11.1190(16) 3.7437(3) 3.7597(2) 10.2109(5) 7.8107(8) 
b/Å 7.3546(5) 8.2091(12) 6.3700(7) 6.1644(4) 11.8937(6) 13.2530(14) 
c/Å 9.3252(6) 18.856(3) 19.0219(19) 19.6660(11) 34.1332(17) 14.2579(15) 
α/° 69.7600(10) 90.00 91.665(9) 92.543(5) 90.00 97.040(2) 
β/° 81.8920(10) 105.787(2) 90.858(7) 90.715(5) 93.0340(10) 104.389(2) 
γ/° 75.2200(10) 90.00 93.699(8) 90.125(5) 90.00 104.932(2) 
Unit cell volume/Å3 443.91(5) 1656.2(4) 452.42(8) 455.30(5) 4139.5(4) 1353.6(2) 
Temperature/K 120(2) 110(2) 120(2) 120(2) 110(2) 110(2) 
Space group P1¯  C2/c P1¯  P1¯  P2(1)/n P1¯  
No. of formula units per unit cell, Z 2 8 2 2 4 2 
No. of reflections measured 6084 8041 7806 4447 55989 13874 
No. of independent reflections 2211 2057 1688 1706 10290 6661 
Rint 0.0124 0.0175 0.0390 0.0286 0.0494 0.0235 
Final R1 values (I > 2σ(I)) 0.0352 0.0373 0.0480 0.0477 0.0330 0.0490 
Final wR(F2) values (I > 2σ(I)) 0.1005 0.0970 0.1249 0.1335 0.0684 0.1227 
Final R1 values (all data) 0.0366 0.0443 0.0574 0.0514 0.0456 0.0719 
Final wR(F2) values (all data) 0.1023 0.1024 0.1316 0.1382 0.0730 0.1367 
CCDC number 764708 764709 773153 773154 764710 764711 
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